0000850261-18-000031.txt : 20180809 0000850261-18-000031.hdr.sgml : 20180809 20180809172113 ACCESSION NUMBER: 0000850261-18-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180809 DATE AS OF CHANGE: 20180809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc. CENTRAL INDEX KEY: 0000850261 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 330344842 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36150 FILM NUMBER: 181006388 BUSINESS ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-203-4100 MAIL ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC DATE OF NAME CHANGE: 19920703 10-Q 1 srne6301810-q.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q

 
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2018
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 001-36150
 
SORRENTO THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
 
33-0344842
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification Number)
4955 Directors Place
San Diego, California 92121
(Address of Principal Executive Offices)
(858) 203-4100
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated file, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
 
Large accelerated filer
 
☐
  
Accelerated filer
 
☒
 
 
 
 
Non-accelerated filer
 
☐ 
  
Smaller reporting company
 
☐
 
 
 
 
 
 
 
Emerging growth company
 
☐  
  
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No   ☒.
The number of shares of the issuer’s common stock, par value $0.0001 per share, outstanding as of August 6, 2018 was 116,732,276.




Sorrento Therapeutics, Inc.
Form 10-Q for the Quarter Ended June 30, 2018
Table of Contents
 
 
 
 
 
 
 
 
 




PART I. FINANCIAL INFORMATION
 
Item 1.    Condensed Consolidated Financial Statements.
 
SORRENTO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except for share amounts)
 
June 30,
2018
 
December 31,
2017
 
 
 
 
ASSETS
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
46,784

 
$
20,429

Marketable securities
323

 
441

Grants and accounts receivables, net
2,204

 
2,211

Income tax receivable
433

 
1,715

Prepaid expenses and other, net
5,002

 
4,904

Total current assets
54,746

 
29,700

Property and equipment, net
19,893

 
19,345

Intangibles, net
69,690

 
71,013

Goodwill
38,298

 
38,298

Cost method investments
237,008

 
237,008

Equity method investments
29,972

 
32,999

Other, net
2,914

 
3,250

Total assets
$
452,521

 
$
431,613

LIABILITIES AND STOCKHOLDERS' EQUITY
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
9,941

 
$
9,911

Accrued payroll and related benefits
6,671

 
4,485

Accrued expenses
4,226

 
7,274

Current portion of deferred revenue
1,878

 
3,864

Current portion of deferred rent
243

 
212

Acquisition consideration payable
14,929

 
53,209

Current portion of debt
1,511

 
—

Total current liabilities
39,399

 
78,955

Long-term debt
16,203

 
5,211

Deferred tax liabilities
13,281

 
15,535

Deferred revenue
118,247

 
119,287

Deferred rent and other
5,926

 
6,015

Total liabilities
193,056

 
225,003

Commitments and contingencies


 


Equity:
 

 
 

Sorrento Therapeutics, Inc. equity
 

 
 

Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding
—

 
—

Common stock, $0.0001 par value; 750,000,000 shares authorized and 116,240,963 and 82,903,567 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively
12

 
9

Additional paid-in capital
574,316

 
413,901

Accumulated other comprehensive income (loss)
153

 
242

Accumulated deficit
(270,646
)
 
(165,120
)
Treasury stock, 7,568,182 shares at cost at June 30, 2018, and December 31, 2017, respectively
(49,464
)
 
(49,464
)
Total Sorrento Therapeutics, Inc. stockholders' equity
254,371

 
199,568

Noncontrolling interests
5,094

 
7,042

Total equity
259,465

 
206,610

Total liabilities and stockholders' equity
$
452,521

 
$
431,613

See accompanying unaudited notes

1


SORRENTO THERAPEUTICS, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 


 
 
Revenues:
 

 
 

 
 

 
 

Grant
$
—

 
$
94

 
$
—

 
$
195

Royalty and license
120

 
2,416

 
240

 
4,833

Sales and services
3,793

 
2,155

 
9,919

 
4,511

Total revenues
3,913

 
4,665

 
10,159

 
9,539

Operating costs and expenses:
 

 
 

 
 

 
 

Costs of revenues
1,226

 
816

 
2,538

 
1,880

Research and development
17,925

 
11,179

 
32,554

 
26,062

Acquired in-process research and development
—

 
—

 
—

 
200

General and administrative
11,039

 
9,092

 
21,000

 
20,979

Intangible amortization
657

 
665

 
1,319

 
1,292

Loss (gain) on contingent liabilities and acquisition consideration payable
1,437

 
(3,629
)
 
13,663

 
(4,090
)
Total operating costs and expenses
32,284

 
18,123

 
71,074

 
46,323

Loss from operations
(28,371
)
 
(13,458
)
 
(60,915
)
 
(36,784
)
Loss on trading securities
(121
)
 
(609
)
 
(118
)
 
(450
)
Loss on foreign currency exchange
(586
)
 
—

 
(569
)
 
—

Interest expense
(45,009
)
 
(1,200
)
 
(46,061
)
 
(2,809
)
Interest income
6

 
232

 
10

 
457

Loss before income tax
(74,081
)
 
(15,035
)
 
(107,653
)
 
(39,586
)
Income tax benefit
(1,377
)
 
(1,398
)
 
(2,325
)
 
(3,094
)
Loss on equity method investments
(2,105
)
 
(1,102
)
 
(3,027
)
 
(2,050
)
Net loss
(74,809
)
 
(14,739
)
 
(108,355
)
 
(38,542
)
Net loss attributable to noncontrolling interests
(945
)
 
(552
)
 
(1,919
)
 
(1,291
)
Net loss attributable to Sorrento
$
(73,864
)
 
$
(14,187
)
 
$
(106,436
)
 
$
(37,251
)
Net loss per share - basic and diluted per share attributable to Sorrento
$
(0.73
)
 
$
(0.20
)
 
$
(1.15
)
 
$
(0.61
)
Weighted-average shares used during period - basic and diluted per share attributable to Sorrento
100,563

 
70,302

 
92,795

 
60,650

 
See accompanying unaudited notes

2


SORRENTO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In thousands)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
 


 
 
 
 
 
 
Net loss
$
(74,809
)
 
$
(14,739
)
 
$
(108,355
)
 
$
(38,542
)
Other comprehensive income:
 

 
 

 
 

 
 

Foreign currency translation adjustments
(199
)
 
274

 
(89
)
 
336

Total other comprehensive income (loss)
(199
)
 
274

 
(89
)
 
336

Comprehensive loss
(75,008
)
 
(14,465
)
 
(108,444
)
 
(38,206
)
Comprehensive loss attributable to noncontrolling interests
(945
)
 
(552
)
 
(1,919
)
 
(1,291
)
Comprehensive loss attributable to Sorrento
$
(74,063
)
 
$
(13,913
)
 
$
(106,525
)
 
$
(36,915
)
 
See accompanying unaudited notes

3


SORRENTO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands, except for share amounts)
 
 
Common Stock
 
Treasury Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Accumulated
Deficit
 
Noncontrolling
Interest
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Total
Balance, December 31, 2017
82,903,567

 
$
9

 
7,568,182

 
(49,464
)
 
$
413,901

 
$
242

 
$
(165,120
)
 
$
7,042

 
$
206,610

Adoption impact of ASC 606
—

 
—

 
—

 
—

 
—

 
—

 
910

 
—

 
910

Issuance of common stock upon exercise of stock options
25,815

 
—

 
—

 
—

 
162

 
—

 
—

 
—

 
162

Issuance of common stock for BDL settlement
309,916

 
—

 
—

 
—

 
2,340

 
—

 
—

 
—

 
2,340

Issuance of common stock for Scilex settlement
1,381,346

 
—

 
—

 
—

 
13,744

 
—

 
—

 
—

 
13,744

Issuance of common stock for public placement, net
7,786,743

 
1

 
—

 
—

 
58,272

 
—

 
—

 
—

 
58,273

Issuance of common stock for Virttu settlement
1,795,011

 
—

 
—

 
—

 
11,308

 
—

 
—

 
—

 
11,308

Issuance of common stock related to conversion of notes payable
22,038,565

 
2

 
—

 
—

 
49,998

 
—

 
—

 
—

 
50,000

Beneficial conversion feature recorded on convertible notes
—

 
—

 
—

 
—

 
12,006

 
—

 
—

 
—

 
12,006

Warrants issued in connection with convertible notes
—

 
—

 
—

 
—

 
9,646

 
—

 
—

 
—

 
9,646

Stock-based compensation
—

 
—

 
—

 
—

 
2,939

 
—

 
—

 
(29
)
 
2,910

Foreign currency translation adjustment
—

 
—

 
—

 
—

 
—

 
(89
)
 
—

 
—

 
(89
)
Net loss
—

 
—

 
—

 
—

 
—

 
—

 
(106,436
)
 
(1,919
)
 
(108,355
)
Balance, June 30, 2018
116,240,963

 
$
12

 
7,568,182

 
(49,464
)
 
$
574,316

 
$
153

 
$
(270,646
)
 
$
5,094

 
$
259,465

 
 
 
Common Stock
 
Treasury Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Accumulated
Deficit
 
Noncontrolling
Interest
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Total
Balance, December 31, 2016
50,882,856

 
$
6

 
7,568,182

 
(49,464
)
 
$
303,865

 
$
(118
)
 
$
(174,252
)
 
$
6,465

 
$
86,502

Scilex acquisition adjustments
—

 
—

 
—

 
—

 
(627
)
 
—

 
—

 
(1,400
)
 
(2,027
)
Issuance of common stock for public placement and investments, net
24,855,872

 
3

 
—

 
—

 
45,595

 
—

 
—

 
—

 
45,598

Issuance of common stock for private placement and investments, net
4,246

 
—

 
—

 
—

 
30

 
—

 
—

 
—

 
30

Stock-based compensation
—

 
—

 
—

 
—

 
2,626

 
—

 
—

 
—

 
2,626

Foreign currency translation adjustment
—

 
—

 
—

 
—

 
—

 
336

 
—

 
—

 
336

Issuance of common stock for private placement and investments, net
797,081

 
—

 
—

 
—

 
1,673

 
—

 
—

 
—

 
1,673

Net loss
—

 
—

 
—

 
—

 
—

 
—

 
(37,251
)
 
(1,291
)
 
(38,542
)
Balance, June 30, 2017
76,540,055

 
$
9

 
7,568,182

 
(49,464
)
 
$
353,162

 
$
218

 
$
(211,503
)
 
$
3,774

 
$
96,196

 
 
See accompanying unaudited notes

4


SORRENTO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) (In thousands)

5


 
Six Months Ended June 30,
 
2018
 
2017
Operating activities


 
 
Net loss
$
(108,355
)
 
$
(38,542
)
Adjustments to reconcile net loss to net cash used in operating activities:
 

 
 

Depreciation and amortization
3,931

 
3,188

Non-cash interest expense
44,272

 
563

Loss on trading securities
118

 
450

Amortization of debt issuance costs and debt discount
515

 
371

Stock-based compensation
2,910

 
2,626

Loss on equity method investments
3,027

 
2,050

Loss (gain) on contingent liabilities and acquisition consideration payable
13,663

 
(4,090
)
Deferred tax provision
(2,253
)
 
(3,064
)
Changes in operating assets and liabilities, excluding effect of acquisitions:
 

 
 

Grants and other receivables
7

 
(680
)
Accrued payroll
2,187

 
(311
)
Prepaid expenses and other
(99
)
 
751

Deposits and other assets
1,622

 
181

Accounts payable
(326
)
 
(1,063
)
Deferred revenue
(2,115
)
 
(4,831
)
Deferred rent and other
(120
)
 
(461
)
Acquisition consideration payable for Scilex
(2,020
)
 
—

Accrued expenses and other liabilities
(3,049
)
 
1,198

Net cash used for operating activities
(46,085
)
 
(41,664
)
Investing activities
 

 
 

Purchases of property and equipment
(2,812
)
 
(6,783
)
     Investment in Celularity
—

 
(3,000
)
Purchase of business, net of cash acquired
—

 
(557
)
Net cash used in investing activities
(2,812
)
 
(10,340
)
Financing activities
 

 
 

Proceeds from bridge loan for Scilex regulatory milestone
20,000

 
—

Repayment of bridge loan for Scilex regulatory milestone
(20,000
)
 
—

Repayment under the amended loan and security agreement
—

 
(21,500
)
Proceeds from loan agreement
1,586

 
—

Payments under deferred compensation arrangements
—

 
(1,012
)
Scilex consideration for regulatory milestone
(22,466
)
 
—

Proceeds from issuance of common stock, net of issuance costs
58,273

 
45,628

Proceeds from issuance of convertible notes
37,849

 
—

Proceeds from exercise of stock options
162

 
—

Net cash provided by financing activities
75,404

 
23,116

Net change in cash and cash equivalents
26,507

 
(28,888
)
Net effect of exchange rate changes on cash
(152
)
 
171

Cash and cash equivalents at beginning of period
20,429

 
82,398

Cash and cash equivalents at end of period
$
46,784

 
$
53,681

Supplemental disclosures:
 

 
 

Cash paid during the period for:
 

 
 

Income taxes
$
15

 
$
30

Interest paid
$
1,128

 
$
2,044

Supplemental disclosures of non-cash investing and financing activities:
 

 
 

Virttu acquisition non-cash consideration
$
11,308

 
$
15,465

BDL non-cash consideration
$
2,340

 
$
—

Property and equipment costs incurred but not paid
$
391

 
$
422

     Scilex non-cash consideration for regulatory milestone
$
13,744

 
$
—

Investment in Celularity
$
—

 
$
2,000

     Conversion of convertible notes
$
50,000

 
$
—

 

6


 See accompanying unaudited notes

7


SORRENTO THERAPEUTICS, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018
 
1. Nature of Operations and Business Activities
Nature of Operations and Basis of Presentation
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the “Company”), is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. The Company’s primary focus is to transform cancer into a treatable or chronically manageable disease. The Company also has programs assessing the use of its technologies and products in auto-immune, inflammatory, neurodegenerative, infectious diseases and pain indications with high unmet medical needs.
At its core, the Company is an antibody-centric company and leverages its proprietary G-MAB™ library to identify, screen and validate fully human antibodies against high impact oncogenic targets and mutations, immune modulators and intracellular targets. To date, the Company has screened over 100 validated targets and generated a number of fully human antibodies against these targets which are at various stages of preclinical development. These include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.
The Company’s vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as T-Cell Receptor (“TCR”)-like antibodies.  With LA Cell, Inc. (“LA Cell”), the Company’s joint venture with City of Hope, the Company’s objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, the Company has acquired and is assessing the regulatory and strategic path forward for its portfolio of late stage biosimilar/biobetter antibodies based on Erbitux®, Remicade®, Xolair®, and Simulect® as these may represent nearer term commercial opportunities.
With each of its programs, the Company aims to tailor its therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape. In addition, the Company’s objective is to focus on tumors that are resistant to current treatments and where the Company can design focused trials based on a genetic signature or biomarker to ensure patients have the best chance of a durable and significant response. The Company has several immuno-oncology programs that are in or near to entering the clinic.  These include cellular therapies, an oncolytic virus and a palliative care program targeted to treat intractable cancer pain.  Finally, as part of its global aim to provide a wide range of therapeutic products to meet underserved therapeutic markets, the Company has made investments and developed a separate pain focused franchise which the Company believes will serve to provide short term upside to its core thesis.
Through June 30, 2018, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure.  
The accompanying condensed consolidated financial statements include the accounts of the Company’s subsidiaries.  For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.  All intercompany balances and transactions have been eliminated in consolidation.
In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal, recurring and necessary for a fair statement of financial position, results of operations and cash flows. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2018 fiscal year, or any subsequent period.
2. Liquidity and Going Concern
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically operated with working capital deficiencies and expects to operate in the future with working capital deficiencies and has incurred substantial net losses for the years ended December 31, 2017 and 2016, and anticipates that it will continue to do so for the foreseeable future as it continues to identify and invest in advancing product

8


candidates, as well as expanding corporate infrastructure. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.
As of June 30, 2018, the Company had $37.8 million of long term debt issued in a private placement (the "Private Placement") pursuant to a Securities Purchase Agreement, dated as of March 26, 2018, as amended by Amendment No. 1 thereto, dated as of June 13, 2018 (the “Securities Purchase Agreement”), among the Company and certain accredited investors (collectively, the “Purchasers”). Pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers (1) convertible promissory notes in an aggregate principal amount of $37,848,750 (the “Notes”), which accrue simple interest at a rate equal to 5.0% per annum and mature upon the earlier to occur of (a) June 13, 2023, and (b) the date of the closing of a change in control of the Company (the “Maturity Date”), and (2) warrants (the “Warrants”) to purchase an aggregate of 2,698,662 shares of the common stock of the Company.
Each of the Notes provide that, upon the occurrence of an event of default, the Purchasers thereof may, by written notice to the Company, declare all of the outstanding principal and interest under such Notes immediately due and payable. For purposes of the Notes, an event of default includes, among other things, one or more events that have, or could reasonably be expected to have, a material adverse effect on (i) the Company’s ability to comply with its obligations under the Securities Purchase Agreement, the Notes or the Warrants or the registration rights agreement entered into with the Purchasers in connection with the Private Placement, or (ii) the rights of the Purchasers under the Notes. The Company believes that it is not probable that the material adverse event clause under the Notes will be exercised.
The Company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company’s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. Although management believes such plans, if executed as planned, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company’s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that the condensed consolidated financial statements are issued.
If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable, the Company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates. The Company may also seek collaborators for one or more of its current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available.
The condensed consolidated financial statements do not reflect any adjustments that might be necessary if the Company is unable to continue as a going concern.
Universal Shelf Registration
In November 2014, the Company filed a universal shelf registration statement on Form S-3 (the “2014 Shelf Registration Statement”) with the SEC, which was declared effective by the SEC in December 2014. This 2014 Shelf Registration Statement provided the Company with the ability to offer up to $250 million of securities, including equity and other securities as described in the registration statement. Included in the 2014 shelf registration was a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that could be issued and sold under a sales agreement with MLV & Co. LLC (the “2014 ATM Facility”). During the twelve months ended December 31, 2017, the Company sold approximately $13.9 million in shares of common stock under the 2014 ATM Facility.
In April 2017, the Company completed a public offering of $47.5 million of shares of common stock pursuant to the 2014 Shelf Registration Statement for net proceeds of approximately $43.1 million.
In November 2017, the Company filed a universal shelf registration statement on Form S-3 (the “2017 Shelf Registration Statement”) with the SEC, which was declared effective by the SEC in December 2017. The 2014 Shelf Registration Statement expired on December 6, 2017 when the 2017 Shelf Registration was declared effective. The 2017 Shelf Registration Statement provides the Company with the ability to offer up to $350 million of securities, including equity and other securities as described in the registration statement. Included in the 2017 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $100.0 million of the Company’s common stock that may be issued and sold under a sales agreement with B. Riley FBR, Inc. (the “ATM Facility”). During the twelve months ended December 31, 2017, the Company sold approximately $0.9 million in shares of common stock under the ATM Facility. During the three and six month periods ended June 30, 2018, the Company sold approximately $9.6 million and $60.2 million in shares of common stock, respectively, under the ATM Facility. The Company can offer up to approximately $38.9 million of additional shares of common stock under the ATM Facility, subject to certain limitations.

9


Pursuant to the 2017 Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all.
2016 Private Investment in Public Entity Financing
On April 3, 2016, the Company entered into a Securities Purchase Agreement (the “ABG Purchase Agreement”) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, “Ally Bridge”), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers designated by Ally Bridge (collectively, the “ABG Purchasers”), in a private placement transaction (the “ABG Private Placement”), up to $50.0 million in shares of the Company’s common stock and warrants to purchase shares of common stock. Upon the closing of the ABG Private Placement, the Company issued to the ABG Purchasers (1) an aggregate of 9,009,005 shares (the “ABG Shares”) of common stock, and (2) warrants to purchase an aggregate of 2,702,700 shares of common stock (each, an “ABG Warrant”).   Each ABG Warrant has an exercise price of $8.50 per share, was immediately exercisable upon issuance, has a term of three years and is exercisable on a cash or cashless exercise basis. 
Under the terms of the ABG Purchase Agreement, the Company was obligated to prepare and file with the SEC, within 30 days of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of common stock issuable upon exercise of each ABG Warrant (the “ABG Warrant Shares”), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain “piggy-back” registration rights granted to the ABG Purchasers.
On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the “Additional Purchase Agreements”) with each of Beijing Shijilongxin Investment Co., Ltd. (“Beijing Shijilongxin”), FREJOY Investment Management Co., Ltd. (“Frejoy”) and Yuhan Corporation (“Yuhan”), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, 8,108,108 shares of common stock, and a warrant to purchase 1,176,471 shares of common stock, for an aggregate purchase price of $45.0 million; (2) to Frejoy, 8,108,108 shares of common stock, and a warrant to purchase 1,176,471 shares of common stock, for an aggregate purchase price of $45.0 million; and (3) to Yuhan, 1,801,802 shares of common stock, and a warrant to purchase 235,294 shares of common stock, for an aggregate purchase price of $10.0 million. The warrants issued pursuant to each of the Additional Purchase Agreements (collectively, the “Additional Warrants” and, together with each ABG Warrant, the “ABG Warrants”) have an exercise price of $8.50 per share, were immediately exercisable upon issuance, have a term of three years and are exercisable on a cash or cashless exercise basis.
Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan had the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor’s shares of common stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of common stock issuable upon exercise of such investor’s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain “piggy-back” registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan.
On May 2, 2016, the Company closed its private placement of common stock and warrants with Yuhan for gross proceeds of $10.0 million.  Yuhan purchased 1,801,802 shares of common stock at $5.55 per share and a warrant to purchase 235,294 shares of common stock.  The warrant is exercisable for three years at an exercise price of $8.50 per share.
Between May 31, 2016 and June 7, 2016, the Company closed on the remainder of the $150.0 million financing with the ABG Purchasers, Beijing Shijilongxin, and Frejoy. The ABG Purchasers led the financing and, together with Beijing Shijilongxin and Frejoy, collectively purchased 25,225,221 shares of common stock at $5.55 per share and warrants to purchase 5,055,642 shares of common stock for total cash consideration of $86.5 million and secured promissory notes (the “ABG Notes”) in an aggregate principal amount of $53.5 million.
On December 31, 2016, the Company entered into Warrant and Note Cancellation and Share Forfeiture Agreements (the “Cancellation and Forfeiture Agreements”) with certain investors (the “Investors”) that held an aggregate of 7,838,259 shares of common stock and certain of the Warrants granting the right to purchase an aggregate of 1,137,316 shares of common stock.  Pursuant to the Cancellation and Forfeiture Agreements, effective December 31, 2016, the ABG Warrants held by the Investors and the ABG Notes, of which $43.5 million was then outstanding, were cancelled and the shares of common stock held by the Investors were forfeited and returned to the Company.

10


2017 Private Investment in Public Entity Financing
On December 11, 2017, the Company entered into a Securities Purchase Agreement (the "December 2017 Securities Purchase Agreement") with certain accredited investors (collectively, the "December 2017 Purchasers"). Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, (1) convertible promissory notes in an aggregate principal amount of $50,000,000 (the "December 2017 Notes"), which accrued simple interest at a rate equal to 5.0% per annum and would mature upon the earlier to occur of (a) December 21, 2022, and (b) the date of the closing of a change in control of the Company (the "December 2017 Warrant Maturity Date"), and (2) warrants (the "December 2017 Warrants") to purchase an aggregate of 12,121,210 shares of the common stock of the Company.
At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser’s December 2017 Note that was equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of $2.26875, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.
Each December 2017 Warrant has an exercise price of $2.61 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.
On May 17, 2018, the December 2017 Purchasers converted the full outstanding principal under the December 2017 Notes into 22,038,565 shares of the Company's common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of $1.0 million in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of $44.3 million was recognized immediately at that date as interest expense.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $44.8 million based on an allocation of proceeds to the Warrants of approximately $12.7 million and a beneficial conversion feature of approximately $32.1 million, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.
2018 Private Investment in Public Entity Financing
On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, the Notes in an aggregate principal amount of $120,500,000 and Warrants to purchase an aggregate of 8,591,794 shares.
On June 13, 2018, the Company entered into an amendment (the “Amendment”) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of the common stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of the common stock of the Company.
At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser’s Note that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such Purchaser’s Note into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. If a Purchaser elects to convert any of the principal amount of their Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Notes contain restrictive covenants and event of default provisions that are customary for transactions of this type.

11


Each Warrant has an exercise price of $8.77 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.
If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
3. Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments
The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:
•
Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
•
Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.
•
Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.
The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities.
Marketable Securities
Marketable securities are designated either as trading or available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations and are classified as short-term available-for-sale securities are reported as a component of current assets in the accompanying condensed

12


consolidated balance sheets. Marketable securities that are not trading securities and are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying condensed consolidated balance sheets.
Securities that are classified as trading are carried at fair value, with changes to fair value reported as a component of income. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method.
All of the Company’s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. For the three and six months ended June 30, 2018 and 2017, no other-than-temporary impairment charges were recorded. 
Grants and Accounts Receivable
Grants receivable at June 30, 2018 and December 31, 2017 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a division of the National Institutes of Health (“NIH”). The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
Accounts receivable at June 30, 2018 and December 31, 2017 consist of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of each of June 30, 2018 and December 31, 2017, the allowance for doubtful accounts was $20 thousand.  
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
Acquisitions and Intangibles
The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
Goodwill and Other Long-Lived Assets
Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2017, noting no impairment. There have not been any triggering events indicating the potential for impairment through June 30, 2018.

13


The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through June 30, 2018.
Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities
Acquisition consideration payable relates to the Company’s acquisition of businesses and various other assets and is recorded on the Company’s condensed consolidated balance sheets at fair value and is re-measured at each balance sheet date until such contingent liabilities have been settled, with changes in fair value recorded as gain or loss on contingent liabilities. The Company estimates the fair value of contingent consideration based on level 3 inputs primarily driven by the probability of achieving certain financing or operating related milestones.  
Debt with Detachable Warrants
Debt with detachable warrants are evaluated for the classification of warrants as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are first allocated to the debt and the warrants at their relative estimated fair values. The portion of the proceeds so allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of embedded derivatives and beneficial conversion features, are allocated to the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds, to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815.
If the amount allocated to the convertible debt results in an effective per share conversion price less than the fair value of the Company’s common stock on the commitment date, the intrinsic value of this beneficial conversion feature is recorded as a discount to the convertible debt with a corresponding increase to additional paid in capital. The beneficial conversion feature discount is equal to the difference between the effective conversion price and the fair value of the Company’s common stock at the commitment date, unless limited by the remaining proceeds allocated to the debt.
Derivative Liability
Derivative liabilities are recorded on the Company’s condensed consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.  The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model.
Investments in Other Entities
The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company’s share of earnings or losses reported in loss on equity method investments.
The Company’s cost method investments are included in cost method investments on the condensed consolidated balance sheets.  The Company’s equity method investments are included in equity method investments on the condensed consolidated balance sheets.
All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: the magnitude of the impairment and length of time that the market value was below the cost basis; financial condition and business prospects of the investee; the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that the Company may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so.

14


Research and Development Costs and Collaborations
All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
Acquired In-Process Research and Development Expense
The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired in-process research and development related to the business combinations of Virttu Biologics Limited ("Virttu") and Scilex Pharmaceuticals Inc. ("Scilex"), for which certain products are under development and expected to be commercialized in the future, was capitalized and recorded within “Intangibles, net” on the accompanying condensed consolidated balance sheet. The Company intends to commence amortization of acquired in-process research and development upon commercialization of the related products. Capitalized in-process research and development will be reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.
Income Taxes
The provisions of ASC Topic 740 “Income Taxes,” addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions.
The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of each of December 31, 2017 and June 30, 2018, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its investment in Scilex.
Revenue Recognition
The Company’s revenues are generated from various NIH grant awards, license fees, the sale of customized reagents and other materials, and the provision of contract manufacturing and other services. The Company does not have significant costs associated with costs to obtain contracts with its customers. Substantially all of the Company’s grants and accounts receivable result from contracts with customers.
Grant Revenues
The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
Royalty and License Revenues
License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period, with the exception of license agreements with no remaining performance obligations or undelivered obligations. The Company applies judgment in determining the timing of revenue recognition related to contracts that include multiple performance obligations. The total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. For goods or services for which observable standalone selling prices are not available, the Company develops an estimated standalone selling price of each performance obligation.
As of December 31, 2017 and June 30, 2018, the future performance obligations for royalty and license revenues relate to the ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) and NantCell, Inc. (“NantCell”) license agreements.

15


The total consideration for the ImmuneOncia license performance obligation, effective September 1, 2016, represented $9.6 million. The estimated revenue expected to be recognized for future performance obligations, as of December 31, 2017 and June 30, 2018, was approximately $9.0 million and $8.7 million, respectively. The Company expects to recognize license revenue of approximately $0.5 million of the remaining performance obligation annually through the remaining term. The Company applied judgment in estimating the 20-year contract term, analogous to the expected life of the patent, over which revenue is recognized over time given the ongoing performance obligation related to the Company's participation on a steering committee for the technologies under the agreement.
As of December 31, 2017 and June 30, 2018, the NantCell license agreement, effective April 21, 2015, represented $110 million of contract liabilities reflected in long-term deferred revenue. See Note 11 for additional information regarding the remaining performance obligation for the significant agreement.
Sales and Services Revenues
Sales and services revenues are comprised of contract manufacturing associated with sales of customized reagents at Concortis Biosystems Corporation, materials and supply agreements, contract manufacturing services at BioServ Corporation, and the Company’s joint development agreement with Celularity Inc.
The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. The Company applied the practical expedient in ASC Topic 606-10-50-14 to the revenue contracts for our Concortis Biosystems Corporation sales and services and materials and supply agreements due to the short-term length of such contracts.
The following table shows sales and service revenues disaggregated by product and services type for the three and six months ended June 30, 2018 and 2017 (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Concortis sales and services
895

 
883

 
2,358

 
2,071

Materials and supply agreements
—

 
85

 
861

 
403

Bioserv sales and services
1,231

 
1,187

 
3,367

 
2,037

Joint development agreement
1,667

 
—

 
3,333

 
—

 
$
3,793

 
$
2,155

 
$
9,919

 
$
4,511

The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
Concortis Biosystems Corporation (“Concortis”)
Contract manufacturing associated with sales of customized reagents for Concortis operations relate to providing synthetic expertise to customers’ synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers which are recognized upon the transfer of control, which is generally upon shipment given the short contract terms which are generally three months or less.
Materials and Supply Agreements
Revenues from the sale of materials associated with our research and development arrangements are recognized upon the transfer of control, which is generally, upon shipment. Outstanding performance obligations related to materials and supply agreements was $1.6 million as of June 30, 2018, and the Company expects to fulfill such obligations during the remainder of 2018.
Bioserv Corporation (“Bioserv”)
Contract manufacturing services associated with the Company's Bioserv operations related to finish and fill activities for drug products and reagents are recognized ratably over the contract term based on a time-based measure which reflects the transfer of services to the customer because the manufactured products are highly customized and do not have an alternative use to the Company. As of December 31, 2017 and June 30, 2018, the Company had approximately $0.5 million and $0.4

16


million of unbilled accounts receivable for which revenue has been recognized but not billed at the reporting date, respectively. As of December 31, 2017 and June 30, 2018, the Company had approximately $0.4 million and $0.3 million of upfront payments related to its contract manufacturing services included in deferred revenue, respectively.
As of December 31, 2017 and June 30, 2018, the estimated revenue expected to be recognized for future performance obligations associated with contract manufacturing services was approximately $3.0 million and $2.6 million, respectively. The Company expects to recognize revenue on approximately $2.1 million of these remaining performance obligations over the next twelve months.
The following table includes Bioserv sales and services revenue expected to be recognized in the future related to performance obligations that are undelivered or partially delivered at the end of the reporting period and do not include contracts with original durations of one year or less (in thousands):
 
 
Remainder of 2018
 
2019
 
2020 and thereafter
Contract manufacturing services
 
$1,640
 
$648
 
$353

Joint Development Agreement
On September 26, 2017, the Company entered into a joint development agreement with Celularity Inc. whereby the Company agreed to provide research services to Celularity Inc. through June 30, 2018 in exchange for an upfront payment of $5.0 million. The revenue related to the joint development agreement of $5.0 million will be recognized over the length of the service agreement as services are performed. The Company recorded sales and services revenues under the joint development agreement of $1.7 million and $3.3 million for the three and six months ended June 30, 2018, respectively, and $1.7 million for the year ended December 31, 2017.
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC Topic 718 “Compensation – Stock Compensation,” which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date.
Comprehensive Income (Loss)
Comprehensive income (loss) is primarily comprised of net income (loss) and adjustments for the change in unrealized gains and losses on the Company’s investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its condensed consolidated statements of comprehensive income (loss).
Net Loss per Share
Basic net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.
These outstanding securities consist of the following:

17


 
Quarters Ended June 30,
 
2018
 
2017
Outstanding options
7,616,950
 
4,375,276
Outstanding warrants
19,528,732
 
5,932,998
Segment Information
The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in one operating segment.
Recent Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU No. 2014-09 was originally effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard for annual reporting periods beginning after December 15, 2017, and interim periods thereafter. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, January 1, 2018 under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of January 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends the guidance in GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. ASU No. 2016-01 is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU No. 2016-02 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU No. 2016-20 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-02 will have on its consolidated financial position, results of operations and cash flows. The Company's leases are discussed in Note 14. The Company currently expects to record right-of-use assets and lease liabilities with regard to its leases in the consolidated balance sheets.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The ASU also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. The ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application will be permitted for all organizations for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2016-13 will have on its consolidated financial position, results of operations and cash flows.

18


In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. The ASU requires that (1) debt extinguishment costs be classified as cash outflows for financing activities and provides additional classification guidance for the statement of cash flows, (2) the classification of cash receipts and payments that have aspects of more than one class of cash flows to be determined by applying specific guidance under generally accepted accounting principles, and (3) each separately identifiable source or use within the cash receipts and payments be classified on the basis of their nature in financing, investing or operating activities. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, to clarify the definition of a business to add guidance for evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Specifically, this ASU provides a screen to assist entities in determining when a set should not be considered a business, which screen provides that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar assets, the set is not a business. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350). This standard eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit’s fair value. This guidance is effective for interim and annual goodwill impairment tests in fiscal years beginning after December 15, 2019 with early adoption permitted. This guidance must be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of ASU No. 2017-04 will have on the Company’s consolidated financial position, results of operations or cash flows.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, to provide clarity and reduce both the diversity in practice and cost of complexity when applying the guidance. Specifically, the ASU provides additional modification conditions in determining whether or not modification accounting should be applied. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and improves the usefulness of information reported to financial statement users. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2018-07 will have on the Company’s consolidated financial position, results of operations or cash flows.
4. Acquisitions
Acquisition of Virttu Biologics Limited
On April 27, 2017, the Company entered into a Share Purchase Agreement (the “Virttu Purchase Agreement”) with TNK Therapeutics, Inc., a majority-owned subsidiary of the Company (“TNK”), Virttu, the shareholders of Virttu (the “Virttu Shareholders”) and Dayspring Ventures Limited, as the representative of the Virttu Shareholders ("Dayspring"), pursuant to which, among other things, TNK acquired from the Virttu Shareholders 100% of the outstanding ordinary shares of Virttu (the “Virttu Acquisition”).
Virttu focuses on the development of oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. Its lead oncolytic virus candidate, Seprehvir, infects and replicates in cancer cells selectively, leaving normal cells unharmed.

19


Under the Virttu Purchase Agreement, the total amount of the consideration payable to the Virttu Shareholders in the Virttu Acquisition is equal to $25 million, less Virttu’s net debt (the “Virttu Base Consideration”). An additional $10 million contingent consideration is payable upon the achievement of certain regulatory milestones (as described below) (the “Regulatory Approval Consideration”).
At the closing of the Virttu Acquisition (the “Closing”), the Company issued to the Virttu Shareholders consideration valued at approximately $2.2 million, which consisted primarily of an aggregate of 797,081 shares (the “Virttu Closing Shares”) and approximately $557,000 in cash (the “Cash Consideration”). The issuance of the Virttu Closing Shares and the payment of the Cash Consideration satisfied TNK’s obligation to pay 20% of the Virttu Base Consideration at the Closing. Under the terms of the Virttu Purchase Agreement, the Company agreed to provide additional consideration to the Virttu Shareholders, as follows:
(1) Upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $50.0 million (a “Qualified Financing”), TNK would have issued to the Virttu Shareholders an aggregate number of shares of its capital stock (“TNK Capital Stock”) as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration by the lowest per share price paid by investors in the Qualified Financing (the “TNK Financing Consideration”); provided, however, that 20% of the TNK Financing Consideration was held in escrow until April 27, 2018 (the “Financing Due Date”), to be used to, among other things, satisfy the indemnification obligations of the Virttu Shareholders. In the event that a Qualified Financing did not occur, then on the Financing Due Date, the Company would issue to the Virttu Shareholders an aggregate number of shares of the Company’s common stock as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration, by $5.55 (as adjusted, as appropriate, to reflect any stock splits or similar events affecting the Company’s common stock after the Closing).
(2) Within 45 business days after Virttu becomes aware that certain governmental bodies in the United States, the European Union, the United Kingdom or Japan have approved for commercialization, on or before October 26, 2024, Seprehvir (or any enhancement, combination or derivative thereof) as a monotherapy or in combination with one or more other active components (each of the first two such approvals by a governmental body being a “Regulatory Approval”), TNK shall pay half of the Regulatory Approval Consideration to the Virttu Shareholders, in a combination of (a) up to $5.0 million in cash (the “Regulatory Approval Cash”) and/or (b) (i) such number of shares of the Company’s common stock as is equal to the quotient obtained by dividing $5.0 million less the Regulatory Approval Cash (the “Regulatory Approval Share Value”) by the 30 Day VWAP (as defined below) of one share of the Company’s common stock; (ii) if TNK has completed its first public offering of TNK Capital Stock, the number of shares of TNK Capital Stock as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP of one share of TNK Capital Stock; or (iii) such number of shares of common stock of a publicly traded company as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the volume weighted average price of the relevant security, as reported on the Nasdaq Capital Market (or other principal stock exchange or securities market on which the shares are then listed or quoted) for the thirty trading days immediately following the receipt of Regulatory Approval (the “30 Day VWAP”), with the composition of the Regulatory Approval Consideration to be at TNK’s option. In order for a second regulatory approval to qualify as a Regulatory Approval under the Purchase Agreement, the second approval must be granted by a different governmental body in a different jurisdiction than that which granted the first Regulatory Approval.
At April 27, 2017, the 80% of the Virttu Base Consideration was valued at $12.8 million. The fair value of the 80% of the Virttu Base Consideration is recorded as a current liability and will be adjusted quarterly for changes in fair value or as events and circumstances arise. At April 27, 2017, the contingent Regulatory Approval Consideration was valued at $1.0 million. The fair value of the contingent Regulatory Approval Consideration is recorded as a non-current liability within "Deferred rent and other" on the accompanying condensed consolidated balance sheet and will be adjusted quarterly for changes in fair value or as events and circumstances arise.
The consolidated financial statements include the preliminary results of operations from this transaction, which have been accounted for as a business combination, and require, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The final valuation of the acquired assets and liabilities resulted in the recognition of identifiable assets of approximately $16.0 million comprised mainly of in-process research and development of approximately $15.4 million, deferred tax liabilities of $0.8 million and goodwill of approximately $1.4 million. Various factors contributed to the establishment of goodwill, including an assembled workforce.
In connection with the Virttu transaction, the Company recorded acquisition costs of approximately $0.9 million in general and administrative expenses for the twelve months ended December 31, 2017, for legal and related costs. No acquisition costs in connection with the Virttu transaction were recorded for the three and six months ended June 30, 2018. Acquisition costs are expensed as incurred.

20


TNK did not complete a Qualified Financing prior to the Financing Due Date and on April 27, 2018, the Company, TNK and Dayspring entered into the Amendment, pursuant to which, among other things, the Company agreed that the acquisition consideration, otherwise payable on April 27, 2018 to the Virttu Shareholders, shall be as follows: (1) an issuance of 1,795,011 shares of its common stock to the Virttu Shareholders and (2) $9.9 million payable in cash .
The Company issued an aggregate of 1,795,011 shares of its common stock to the Virttu Shareholders on April 27, 2018 for a value of $11.3 million. The approximately $9.9 million payable in cash has not been paid as of the date of this filing.
Acquisition of Scilex Pharmaceuticals Inc.
On November 8, 2016, the Company entered into a Stock Purchase Agreement (the “Scilex Purchase Agreement”) with Scilex and a majority of the stockholders of Scilex (the “Scilex Stockholders”) pursuant to which, on November 8, 2016, the Company acquired from the Scilex Stockholders, and the Scilex Stockholders sold to the Company, approximately 72% of the outstanding capital stock of Scilex (the “Scilex Acquisition”). The remainder of the outstanding capital stock of Scilex represents a noncontrolling interest of which approximately 23% continues to be held by ITOCHU CHEMICAL FRONTIER CORPORATION following the Scilex Acquisition.
Scilex focuses on the development and commercialization of specialty pharmaceutical products for the treatment of pain; its lead product, ZTlidoTM (lidocaine topical system 1.8%, is a branded lidocaine topical system formulation being developed for the treatment of chronic pain. ZTlido™ (lidocaine topical system 1.8%) will be manufactured by a contract manufacturer.
Under the terms of the Scilex Purchase Agreement, upon receipt of notice from the U.S. Food and Drug Administration (the "FDA") that the FDA has approved Scilex's new drug application for ZTlido™ (lidocaine topical system 1.8%) for the treatment of postherpetic neuralgia (the "NDA") for commercialization, the Company was obligated to deliver to the Scilex Stockholders cash and shares of its common stock in such proportion to be determined in the Company’s sole discretion as a milestone payment. On February 28, 2018, the Company received notice from the FDA that the FDA had approved the NDA. As a result, the Company issued to the Scilex Stockholders consideration valued at approximately $38.2 million, which included an aggregate of 1,381,346 shares of common stock of approximately $13.7 million, cash payment of approximately $24.5 million, which included a bridge loan of approximately $20.0 million with B. Riley FBR to facilitate the timing of the cash payment and resulted in a change in fair value of $6.0 million since December 31, 2017, for the contingent consideration upon settlement.
Acquired In-process Research and Development of BDL
In August 2015, the Company and TNK entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with BDL Products, Inc. (“BDL”) and the stockholders of BDL (“Stockholders”) pursuant to which the Stockholders sold all of their shares of capital stock in BDL to TNK for: (1) a cash payment of $100.00, and (2) $6.0 million in shares of TNK Class A Stock, subject to adjustment in certain circumstances, to be issued to the Stockholders upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $50.0 million (a “Qualified Financing”).  In accordance with subsequent amendments to the Stock Purchase Agreement, in the event a Qualified Financing does not occur by October 15, 2017 (which is subject to further extension as implied and based on previously amended dates) or TNK does not complete an initial public offering of shares of its capital stock by September 15, 2017, in lieu of receiving shares of TNK pursuant to the acquisition, the Stockholders shall receive an aggregate of 309,916 shares of the Company’s common stock, subject to adjustment in certain circumstances. TNK did not complete a Qualified Financing by the financing deadline and the Company issued 309,916 shares of its common stock to the Stockholders on March 19, 2018.
5. Fair Value Measurements 
Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.
Level 3—Unobservable inputs based on the Company's own assumptions.

21


The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis.  (in thousands):
 
Fair Value Measurements at June 30, 2018
 
Balance
 
Quoted Prices in Active Markets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
46,784

 
$
46,784

 
$
—

 
$
—

Marketable securities
$
323

 
$
266

 
$
—

 
$
57

Total assets
$
47,107

 
$
47,050

 
$
—

 
$
57

Liabilities:
 

 
 

 
 

 
 

Acquisition consideration payable
$
16,055

 
$
—

 
$
—

 
$
16,055

Total liabilities
$
16,055

 
$
—

 
$
—

 
$
16,055

 
 
 
 
 
 
 
 
 
Fair Value Measurements at December 31, 2017
 
Balance
 
Quoted Prices in Active Markets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
20,429

 
$
20,429

 
$
—

 
$
—

Marketable securities
$
441

 
$
356

 
$
—

 
$
85

Total assets
$
20,870

 
$
20,785

 
$
—

 
$
85

Liabilities:
 

 
 

 
 

 
 

Acquisition consideration payable
$
54,272

 
$
—

 
$
—

 
$
54,272

Total liabilities
$
54,272

 
$
—

 
$
—

 
$
54,272

The Company's financial assets and liabilities carried at fair value are comprised of cash and cash equivalents and acquisition consideration payable. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These investments are valued using inputs observable in active markets for identical securities. Marketable securities are valued using inputs observable in active markets for identical securities. The Company recorded contingent consideration as part of its investment in Shanghai Three Alliance Biotech Co. LTD (“Shanghai Three”), agreement with Roger Williams Medical Center (“RWMC”), and acquisitions of Concortis, Inc., (“Concortis”), and Virttu. The fair value of the contingent consideration is measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Contingent consideration is measured using the income approach and discounting to present value the contingent payments expected to be made based on assessment of the probability that the company would be required to make such future payment.
The following table includes a summary of the Company’s contingent consideration liabilities and acquisition consideration payables associated with acquisitions. The contingent consideration is measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018:
(in thousands)
 
Fair Value
Beginning Balance at December 31, 2017
 
54,272

Re-measurement of Fair Value
 
13,663

Payment of current year contingent consideration
 
(51,880
)
Ending Balance at June 30, 2018
 
$
16,055

The payment of current year contingent consideration for the six months ended June 30, 2018 includes the settlement of Scilex and BDL liabilities for $38.2 million and $2.3 million, respectively, and the $11.3 million partial settlement of the Virttu financing milestone in common shares of the Company ($9.9 million of the Virttu contingent liability remains to be paid in cash).
The following table includes a summary of the Company’s contingent and financing liabilities, related inputs used to determine fair value, and the valuation methodologies used for the fair value measurements using significant unobservable inputs (Level 3) at June 30, 2018: 

22


(in thousands)
 
Fair Value Measurements at June 30, 2018
 
Valuation Methodology
 
Significant Unobservable Input
 
Weighted Average
(range, if applicable)
Virttu Contingent Consideration (Non-current)
 
$
1,126

 
Multiple outcome
discounted cash flow
 
Discount Rate
Probability of Regulatory Milestone
 
12.21%
16%
Concortis Contingent Consideration
 
$
511

 
Multiple outcome
discounted cash flow
 
Discount Rate
Percent probabilities assigned to scenarios
 
19.20%
20%
Shanghai Three Contingent Consideration
 
$
1,782

 
Multiple outcome
discounted cash flow
 
Discount Rate
Percent probabilities assigned to scenarios
 
12.21%
50%
RWMC Contingent Consideration
 
$
2,673

 
Multiple outcome
discounted cash flow
 
Discount Rate,
Percent probabilities assigned to scenarios
 
12.21%
50%
 
The principal significant unobservable inputs used in the valuations of the contingent considerations are the discount rates and probabilities assigned to scenario outcomes. An increase in the discount rate or decrease in the probability of regulatory milestone achievement will cause a decrease in the fair value of the contingent consideration. Conversely, a decrease in the discount rate will cause an increase in the fair value of the contingent consideration. An increase in the probabilities assigned to certain scenarios will cause the fair value of contingent consideration to increase. Conversely, a decrease in the probabilities assigned to certain scenarios will cause the fair value of contingent considerations to decrease.
6. Marketable Securities
Marketable securities consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
Cost
 
Gross Unrealized Gains (Losses)
 
Gross Realized Gains (Losses)
 
Fair Value
Trading securities:
 

 
 

 
 

 
 

MedoveX common shares and warrants
$
750

 
$
(427
)
 
$
—

 
$
323

 
December 31, 2017
 
Cost
 
Gross Unrealized Gains (Losses)
 
Gross Realized Gains (Losses)
 
Fair Value
Trading securities:
 

 
 

 
 

 
 

MedoveX common shares and warrants
$
750

 
$
(309
)
 
$
—

 
$
441

Trading Securities
On August 5, 2016, the Company entered into a Unit Purchase Agreement (the “Unit Purchase Agreement”) with MedoveX Corporation (“MedoveX”). Pursuant to the terms of the Unit Purchase Agreement, the Company purchased three Units for $750,000.  Each Unit had a purchase price of $250,000 and consisted of (i) 208,333 shares of MedoveX common stock (the “MedoveX Common Stock”), and (ii) a warrant to purchase 104,167 shares of MedoveX Common Stock (the “MedoveX Warrant”).  The MedoveX Warrant has an initial exercise price of $1.52 per share, subject to adjustment, and is initially exercisable six months following the date of issuance for a period of five years from the date of issuance.  In addition, the Company entered into a Registration Rights Agreement with MedoveX pursuant to which MedoveX was required to file a registration statement registering for resale all shares of MedoveX Common Stock and shares of MedoveX Common Stock issuable pursuant to the MedoveX Warrant issued as part of the Units. 
For the three months ended June 30, 2018 and 2017, the Company recorded a loss of $0.1 million and $0.6 million, respectively, on trading securities. For the the six months ended June 30, 2018 and 2017, the Company recorded a loss of $0.1 million and $0.5 million on trading securities, respectively. The Company’s investment in MedoveX will be revalued on each balance sheet date.  The fair value of the Company’s holding in MedoveX Common Stock at June 30, 2018 is a Level 1 measurement.  The fair value of the Company’s holdings in the MedoveX Warrant was estimated using the Black-Scholes option-pricing method. The risk-free rate was derived from the U.S. Treasury yield curve, matching the MedoveX Warrant’s

23


term, in effect at the measurement date. The volatility factor was determined based on MedoveX’s historical stock prices. The warrant valuation is a Level 3 measurement.
The following table includes a summary of the warrant measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018 (in thousands):
 
Total
Beginning balance at December 31, 2017
$
84

Change in fair value of warrant
(27
)
Ending balance at June 30, 2018
$
57

7. Property and Equipment
Property and equipment consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
December 31, 2017
Furniture and fixtures
1,077

 
1,035

Office equipment
479

 
493

Machinery and lab equipment
22,573

 
19,868

Leasehold improvements
7,460

 
7,327

Construction in progress
292

 
—

 
31,881

 
28,723

Less accumulated depreciation
(11,988
)
 
(9,378
)
 
$
19,893

 
$
19,345

Depreciation expense for the three months ended June 30, 2018 and 2017 was $1.3 million and $1.1 million, respectively. Depreciation expense for the six months ended June 30, 2018 and 2017 was $2.6 million and $1.9 million, respectively.
8. Cost Method Investments
As of June 30, 2018 and December 31, 2017, the aggregate carrying amount of the Company’s cost-method investments in non-publicly traded companies was $237.0 million and included an ownership interest in NantCell, Inc. (“NantCell”), NantBioScience, Inc. (“NantBioScience”), Globavir Biosciences, Inc., Brink Biologics, Inc., Coneksis, Inc., and Celularity Inc.
The Company’s cost-method investments are assessed for impairment quarterly. The Company has determined that it is not practicable to estimate the fair value of its cost-method investments on a regular basis and does not reassess the fair value of cost-method investments if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investments.  No impairment losses were recorded during the six months ended June 30, 2018.
9. Equity Method Investments 
NANTibody
In 2013, the Company acquired IgDraSol Inc. (“IgDraSol”), a private company focused on the development of oncologic agents for the treatment of cancer, from a third party unrelated to the NantWorks, LLC (“NantWorks”) affiliated entities for 3.0 million shares of the Company's common stock and $380,000 of cash for a total purchase price of $29.1 million. This transaction included the acquisition of IgDraSol’s lead compound, CynviloqTM, a micellar diblock copolymeric paclitaxel formulation drug product.
In May 2015, the Company entered into an agreement with NantPharma, LLC (“NantPharma”), a NantWorks company, pursuant to which the Company sold to NantPharma all of its equity interests in IgDraSol, which continued to hold the rights to CynviloqTM. Pursuant to the agreement, NantPharma paid the Company an upfront fee of $90.1 million, of which $60.0 million was required to be used by the Company to fund two joint ventures, as described below.
In April 2015, the Company and NantCell, a subsidiary of NantWorks, a private company owned by Dr. Patrick Soon-Shiong, established a new entity called Immunotherapy NANTibody, LLC (“NANTibody”) as a stand-alone biotechnology

24


company with $100.0 million initial joint funding. NantCell owns 60% of the equity interest of NANTibody and agreed to contribute $60.0 million to NANTibody. The Company owns 40% of NANTibody and in July 2015, the Company had NantPharma, contribute its portion of the initial joint funding of $40.0 million to NANTibody from the proceeds of the sale of IgDraSol. Additionally, the Company and NantCell were allowed to appoint two and three representatives, respectively, to NANTibody’s five-member Board of Directors. NANTibody will focus on accelerating the development of multiple immuno-oncology mAbs for the treatment of cancer, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA4mAbs, and other immune-check point antibodies as well as ADCs and bispecific antibodies.
NANTibody had been formed to advance pre-clinical and clinical immunology assets contributed by the Company and NantCell. The Company continues to hold 40% of the outstanding equity of NANTibody and NantCell holds the remaining 60%. Until July 2, 2017, NANTibody held approximately $100.0 million of cash and cash equivalents, and the Company recorded its investment in NANTibody at approximately $40.0 million. As an equity method investment, the Company's ratable portion of 40% of money expended for the development of intellectual property assets held by NANTibody would be reflected within income (loss) on equity method investments in its statement of operations. As a result of limited spending at NANTibody, the cash on hand at NANTibody remained at approximately at $100.0 million since the inception of the NANTibody joint venture until July 2, 2017. Further, the Company's equity method investment in NANTibody remained at approximately $40.0 million until July 2, 2017.
The financial statements of NANTibody are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag.
In February 2018, NANTibody notified the Company that on July 2, 2017, NANTibody acquired all of the outstanding equity of IgDraSol in exchange for $90.1 million in cash. NANTibody purchased IgDraSol from NantPharma, which is controlled by NantWorks, an entity with a controlling interest in NantCell and NantPharma.
Although the Company has had a designee serving on the Board of Directors of NANTibody since the formation of NANTibody in April 2015, and although the Company has held 40% of the outstanding equity of NANTibody since NANTibody’s formation, neither the Company nor its director designee was given any advance notice of NANTibody’s purchase of IgDraSol or of any board meeting or action to approve such purchase. As such, the Company's designee on NANTibody’s Board of Directors was not given an opportunity to consider or vote on the transaction as a director and the Company was not given an opportunity to consider or vote on the transaction in its position as a significant (40%) equity holder of NANTibody.
As a result of the July 2, 2017 purchase of IgDraSol, NANTibody’s cash and cash equivalents were reduced from $99.6 million as of June 30, 2017 to $9.5 million as of September 30, 2017, and NANTibody’s contributed capital was reduced from $100.0 million as of June 30, 2017 to $10.0 million as of September 30, 2017, to effect the transfer of IgDraSol from NantPharma to NANTibody. No additional information was provided to the Company to explain why NANTibody’s total assets as of September 30, 2017 were reduced by approximately $90.1 million. The Company requested, but did not receive, additional information from NANTibody for purposes of supporting the value of IgDraSol, including any information regarding clinical advancements in the entity since the sale of IgDraSol by the Company in May 2015.
Prior to the communication of the transfer of IgDraSol from NantPharma to NANTibody, the Company relied on the cash and cash equivalents of NANTibody for purposes of determining the value of its investment in NANTibody, which capital was expended by NANTibody to acquire IgDraSol on July 2, 2017. As a result of the transfer of IgDraSol, the Company reassessed the recoverability of its equity method investment in NANTibody as of July 2, 2017. In doing so, the Company considered the expected outcomes for the intellectual property assets held by NANTibody as of July 2, 2017. As a result of the lack of evidence of any development activity associated with any of the assets held in NANTibody, given the passage of time since the formation of the joint venture, many competitive products from other drug developers worldwide have advanced and/or commercialized for the targeted disease indications of the assets held in NANTibody, and given the Company's minority interest in NANTibody (the investee), the Company concluded that it does not have the ability to recover the carrying amount of the investment and an other-than-temporary decline in the value of the investment had occurred. Accordingly, an impairment was recorded to the Company's equity method investment in NANTibody for the three and nine months ended September 30, 2017. The fair value of the Company’s investment in NANTibody was measured at fair value on July 2, 2017 using significant unobservable inputs (Level 3) due to the determination of fair value requiring significant judgment, including the potential outcomes of the intellectual property assets held by NANTibody. For these reasons, fair value was determined by applying the Company's 40% equity interest in NANTibody to the remaining cash and cash equivalents, which resulted in an impairment of $36.0 million. The impairment resulted in a revised carrying value of the Company's investment in NANTibody of $3.7 million which approximates its ratable 40% ownership of the cash maintained by NANTibody expected to be used for future research and development. As of June 30, 2018, the carrying value of the Company’s investment in NANTibody was approximately $3.5 million.

25


NANTibody recorded net loss of $73 thousand and net profit $276 thousand for the three months ended March 31, 2018 and 2017, respectively. The Company recorded its portion of loss from NANTibody in loss on equity method investments on its condensed consolidated statement of operations for the six months ended June 30, 2018 and 2017.  As of March 31, 2018, NANTibody had $9.8 million in current assets and $1.8 million in current liabilities and no noncurrent assets or noncurrent liabilities.
NantStem
In July 2015, the Company and NantBioScience, a wholly-owned subsidiary of NantWorks, established a new entity called NantCancerStemCell, LLC (“NantStem”) as a stand-alone biotechnology company with $100.0 million initial joint funding.  As initially organized, NantBioScience was obligated to make a $60.0 million cash contribution to NantStem for a 60% equity interest in NantStem, and the Company was obligated to make a $40.0 million cash contribution to NantStem for a 40% equity interest in NantStem.  Fifty percent of these contributions were funded in July 2015 and the remaining amounts were to be made by no later than September 30, 2015. The Company had NantPharma contribute its portion of the initial joint funding of $20.0 million to NantStem from the proceeds of the sale of IgDraSol.  Pursuant to a Side Letter dated October 13, 2015, the NantStem joint venture agreement was amended to relieve the Company of the obligation to contribute the second $20.0 million payment, and its ownership interest in NantStem was reduced to 20%.  NantBioScience’s funding obligations were unchanged.  The Side Letter was negotiated at the same time the Company issued a call option on shares of NantKwest that it owned to Cambridge Equities, L.P. (“Cambridge”), a related party to NantBioScience.  
In the fourth quarter of 2015, the Company determined it had an other-than-temporary decline in the value of NantStem and recognized a loss of $4.0 million in loss on equity method investments on its condensed consolidated statement of operations for the year ended December 31, 2015. There was no loss related to other-than-temporary impairment recognized for the equity investment for the year ended December†31, 2017. A loss related to other-than-temporary impairment of $0.5 million was recognized for the equity investment in NantStem for the three months ended June 30, 2018.
The Company is accounting for its interest in NantStem as an equity method investment, due to the significant influence the Company has over the operations of NantStem through its board representation and 20% voting interest.  The Company’s investment in NantStem is reported in equity method investments on its condensed consolidated balance sheets and its share of NantStem’s loss is recorded in loss on equity method investments on its condensed consolidated statement of operations.  As of June 30, 2018, the carrying value of the Company’s investment in NantStem was approximately $18.2 million. The difference between the Company’s investment in NantStem and the Company’s 20% interest in the net assets of Nantstem was approximately $1.7 million at June 30, 2018.
The financial statements of NantStem are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag.
NantStem recorded net loss of $331 thousand and net profit of $369 thousand for the three months ended March 31, 2018 and 2017, respectively.  The Company recorded its portion of loss from NantStem (in addition to the immaterial impairment) in loss on equity method investments on its condensed consolidated statement of operations for the three and six months ended June 30, 2018 and 2017.  As of March 31, 2018, NantStem had $82.3 million in current assets and $27 thousand in current liabilities and no noncurrent assets or noncurrent liabilities.
Yuhan Agreement
In March 2016, the Company and Yuhan , a South Korea company, entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.  Under the terms of the joint venture agreement, Yuhan contributed an initial investment of $10.0 million to ImmuneOncia, and the Company granted ImmuneOncia an exclusive license to one of its immune checkpoint antibodies for specified countries while retaining the rights for the U.S., European and Japanese markets, as well as global rights for ImmuneOncia to two additional antibodies that will be selected by ImmuneOncia from a group of pre-specified antibodies from the Company’s immuno-oncology antibody portfolio. During October 2016, funding and operations of ImmuneOncia commenced. Yuhan owns 51% of ImmuneOncia, while the Company owns 49%.
The Company is accounting for its interest in ImmuneOncia as an equity method investment, due to the significant influence the Company has over the operations of ImmuneOncia through its board representation and 49% voting interest while not sharing joint control with Yuhan.  The Company’s investment in ImmuneOncia is reported in equity method investments on its condensed consolidated balance sheets and its share of ImmuneOncia’s loss is recorded in loss on equity method investments on its condensed consolidated statement of operations.  As of June 30, 2018, the carrying value of the Company’s

26


investment in ImmuneOncia was approximately $4.5 million. The difference between the Company’s investment in ImmuneOncia and the Company’s 49% interest in the net assets of ImmuneOncia was approximately $0.8 million at June 30, 2018.
ImmuneOncia recorded a net loss of $3.1 million and $1.0 million for the three months ended June 30, 2018 and 2017, respectively.  ImmuneOncia recorded a net loss of $4.7 million and $1.5 million for the six months ended June 30, 2018 and 2017, respectively. The Company recorded its portion (49% equity interest) of loss from ImmuneOncia in loss on equity method investments on its condensed consolidated statement of operations for the three and six months ended June 30, 2018 and 2017.  As of June 30, 2018, ImmuneOncia had $3.1 million in current assets, $344 thousand in current liabilities, $7.8 million in noncurrent assets, and no noncurrent liabilities.
In April 2016, Yuhan purchased $10.0 million of shares of common stock, and warrants as part of the Company’s private placement offering.
Shanghai Three
On March 7, 2016, TNK agreed to issue to SiniWest Holdings, Inc. (“SiniWest Holdings”) $4.0 million in shares of TNK Class A Stock, subject to certain circumstances, to be issued upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $10.0 million and a $1.0 million upfront cash payment in exchange for SiniWest Holdings transferring certain assets to TNK, including SiniWest Holdings’ 25% interest in Shanghai Three, a China based company. The Company is accounting for its interest in Shanghai Three as an equity method investment, due to the significant influence the Company has over the operations of Shanghai Three through its 25% voting interest.  The Company’s investment in Shanghai Three is reported in equity method investments on the condensed consolidated balance sheets and its share of Shanghai Three’s income or loss is recorded in income (loss) on equity method investments on the condensed consolidated statement of operations.  As of June 30, 2018, the carrying value of the Company’s investment in Shanghai Three was approximately $3.8 million.
The financial statements of Shanghai Three are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag. 
Shanghai Three incurred no operating expenses or net loss for the three and six months ended March 31, 2018 and 2017.  As of March 31, 2018, Shanghai Three had $0.4 million in current assets, $2.9 million in current liabilities, $5.5 million in noncurrent assets, and $2.2 million in noncurrent liabilities. 
Fair Value of Equity Method Investment
The Company periodically evaluates the carrying value of its equity method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. The Company determines the fair value of its equity method investments to evaluate whether impairment losses shall be recorded using Level 3 inputs. These investments include the Company's holdings in privately held biotechnology companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values and unobservable inputs, including future cash flows.


27


10. Goodwill and Intangible Assets
 At June 30, 2018 and December 31, 2017, the Company had recorded goodwill of $38.3 million.  The Company performed a qualitative test for goodwill impairment as of December 31, 2017. Based upon the results of the qualitative testing the Company concluded that it is more-likely-than-not that the fair values of the Company’s goodwill was in excess of its carrying value and therefore performing the first step of the two-step impairment test was unnecessary. No goodwill impairment was recognized for the three and six months ended June 30, 2018 and 2017. A summary of the Company's goodwill as of June 30, 2018 is as follows (in thousands):
 
Total
Balance at December 31, 2017
$
38,298

    Goodwill Acquired from Acquisitions
—

Balance at June 30, 2018
$
38,298

The Company’s intangible assets, excluding goodwill, include acquired license and patent rights, core technologies, customer relationships and acquired in-process research and development. Amortization for the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives.  A summary of the Company’s identifiable intangible assets as of June 30, 2018 and December 31, 2017 is as follows (in thousands):
 
June 30, 2018
 
Gross Carrying Amount
 
Accumulated Amortization
 
Intangibles, net
Customer relationships
$
1,585

 
$
1,236

 
$
349

Acquired technology
3,410

 
797

 
2,613

Acquired in-process research and development
37,660

 
—

 
37,660

Patent rights
32,720

 
3,652

 
29,068

Total intangible assets
$
75,375

 
$
5,685

 
$
69,690

 
December 31, 2017
 
Gross Carrying Amount
 
Accumulated Amortization
 
Intangibles, net
Customer relationships
$
1,585

 
$
1,091

 
$
494

Acquired technology
3,410

 
709

 
2,701

Acquired in-process research and development
37,660

 
—

 
37,660

Patent rights
32,720

 
2,562

 
30,158

Total intangible assets
$
75,375

 
$
4,362

 
$
71,013

As of June 30, 2018, the remaining weighted average life for identifiable intangible assets is 15 years.
Patent rights are stated at cost and amortized on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years or nineteen years from the date of transfer of the rights to the Company. Amortization expense for the three months ended June 30, 2018 and 2017 was $545 thousand and $552 thousand, respectively, which has been included in intangible amortization on the condensed consolidated statement of operations. Amortization expense for the six months ended June 30, 2018 and 2017 was $1,090 thousand and $1,059 thousand, respectively, which has been included in intangible amortization on the condensed consolidated statement of operations.
Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately 19 years from the date of acquisition of the technology in December 2013. Amortization expense for each of the three months ended June 30, 2018 and 2017 was $44 thousand, which has been included in intangibles amortization on the condensed consolidated statement of operations. Amortization expense for each of the six months ended June 30, 2018 and 2017 was $88 thousand, which has been included in intangible amortization on the condensed consolidated statement of operations.
Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition. Amortization expense for the three months ended June 30, 2018 and 2017, was $72 thousand and $73 thousand, respectively, which has been included in intangibles

28


amortization. Amortization expense for each of the six months ended June 30, 2018 and 2017 was $145 thousand, which has been included in intangible amortization on the condensed consolidated statement of operations.
Acquired in-process research and development is stated at cost and may be immediately expensed if there is no alternative future use. The Company intends to begin amortization of acquired in-process research and development costs associated with the Scilex and Virttu business combinations upon commercialization of the respective products. The acquired in-process research and development is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.
Estimated future amortization expense related to intangible assets at June 30, 2018 is as follows (in thousands):
Years Ending December 31,
 
Amount
2018
 
$
1,680

2019
 
3,845

2020
 
3,845

2021
 
5,040

2022
 
5,040

Thereafter
 
50,240

Total
 
$
69,690

11. Significant Agreements and Contracts
License Agreement with Mabtech Limited
In August 2015, the Company entered into an exclusive licensing agreement to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from Mabtech Limited.  Under the terms of the agreement, the Company will develop and market four mAbs for the North American, European and Japanese markets. The Company made an initial license payment of $10.0 million and in February 2016, paid an additional $10.0 million license payment, both of which were recognized as acquired in-process research and development expense in the condensed consolidated statements of operations as the Company determined there was no alternative future use for the license.  
In June 2016, the Company agreed to accelerate and pay a $30.0 million milestone license payment which has been recognized as acquired in-process research and development expense in the condensed consolidated statements of operations, in exchange for the purchase by Mabtech Limited in June 2016, of $10.0 million of shares of common stock and warrants. 
In December 2017, the Company agreed to accelerate and, as a result, paid a $25.0 million milestone license payment, which has been recognized as acquired in-process research and development expense in the consolidated statements of operations for the year ended December 31, 2017. The amended agreement includes additional milestone payments totaling $125.0 million payable following the completion of the technology transfer from Mabtech Limited and for payables to extend the license agreement. The remaining anniversary payments are due on December 31, 2018 and 2019, respectively. The Company is not obligated to extend the license agreement. Accordingly, the additional future milestone payments have not yet been accrued as of June 30, 2018.
Immunotherapy Research Collaboration Agreement with Roger Williams Medical Center
In April 2016, the Company entered into an immunotherapy research collaboration agreement with RWMC to provide certain clinical trial, research and manufacturing services. Under the terms of the agreement, RWMC will perform pre-clinical and clinical research related to the development and delivery of CAR-T immunotherapies. In exchange, the Company granted RWMC $6.0 million in shares of TNK Class A Stock, subject to adjustment in certain circumstances, to be issued upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $20.0 million.  The Company determined the fair value of this obligation was $3.4 million as of the April of 2016 agreement effective date, and the amount was recognized as prepaid expense and other and acquisition consideration payable in the condensed consolidated balance sheet.  The Company will recognize the upfront payment over the expected performance period of five years. During each of the quarters ended June 30, 2018 and 2017, the Company recognized approximately $170 thousand in pre-clinical research and development expense pursuant to the agreement. During each of the six months ended June 30, 2018 and 2017, the Company recognized approximately $340 thousand in pre-clinical research and development expense pursuant to the agreement.

29


License Agreement with NantCell
In April 2015, the Company and NantCell entered into a license agreement. Under the terms of the agreement the Company granted an exclusive license to NantCell covering patent rights, know-how, and materials related to certain antibodies, ADCs and two CAR-TNK products.  NantCell agreed to pay a royalty not to exceed five percent (5%) to the Company on any net sales of products (as defined) from the assets licensed by the Company to NantCell.  In addition to the future royalties payable under this agreement, NantCell paid an upfront payment of $10.0 million to the Company and issued 10 million shares of NantCell common stock to the Company valued at $100.0 million based on a recent equity sale of NantCell common stock to a third party.  As of June 30, 2018, the Company had not yet provided all of the items noted in the agreement, including research services for and on behalf of NantCell, and therefore has recorded the entire upfront payment and value of the equity interest received as deferred revenue. Specifically, only a portion of the materials associated with the licensed assets have been delivered while the majority of the licensed assets remain undelivered and the related research activities are still to be performed. The Company will recognize the upfront payment and the value of the equity interest received over the period beginning with the commencement of the last item delivered. The Company’s ownership interest in NantCell does not provide the Company with control or the ability to exercise significant influence; therefore the $100.0 million investment is carried at cost in the condensed consolidated balance sheets and evaluated for other-than-temporary impairment on a quarterly basis.
License Agreement with The Scripps Research Institute
In January 2010, the Company entered into a license agreement (the “TSRI License”) with The Scripps Research Institute (“TSRI”). Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus ("S. aureus" or “Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved and (iii) agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days’ notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For each of the quarters ended June 30, 2018 and 2017, the Company recorded $14 thousand in patent prosecution and maintenance costs associated with the TSRI License. For the six months ended June 30, 2018 and 2017, the Company recorded $24 thousand and $41 thousand in patent prosecution and maintenance costs associated with the TSRI License, respectively. All such costs have been included in general and administrative expenses.
NIH Grants
In June 2014, the NIAID awarded the Company a Phase II Small Business Technology Transfer (“STTR”) grant (the “Staph Grant III Award”) to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staph infections, including methicillin-resistant S. aureus (“MRSA”). The project period for the Staph Grant III Award covered a two-year period which commenced in June 2014, which was subsequently extended by one year, with total funds available of approximately $1.0 million per year for up to two years. The Staph Grant III Award was not extended beyond June 30, 2017 and the remaining amounts for the award have been recorded as of June 30, 2018. During each of the quarters ended June 30, 2018 and 2017, the Company recorded $0 and $94 thousand of revenue associated with the Staph Grant III Award, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded $0 and $195 thousand of revenue associated with the Staph Grant III Award, respectively.

30


12. Loan and Security Agreement and Convertible Notes
Loan and Security Agreement with Hercules Capital, Inc.
On November 23, 2016, the Company and certain of its domestic subsidiaries (together with the Company, the “Borrowers”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), as a lender and agent for several banks and other financial institutions or entities from time to time party to the Loan Agreement (collectively, the “Lenders”) for a term loan of up to $75.0 million, subject to funding in multiple tranches (the “Term Loan”). The Term Loan will mature on December 1, 2020. The proceeds of the Term Loan will be used for general corporate purposes and coincided with the repayment of the outstanding debt financing arrangement with Oxford Finance LLC and Silicon Valley Bank.
The first tranche of $50.0 million was funded upon execution of the Loan Agreement on November 23, 2016. Under the terms of the Loan Agreement, the Borrowers may, but are not obligated to, request additional funds of up to $25.0 million which are available until June 30, 2018, subject to approval by Hercules’ Investment Committee. Pursuant to the terms of the third amendment to the Loan Agreement entered into on March 15, 2017, the Company paid Hercules $1.5 million for a portion of the backend fee. Pursuant to the terms of the fourth amendment to the Loan Agreement entered into on March 23, 2017 (the “Fourth Amendment”), the Company repaid Hercules, without repayment penalty, $20.0 million of the outstanding principal and unpaid interest accrued thereon on March 23, 2017.  The Fourth Amendment also provided for the following: (1) Hercules reduced the minimum amount of unrestricted cash that the Company must maintain under the Loan Agreement, and (2) the parties agreed to change the date by which the Company must achieve a fundraising milestone.
The Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties, including financial reporting obligations and significant limitations on dividends, indebtedness, liens (including a negative pledge on intellectual property and other assets), collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. Additionally, the Loan Agreement contains covenants requiring the Borrowers (i) to achieve certain fundraising requirements by certain dates and (ii) to maintain $20.0 million of unrestricted cash prior to achieving its corporate and fundraising milestones. The Company's public offering for net proceeds of $43.1 million satisfied the fundraising requirements and fundraising milestone.
Pursuant to the terms of the seventh amendment to the Loan Agreement entered into on November 6, 2017 (the “Seventh Amendment”), (i) the Company repaid Hercules, without repayment penalty, $10.0 million of the outstanding principal and unpaid interest accrued thereon on November 6, 2017, and (ii) Hercules agreed to reduce the minimum amount of unrestricted cash that the Company must maintain under the Loan Agreement from $20.0 million to $8.0 million.
On December 21, 2017, the Company paid off all obligations owing under, and terminated, the Loan Agreement. The secured interests were terminated in connection with the Company’s discharge of indebtedness thereunder.
In connection with the Loan Agreement, the Company issued Hercules a warrant, dated November 23, 2016 (the “Hercules Warrant”), to purchase up to 460,123 shares of common stock, at an initial exercise price of $4.89, subject to adjustment as provided in the Hercules Warrant. The Hercules Warrant is initially exercisable for 306,748 shares of common stock, and may automatically become exercisable for additional shares of common stock on such dates (if any) based upon the funding amounts of any additional tranches of the Term Loan that may be extended to the Borrowers. The Hercules Warrant will terminate, if not earlier exercised, on the earlier of November 23, 2023 and the closing of certain merger or other transactions in which the consideration is cash, stock of a publicly-traded acquirer or a combination thereof.
In connection with the extinguishment of the Loan Agreement on December 21, 2017, a loss of $4.3 million on the extinguishment of debt was recorded representing the difference between the reacquisition price of debt and the net carrying amount of the loan as of December 21, 2017.
2018 Chinese Yuan (“RMB”) Loan
In March 2018, the Company entered into a term loan in the aggregate principal amount of $1.6 million ("RMB 10.0 million") with the Bank of China and the Agricultural Bank of China, which is guaranteed by Levena Suzhou Biopharma, Co. Ltd. This one year bank facility was used for working capital purposes. The proceeds from the loan agreement are reflected as financing activities in the condensed consolidated statements of cash flows for the six months ended June 30, 2018. The outstanding balance is repayable from February 2018 to March 2019. The interest rate on this loan is 5%.
2017 Securities Purchase Agreement in Private Placement
On December 11, 2017, the Company entered into the December 2017 Securities Purchase Agreement with the December 2017 Purchasers. Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the

31


Company issued and sold to the December 2017 Purchasers, in a private placement transaction, the December 2017 Notes and the December 2017 Warrants.
At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser’s December 2017 Note that was equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of $2.26875, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.
Each December 2017 Warrant has an exercise price of $2.61 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.
On May 17, 2018, the December 2017 Purchasers converted in full the outstanding principal and accrued interest under the December 2017 Notes into 22,038,565 shares of the Company’s common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of $1.0 million in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of $44.3 million was recognized immediately at that date as interest expense.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $44.8 million based on an allocation of proceeds to the Warrants of approximately $12.7 million and a beneficial conversion feature of approximately $32.1 million, before issuance costs.
2018 Securities Purchase Agreement in Private Placement
On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, (1) the Notes in an aggregate principal amount of $120,500,000, and (2) the Warrants to purchase 8,591,794 shares of the common stock of the Company.
On June 13, 2018, the Company entered into an amendment (the “Amendment”) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of Common Stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of Common Stock.
At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser’s Note that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such Purchaser’s Note into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018.
Each Warrant has an exercise price of $8.77 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $21.6 million based on an allocation of proceeds to the Warrants of approximately $9.6 million and a beneficial conversion feature of approximately $12.0

32


million, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.
The fair value of the Notes was estimated using a lattice model with Level 2 inputs including the stock price volatility, risk-free interest rate, and debt yield. As of June 30, 2018, the estimated fair value of the Notes was approximately $40.6 million, compared to the carrying value of $16.2 million, as a result of unamortized debt discount. A substantial portion of the market value of the Company's debt in excess of the outstanding principal amount relates to the conversion premium on the Notes.
Convertible debt and unamortized discount balances are as follows (in thousands):
Face value of loan
$
37,849

Debt discount - warrant
(9,643
)
Debt discount - beneficial conversion feature
(12,005
)
Capitalized debt issuance costs
(98
)
Accretion of debt issuance costs and other
—

Accretion of debt discount
100

Balance at June 30, 2018
16,203

Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands) as of June 30, 2018:
Years Ending December 31,
 
2018
946

2019
1,892

2020
1,893

2021
1,892

2022
1,893

2023
38,795

Total future minimum payments
47,311

Unpaid interest
(9,462
)
Unamortized debt discount
(21,549
)
Unamortized capitalized debt issuance costs
(97
)
Total minimum payment
16,203

Current portion
—

Long-term debt
$
16,203

13. Stock Incentive Plans
2009 Non-Employee Director Grants
In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved the reservation and issuance of 8,000 non-statutory stock options to the Company’s non-employee directors. The options vested on the one year anniversary of the vesting commencement date in October 2010, and are exercisable for up to ten years from the grant date. No further shares may be granted under this plan and, as of June 30, 2018, 3,200 options with a weighted-average exercise price of $1.12 were outstanding.
2009 Stock Incentive Plan
In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan. In July 2017, the Company’s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan (as amended and restated, the “Stock Plan”) to increase the number of shares of the Company’s common stock authorized to be issued pursuant to the Stock Plan to 11,260,000. Such shares of the Company’s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of

33


grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. Stock options are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement.
The following table summarizes stock option activity as of June 30, 2018 and the changes for the period then ended (dollar values in thousands, other than weighted-average exercise price):
 
Options
Outstanding
 
Weighted-
Average
Exercise Price
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2017
6,343,400

 
$
4.74

 
$
6,290

Options Granted
1,566,200

 
$
7.23

 
 

Options Canceled
(266,835
)
 
$
4.36

 
 

Options Exercised
(25,815
)
 
$
6.04

 
 

Outstanding at June 30, 2018
7,616,950

 
$
5.26

 
$
19,460

The aggregate intrinsic value of options exercised during the three months ended June 30, 2018 and 2017 was $4 thousand and $0, respectively.  The aggregate intrinsic value of options exercised during the six months ended June 30, 2018 and 2017 was $52 thousand and $0, respectively. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of employee stock options was estimated at the grant date using the following assumptions:
 
Six Months Ended June 30,
 
2018
 
2017
Weighted-average grant date fair value
$
7.39

 
$
5.20

Dividend yield
—
%
 
—
%
Volatility
81
%
 
64
%
Risk-free interest rate
2.52
%
 
2.16
%
Expected life of options
6.1 years

 
6.1 years

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.
The total employee and director stock-based compensation recorded as operating expenses was $1.0 million and $1.2 million for the three months ended June 30, 2018 and 2017, respectively, and $2.2 million and $2.5 million for the six months ended June 30, 2018 and 2017, respectively.
The total unrecognized compensation cost related to unvested employee and director stock option grants as of June 30, 2018 was $10.8 million and the weighted average period over which these grants are expected to vest is 3.0 years.
The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $178 thousand and $8 thousand for the three months ended June 30, 2018 and 2017, respectively, and $275 thousand and $34 thousand for the six months ended June 30, 2018 and 2017, respectively.

34


Common Stock Reserved for Future Issuance
Common stock reserved for future issuance consists of the following at June 30, 2018:
Common stock warrants outstanding under the underwriters agreement
182,600

Common stock warrants outstanding under the loan and security agreement
65,892

Common stock warrants outstanding under the Hercules securities agreement
306,748

Common stock warrants outstanding under the convertible notes
14,819,872

Common stock warrants outstanding under private placements
4,153,620

Common stock options outstanding under the Non-Employee Director Plan
3,200

Authorized for future grant or issuance under the 2009 Stock Incentive Plan
10,756,281

Shares issuable upon the conversion of the 2018 Notes
5,397,325

Issuable under assignment agreement based upon achievement of certain milestones
80,000

 
35,765,538

 
2017 Equity Incentive Plan
In June 2017, the Company’s subsidiary, Scilex, adopted the Scilex 2017 Equity Incentive Plan, reserved 4.0 million shares of Scilex common stock and awarded 1.0 million options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. As of June 30, 2018, 0.5 million options were outstanding.
2015 Stock Option Plans
In May 2015, the Company’s subsidiary, TNK, adopted the TNK 2015 Stock Option Plan, reserved 10.0 million shares of TNK class A common stock and awarded 3.6 million options to certain Company personnel, directors and consultants under such plan. In November 2015, TNK awarded 0.5 million options to certain Company personnel.  Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.0 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.2 million shares were canceled. As of June 30, 2018, 0.9 million options were outstanding.
In May 2015, TNK granted a warrant to the Company’s CEO to purchase 9.5 million shares of TNK class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
In May 2015, the Company’s subsidiary, LA Cell, adopted the LA Cell 2015 Stock Option Plan reserved 10.0 million shares of LA Cell class A common stock and awarded 2.9 million options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.5 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.2 million shares were canceled. As of June 30, 2018, 0.3 million options were outstanding.
In May 2015, LA Cell granted a warrant to the Company’s CEO to purchase 9.5 million shares of LA Cell class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
In October 2015, the Company’s subsidiary, Concortis Biosystems, Corp. (“CBC”), adopted the CBC 2015 Stock Option Plan and reserved 10.0 million shares of CBC class A common stock and awarded 1.8 million options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.6 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.1 million shares were canceled. As of June 30, 2018, no options were outstanding.

35


In October 2015, CBC granted a warrant to the Company’s CEO to purchase 9.5 million shares of CBC class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.25 per share.  This warrant was canceled in its entirety effective August 29, 2017.
In October 2015, the Company’s subsidiary, Scintilla, adopted the Scintilla 2015 Stock Option Plan, reserved 10.0 million shares of Scintilla class A common stock and awarded 1.8 million options to certain Company personnel, directors and consultants under such plan.   Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 0.8 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.1 million shares were canceled. As of June 30, 2018, no options were outstanding.
In October 2015, Scintilla granted a warrant to the Company’s CEO to purchase 9.5 million shares of Scintilla class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
In October 2015, the Company’s subsidiary, Sorrento Biologics, Inc. (“Biologics”), adopted the Biologics 2015 Stock Option Plan, reserved 10.0 million shares of Biologics class A common stock and awarded 2.6 million options to certain Company personnel, directors and consultants under such plan.  Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.3 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 75,000 shares were canceled. As of June 30, 2018, no options were outstanding.
In October 2015, Biologics granted a warrant to the Company’s CEO to purchase 9.5 million shares of Biologics class B common stock which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
On August 29, 2017, the options and warrants were canceled in accordance with the terms of a settlement agreement with Wildcat Liquid Alpha, LLC and, as a result, unrecognized compensation expense of $281 thousand associated with these previously issued shares was accelerated and recognized upon cancellation.
The total director stock-based compensation recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics for the three months ended June 30, 2018 and 2017 was $0 and $54 thousand, respectively and was $0 and $96 thousand for the six months ended June 30, 2018 and 2017, respectively. No unrecognized stock-based compensation expense related to unvested director stock option and warrant grants remained for these entities as of June 30, 2018.  The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest.  Stock based compensation expense related to non-employee consultants recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics was $149 thousand for each of the three months ended June 30, 2018 and 2017, and was $358 thousand for each of the six months ended June 30, 2018 and 2017.
The weighted-average assumptions used in the Black-Scholes option and warrant pricing model used by TNK, LA Cell, CBC, Scintilla and Biologics to determine the fair value of stock option grants for directors and non-employee consultants for the six months ended June 30, 2018 were as follows: expected dividend yield – 0%, risk-free interest rate –2.42% to 2.48%, expected volatility – 65% to 77%, and expected term of 4.0 to 6.1 years.
2014 Stock Option Plan
In May 2014, the Company’s subsidiary, Ark Animal Health, Inc. (“Ark”), adopted the Ark 2014 Stock Option Plan and reserved and awarded 600,000 options to certain directors and consultants under such plan. Stock options granted under such plan typically vest a portion immediately upon grant and the remaining options over one year from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 135,000 shares were canceled. As of June 30, 2018, 88,000 options were outstanding.
The total director and consultant stock-based compensation recorded as operating expenses by the Company for Ark was $0 for each of the three and six months ended June 30, 2018 and 2017. No unrecognized stock-based compensation expense remains related to stock option grants as of June 30, 2018.

36


14. Commitments and Contingencies
Litigation
In the normal course of business, the Company may be named as a defendant in one or more lawsuits. The Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.
Derivative Action Litigation
On September 8, 2016, Yvonne Williams filed an action both derivatively and on behalf of a purported class of stockholders in the Court of Chancery of the State of Delaware (the "Court") against each of the members of the Henry Ji, William S. Marth, Kim D. Janda, Jaisim Shah, David H. Deming, and Douglas Ebersole (the “Prior Board”); George Ng, the Company’s Executive Vice President, Chief Administrative Officer, and Chief Legal Officer; Jeffrey Su, the Company’s Executive Vice President & Chief Operating Officer; and the Company as nominal defendant, alleging: (1) breach of fiduciary duty with respect to the formation of, and certain options and warrants issued by, certain of the Company’s subsidiaries to Dr. Ji and members of the Prior Board; (2) breach of fiduciary duty with respect to the Company’s prior announcement that it had entered into a voting agreement with Yuhan Corporation in connection with a transaction through which it purchased $10 million of shares of the Company's common stock and warrants (the “Williams Action”). On November 14, 2016, the Company filed motions to dismiss or in the alternative stay the Williams Action. George Ng and Jeffrey Su were dismissed as defendants by plaintiff during the briefing on the motions. The Court denied the motions on June 28, 2017.
On October 25, 2017, Yvonne Williams filed a Supplemental and Amended Class Action and Derivative Complaint which re-added George Ng as a defendant, added Eragon Ventures, LLC as a defendant, and added certain claims challenging transactions whereby Eragon Ventures, LLC agreed to purchase certain stock in the Company’s subsidiary, LA Cell, Inc. Following a mediation held on November 16, 2017, the parties agreed that day to a term sheet reflecting a settlement of the Williams Action, which agreement was memorialized in a Stipulation and Agreement of Settlement executed on December 22, 2017 and filed with the Court. The settlement consisted of non-monetary consideration, such as the cancellation of certain subsidiary shares of stock that were obtained by defendants pursuant to options previously exercised by defendants. The settlement and plaintiff’s counsel’s request for an award of attorneys’ fees were submitted to the Court for approval. On May 15, 2018, the Court held a hearing on the request for approval of the settlement and approved the settlement and awarded plaintiff’s counsel attorneys’ fees of $3.25 million. This case was dismissed with prejudice. The Company has caused the attorneys’ fees payment to be made, which payment was covered in large part, but not in whole, by insurance.
Immunomedics Litigation
On June 26, 2015, Immunomedics, Inc. (“Immunomedics”) filed a complaint in the United States District Court for the District of New Jersey (the “New Jersey Case”) against the Board of Directors of RWMC, Dr. Richard P. Junghans, Dr. Steven C. Katz, the Office of the Board of Advisors of Tufts University School of Medicine, and one or more individuals or entities to be identified later. This complaint (the "Initial Complaint") alleged, among other things: (1) breach of contract; (2) breach of covenant of good faith and fair dealing; (3) tortious interference with prospective economic gain; (4) tortious interference with contracts; (5) misappropriation; (6) conversion; (7) bailment; (8) negligence; (9) vicarious liability; and (10) patent infringement. Overall, the allegations in the Initial Complaint were generally directed to an alleged material transfer agreement dated December 2008 and Immunomedics’ alleged request for the return of certain alleged research material, as well as the alleged improper use and conversion of such research materials outside the scope of the material transfer agreement.
On October 22, 2015, Immunomedics filed an amended complaint (the “First Amended Complaint”), which, among other things, no longer named the Board of Directors of RWMC and The Office of the Board of Advisors of Tufts University School of Medicine as defendants. RWMC and Tufts Medical Center were added as new defendants. On January 14, 2016, Immunomedics filed a second amended complaint (the "Second Amended Complaint"), which, among other things, no longer named Tufts Medical Center as a defendant. In addition, the Second Amended Complaint contained allegations directed to two additional alleged material transfer agreements dated September 1993 and May 2010, respectively, and also added an allegation of unjust enrichment. The Second Amended Complaint also no longer asserted claims for (1) breach of covenant of good faith and fair dealing; (2) misappropriation; (3) bailment; (4) negligence; and (5) vicarious liability.
On October 12, 2016, Immunomedics filed a third amended complaint (the “Third Amended Complaint”), which added the Company, TNK, BDL and CARgenix as defendants. TNK is a subsidiary of the Company and purchased BDL and CARgenix in August 2015. The Third Amended Complaint included, among other things, allegations against the Company, TNK, BDL and CARgenix regarding (1) conversion; (2) tortious interference; and (3) unjust enrichment. On December 2, 2016, the Company, TNK, BDL, and CARgenix filed a motion to dismiss Immunomedics’s complaint against them for lack of personal jurisdiction. On January 25, 2017, the District of New Jersey granted this motion, and the Company, TNK, BDL and

37


CARgenix were dismissed as defendants from the New Jersey Case. Under various agreements, TNK has certain indemnification obligations to RWMC, Dr. Richard P. Junghans and Dr. Steven C. Katz that may be implicated by the New Jersey Case. The New Jersey Case remains pending against defendants RWMC, Dr. Junghans, and Dr. Katz. A trial date has not yet been set.
On April 27, 2018, Immunomedics filed a complaint against the Company and TNK in San Diego Superior Court, Case No. 37-2018-00021006-CU-NP-CTL (the “San Diego Case”). The complaint includes, among other things, allegations against the Company and TNK regarding: (1) conversion; (2) tortious interference; and (3) inducing breach of contract. No trial date has yet been set in the San Diego Case.

The Company believes that the New Jersey Case and the San Diego Case are without merit, and will vigorously defend itself in the litigation. However, should Immunomedics prevail against the Company, RWMC or other defendants, certain patent rights optioned, owned and/or licensed by the Company could be at risk of invalidity or enforceability, or the litigation could otherwise adversely impact the Company’s ownership or other rights in certain intellectual property.  At this point in time, the Company is unable to determine whether any loss is probable or reasonably possible with respect to the New Jersey Case or the San Diego Case or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.

Cantor Fitzgerald & Co. Litigation

On May 25, 2018, Cantor Fitzgerald & Co. (“CF&Co.”) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, Index No. 652633/2018. The complaint includes, among other things, allegations against the Company for breach of contract arising out of a letter agreement whereby CF&Co. was to supply certain services to the Company in exchange for a fee (the “CF & Co. Litigation”). The Company has filed an Answer and Counterclaim for breach of contract against CF&Co claiming that CF&Co. did not perform under the letter agreement. The Company believes CF&Co.’s claims against the Company are without merit and will vigorously defend itself in the litigation. At this point in time, the Company is unable to determine whether any loss is probable or reasonably possible with respect to the CF&Co. Litigation or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.
Operating Leases
The Company currently leases in San Diego, California approximately 130,575 square feet of corporate office and laboratory space and approximately 1,405 square feet of office space at a second location as well as approximately 36,400 square feet for offices, facilities for cGMP fill and finish and storage space.
The Company’s lease agreements in San Diego, as amended, for its corporate office and laboratory space, its second laboratory and office space and its third office space, expire in December 2026, November 2025 and September 2020, respectively.  The Company also leases 25,381 square feet of office and laboratory space in Suzhou, China, which lease expires in June 2018. The Company leases 2,312 square feet of office, laboratory, and storage space in Scotland, which lease expires in March 2021. The Company subleases in New York, New York for approximately 4,550 square feet of additional corporate office space. The sublease began in July of 2017 and expires in December 2020.
15. Income Taxes
The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company's ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company's U.S. federal and state deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its Scilex subsidiary.
The Company’s income tax benefit of $2.3 million and $3.1 million reflect effective tax rates of 2.1% and 7.5% for the six months ended June 30, 2018 and 2017, respectively.
The difference between the expected statutory federal tax expense of 21% and the 2.1% effective tax expense for the six months ended June 30, 2018 was primarily attributable to the valuation allowance against most of the Company’s deferred tax assets.

38


The Company is subject to taxation in the U.S. and various state jurisdictions. The Company's tax years for 2007 and later are subject to examination by the U.S. and state tax authorities due to the existence of the NOL carryforwards.
As of June 30, 2018, the Company had approximately $3.9 million of unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance. As of June 30, 2017, the Company had approximately $2.8 million of unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance.
The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. For the six months ended June 30, 2018 and 2017, no expense was recorded related to interest and penalties. The Company believes that no significant amount of the liabilities for uncertain tax positions will expire within twelve months of June 30, 2018.
U.S. Tax Reform

The Tax Cuts and Jobs Act (“Tax Act”) was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, as well as making several other significant changes to the tax law, effective January 1, 2018. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), given the amount and complexity of the changes in tax law resulting from the Tax Act, the Company has not finalized the accounting for the income tax effects of the Tax Act. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to the Company's valuation allowance. The impact of the Tax Act may differ from this estimate, during the one-year measurement period due to, among other things, further refinement of the Company's calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Act. The Company is still analyzing certain aspects of the Tax Act and refining its calculations, which could potentially affect the analysis of the Company’s deferred tax assets and liabilities. Any subsequent adjustment is expected to be offset by a change in valuation allowance and have no impact on the Company’s financial position or results of operations.
16. Related Party Agreements
During the year ended December 31, 2015, the Company entered into a joint venture called NANTibody, with NantCell, a subsidiary of NantWorks.  In July 2015, the Company contributed its portion of the initial joint funding of $40.0 million to the NANTibody joint venture.  The Company and NantCell have also entered into a license agreement pursuant to which the Company received a $10.0 million upfront license payment and $100.0 million of vested NantCell common stock.  
During the year ended December 31, 2015, the Company entered into a joint venture called NantStem, with NantBioScience, a wholly-owned subsidiary of NantWorks.  In connection with negotiated changes to the structure of NantStem the Company issued a call option on shares of NantKwest that it owned to Cambridge, a related party to the Company and to NantBioScience.  In April 2015, the Company purchased 1.0 million shares of NantBioScience common stock for $10.0 million.  
In March 2016, the Company and Yuhan entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.  As of June 30, 2018, the carrying value of the Company’s investment in ImmuneOncia Therapeutics, LLC was approximately $4.5 million. During the three months ended June 30, 2016, Yuhan purchased $10.0 million of common stock and warrants.
On August 15, 2017, the transactions contemplated by that certain Contribution Agreement, dated June 12, 2017, by and among the Company, TNK and Celularity Inc. (“Celularity”), pursuant to which, among other things, the Company and TNK agreed to contribute certain intellectual property rights related to their proprietary chimeric antigen receptor constructs and related CARs to Celularity in exchange for shares of Celularity’s Series A Preferred Stock equal to 25% of Celularity’s outstanding shares of capital stock, calculated on a fully-diluted basis closed. Dr. Henry Ji, the Company's Chairman of the Board, President and Chief Executive Officer, Jaisim Shah, a member of the Company’s Board of Directors and David Deming, a member of the Company’s Board of Directors, were previously appointed as members of the board of directors of Celularity.
On November 8, 2016, the Company entered into the Scilex Purchase Agreement, pursuant to which the Company acquired from the Scilex Stockholders approximately 72% of the outstanding capital stock of Scilex. Dr. Henry Ji, the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and George K. Ng, the

39


Company’s Vice President, Chief Administrative Officer and Chief Legal Officer, were stockholders of Scilex prior to the acquisition transaction.
17. Loss Per Share
For the three and six months ended June 30, 2018 and 2017, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.
The following table sets forth the reconciliation of basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 (in thousands):
 
Three Months Ended June 30,
Six Months Ended June 30,
 
2018
 
2017
2018
 
2017
Basic and Diluted


 


 
 
 
Net loss
$
(73,864
)
 
$
(14,187
)
$
(106,436
)
 
$
(37,251
)
 
 
 
 
 
 
 
Denominator for Basic and Diluted Loss Per Share
100,563

 
70,302

92,795

 
60,650

Basic and Diluted Loss Per Share
$
(0.73
)
 
$
(0.20
)
$
(1.15
)
 
$
(0.61
)
The potentially dilutive stock options that would have been excluded because the effect would have been antidilutive for the three months ended June 30, 2018 and 2017 were 2.5 million and 4.3 million, respectively. The potentially dilutive warrants that would have been excluded because the effect would have been antidilutive for the three months ended June 30, 2018 and 2017 were 1.1 million and 1.1 million, respectively.

The potentially dilutive stock options that would have been excluded because the effect would have been antidilutive for the six months ended June 30, 2018 and 2017 were 2.5 million and 4.3 million, respectively. The potentially dilutive warrants that would have been excluded because the effect would have been antidilutive for the six months ended June 30, 2018 and 2017 were 2.2 million and 2.2 million, respectively.
    
Basic and diluted per share amounts are computed independently in the consolidated statements of operations. Therefore, the sum of per share components may not equal the per share amounts presented.
18. Subsequent Events
SofusaTM Acquisition
On July 2, 2018, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Kimberly-Clark Corporation (“KCC”); Kimberly-Clark Global Sales, LLC (“KCCGS”); and Kimberly-Clark Worldwide, Inc. (“KCCW” and together with KCC and KCCGS, “Kimberly-Clark”) pursuant to which, among other things, the Company acquired certain of Kimberly-Clark’s assets related to microneedle drug delivery systems, including the SofusaTM platform (the “Assets”), and assumed certain of Kimberly-Clark’s liabilities related to the Assets (the “Acquisition”).  The closing of the Acquisition (the “Closing”) occurred on July 2, 2018. At the Closing, the Company paid $10 million and agreed to pay additional consideration to Kimberly-Clark upon the achievement of certain regulatory and net sales milestones, as well as a percentage in the low double-digits of any non-royalty amounts received by the Company in connection with any license, sale or other grant of rights by the Company to develop or commercialize the Assets (all such additional consideration, the “Contingent Consideration”). Under the Purchase Agreement, the aggregate amount of the Contingent Consideration payable by the Company will not exceed $300.0 million.  The Company also agreed to pay Kimberly-Clark a low single-digit royalty on all net sales with respect to the first five products developed by the Company or its licensees that utilizes intellectual property included in the Assets.


Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations


This Quarterly Report on Form 10-Q contains “forward-looking statements” about our expectations, beliefs or intentions regarding our potential product offerings, business, financial condition, results of operations, strategies or prospects. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current

40


matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made and are often identified by the use of words such as “assumes,” “plans,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” or “will,” and similar expressions or variations. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described under the caption “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (the “SEC”). Furthermore, such forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.
Overview
We are a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. Our primary focus is to transform cancer into a treatable or chronically manageable disease. We also have programs assessing the use of our technologies and products in auto-immune, inflammatory, neurodegenerative and infectious diseases and pain indications with high unmet medical needs.
At our core, we are an antibody-centric company and leverage our proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. Our validated fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others. Our vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as TCR-like antibodies. With LA Cell, Inc. (“LA Cell”), our joint venture with City of Hope, our objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, we have acquired and are assessing the regulatory and strategic path forward for our portfolio of late stage biosimilar/biobetter antibodies based on Erbitux®, Remicade®, Xolair®, and Simulect® as these may represent nearer term commercial opportunities.
Although we intend to retain ownership and control of product candidates by advancing their development, we regularly also consider, (i) partnerships with pharmaceutical or biopharmaceutical companies and (ii) license or sale of certain products in each case, in order to balance the risks and costs associated with drug discovery, development and commercialization with efforts to maximize our stockholders’ returns. Our partnering objectives include generating revenue through license fees, milestone-related development fees and royalties as well as profit shares or joint ventures to generate potential returns from our product candidates and technologies.
Recent Developments
Acquisition of Virttu Biologics Limited
On April 27, 2017, we entered into a Share Purchase Agreement (the “Virttu Purchase Agreement”) with TNK Therapeutics, Inc., our majority-owned subsidiary (“TNK”), Virttu Biologics Limited (“Virttu”), the shareholders of Virttu (the “Virttu Shareholders”) and Dayspring Ventures Limited, as the representative of the Virttu Shareholders, pursuant to which, among other things, TNK acquired from the Virttu Shareholders 100% of the outstanding ordinary shares of Virttu (the “Virttu Acquisition”).
Virttu focuses on the development of oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. Its lead oncolytic virus candidate, Seprehvir, infects and replicates in cancer cells selectively, leaving normal cells unharmed.
Under the Virttu Purchase Agreement, the total amount of the consideration payable to the Virttu Shareholders in the Virttu Acquisition is equal to $25 million, less Virttu’s net debt (the “Virttu Base Consideration”). An additional $10 million contingent consideration is payable upon the achievement of certain regulatory milestones (as described below) (the “Regulatory Approval Consideration”).
At the closing of the Virttu Acquisition (the “Closing”), we issued to the Virttu Shareholders consideration valued at approximately $2.2 million, which consisted primarily of an aggregate of 797,081 shares (the “Virttu Closing Shares”) and approximately $557,000 in cash (the “Cash Consideration”). The issuance of the Virttu Closing Shares and the payment of the

41


Cash Consideration satisfied TNK’s obligation to pay 20% of the Virttu Base Consideration at the Closing. Under the terms of the Virttu Purchase Agreement, we agreed to provide additional consideration to the Virttu Shareholders, as follows:
(1) Upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $50.0 million (a “Qualified Financing”), TNK would have issued to the Virttu Shareholders an aggregate number of shares of its capital stock (“TNK Capital Stock”) as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration by the lowest per share price paid by investors in the Qualified Financing (the “TNK Financing Consideration”); provided, however, that 20% of the TNK Financing Consideration was held in escrow until April 27, 2018 (the “Financing Due Date”), to be used to, among other things, satisfy the indemnification obligations of the Virttu Shareholders. In the event that a Qualified Financing did not occur, then on the Financing Due Date, we would issue to the Virttu Shareholders an aggregate number of shares of our common stock as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration, by $5.55 (as adjusted, as appropriate, to reflect any stock splits or similar events affecting our common stock after the Closing).
(2) Within 45 business days after Virttu becomes aware that certain governmental bodies in the United States, the European Union, the United Kingdom or Japan have approved for commercialization, on or before October 26, 2024, Seprehvir (or any enhancement, combination or derivative thereof) as a monotherapy or in combination with one or more other active components (each of the first two such approvals by a governmental body being a “Regulatory Approval”), TNK shall pay half of the Regulatory Approval Consideration to the Virttu Shareholders, in a combination of (a) up to $5.0 million in cash (the “Regulatory Approval Cash”) and/or (b) (i) such number of shares of our common stock as is equal to the quotient obtained by dividing $5.0 million less the Regulatory Approval Cash (the “Regulatory Approval Share Value”) by the 30 Day VWAP (as defined below) of one share of our common stock; (ii) if TNK has completed its first public offering of TNK Capital Stock, the number of shares of TNK Capital Stock as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP of one share of TNK Capital Stock; or (iii) such number of shares of common stock of a publicly traded company as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the volume weighted average price of the relevant security, as reported on the Nasdaq Capital Market (or other principal stock exchange or securities market on which the shares are then listed or quoted) for the thirty trading days immediately following the receipt of Regulatory Approval (the “30 Day VWAP”), with the composition of the Regulatory Approval Consideration to be at TNK’s option. In order for a second regulatory approval to qualify as a Regulatory Approval under the Purchase Agreement, the second approval must be granted by a different governmental body in a different jurisdiction than that which granted the first Regulatory Approval.
TNK did not complete a Qualified Financing prior to the Financing Due Date and on April 27, 2018. Us, TNK and Dayspring entered into the Amendment, pursuant to which, among other things, we agreed that the acquisition consideration, otherwise payable on April 27, 2018 to the Virttu Shareholders, shall be as follows: (1) an issuance of 1,795,011 shares of our common stock to the Virttu Shareholders and (2) $9.9 million payable in cash .
We issued an aggregate of 1,795,011 shares of our common stock to the Virttu Shareholders on April 27, 2018 for a value of $11.3 million. The approximately $9.9 million payable in cash has not been paid as of the date of this filing.
Celularity Transaction
On November 1, 2016, we loaned $5.0 million to Celularity Inc., a research and development company (“Celularity”), pursuant to a promissory note issued by us to Celularity, as amended (as so amended, the “Celularity Note”), in connection with the entry into a nonbinding term sheet by us, TNK and Celularity.  Pursuant to the terms of the Celularity Note, the loan will be due and payable in full on the earlier of November 1, 2017 and the occurrence of an event of default under the Celularity Note (the “Celularity Maturity Date”). Under the terms of the Celularity Note, in the event that Celularity met certain minimum financing conditions prior to the Maturity Date, all outstanding amounts under the Celularity Note would be forgiven and converted to equity. On May 31, 2017, we loaned an additional $2.0 million to Celularity pursuant to the terms of the Celularity Note. On June 14, 2017, we loaned an additional $1.0 million to Celularity. Additionally, on July 7, 2017, we loaned an additional $2.0 million to Celularity. The loan amounts were forgiven and converted to additional equity investment in Celularity as part of the closing of the Contribution Agreement (as defined below) on June 12, 2017.
On June 12, 2017, we entered into a Contribution Agreement (the “Contribution Agreement”) with TNK and Celularity, pursuant to which, among other things, we and TNK agreed to contribute certain intellectual property rights related to our proprietary chimeric antigen receptor (“CAR”) constructs and related CARs to Celularity in exchange for shares of Celularity’s Series A Preferred Stock equal to 25% of Celularity’s outstanding shares of capital stock, calculated on a fully-diluted basis (the "Celularity Shares").
On August 15, 2017, the transactions contemplated by the Contribution Agreement closed, the loan amounts were forgiven, and, on such date, among other things, (a) Celularity issued the Celularity Shares to TNK, and (b) we, TNK and Celularity entered into a License and Transfer Agreement (the "License Agreement"). Pursuant to the License Agreement (i)

42


TNK and we agreed to provide to Celularity (1) our CAR constructs and related CARs for use worldwide in combination with placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder except that anti-CD38 CAR constructs and related CARs may also be used in adult cells for the treatment of multiple myeloma unless TNK exercises its termination rights, and (2) our know-how relating to the foregoing, (ii) TNK and we granted to Celularity a limited, perpetual, transferable and sublicensable license and covenant not to sue with respect to certain of their patents and other intellectual property rights, which license is exclusive for a subset of such patents, and (iii) Celularity agreed to pay to TNK 50% of the first $200 million and 20% thereafter of any upfront and milestone payments that Celularity receives in connection with any sublicense of a combination of anti-CD38 CAR constructs and either placenta-driven cells and/or cord blood–derived cells or adult cells.
On April 5, 2018, we issued a press release announcing that we and Celularity have started screening patients for our leading CD 38 CAR T cell therapy drug development program, following the U.S. Food and Drug Administration's (the "FDA") review allowing clinical trial initiation.
Scilex Pharmaceuticals: ZTlido™ (lidocaine topical system 1.8%)
ZTlido™ (lidocaine topical system 1.8%) is based on a novel and proprietary technology that contains only 36 mg of lidocaine versus Endo Pharmaceuticals, Inc.'s Lidoderm® (lidocaine patch 5%), which holds 700 mg of lidocaine per patch. In December 2016 and January 2017, Scilex Pharmaceuticals Inc. ("Scilex") reported key endpoints were met in the pivotal bioequivalence clinical trials for ZTlido™ (lidocaine topical system 1.8%). The full data package was resubmitted (the first 505(b)(2) new drug application filed in 2015 resulted in a Complete Response Letter from the FDA in May 2016, which meant that the FDA considered the drug application not ready for approval at that time) to the FDA as part of the 505(b)(2) new drug application (“NDA”) and accepted by the FDA in September 2017 (setting the Prescription Drug User Fee Act or FDA decision date on the resubmitted 505(b)(2) NDA for February 28, 2018) and filed with the Medicines and Healthcare products Regulatory Agency in the United Kingdom a hybrid Marketing Authorization Application in November 2017. On February 28, 2018, the FDA approved ZTlido™ (lidocaine topical system 1.8%) for the relief of pain associated with post-herpetic neuralgia. Scilex is currently in preparations for a commercial launch of ZTlido™ (lidocaine topical system 1.8%) and exploring potential partnerships for the product.
Private Placement of Convertible Promissory Notes and Warrants
2017 Securities Purchase Agreement in Private Placement
On December 11, 2017, we entered into a Securities Purchase Agreement (the “December 2017 Securities Purchase Agreement”) with certain accredited investors (collectively, the “December 2017 Purchasers”). Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, we issued and sold to the December 2017 Purchasers, in a private placement transaction, (1) convertible promissory notes in an aggregate principal amount of $50,000,000 (the “December 2017 Notes”), which will accrue simple interest at a rate equal to 5.0% per annum and mature upon the earlier to occur of (a) December 21, 2022, and (b) the date of the closing of a change in control (the “December 2017 Warrant Maturity Date”), and (2) warrants (the “December 2017 Warrants”) to purchase an aggregate of 12,121,210 shares of our common stock.
At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser’s December 2017 Note that was equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of $2.26875, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.
Each December 2017 Warrant has an exercise price of $2.61 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.
On May 17, 2018, the December 2017 Purchasers converted in full the outstanding principal and accrued interest under the December 2017 Notes into 22,038,565 shares of our common stock. On May 17, 2018, the December 2017 Purchasers converted in full the outstanding principal and accrued interest under the December 2017 Notes into 22,038,565 shares of our common stock.

43


2018 Securities Purchase Agreement in Private Placement
On March 26, 2018, we entered into a Securities Purchase Agreement (the “March 2018 Securities Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”). Pursuant to the March 2018 Securities Purchase Agreement, we agreed to issue and sell to the Purchasers, in a private placement transaction (the “Private Placement”), (1) convertible promissory notes in an aggregate principal amount of $120,500,000 (the “Notes”), which would accrue simple interest at a rate equal to 5.0% per annum and mature upon the earlier to occur of (a) the date that is five years from the date of issuance, and (b) the date of the closing of a change in control, and (2) warrants to purchase 8,591,794 shares of the common stock of our common stock (the “Warrants”).

On June 13, 2018, we entered into an amendment (the “Amendment”) to the March 2018 Securities Purchase Agreement (as amended, the “Securities Purchase Agreement”). Under the terms of the Amendment, we and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of Common Stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, we issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of Common Stock.

At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser’s Note that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such Purchaser’s Note into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. If a Purchaser elects to convert any of the principal amount of their Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Notes contain restrictive covenants and event of default provisions that are customary for transactions of this type.

Each Warrant has an exercise price of $8.77 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements which are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to debt with detachable warrants, acquisition consideration payable, income taxes and stock-based compensation. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known.
During the quarter ended June 30, 2018, there were no significant changes to the items that we disclosed as our critical accounting policies and estimates in Note 4 to our consolidated financial statements for the year ended December 31, 2017 contained in our Annual Report on Form 10-K for the year ended December 31, 2017, as amended, as filed with the SEC.
Results of Operations
The following describes certain line items set forth in our condensed consolidated statements of operations.
Comparison of the Three Months Ended June 30, 2018 and 2017

44


Revenues. Revenues were $3.9 million for the three months ended June 30, 2018, as compared to $4.7 million for the three months ended June 30, 2017. The net decrease of $0.8 million is primarily due to a decrease of $2.3 million in our royalty and license revenue due to higher revenues associated with the termination of the Servier license agreement in November 2017, offset by an increase of $1.6 million in our sales and services revenue, related primarily to our joint development agreement with Celularity.
In June 2014, the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (the "NIH") awarded us a Phase II STTR grant to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staphylococcus aureus ("S. aureus" or "Staph") infections (the “Staph Grant III award”). The project period for this Phase II grant covered a two-year period which commenced in June 2014, which was subsequently extended by one year, with total funds available of approximately $1.0 million per year. During the three months ended June 30, 2018 and 2017, we recorded $0 and $95 thousand of revenue, respectively, associated with the Staph Grant III award.
We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the unpredictability of the demand for products and services offered as well as the timing and amount of grant awards, research and development reimbursements and other payments received under any strategic collaborations, if any.
Cost of revenues. Cost of revenues for the three months ended June 30, 2018 and 2017 were $1.2 million and $0.8 million, respectively, and relate to the sale of customized reagents and providing contract development services. The costs generally include employee-related expenses including salary and benefits, direct materials and overhead costs including rent, depreciation, utilities, facility maintenance and insurance. The increase of $0.4 million is primarily attributable to increased indirect costs associated with certain contract manufacturing services.
Research and Development Expenses. Research and development expenses for the three months ended June 30, 2018 and 2017 were $17.9 million and $11.2 million, respectively. Research and development expenses include the costs to advance our Chimeric Antigen Receptor T-Cell ("CAR-T") programs for solid tumors, our resiniferatoxin ("RTX") program towards entering into future clinical trials, our biosimilar/biobetter antibodies development, costs to identify, isolate and advance human antibody drug candidates derived from our libraries as well as advancing our antibody drug conjugate ("ADC") preclinical drug candidates, preclinical testing expenses and the expenses associated with fulfilling our development obligations related to the NIH grant awards, collectively the NIH Grants. Such expenses consist primarily of salaries and personnel related expenses, stock-based compensation expense, clinical development expenses, preclinical testing, lab supplies, consulting costs, depreciation and other expenses.
The increase of $6.7 million is primarily attributable to the change in payroll expense for research and development, facilities costs and an increase in R&D program costs in areas such as CAR-T and RTX. We expect research and development expenses to increase in absolute dollars as we: (i) advance our CAR-T programs, (ii) advance RTX into clinical trials and pursue other potential indications, the cost of acquiring, developing and manufacturing clinical trial materials, and other regulatory operating activities, (iii) advance our biosimilar/biobetter antibodies clinical development program, (iv) incur incremental expenses associated with our efforts to further advance a number of potential product candidates into preclinical development activities, (v) continue to identify and advance a number of fully human therapeutic antibody and ADC preclinical product candidates, (vi) incur higher salary, lab supply and infrastructure costs incurred in connection with supporting all of our programs, and (vii) invest in our JVs or other third party agreements.
Acquired In-process Research and Development Expenses. There was no expense related to acquired in-process research and development for each of the three months ended June 30, 2018 and 2017.
General and Administrative Expenses. General and administrative expenses for the three months ended June 30, 2018 and 2017 were $11.0 million and $9.1 million, respectively. General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expense, professional fees, infrastructure expenses, legal and accounting expenses and other general corporate expenses. The increase of $1.9 million is primarily attributable to increased personnel costs as well as outside legal costs compared to prior year.
We expect general and administrative expenses to increase in absolute dollars as we: (i) incur incremental expenses associated with expanded operations and development efforts, (ii) continue our efforts to monitor and ensure compliance with our public reporting obligations, (iii) incur increased infrastructure costs, and (iv) invest in our JVs or other third party agreements.
Intangible Amortization. Intangible amortization for each of the three months ended June 30, 2018 and 2017 was $0.7 million.

45


Contingent Liabilities and Acquisition Consideration Payable. Changes in acquisition consideration payable for the three months ended June 30, 2018 and 2017 resulted in a loss of $1.4 million and a gain of $3.6 million, respectively. The change in acquisition consideration payable for the three months ended June 30, 2018 relates primarily to changes in the fair value of contingent consideration for the Virttu acquisitions of $2.6 million.
Virttu financing related contingent consideration was settled in part by issuing shares of our common stock during the three months ended June 30, 2018. The increase in the fair value of the contingent consideration related to Virttu of $2.6 million during the three months ended June 30, 2018 is primarily related to an increase in the value of our common stock during the same period.
Interest Expense. Interest expense for the three months ended June 30, 2018 and 2017 was $45.0 million and $1.2 million, respectively. The increase in interest expense of $43.8 million resulted primarily from the conversion of the December 2017 Notes during the three months ended June 30, 2018. The unamortized discount remaining at the date of conversion was recognized as interest expense in the three months ended June 30, 2018.
Interest Income. Interest income for the three months ended June 30, 2018 and 2017 was $6 thousand and $232 thousand, respectively. We expect that continued low interest rates will significantly limit our interest income in the near term.
Income tax benefit. Income tax benefit for the three months ended June 30, 2018 and 2017 was $1.4 million and $1.4 million, respectively.
Loss on equity method investments.  Loss on equity method investments for the three months ended June 30, 2018 and 2017 was $2.1 million and $1.1 million, respectively. (See Note 9 of the accompanying notes to the condensed consolidated financial statements for additional information.) 
Net Loss. Net loss for the three months ended June 30, 2018 and 2017 was $74.8 million and $14.7 million, respectively.  
Comparison of the Six Months Ended June 30, 2018 and 2017
Revenues. Revenues were $10.2 million for the six months ended June 30, 2018, as compared to $9.5 million for the six months ended June 30, 2017. The net increase of $0.6 million is primarily due to an increase of $5.4 million in our sales and services related to contract manufacturing services as well as revenue related to a joint development agreement, offset by a decrease of $4.6 million in our royalty and license revenues resulting primarily from the termination of the Servier license agreement in November 2017.
In June 2014, the NIH awarded us the Staph Grant III award. The project period for this Phase II grant covered a two-year period which commenced in June 2014, which was subsequently extended by one year, with total funds available of approximately $1.0 million per year. During the six months ended June 30, 2018 and 2017, we recorded $0 and $195 thousand of revenue, respectively, associated with the Staph Grant III award.
We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the unpredictability of the demand for products and services offered as well as the timing and amount of grant awards, research and development reimbursements and other payments received under any strategic collaborations, if any.
Cost of revenues. Cost of revenues for the six months ended June 30, 2018 and 2017 were $2.5 million and $1.9 million, respectively, and relate to the sale of customized reagents and providing contract development services. The costs generally include employee-related expenses including salary and benefits, direct materials and overhead costs including rent, depreciation, utilities, facility maintenance and insurance. The increase of $658 thousand is primarily attributable to increased indirect costs associated with the higher sales and service revenues for next generation homogenous antibody drug conjugate development.
Research and Development Expenses. Research and development expenses for the six months ended June 30, 2018 and 2017 were $32.6 million and $26.1 million, respectively. Research and development expenses include the costs to advance our CAR-T programs for solid tumors, our RTX program towards entering into future clinical trials, our biosimilar/biobetter antibodies development, costs to identify, isolate and advance human antibody drug candidates derived from our libraries as well as advancing our ADC preclinical drug candidates, preclinical testing expenses and the expenses associated with fulfilling our development obligations related to the NIH grant awards, collectively the NIH Grants. Such expenses consist primarily of salaries and personnel related expenses, stock-based compensation expense, clinical development expenses, preclinical testing, lab supplies, consulting costs, depreciation and other expenses.
The increase of $6.5 million is primarily attributable to an increase in payroll expense for research and development, facilities costs and an increase in R&D program costs in areas such as CAR-T and RTX. We expect research and development

46


expenses to increase in absolute dollars as we: (i) advance our CAR-T programs, (ii) advance RTX into clinical trials and pursue other potential indications, the cost of acquiring, developing and manufacturing clinical trial materials, and other regulatory operating activities, (iii) advance our biosimilar/biobetter antibodies clinical development program, (iv) incur incremental expenses associated with our efforts to further advance a number of potential product candidates into preclinical development activities, (v) continue to identify and advance a number of fully human therapeutic antibody and ADC preclinical product candidates, (vi) incur higher salary, lab supply and infrastructure costs incurred in connection with supporting all of our programs, and (vii) invest in our JVs or other third party agreements.
Acquired In-process Research and Development Expenses. Acquired in-process research and development expenses for the six months ended June 30, 2018 and 2017 were $0 and $0.2 million, respectively.
General and Administrative Expenses. General and administrative expenses for each of the six months ended June 30, 2018 and 2017 were $21.0 million. General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expense, professional fees, infrastructure expenses, legal and accounting expenses and other general corporate expenses.
We expect general and administrative expenses to increase in absolute dollars as we: (i) incur incremental expenses associated with expanded operations and development efforts, (ii) continue our efforts to monitor and ensure compliance with our public reporting obligations, (iii) incur increased infrastructure costs, and (iv) invest in our JVs or other third party agreements.
Intangible Amortization. Intangible amortization for each of the six months ended June 30, 2018 and 2017 was $1.3 million.
Contingent Liabilities and Acquisition Consideration Payable. Changes in acquisition consideration payable for the six months ended June 30, 2018 and 2017 resulted in a loss of $13.7 million and a gain of $4.1 million, respectively.
The loss resulting from the change in acquisition consideration payable for the six months ended June 30, 2018 relates primarily to changes in the fair value of contingent consideration from the Scilex and Virttu acquisitions of $6.0 million and $6.4 million, respectively.
In advance of our settlement of the Scilex contingent consideration on February 28, 2018 for $38.2 million, the fair value of the obligation increased by $6.0 million from December 31, 2017 primarily due to an increase in the probability of achieving the clinical development milestone triggering the settlement of the contingent consideration from 95% to 100%. Additionally, a portion of the consideration was payable in shares of our common stock, which increased in value during the same period.
Virttu contingent consideration was settled in part by issuing shares of our common stock. The increase in the fair value of the contingent consideration related to Virttu of $6.4 million during the six months ended June 30, 2018 is primarily related to an increase in the value of our common stock during the same period.
Interest Expense. Interest expense for the six months ended June 30, 2018 and 2017 was $46.1 million and $2.8 million, respectively. The increase in interest expense resulted primarily from the conversion of the December 2017 Notes during the three months ended June 30, 2018. The unamortized discount remaining at the date of conversion of $44.3 million was recognized as interest expense in the six months ended June 30, 2018.
Interest Income. Interest income for the six months ended June 30, 2018 and 2017 was $10 thousand and $457 thousand, respectively. We expect that continued low interest rates will significantly limit our interest income in the near term.
Income tax benefit. Income tax benefit for the six months ended June 30, 2018 and 2017 was $2.3 million and $3.1 million, respectively. The decrease in income tax benefit resulted mainly from the reduced effective tax rate due to tax reform.
Income (loss) on equity investments.  Income (loss) on equity investments for the six months ended June 30, 2018 and 2017 was $3.0 million and $2.1 million, respectively.  
Net Loss. Net loss for the six months ended June 30, 2018 and 2017 was $108.4 million and $38.5 million, respectively.  
Liquidity and Capital Resources
As of June 30, 2018, we had $46.8 million in cash and cash equivalents.

47


On March 26, 2018, we entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, we agreed to issue and sell to the Purchasers, in the Private Placement, the Notes in an aggregate principal amount of $120,500,000 and Warrants to purchase an aggregate of 8,591,794 shares.
On June 13, 2018, we entered into the Amendment, pursuant to which we and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of Common Stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, we issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of our common stock.
We cannot be certain that additional funding will be available on acceptable terms, or at all. If we issue additional equity securities to raise funds, the ownership percentage of existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. We may also seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. These factors raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q do not include any adjustments that might result from the outcome of this uncertainty.
Cash Flows from Operating Activities. Net cash used for operating activities was $46.1 million for the six months ended June 30, 2018 as compared to $41.7 million for the six months ended June 30, 2017. Cash used for operating activities increased by approximately $4.4 million and is primarily attributable to an increase in cash used for acquisition consideration for Scilex, rent expenses related to the relocation of our corporate offices, expenses resulting from non-compete agreements, and other operating activities.
We expect to continue to incur substantial and increasing losses and negative net cash flows from operating activities as we seek to expand and support our clinical and pre-clinical development and research activities and fund our joint ventures, collaborations and other third party agreements.
Cash Flows from Investing Activities. Net cash used for investing activities was $2.8 million for the six months ended June 30, 2018 as compared to $10.3 million for the six months ended June 30, 2017. Cash used for investing activities decreased by approximately $7.0 million primarily due to higher spend in research and development equipment and the investment in Celularity in the prior year.
We expect to increase our investment in equipment as we seek to expand and progress our research and development capabilities.
Cash Flows from Financing Activities. Net cash provided by financing activities was $75.4 million for the six months ended June 30, 2018 as compared to net cash used in financing of $23.1 million for the six months ended June 30, 2017. Cash provided by financing activities increased by approximately $52.3 million primarily due to sales of shares under the ATM Facility (as defined below) of approximately $58.3 million, the issuance of convertible notes of approximately $37.8 million in the current year, and the partial repayment of the amended loan and security agreement of approximately $21.5 million in the prior year, partially offset by the payments associated with the Scilex earn-out settlement of approximately $22.5 million for the six months ended June 30, 2018.
Future Liquidity Needs. We have principally financed our operations through underwritten public offerings and private equity financings with aggregate net proceeds of approximately $269.7 million since inception, as we have not generated any product related revenue to date from our principal operations of commercializing the Company's intellectual property assets focused on delivering clinically meaningful therapies, as well as the out-licensing of our technologies, and do not expect to generate significant revenue for several years, if ever. We will need to raise additional capital before we exhaust our current cash resources in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development and commercialization, as well as to fund operations generally. As and if necessary, we will seek to raise additional funds through various potential sources, such as equity and debt financings, or through corporate collaboration and license agreements. We can give no assurances that we will be able to secure such additional sources of funds to support our operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs.

48


We anticipate that we will continue to incur net losses into the foreseeable future as we: (i) advance RTX and other product candidates into clinical trials and potentially pursue other development, (ii) continue to identify and advance a number of potential mAb and ADC product candidates into preclinical development activities, (iii) continue our development of, and seek regulatory approvals for, our product candidates, (iv) expand our corporate infrastructure, including the costs associated with being a Nasdaq listed public company, and (v) incur our share of joint venture and collaboration costs for our products and technologies.
We plan to continue to fund our operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements.
In November 2014, we filed a universal shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC in December 2014 (the "2014 Shelf Registration"). The 2014 Shelf Registration Statement provided us with the ability to offer up to $250 million of securities, including equity and other securities as described in the registration statement. Included in the November 2014 shelf registration was a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $50.0 million of our common stock that may be issued and sold under a sales agreement with MLV & Co. LLC. On April 19, 2017, we completed the offering of $47.5 million of common stock pursuant to the 2014 Shelf Registration Statement and received net proceeds of approximately $43.5 million. On November 9, 2017, we filed a universal shelf registration statement on Form S-3 with the SEC (the "2017 Shelf Registration Statement") to replace the 2014 Shelf Registration Statement. The 2014 Shelf Registration Statement expired on December 6, 2017, when the 2017 Shelf Registration Statement was declared effective by the SEC. Included in the 2017 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our Common Stock that may be issued and sold under a sales agreement with B. Riley FBR, Inc. (the "ATM Facility"). During the twelve months ended December 31, 2017 and the six months ended June 30, 2018, we sold approximately $0.9 million and approximately $60.2 million in shares of common stock under the ATM Facility, respectively.  We have the ability to offer up to approximately $39.8 million of additional shares of common stock under the ATM Facility, subject to certain limitations.
Pursuant to the 2017 Shelf Registration Statement, we may offer additional securities from time to time and through one or more methods of distribution, subject to market conditions and our capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering.
On April 13, 2017, we entered into an underwriting agreement (the "Underwriting Agreement") with underwriters (the "Underwriters"), relating to the offering of 23,625,084 shares of our common stock (the "Offering"). The public offering price was $2.00 per share of our common stock and the Underwriters agreed to purchase the shares of common stock pursuant to the Underwriting Agreement at a price of $1.8571 per share. Under the terms of the Underwriting Agreement, we also granted to the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the closing of the Offering, to purchase up to an additional 3,543,763 shares of our common stock at the public offering price. 
On April 19, 2017, the Offering was completed and resulted in net proceeds of approximately $43.1 million (excluding any sale of shares of common stock pursuant to the option granted to the Underwriters), after deducting underwriting discounts and commissions and estimated Offering expenses payable by us.
On December 11, 2017, we entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, on December 21, 2017, we issued and sold to the Purchasers, in the Private Placement, (1) the Notes, which will accrue simple interest at a rate equal to 5.0% per annum and mature upon the Maturity Date, and (2) the Warrants to purchase an aggregate of 12,121,210 shares of our common stock. (See Note 12 of the accompanying notes to the condensed consolidated financial statements for additional information.)
On May 17, 2018, the December 2017 Purchasers converted in full the outstanding principal and accrued interest under the December 2017 Notes into 22,038,565 shares of the Company’s common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of $1.0 million in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of $44.3 million was recognized immediately at that date as interest expense.
If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Uses of Cash. We have and plan to expand our business and intellectual property portfolio through the acquisition of new businesses and technologies as well as entering into licensing arrangements.

49


Acquisition of Virttu Biologics Limited
On April 27, 2017, we entered into the Virttu Purchase Agreement with TNK, Virttu, the Virttu Shareholders and Dayspring Ventures Limited, as the representative of the Virttu Shareholders.
At the Closing, we issued to the Virttu Shareholders consideration valued at approximately $2.2 million, which consisted primarily of the Virttu Closing Shares and the Cash Consideration. The issuance of the Virttu Closing Shares and the payment of the Cash Consideration satisfied TNK’s obligation to pay 20% of the Virttu Base Consideration at the Closing. Under the terms of the Virttu Purchase Agreement, we agreed to provide additional consideration to the Virttu Shareholders, as follows:
(1) Upon a Qualified Financing, TNK would have issued to the Virttu Shareholders the TNK Financing Consideration; provided, however, that 20% of the TNK Financing Consideration was held in escrow until the Financing Due Date, to be used to, among other things, satisfy the indemnification obligations of the Virttu Shareholders. In the event that a Qualified Financing did not occur, then on the Financing Due Date, we would issue to the Virttu Shareholders an aggregate number of shares of our common stock as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration, by $5.55 (as adjusted, as appropriate, to reflect any stock splits or similar events affecting our common stock after the Closing).

(2) Within 45 business days after Virttu becomes aware of a Regulatory Approval, TNK shall pay half of the Regulatory Approval Consideration to the Virttu Shareholders, in a combination of (a) the Regulatory Approval Cash and/or (b) (i) such number of shares of our common stock as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP (as defined below) of one share of our common stock; (ii) if TNK has completed its first public offering of TNK Capital Stock, the number of shares of TNK Capital Stock as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP of one share of TNK Capital Stock; or (iii) such number of shares of common stock of a publicly traded company as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP, with the composition of the Regulatory Approval Consideration to be at TNK’s option. In order for a second regulatory approval to qualify as a Regulatory Approval under the Purchase Agreement, the second approval must be granted by a different governmental body in a different jurisdiction than that which granted the first Regulatory Approval.
In connection with the Virttu transaction, we recorded acquisition costs of approximately $0.9 million in general and administrative expenses for the twelve months ended December 31, 2017, for legal and related costs. No acquisition costs in connection with the Virttu transaction were recorded for the three or six months ended June 30, 2018. Acquisition costs are expensed as incurred.
TNK did not complete a Qualified Financing prior to the Financing Due Date and on April 27, 2018. Us, TNK and Dayspring entered into the Amendment, pursuant to which, among other things, we agreed that the acquisition consideration, otherwise payable on April 27, 2018 to the Virttu Shareholders, shall be as follows: (1) an issuance of 1,795,011 shares of our common stock to the Virttu Shareholders and (2) $9.9 million payable in cash .
We issued an aggregate of 1,795,011 shares of our common stock to the Virttu Shareholders on April 27, 2018 for a value of $11.3 million. The approximately $9.9 million payable in cash has not been paid as of the date of this filing.
Acquisition of Scilex Pharmaceuticals Inc.
On November 8, 2016, we entered into a Stock Purchase Agreement (the “Scilex Purchase Agreement”) with Scilex and a majority of the stockholders of Scilex (the “Scilex Stockholders”) pursuant to which, on November 8, 2016, we acquired from the Scilex Stockholders, and the Scilex Stockholders sold to us, approximately 72% of the outstanding capital stock of Scilex (the “Scilex Acquisition”). The remainder of the outstanding capital stock of Scilex represents a noncontrolling interest of which approximately 23% continues to be held by ITOCHU CHEMICAL FRONTIER CORPORATION following the Scilex Acquisition.
Under the terms of the Scilex Purchase Agreement, upon receipt of notice from the U.S. Food and Drug Administration (the "FDA") that the FDA has approved Scilex's new drug application for ZTlido™ (lidocaine topical system 1.8%) for the treatment of postherpetic neuralgia (the "NDA") for commercialization, we were obligated to deliver to the Scilex Stockholders cash and shares of its common stock in such proportion to be determined in our sole discretion as a milestone payment. On February 28, 2018, we received notice from the FDA that the FDA had approved the NDA. As a result, we issued to the Scilex Stockholders consideration valued at approximately $38.2 million, which included an aggregate of 1,381,346 shares of common stock of approximately $13.7 million, cash payment of approximately $24.5 million, including a bridge loan of approximately $20.0 million with B. Riley FBR and resulted in a change in fair value of $6.0 million since December 31, 2017, for the contingent consideration upon settlement.
License Agreement with Mabtech Limited

50


In August 2015, we entered into an exclusive licensing agreement to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from Mabtech Limited.  Under the terms of the agreement, we will develop and market four mAbs for the North American, European and Japanese markets. We made an initial license payment of $10.0 million and in February 2016, paid an additional $10.0 million license payment, both of which were recognized as acquired in-process research and development expense in the condensed consolidated statements of operations as we determined there was no alternative future use for the license.  
In June 2016, we agreed to accelerate and pay a $30.0 million milestone license payment which has been recognized as acquired in-process research and development expense in the condensed consolidated statements of operations, in exchange for the purchase by Mabtech Limited in June 2016, of $10.0 million of shares of common stock and warrants. 
In December 2017, we agreed to accelerate and, as a result, paid a $25.0 million milestone license payment, which has been recognized as acquired in-process research and development expense in the consolidated statements of operations for the year ended December 31, 2017. The amended agreement includes additional milestone payments totaling $125.0 million payable following the completion of the technology transfer from Mabtech Limited and for payables to extend the license agreement. The remaining anniversary payments are due on December 31, 2018 and 2019. We are not obligated to extend the license agreement. Accordingly, the additional future milestone payments have not yet been accrued as of June 30, 2018.
Off-Balance Sheet Arrangements
Since our inception through June 30, 2018, we have not engaged in any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.
New Accounting Pronouncements
Refer to Note 3, “Significant Accounting Policies,” in the accompanying notes to the condensed consolidated financial statements for a discussion of recent accounting pronouncements.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk. 
Interest Rate Risk. Our exposure to market risk is confined to our cash and cash equivalents. We have cash and cash equivalents and invest primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. We do not believe that we have any material exposure to interest rate risk arising from our investments.  
Capital Market Risk. We currently do not have significant revenues from grants or sales and services and we have no product revenues from our planned principal operations of commercializing the Company's intellectual property assets focused on delivering clinically meaningful therapies, as well as the out-licensing of the Company's technologies, and therefore depend on funds raised through other sources. One source of funding is through future debt or equity offerings. Our ability to raise funds in this manner depends upon, among other things, capital market forces affecting our stock price.
Item 4.    Controls and Procedures.
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s regulations, rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure.
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) promulgated by the SEC under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on the foregoing, our principal executive officer and principal

51


financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report on Form 10-Q as a result of the material weaknesses described below.
In March 2017, in connection with the preparation of our 2016 financial statements, we identified certain purchase agreements which contained terms for contingent consideration that were not identified timely and accounted for in our historical financial statements on a timely basis.  Further, certain other purchase agreements containing terms for contingent consideration were identified timely, but we failed to adjust the liabilities for changes in fair value at each subsequent reporting period. Accordingly, we did not appropriately account for liabilities for contingent consideration payable and the related adjustments to earnings.
Based on these findings and the criteria discussed above, our management identified a material weakness in our review controls over unusual or non-recurring and significant transactions.  Specifically, our controls were not properly designed to provide reasonable assurance that we (1) timely identify and assess the accounting implications of terms in unusual or non-recurring agreements and (2) reassess the valuation of associated assets or liabilities at the end of each reporting period.
As a result of the material weakness, we have initiated and will continue to implement remediation measures including, but not limited to, improving centralized documentation control, improving the internal communication procedures between senior executive management, accounting personnel, and related business owners, leveraging external accounting experts as appropriate, and strengthening policies and procedures related to the transferring of responsibilities and the handoff of personnel duties. We believe that our remediation measures, when implemented, will ensure that we timely identify terms in agreements that could have material accounting implications, assesses the accounting and disclosures implications of the terms, and accounts for such items in the financial statements appropriately.  Any failure to implement these improvements to our internal control over financial reporting may render our future assertions as ineffective and potentially impact our ability to produce reliable financial reports, effectively manage the company or prevent fraud, and could potentially harm our business and our performance.
As a result of the restatement of the condensed consolidated financial statements for the three and nine months ended September 30, 2017 for the impairment discussed in Note 9 to the financial statements, our management identified a material weakness in our review controls with respect to our equity method investments. Specifically, our review controls to assess and monitor the appropriateness of the financial information provided by our equity method investees were not operating effectively beginning in the quarter ended September 30, 2017, to provide reasonable assurance that we timely identify and assess the accounting implications of transactions and events occurring at our equity method investees and properly report such investee financial information in our financial statements. Accordingly, our principal executive officer and principal financial officer concluded that, at September 30, 2017, our internal control over financial reporting was not effective.
As a result of the material weakness, we have initiated and will continue to implement remediation measures including, but not limited to, establishing procedures to ensure that our existing controls to assess and monitor the appropriateness of the financial information provided by our equity method investees operate as designed. We believe that our remediation measures, when implemented, will provide reasonable assurance that we timely identify transactions and events occurring at our equity method investments that could have material accounting implications, assess the accounting and disclosures implications of the transactions and events, and account for such items in the financial statements appropriately in the time period in which such transactions and events occur.  Any failure to implement these improvements to our internal control over financial reporting may render our future assertions as ineffective and potentially impact our ability to produce reliable financial reports, effectively manage the company or prevent fraud, and could potentially harm our business and our performance.
Changes in Internal Control Over Financial Reporting
There has been no change in our internal control over financial reporting during the quarter ended June 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Our plans for remediating such material weaknesses, as identified above, are still in progress and would constitute changes in our internal control over financial reporting prospectively once implemented.


52


PART II. OTHER INFORMATION
Item 1.    Legal Proceedings.
To the best of our knowledge, we (the “Company”) are not a party to any legal proceedings that, individually or in the aggregate, are deemed to be material to our financial condition or results of operations.  
In the normal course of business, we may be named as a defendant in one or more lawsuits. We are not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to our financial condition or results of operations.  
Derivative Action Litigation
On September 8, 2016, Yvonne Williams filed an action both derivatively and on behalf of a purported class of stockholders in the Court of Chancery of the State of Delaware (the "Court") against each of the members of the Henry Ji, William S. Marth, Kim D. Janda, Jaisim Shah, David H. Deming, and Douglas Ebersole (the “Prior Board”); George Ng, the Company’s Executive Vice President, Chief Administrative Officer, and Chief Legal Officer; Jeffrey Su, the Company’s Executive Vice President & Chief Operating Officer; and the Company as nominal defendant, alleging: (1) breach of fiduciary duty with respect to the formation of, and certain options and warrants issued by, certain of the Company’s subsidiaries to Dr. Ji and members of the Prior Board; (2) breach of fiduciary duty with respect to the Company’s prior announcement that it had entered into a voting agreement with Yuhan Corporation in connection with a transaction through which it purchased $10 million of shares of our common stock and warrants (the “Williams Action”). On November 14, 2016, the Company filed motions to dismiss or in the alternative stay the Williams Action. George Ng and Jeffrey Su were dismissed as defendants by plaintiff during the briefing on the motions. The Court denied the motions on June 28, 2017.
On October 25, 2017, Yvonne Williams filed a Supplemental and Amended Class Action and Derivative Complaint which re-added George Ng as a defendant, added Eragon Ventures, LLC as a defendant, and added certain claims challenging transactions whereby Eragon Ventures, LLC agreed to purchase certain stock in the Company’s subsidiary, LA Cell. Following a mediation held on November 16, 2017, the parties agreed that day to a term sheet reflecting a settlement of the Williams Action, which agreement was memorialized in a Stipulation and Agreement of Settlement executed on December 22, 2017 and filed with the Court. The settlement consisted of non-monetary consideration, such as the cancellation of certain subsidiary shares of stock that were obtained by defendants pursuant to options previously exercised by defendants. The settlement and plaintiff’s counsel’s request for an award of attorneys’ fees were submitted to the Court for approval. On May 15, 2018, the Court held a hearing on the request for approval of the settlement and approved the settlement and awarded plaintiff’s counsel attorneys’ fees of $3.25 million. This case was dismissed with prejudice. The Company has caused the attorneys’ fees payment to be made, which payment was covered in large part, but not in whole, by insurance.
Immunomedics Litigation
On June 26, 2015, Immunomedics, Inc. (“Immunomedics”) filed a complaint in the United States District Court for the District of New Jersey (the “New Jersey Case”) against the Board of Directors of Roger Williams Medical Center, Dr. Richard P. Junghans, Dr. Steven C. Katz, the Office of the Board of Advisors of Tufts University School of Medicine, and one or more individuals or entities to be identified later. This complaint (the "Initial Complaint") alleged, among other things: (1) breach of contract; (2) breach of covenant of good faith and fair dealing; (3) tortious interference with prospective economic gain; (4) tortious interference with contracts; (5) misappropriation; (6) conversion; (7) bailment; (8) negligence; (9) vicarious liability; and (10) patent infringement. Overall, the allegations in the Initial Complaint were generally directed to an alleged material transfer agreement dated December 2008 and Immunomedics’ alleged request for the return of certain alleged research material, as well as the alleged improper use and conversion of such research materials outside the scope of the material transfer agreement.
On October 22, 2015, Immunomedics filed an amended complaint (the “First Amended Complaint”), which, among other things, no longer named the Board of Directors of Roger Williams Medical Center and The Office of the Board of Advisors of Tufts University School of Medicine as defendants. Roger Williams Medical Center and Tufts Medical Center were added as new defendants. On January 14, 2016, Immunomedics filed a second amended complaint (the "Second Amended Complaint"), which, among other things, no longer named Tufts Medical Center as a defendant. In addition, the Second Amended Complaint contained allegations directed to two additional alleged material transfer agreements dated September 1993 and May 2010, respectively, and also added an allegation of unjust enrichment. The Second Amended Complaint also no longer asserted claims for (1) breach of covenant of good faith and fair dealing; (2) misappropriation; (3) bailment; (4) negligence; and (5) vicarious liability.

53


On October 12, 2016, Immunomedics filed a third amended complaint (the “Third Amended Complaint”), which added the Company, TNK, BDL and CARgenix as defendants. TNK is a subsidiary of the Company and purchased BDL and CARgenix in August 2015. The Third Amended Complaint included, among other things, allegations against the Company, TNK, BDL and CARgenix regarding (1) conversion; (2) tortious interference; and (3) unjust enrichment. On December 2, 2016, the Company, TNK, BDL, and CARgenix filed a motion to dismiss Immunomedics’s complaint against them for lack of personal jurisdiction. On January 25, 2017, the District of New Jersey granted this motion, and the Company, TNK, BDL and CARgenix were dismissed as defendants from the New Jersey Case. Under various agreements, TNK has certain indemnification obligations to Roger Williams Medical Center, Dr. Richard P. Junghans and Dr. Steven C. Katz that may be implicated by the New Jersey Case. The New Jersey Case remains pending against defendants Roger Williams Medical Center ("RWMC"), Dr. Junghans, and Dr. Katz. A trial date has not yet been set.
On April 27, 2018, Immunomedics filed a complaint against the Company and TNK in Superior Court, Case No. 37-2018-00021006-CU-NP-CTL (the “ San Diego Case”). The complaint includes, among other things, allegations against the Company and TNK regarding: (1) conversion; (2) tortious interference; and (3) inducing breach of contract. No trial date has yet been set in the San Diego Case.
The Company believes that the New Jersey Case and the San Diego Case are without merit, and will vigorously defend itself in the litigation. However, should Immunomedics prevail against the Company, RWMC or other defendants, certain patent rights optioned, owned and/or licensed by the Company could be at risk of invalidity or enforceability, or the litigation could otherwise adversely impact the Company’s ownership or other rights in certain intellectual property.  At this point in time, the Company is unable to determine whether any loss will occur with respect to the New Jersey Case or the San Diego Case or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.

Cantor Fitzgerald & Co. Litigation

On May 25, 2018, Cantor Fitzgerald & Co. (“CF&Co.”) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, Index No. 652633/2018. The complaint includes, among other things, allegations against the Company for breach of contract arising out of a letter agreement whereby CF&Co. was to supply certain services to the Company in exchange for a fee (the “CF & Co. Litigation”). The Company has filed an Answer and Counterclaim for breach of contract against CF&Co claiming that CF&Co. did not perform under the letter agreement. The Company believes CF&Co.’s claims against the Company are without merit and will vigorously defend itself in the litigation. At this point in time, the Company is unable to determine whether any loss will occur with respect to the CF&Co. Litigation or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.

54


Item 1A.    Risk Factors.
Our Annual Report on Form 10-K for the year ended December 31, 2017, Part I –Item 1A, Risk Factors, describes important risk factors that could cause our business, financial condition, results of operations and growth prospects to differ materially from those indicated or suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or presented elsewhere by management from time to time. Except as set forth below, there have been no material changes in our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2017. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business.
Risks Related to Our Business and Industry

We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future.

As of June 30, 2018 and December 31, 2017, we had an accumulated deficit of $270.6 million and $165.1 million, respectively. We continue to incur significant research and development and other expenses related to our ongoing operations. We have incurred operating losses since our inception, expect to continue to incur significant operating losses for the foreseeable future, and we expect these losses to increase as we: (i) advance resiniferatoxin ("RTX") and our other product candidates into clinical trials and pursue other development, acquire, develop and manufacture clinical trial materials and increase other regulatory operating activities, (ii) incur incremental expenses associated with our efforts to further advance a number of potential product candidates into preclinical development activities, (iii) continue to identify and advance a number of fully human therapeutic antibody and antibody drug conjugate ("ADC") preclinical product candidates, (iv) incur higher salary, lab supply and infrastructure costs incurred in connection with supporting all of our programs, (v) invest in our joint ventures, collaborations or other third party agreements, (vi) incur expenses in conjunction with defending and enforcing our rights in various litigation matters, (vii) expand our corporate, development and manufacturing infrastructure, and (viii) support our subsidiaries, such as Scilex Pharmaceuticals Inc. (“Scilex”), in their commercialization efforts. As such, we are subject to all risks incidental to the development of new biopharmaceutical products and related companion diagnostics, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.

Clinical testing is expensive and can take many years to complete, and its outcome is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.

This drug candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes do carry the risk that they will not achieve these intended objectives.

Other than with respect to ZTlido™ (lidocaine topical system 1.8%), we have not previously initiated or completed a corporate-sponsored clinical trial. Consequently, we may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate, including our planned clinical trials of RTX, clinical trials of CAR-T including targeting CD38 using a CAR-T cell therapy, our biosimilar/biobetters antibodies and other product candidates, in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all.


55


In the event we are able to conduct a pivotal clinical trial of a product candidate, the results of such trial may not be adequate to support marketing approval. Because our product candidates are intended for use in life-threatening diseases, in some cases we ultimately intend to seek marketing approval for each product candidate based on the results of a single pivotal clinical trial. As a result, these trials may receive enhanced scrutiny from the U.S. Food and Drug Administration ("FDA"). For any such pivotal trial, if the FDA disagrees with our choice of primary endpoint or the results for the primary endpoint are not robust or significant relative to control, are subject to confounding factors, or are not adequately supported by other study endpoints, including possibly overall survival or complete response rate, the FDA may refuse to approve a New Drug Application, Biologics License Application or other application for marketing based on such pivotal trial. The FDA may require additional clinical trials as a condition for approving our product candidates.

The terms of our outstanding convertible promissory notes place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.

On June 13, 2018, we issued and sold convertible promissory notes in an aggregate principal amount of $37.8 million (the “Convertible Notes”) to certain accredited investors pursuant to a Securities Purchase Agreement, as amended (the “Securities Purchase Agreement”). The Convertible Notes accrue interest at a rate equal to 5.0% per annum and mature upon the earlier to occur of June 13, 2023 and the date of the closing of a change of control (the “Maturity Date”). At any time and from time to time before the Maturity Date, the holders of the Convertible Notes have the option to convert any portion of the outstanding principal amount of the Convertible Notes that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of the Convertible Note being converted into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Any conversion of the Convertible Notes could result in material dilution to the Company's existing stockholders. Accrued but unpaid interest on the Convertible Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018. If a holder elects to convert any of the principal amount of their Convertible Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Securities Purchase Agreement and the Convertible Notes contain customary restrictive covenants, which will remain in effect so long as the aggregate outstanding principal amount of the Convertible Notes is at least $18.8 million, including significant limitations on incurring additional indebtedness, liens, declaring cash dividends or making cash distributions and dispositions of our assets, in each case subject to customary exceptions. The breach of such covenants or the occurrence of certain other events would result in the occurrence of an event of default. Upon the occurrence of an event of default and following any applicable cure periods, the interest rate under the Convertible Notes will automatically increase to 12.0% per annum, effective until the day after such default is cured, and the holders of the Convertible Notes may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Convertible Notes, potentially requiring us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Any declaration by the holders of the Convertible Notes of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.

Our operations in China subject us to risks and uncertainties relating to the laws and regulations of China.

Certain of our operations are currently based in China. Under its current leadership, the government of China has been pursuing economic reform policies, including by encouraging foreign trade and investment.  However, there is no assurance that the Chinese government will continue to pursue such policies, that such policies will be successfully implemented, that such policies will not be significantly altered, or that such policies will be beneficial to our operations in China.  China’s system of laws can be unpredictable, especially with respect to foreign investment and foreign trade.  The promulgation of new laws and regulations and changes to existing laws and regulations may adversely affect foreign investors and foreign entities with operations in China. For example, the U.S. government has called for substantial changes to foreign trade policy with China and has recently raised, and has proposed to further raise in the future, tariffs on several Chinese goods. China has retaliated with increased tariffs on U.S. goods, which we anticipate will increase our cost of doing business in China. Any further changes in U.S. trade policy could trigger retaliatory actions by affected countries, including China, resulting in trade wars and in increased costs for goods imported into the United States and our ability to sell goods and services in the affected countries, which may reduce customer demand for our products and services, especially if the parties having to pay those tariffs increase their prices, or in trading partners limiting their trade with the United States. If these consequences are realized, this may materially and adversely affect our sales and our business.


56


Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government.  Changes to Chinese regulations affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our Chinese operations and on our business and financial condition.

Risks Related to Our Intellectual Property

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.
Risks Related to Ownership of Our Common Stock

We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.

We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. Pursuant to our outstanding convertible notes issued in June 2018, so long as the outstanding principal amount under all such notes is at least $18,845,851, we are prohibited from paying any dividends without the prior written consent of the holders of such notes. The payment of dividends on our capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the common stock price appreciates.

These risks and others as described in our Annual Report on Form 10-K for the year ended December 31, 2017 may have a material adverse effect on our global operations and on our business and financial condition.


57




Item 6.    Exhibits.


58


EXHIBIT INDEX
4.1
 

 
 
 
4.2
 

 
 
 
4.3
 
 
 
 
10.1
 
 
 
 
10.2
 

 
 
 
12.1
 
 
 
 
31.1
  
 
 
 
31.2
  
 
 
 
32.1
  
 
 
 
101.INS
  
XBRL Instance Document
 
 
 
101.SCH
  
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF
  
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB
  
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 

59


 
 
Sorrento Therapeutics, Inc.
 
 
 
 
Date:
August 9, 2018
By:  
/s/ Henry Ji, Ph.D. 
 
 
 
Henry Ji, Ph.D.
 
 
 
Chairman of the Board of Directors, Chief Executive Officer & President
 
 
 
(Principal Executive Officer)
 
 
 
 
Date:
August 9, 2018
By:  
/s/ Jiong Shao
 
 
 
Jiong Shao

 
 
 
Executive Vice President & Chief Financial Officer
 
 
 
(Principal Financial Officer)

60
 EX-12.1 2 exhibit121.htm EXHIBIT 12.1 Exhibit
Exhibit 12.1
Sorrento Therapeutics, Inc.
Ratio of Earnings to Fixed Charges
(Dollars in thousands)

 
 
Six Months Ended
 
Fiscal Year Ended December, 31
(in $ thousands)
 
June 30, 2018
 
2017
2016
2015
2014
2013
 
 
 
 
 
 
 
 
 
Pretax Income (Loss) from Continuing Operations
 
(107,653)
 
15,315
(65,268)
(9,719)
(36,359)
(21,911)
Fixed Charges (per below)
 
46,136
 
5,201
1,712
1,651
1,628
254
Interests Capitalized
 
-
 
-
-
-
-
-
 
 
 
 
 
 
 
 
 
Earnings
 
(61,517)
 
20,516
(63,556)
(8,068)
(34,731)
(21,657)
 
 
 
 
 
 
 
 
 
Interests and Other Financial Charges
 
46,032
 
4,980
1,615
1,651
1,628
254
Interests Portion of Rental Expense
 
104
 
221
97
-
-
-
 
 
 
 
 
 
 
 
 
Fixed Charges
 
46,136
 
5,201
1,712
1,651
1,628
254
 
 
 
 
 
 
 
 
 
Ratio of Earnings to Fixed Charges
 
(1.3)
 
3.9
(37.1)
(4.9)
(21.3)
(85.3)


 EX-31.1 3 exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
Pursuant to Rule 13a-14(a) adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Henry Ji, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Sorrento Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Henry Ji, Ph.D.
Henry Ji, Ph.D.
Chairman of the Board of Directors, Chief Executive Officer and President
(Principal Executive Officer)
Dated: August 9, 2018
 


 EX-31.2 4 exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
Pursuant to Rule 13a-14(a) adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Jiong Shao, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Sorrento Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Jiong Shao
Jiong Shao
Chief Financial Officer
(Principal Financial Officer)
Dated: August 9, 2018
 


 EX-32.1 5 exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATIONS OF
PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Henry Ji, Principal executive officer of Sorrento Therapeutics, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
1. The Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
August 9, 2018
By: 
/s/ Henry Ji, Ph.D.
 
 
 
Henry Ji, Ph.D.
 
 
 
Chairman of the Board of Directors, Chief Executive Officer and President
 
 
 
(Principal Executive Officer)
I, Jiong Shao, Principal financial officer of Sorrento Therapeutics, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
1. The Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
August 9, 2018

By: 
/s/ Jiong Shao
 
 
 
Jiong Shao
 
 
 
Chief Financial Officer
 
 
 
(Principal Financial Officer)
A signed original of these certifications has been provided to Sorrento Therapeutics, Inc. and will be retained by Sorrento Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Sorrento Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.


 EX-101.INS 6 srne-20180630.xml XBRL INSTANCE DOCUMENT 0000850261 2018-01-01 2018-06-30 0000850261 2018-08-06 0000850261 2017-12-31 0000850261 2018-06-30 0000850261 2017-04-01 2017-06-30 0000850261 2017-01-01 2017-06-30 0000850261 2018-04-01 2018-06-30 0000850261 us-gaap:GrantMember 2017-01-01 2017-06-30 0000850261 srne:ProductAndServiceMember 2018-01-01 2018-06-30 0000850261 us-gaap:GrantMember 2018-04-01 2018-06-30 0000850261 srne:RoyaltyAndLicenseMember 2018-01-01 2018-06-30 0000850261 srne:RoyaltyAndLicenseMember 2017-01-01 2017-06-30 0000850261 srne:RoyaltyAndLicenseMember 2017-04-01 2017-06-30 0000850261 srne:ProductAndServiceMember 2017-01-01 2017-06-30 0000850261 us-gaap:GrantMember 2017-04-01 2017-06-30 0000850261 srne:RoyaltyAndLicenseMember 2018-04-01 2018-06-30 0000850261 srne:ProductAndServiceMember 2018-04-01 2018-06-30 0000850261 srne:ProductAndServiceMember 2017-04-01 2017-06-30 0000850261 us-gaap:GrantMember 2018-01-01 2018-06-30 0000850261 us-gaap:RetainedEarningsMember 2017-12-31 0000850261 us-gaap:CommonStockMember 2017-12-31 0000850261 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000850261 us-gaap:TreasuryStockMember 2018-06-30 0000850261 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000850261 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000850261 us-gaap:RetainedEarningsMember 2018-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000850261 us-gaap:CommonStockMember 2018-06-30 0000850261 us-gaap:TreasuryStockMember 2017-12-31 0000850261 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-06-30 0000850261 srne:BDLProductsIncMember 2018-01-01 2018-06-30 0000850261 srne:VirttuBiologicsLimitedMember 2018-01-01 2018-06-30 0000850261 srne:BDLProductsIncMember us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000850261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000850261 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000850261 srne:VirttuBiologicsLimitedMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000850261 us-gaap:NoncontrollingInterestMember 2017-12-31 0000850261 us-gaap:NoncontrollingInterestMember 2018-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember 2018-01-01 2018-06-30 0000850261 srne:VirttuBiologicsLimitedMember us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000850261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000850261 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0000850261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000850261 srne:BDLProductsIncMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000850261 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0000850261 us-gaap:TreasuryStockMember 2016-12-31 0000850261 us-gaap:NoncontrollingInterestMember 2017-06-30 0000850261 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-06-30 0000850261 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0000850261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000850261 us-gaap:CommonStockMember 2017-06-30 0000850261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000850261 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000850261 us-gaap:TreasuryStockMember 2017-06-30 0000850261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000850261 us-gaap:CommonStockMember 2016-12-31 0000850261 us-gaap:RetainedEarningsMember 2017-06-30 0000850261 2017-06-30 0000850261 us-gaap:NoncontrollingInterestMember 2016-12-31 0000850261 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0000850261 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000850261 2016-12-31 0000850261 us-gaap:RetainedEarningsMember 2016-12-31 0000850261 us-gaap:CommonStockMember 2017-04-01 2017-04-30 0000850261 srne:ABGPurchaseAgreementMember us-gaap:PrivatePlacementMember 2016-04-03 0000850261 srne:A2017WarrantsMember us-gaap:PrivatePlacementMember 2017-12-21 0000850261 srne:PromissoryNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-12-21 0000850261 srne:YuhanCorporationMember us-gaap:PrivatePlacementMember 2016-05-02 2016-05-02 0000850261 srne:NovemberTwoThousandFourteenRegistrationMember 2017-01-01 2017-12-31 0000850261 srne:CancellationAndForfeitureAgreementsMember us-gaap:InvestorMember 2016-12-31 2016-12-31 0000850261 srne:PromissoryNoteDue2023Member us-gaap:ConvertibleDebtMember 2018-06-13 0000850261 srne:March2018WarrantMember us-gaap:PrivatePlacementMember 2018-06-13 0000850261 srne:YuhanCorporationMember us-gaap:PrivatePlacementMember 2016-05-02 0000850261 srne:AdditionalPurchaseAgreementsMember srne:BeijingShijilongxinInvestmentCoLtdMember us-gaap:PrivatePlacementMember 2016-04-03 2016-04-03 0000850261 srne:ABGPurchaseAgreementMember us-gaap:PrivatePlacementMember 2016-04-03 2016-04-03 0000850261 srne:LoanAndSecurityAgreementMember 2018-06-30 0000850261 srne:PromissoryNotesDue2022Member us-gaap:ConvertibleDebtMember 2018-05-17 0000850261 srne:ABGPurchasersBeijingShijilongxinAndFrejoyMember 2016-06-07 0000850261 srne:November2017RegistrationMember us-gaap:CommonStockMember srne:ATMFacilityMember 2018-04-01 2018-06-30 0000850261 srt:MaximumMember srne:ABGPurchaseAgreementMember us-gaap:PrivatePlacementMember 2016-04-03 2016-04-03 0000850261 srne:ABGPurchasersBeijingShijilongxinAndFrejoyMember 2016-05-31 2016-06-07 0000850261 2014-12-31 0000850261 srne:March2018NotesMember us-gaap:ConvertibleDebtMember 2018-03-26 0000850261 srne:March2018WarrantMember us-gaap:PrivatePlacementMember 2018-03-26 0000850261 srne:AdditionalPurchaseAgreementsMember srne:FREJOYInvestmentManagementCoLtdMember us-gaap:PrivatePlacementMember 2016-04-03 2016-04-03 0000850261 us-gaap:CommonStockMember 2018-05-17 2018-05-17 0000850261 2017-12-21 2017-12-21 0000850261 srne:SecuredPromissoryNotesMember srne:CancellationAndForfeitureAgreementsMember us-gaap:InvestorMember 2016-12-31 2016-12-31 0000850261 srne:AdditionalPurchaseAgreementsMember srne:YuhanCorporationMember us-gaap:PrivatePlacementMember 2016-04-03 2016-04-03 0000850261 srne:March2018NotesMember us-gaap:ConvertibleDebtMember 2018-06-13 0000850261 srne:PromissoryNotesDue2022Member us-gaap:ConvertibleDebtMember 2018-05-17 2018-05-17 0000850261 srne:November2017RegistrationMember 2017-11-30 0000850261 srne:AdditionalPurchaseAgreementsMember srne:BeijingShijilongxinInvestmentCoLtdMember us-gaap:PrivatePlacementMember 2016-04-03 0000850261 srne:A2017WarrantsMember 2018-06-13 0000850261 srne:November2017RegistrationMember us-gaap:CommonStockMember srne:ATMFacilityMember 2018-01-01 2018-06-30 0000850261 srne:November2017RegistrationMember srne:ATMFacilityMember 2018-06-30 0000850261 srne:November2017RegistrationMember srne:ATMFacilityMember 2017-11-30 0000850261 srne:November2017RegistrationMember us-gaap:CommonStockMember srne:ATMFacilityMember 2017-01-01 2017-12-31 0000850261 srne:A2017WarrantsMember us-gaap:PrivatePlacementMember 2017-12-21 2017-12-21 0000850261 srne:March2018WarrantMember us-gaap:PrivatePlacementMember 2018-03-26 2018-03-26 0000850261 srne:AdditionalPurchaseAgreementsMember srne:FREJOYInvestmentManagementCoLtdMember us-gaap:PrivatePlacementMember 2016-04-03 0000850261 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000850261 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000850261 us-gaap:WarrantMember 2017-01-01 2017-06-30 0000850261 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2018-07-01 2018-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2018-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2019-01-01 2018-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2018-01-01 2018-06-30 0000850261 srne:SaleAndServiceMaterialSupplyMember 2018-04-01 2018-06-30 0000850261 srne:SaleAndServiceMaterialSupplyMember 2017-01-01 2017-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2017-01-01 2017-06-30 0000850261 srne:SaleAndServiceMaterialSupplyMember 2018-01-01 2018-06-30 0000850261 srne:SaleAndServiceCustomizedReagentsMember 2018-01-01 2018-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2018-01-01 2018-06-30 0000850261 srne:SaleAndServiceMaterialSupplyMember 2017-04-01 2017-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2017-04-01 2017-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2018-04-01 2018-06-30 0000850261 srne:SaleAndServiceCustomizedReagentsMember 2017-04-01 2017-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2018-04-01 2018-06-30 0000850261 srne:SaleAndServiceCustomizedReagentsMember 2017-01-01 2017-06-30 0000850261 srne:SaleAndServiceCustomizedReagentsMember 2018-04-01 2018-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2017-04-01 2017-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2017-01-01 2017-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2017-01-01 2017-12-31 0000850261 srne:SaleAndServiceDrugandReagentsMember 2018-06-30 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember srne:RoyaltyAndLicenseMember 2018-06-30 0000850261 srne:SaleAndServiceDrugandReagentsMember 2017-12-31 0000850261 srne:SaleAndServiceMaterialSupplyMember 2018-06-30 0000850261 srne:GrantsReceivableMember 2018-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2017-09-26 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember srne:RoyaltyAndLicenseMember 2018-06-30 0000850261 srt:MinimumMember 2018-01-01 2018-06-30 0000850261 2017-10-01 2017-12-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember srne:RoyaltyAndLicenseMember 2017-12-31 0000850261 us-gaap:TradeAccountsReceivableMember 2018-06-30 0000850261 srt:MaximumMember 2018-01-01 2018-06-30 0000850261 srne:SaleAndServiceJointDevelopmentMember 2017-09-26 2017-09-26 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember srne:RoyaltyAndLicenseMember 2018-01-01 2018-06-30 0000850261 srne:NantCellMember srne:RoyaltyAndLicenseMember 2018-06-30 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember srne:RoyaltyAndLicenseMember 2016-09-01 2016-09-01 0000850261 srne:GrantsReceivableMember 2017-12-31 0000850261 us-gaap:TradeAccountsReceivableMember 2017-12-31 0000850261 srne:NantCellMember srne:RoyaltyAndLicenseMember 2017-12-31 0000850261 srne:BDLProductsIncMember srne:StockPurchaseAgreementMember 2018-03-19 2018-03-19 0000850261 srne:ScilexPharmaceuticalsIncMember srne:FDAApprovalForCommercializationMember 2018-02-28 2018-02-28 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember srne:RegulatoryApprovalConsiderationMember 2017-04-27 2017-04-27 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember 2018-04-27 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember 2017-04-27 2017-04-27 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember 2017-04-27 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember us-gaap:InProcessResearchAndDevelopmentMember 2017-04-27 0000850261 us-gaap:LoansReceivableMember srne:ScilexPharmaceuticalsIncMember srne:FDAApprovalForCommercializationMember 2018-02-28 2018-02-28 0000850261 srne:TNKTherapeuticsIncMember srt:MinimumMember srne:VirttuBiologicsLimitedMember 2017-04-27 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember srne:RegulatoryApprovalConsiderationMember 2017-04-27 0000850261 srne:ScilexPharmaceuticalsIncMember srne:FDAApprovalForCommercializationMember 2018-02-28 0000850261 srne:ScilexPharmaceuticalsIncMember 2016-11-08 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember 2018-04-27 2018-04-27 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0000850261 srne:BDLProductsIncMember srne:StockPurchaseAgreementMember 2015-08-31 0000850261 srne:TNKTherapeuticsIncMember srt:MaximumMember srne:VirttuBiologicsLimitedMember srne:RegulatoryApprovalConsiderationMember 2017-04-27 0000850261 srne:BDLProductsIncMember srne:StockPurchaseAgreementMember 2015-08-01 2015-08-31 0000850261 srne:ItochuChemicalFrontierCorporationMember 2016-11-08 0000850261 srne:BDLProductsIncMember us-gaap:CommonClassAMember srne:StockPurchaseAgreementMember 2015-08-31 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember 2018-06-30 0000850261 srne:TNKTherapeuticsIncMember srne:VirttuBiologicsLimitedMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0000850261 srne:VirttuBiologicsLimitedMember srne:MilestonesAchievementMember 2018-01-01 2018-06-30 0000850261 srne:VirttuBiologicsLimitedMember srne:MilestonesAchievementMember 2018-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember srne:MilestonesAchievementMember 2018-01-01 2018-06-30 0000850261 srne:BDLProductsIncMember srne:MilestonesAchievementMember 2018-01-01 2018-06-30 0000850261 srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueInputsLevel2Member srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueInputsLevel2Member srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueInputsLevel1Member srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueInputsLevel1Member srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:FairValueInputsLevel3Member srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:InvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:FairValueInputsLevel3Member srne:ContingentConsiderationCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000850261 srne:ShanghaiThreeMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember 2018-06-30 0000850261 srne:VirttuBiologicsLimitedMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember 2018-06-30 0000850261 srne:ConcortisMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember 2018-06-30 0000850261 srne:RWMCMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember 2018-06-30 0000850261 srne:ContingentConsiderationLiabilitiesMember 2017-12-31 0000850261 srne:ContingentConsiderationLiabilitiesMember 2018-01-01 2018-06-30 0000850261 srne:ContingentConsiderationLiabilitiesMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:RWMCMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDiscountRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:ConcortisMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDefaultRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:ShanghaiThreeMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDiscountRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:VirttuBiologicsLimitedMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDiscountRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:ConcortisMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDiscountRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:RWMCMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDefaultRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:VirttuBiologicsLimitedMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDefaultRateMember 2018-06-30 0000850261 srt:WeightedAverageMember srne:ShanghaiThreeMember us-gaap:FairValueInputsLevel3Member srne:ContingentLiabilitiesMember us-gaap:MeasurementInputDefaultRateMember 2018-06-30 0000850261 srne:MedoveXCommonSharesAndWarrantsMember 2018-06-30 0000850261 srne:MedoveXCommonSharesAndWarrantsMember 2017-12-31 0000850261 us-gaap:WarrantMember 2017-12-31 0000850261 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000850261 us-gaap:WarrantMember 2018-06-30 0000850261 srne:UnitPurchaseAgreementMember srne:MedoveXCorporationMember 2016-08-05 0000850261 srne:MedoveXCommonSharesAndWarrantsMember 2018-04-01 2018-06-30 0000850261 srne:UnitPurchaseAgreementMember srne:MedoveXCorporationMember 2016-08-05 2016-08-05 0000850261 srne:MedoveXCommonSharesAndWarrantsMember 2018-01-01 2018-06-30 0000850261 srne:MedoveXCommonSharesAndWarrantsMember 2017-04-01 2017-06-30 0000850261 srne:MedoveXCommonSharesAndWarrantsMember 2017-01-01 2017-06-30 0000850261 us-gaap:LeaseholdImprovementsMember 2017-12-31 0000850261 us-gaap:FurnitureAndFixturesMember 2018-06-30 0000850261 us-gaap:MachineryAndEquipmentMember 2018-06-30 0000850261 us-gaap:LeaseholdImprovementsMember 2018-06-30 0000850261 us-gaap:ConstructionInProgressMember 2017-12-31 0000850261 us-gaap:OfficeEquipmentMember 2018-06-30 0000850261 us-gaap:OfficeEquipmentMember 2017-12-31 0000850261 us-gaap:MachineryAndEquipmentMember 2017-12-31 0000850261 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000850261 us-gaap:ConstructionInProgressMember 2018-06-30 0000850261 srne:NantCancerStemLLCMember 2015-07-01 2015-07-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2018-06-30 0000850261 srne:ShanghaiThreeMember 2018-06-30 0000850261 srne:NANTibodyMember 2017-12-31 0000850261 srne:IgDraSolIncMember 2013-01-01 2013-12-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2017-01-01 2017-06-30 0000850261 srne:NantCellMember srne:NANTibodyMember 2015-07-31 0000850261 srne:ShanghaiThreeMember 2018-04-01 2018-06-30 0000850261 srne:NANTibodyMember 2015-04-30 0000850261 srne:NANTibodyMember 2017-06-30 0000850261 srne:NantCancerStemLLCMember 2018-03-31 0000850261 srne:NANTibodyMember 2017-07-01 2017-09-30 0000850261 srne:NantCancerStemLLCMember 2015-07-31 0000850261 srne:NANTibodyMember 2018-03-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2018-01-01 2018-06-30 0000850261 srne:NantCancerStemLLCMember 2018-04-01 2018-06-30 0000850261 srne:NantCancerStemLLCMember 2018-06-30 0000850261 srne:NANTibodyMember 2017-09-30 0000850261 srne:NantCancerStemLLCMember 2015-10-13 2015-10-13 0000850261 srne:NANTibodyMember 2015-07-31 0000850261 srne:NANTibodyMember 2018-06-30 0000850261 srne:TNKTherapeuticsIncMember 2016-03-07 2016-03-07 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2018-04-01 2018-06-30 0000850261 srne:YuhanCorporationMember srne:ImmuneOnciaTherapeuticsLLCMember 2016-03-31 0000850261 srne:NANTibodyMember us-gaap:EquityMethodInvestmentsMember 2017-07-02 2017-07-02 0000850261 srne:NantCancerStemLLCMember 2017-01-01 2017-03-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2016-03-31 0000850261 srne:NantCellMember srne:NANTibodyMember 2015-04-30 0000850261 srne:NANTibodyMember 2016-12-31 0000850261 srne:IgDraSolIncMember 2015-05-01 2015-05-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2017-04-01 2017-06-30 0000850261 srne:NantCancerStemLLCMember 2015-10-01 2015-12-31 0000850261 srne:NANTibodyMember 2018-01-01 2018-03-31 0000850261 srne:NantCancerStemLLCMember 2017-06-30 0000850261 srne:NantCancerStemLLCMember 2015-10-13 0000850261 srne:NANTibodyMember 2017-01-01 2017-03-31 0000850261 srne:NantCellMember srne:NantCancerStemLLCMember 2015-04-30 0000850261 srne:YuhanCorporationMember srne:ImmuneOnciaTherapeuticsLLCMember 2016-10-31 0000850261 srne:TNKTherapeuticsIncMember us-gaap:CommonClassAMember 2016-03-07 0000850261 srne:NantCancerStemLLCMember 2018-01-01 2018-03-31 0000850261 srne:NantBioScienceIncMember srne:NantCancerStemLLCMember 2015-07-31 0000850261 srne:YuhanCorporationMember us-gaap:PrivatePlacementMember 2016-04-01 2016-04-30 0000850261 2015-05-31 0000850261 srne:NANTibodyMember 2015-07-31 0000850261 srne:ImmuneOnciaTherapeuticsLLCMember 2016-10-31 0000850261 srne:ShanghaiThreeMember 2016-10-01 2017-03-31 0000850261 srne:ShanghaiThreeMember 2017-04-01 2017-06-30 0000850261 srne:ShanghaiThreeMember 2017-10-01 2018-03-31 0000850261 us-gaap:CustomerRelationshipsMember 2018-06-30 0000850261 us-gaap:InProcessResearchAndDevelopmentMember 2018-06-30 0000850261 srne:AcquiredTechnologyMember 2018-06-30 0000850261 us-gaap:PatentsMember 2018-06-30 0000850261 us-gaap:PatentsMember 2017-01-01 2017-06-30 0000850261 srt:MaximumMember us-gaap:PatentsMember 2018-01-01 2018-06-30 0000850261 srne:AcquiredTechnologyMember 2018-01-01 2018-06-30 0000850261 us-gaap:CustomerRelationshipsMember 2017-04-01 2017-06-30 0000850261 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0000850261 us-gaap:PatentsMember 2018-01-01 2018-06-30 0000850261 srt:WeightedAverageMember 2018-01-01 2018-06-30 0000850261 srt:MinimumMember us-gaap:PatentsMember 2018-01-01 2018-06-30 0000850261 us-gaap:CustomerRelationshipsMember 2018-04-01 2018-06-30 0000850261 us-gaap:PatentsMember 2018-04-01 2018-06-30 0000850261 us-gaap:PatentsMember 2017-04-01 2017-06-30 0000850261 srne:AcquiredTechnologyMember 2018-04-01 2018-06-30 0000850261 srne:AcquiredTechnologyMember 2017-12-31 0000850261 us-gaap:PatentsMember 2017-12-31 0000850261 us-gaap:CustomerRelationshipsMember 2017-12-31 0000850261 us-gaap:InProcessResearchAndDevelopmentMember 2017-12-31 0000850261 srne:AcquiredTechnologyMember 2017-04-01 2017-06-30 0000850261 srne:AcquiredTechnologyMember 2017-01-01 2017-06-30 0000850261 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-06-30 0000850261 us-gaap:GeneralAndAdministrativeExpenseMember srne:TSRILicenseMember 2018-01-01 2018-06-30 0000850261 srt:MaximumMember srne:NantCellMember 2015-04-01 2015-04-30 0000850261 srne:NantCellMember 2015-04-30 0000850261 srne:TNKTherapeuticsIncMember srne:RogerWilliamsMedicalCenterMember us-gaap:CommonClassAMember 2016-04-30 0000850261 srne:RogerWilliamsMedicalCenterMember 2018-04-01 2018-06-30 0000850261 us-gaap:GrantMember srne:StaphGrantThreeAwardMember 2018-01-01 2018-06-30 0000850261 country:CN srne:MabtechLimitedMember 2017-12-31 0000850261 srne:StaphGrantThreeAwardMember 2014-06-01 2014-06-30 0000850261 country:CN srne:AcquiredInProgressResearchAndDevelopmentExpenseMember srne:MabtechLimitedMember 2015-08-01 2015-08-31 0000850261 us-gaap:GeneralAndAdministrativeExpenseMember srne:TSRILicenseMember 2017-01-01 2017-06-30 0000850261 us-gaap:GeneralAndAdministrativeExpenseMember srne:TSRILicenseMember 2018-04-01 2018-06-30 0000850261 us-gaap:GrantMember srne:StaphGrantThreeAwardMember 2017-01-01 2017-06-30 0000850261 srne:RogerWilliamsMedicalCenterMember 2016-04-01 2016-04-30 0000850261 srne:NantCellMember 2018-06-30 0000850261 srne:NantCellMember 2015-04-01 2015-04-30 0000850261 us-gaap:GrantMember srne:StaphGrantThreeAwardMember 2017-04-01 2017-06-30 0000850261 srne:TSRILicenseMember 2010-01-01 2010-01-31 0000850261 srne:TNKTherapeuticsIncMember srne:RogerWilliamsMedicalCenterMember us-gaap:CommonClassAMember 2016-04-01 2016-04-30 0000850261 country:CN srne:MabtechLimitedMember 2016-06-01 2016-06-30 0000850261 country:CN srne:AcquiredInProgressResearchAndDevelopmentExpenseMember srne:MabtechLimitedMember 2016-06-01 2016-06-30 0000850261 country:CN srne:MabtechLimitedMember 2015-08-31 0000850261 srne:RogerWilliamsMedicalCenterMember 2018-01-01 2018-06-30 0000850261 srne:AcquiredInProgressResearchAndDevelopmentExpenseMember srne:MabtechLimitedMember 2017-12-01 2017-12-31 0000850261 country:CN srne:MabtechLimitedMember 2016-02-01 2016-02-29 0000850261 us-gaap:GrantMember srne:StaphGrantThreeAwardMember 2018-04-01 2018-06-30 0000850261 us-gaap:GeneralAndAdministrativeExpenseMember srne:TSRILicenseMember 2017-04-01 2017-06-30 0000850261 srne:RogerWilliamsMedicalCenterMember 2017-01-01 2017-06-30 0000850261 srne:RogerWilliamsMedicalCenterMember 2017-04-01 2017-06-30 0000850261 srne:AmendedLoanAndSecurityAgreementMember 2017-11-06 0000850261 2016-11-23 2016-11-23 0000850261 srne:ChineseYuanTermLoanMember 2018-03-31 0000850261 srne:TermLoanTrancheTwoMember 2016-11-23 0000850261 2017-12-21 0000850261 srne:LoanAndSecurityAgreementMember 2017-03-23 0000850261 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000850261 srne:March2018WarrantMember srne:March2018NotesMember us-gaap:ConvertibleDebtMember 2018-06-13 0000850261 srne:TermLoanMember 2017-11-06 2017-11-06 0000850261 srne:PromissoryNotesDue2022Member us-gaap:ConvertibleDebtMember us-gaap:PrivatePlacementMember 2017-12-21 0000850261 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000850261 srne:TermLoanTrancheOneMember 2017-03-15 2017-03-15 0000850261 srne:ChineseYuanTermLoanMember 2018-03-01 2018-03-31 0000850261 srne:March2018NotesMember us-gaap:ConvertibleDebtMember 2018-06-13 2018-06-13 0000850261 srne:TermLoanTrancheOneMember 2016-11-23 0000850261 srne:TermLoanMember 2016-11-23 0000850261 srne:TermLoanMember 2017-03-23 2017-03-23 0000850261 us-gaap:ConvertibleDebtMember 2018-06-30 0000850261 us-gaap:ConvertibleDebtMember 2018-01-01 2018-06-30 0000850261 us-gaap:ConvertibleDebtMember 2017-12-31 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2018-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2018-01-01 2018-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2017-12-31 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2018-06-30 0000850261 srne:AssignmentAgreementMember 2018-06-30 0000850261 srne:UnderwritersAgreementMember us-gaap:WarrantMember 2018-06-30 0000850261 us-gaap:EmployeeStockOptionMember srne:NonEmployeeDirectorPlanMember 2018-06-30 0000850261 srne:LoanAndSecurityAgreementMember us-gaap:WarrantMember 2018-06-30 0000850261 srne:HerculesSecuritiesAgreementMember us-gaap:WarrantMember 2018-06-30 0000850261 us-gaap:ConvertibleDebtSecuritiesMember us-gaap:WarrantMember 2018-06-30 0000850261 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2018-06-30 0000850261 srne:VirttuAcquisitionAgreementMember 2018-06-30 0000850261 srne:TNKTherapeuticsIncMember srt:MaximumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-01 2015-05-31 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassBMember us-gaap:ChiefExecutiveOfficerMember 2015-05-31 0000850261 srne:ScintillaPharmaceuticalsIncMember srt:MaximumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassBMember us-gaap:ChiefExecutiveOfficerMember 2015-10-31 0000850261 srne:TwoThousandFifteenStockOptionPlanMember us-gaap:DirectorMember 2017-01-01 2017-06-30 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-31 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2018-06-30 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-05-31 0000850261 srne:SorrentoBiologicsIncMember srt:MaximumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-10-31 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:EmployeeAndDirectorMember 2018-01-01 2018-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:NonEmployeeConsultantsMember 2017-04-01 2017-06-30 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-01 2015-05-31 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember 2018-05-16 2018-05-16 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-01 2015-05-31 0000850261 srt:MaximumMember srne:TwoThousandFifteenStockOptionPlanMember srne:DirectorsAndNonEmployeeConsultantsMember 2018-01-01 2018-06-30 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-31 0000850261 us-gaap:EmployeeStockOptionMember srne:TwoThousandNineStockIncentivePlanMember 2017-07-01 2017-07-31 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2018-05-16 2018-05-16 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2018-04-01 2018-06-30 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2017-08-29 2017-08-29 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:EmployeeAndDirectorMember 2018-04-01 2018-06-30 0000850261 srne:TwoThousandFifteenStockOptionPlanMember us-gaap:DirectorMember 2018-04-01 2018-06-30 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassBMember us-gaap:ChiefExecutiveOfficerMember 2015-10-31 0000850261 srne:ScilexPharmaceuticalsIncMember srne:A2017StockOptionsPlansMember us-gaap:CommonClassAMember 2017-06-30 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2018-06-30 0000850261 srne:LACellMember srt:MaximumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-01 2015-05-31 0000850261 srne:SorrentoBiologicsIncMember srt:MinimumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:TwoThousandFifteenStockOptionPlanMember srne:NonEmployeeConsultantsMember 2018-04-01 2018-06-30 0000850261 srne:TwoThousandFifteenStockOptionPlanMember srne:DirectorsAndNonEmployeeConsultantsMember 2018-01-01 2018-06-30 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2014-05-01 2014-05-31 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-10-31 0000850261 srne:TwoThousandNineNonEmployeeDirectorGrantsMember srne:NonEmployeeDirectorsMember 2009-09-30 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2017-08-29 2017-08-29 0000850261 srne:TNKTherapeuticsIncMember srt:MinimumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-01 2015-05-31 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-31 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember 2018-05-16 2018-05-16 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember 2018-06-30 0000850261 srne:ConcortisBiosystemsCorporationMember srt:MaximumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember 2017-08-29 2017-08-29 0000850261 srne:TwoThousandFifteenStockOptionPlanMember us-gaap:DirectorMember 2018-01-01 2018-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember srne:A2017StockOptionsPlansMember 2017-06-01 2017-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:NonEmployeeConsultantsMember 2018-01-01 2018-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2017-01-01 2017-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2017-07-31 0000850261 srne:TwoThousandFifteenStockOptionPlanMember srne:NonEmployeeConsultantsMember 2018-01-01 2018-06-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:EmployeeAndDirectorMember 2017-01-01 2017-06-30 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-10-31 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2018-05-16 2018-05-16 0000850261 srne:TwoThousandNineStockIncentivePlanMember 2017-04-01 2017-06-30 0000850261 srt:MinimumMember srne:TwoThousandFifteenStockOptionPlanMember srne:DirectorsAndNonEmployeeConsultantsMember 2018-01-01 2018-06-30 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-31 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-10-01 2015-10-31 0000850261 srne:TwoThousandNineNonEmployeeDirectorGrantsMember srne:NonEmployeeDirectorsMember 2018-06-30 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassBMember us-gaap:ChiefExecutiveOfficerMember 2015-10-31 0000850261 srne:TwoThousandFifteenStockOptionPlanMember us-gaap:DirectorMember 2018-03-31 0000850261 srt:MaximumMember srne:TwoThousandNineNonEmployeeDirectorGrantsMember srne:NonEmployeeDirectorsMember 2009-09-30 2009-09-30 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassBMember us-gaap:ChiefExecutiveOfficerMember 2015-05-31 0000850261 srne:ConcortisBiosystemsCorporationMember srne:TwoThousandFifteenStockOptionPlanMember 2018-06-30 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2018-06-30 0000850261 srne:SorrentoBiologicsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2018-06-30 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2018-04-01 2018-06-30 0000850261 srne:LACellMember srt:MinimumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-01 2015-05-31 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2017-08-29 2017-08-29 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2017-08-29 2017-08-29 0000850261 srne:ScintillaPharmaceuticalsIncMember srt:MinimumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember 2015-05-31 0000850261 srne:ConcortisBiosystemsCorporationMember srt:MinimumMember srne:TwoThousandFifteenStockOptionPlanMember 2015-10-01 2015-10-31 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-05-31 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2015-11-01 2015-11-30 0000850261 srne:ScilexPharmaceuticalsIncMember srne:A2017StockOptionsPlansMember 2018-06-30 0000850261 srne:ScintillaPharmaceuticalsIncMember srne:TwoThousandFifteenStockOptionPlanMember us-gaap:CommonClassAMember 2015-10-01 2015-10-31 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:NonEmployeeConsultantsMember 2018-04-01 2018-06-30 0000850261 srne:TwoThousandFifteenStockOptionPlanMember 2017-08-29 2017-08-29 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:EmployeeAndDirectorMember 2017-04-01 2017-06-30 0000850261 srne:TwoThousandNineNonEmployeeDirectorGrantsMember srne:NonEmployeeDirectorsMember 2009-09-30 2009-09-30 0000850261 srne:TwoThousandNineStockIncentivePlanMember srne:NonEmployeeConsultantsMember 2017-01-01 2017-06-30 0000850261 srne:TwoThousandFifteenStockOptionPlanMember us-gaap:DirectorMember 2017-04-01 2017-06-30 0000850261 srne:TNKTherapeuticsIncMember srne:TwoThousandFifteenStockOptionPlanMember 2018-05-16 2018-05-16 0000850261 srne:LACellMember srne:TwoThousandFifteenStockOptionPlanMember 2017-08-29 2017-08-29 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2017-01-01 2017-06-30 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2018-01-01 2018-06-30 0000850261 srne:ArkAnimalHealthIncMember srne:TwoThousandFourteenEmployeeStockOptionPlanMember srne:DirectorsAndConsultantsMember 2017-04-01 2017-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember srne:A2017StockOptionsPlansMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-06-01 2017-06-30 0000850261 srne:ScilexPharmaceuticalsIncMember srne:A2017StockOptionsPlansMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-06-01 2017-06-30 0000850261 srne:TwoThousandFifteenStockOptionPlanMember srne:NonEmployeeConsultantsMember 2017-04-01 2017-06-30 0000850261 srne:TwoThousandFifteenStockOptionPlanMember srne:NonEmployeeConsultantsMember 2017-01-01 2017-06-30 0000850261 srne:YuhanAgreementClaimMember us-gaap:SettledLitigationMember 2018-05-15 2018-05-15 0000850261 srne:SanDiegoCaliforniaMember srne:OfficeAndLaboratorySpaceMember 2018-06-30 0000850261 stpr:NY srne:OfficeSpaceMember 2017-07-31 0000850261 srne:SanDiegoCaliforniaMember srne:OfficeAndStorageSpaceMember 2018-06-30 0000850261 srne:YuhanAgreementClaimMember 2016-09-08 2016-09-08 0000850261 srne:SuzhouChinaMember srne:OfficeAndLaboratorySpaceMember 2018-06-30 0000850261 srne:SanDiegoCaliforniaMember srne:OfficeSpaceMember 2018-06-30 0000850261 srne:ScotlandMember srne:OfficeAndLaboratorySpaceMember 2018-06-30 0000850261 srne:YuhanCorporationMember 2016-04-01 2016-06-30 0000850261 srne:NantBioScienceIncMember 2015-04-30 0000850261 srne:NantCellMember 2015-07-01 2015-07-31 0000850261 srne:CelularityIncMember 2017-06-12 0000850261 srne:NantCellMember 2015-07-31 0000850261 us-gaap:WarrantMember 2017-01-01 2017-06-30 0000850261 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000850261 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0000850261 us-gaap:WarrantMember 2018-04-01 2018-06-30 0000850261 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000850261 us-gaap:WarrantMember 2017-04-01 2017-06-30 0000850261 srne:SofusaMember srne:MilestonesAchievementMember us-gaap:SubsequentEventMember 2018-07-03 0000850261 srne:SofusaMember us-gaap:SubsequentEventMember 2018-07-03 2018-07-03 srne:day srne:unit xbrli:shares srne:board_member srne:antibody xbrli:pure iso4217:USD srne:target iso4217:USD xbrli:shares srne:segment iso4217:CNY utreg:sqft srne:joint_venture srne:CAR false --12-31 Q2 2018 2018-06-30 10-Q 0000850261 116732276 Accelerated Filer Sorrento Therapeutics, Inc. SRNE 4.89 0 36400 10000000 30000000 25000000 -2027000 -627000 -1400000 10000000 250000 10000000 309916 45 5000000 5000000 50000000 0.20 P3Y P3Y P3Y P3Y P5Y 4000000 4000000 4000000 4000000 4000000 P4Y P40M P4Y P40M P4Y P40M P4Y P40M P4Y P40M P5Y6M P5Y6M 150000000 38900000 1137316 10000000 6000000 4000000 10 10 10 10 10 53500000 4000000 4000000 4000000 9462000 -461000 -120000 0 0 0 0 100000000 99600000 9500000 -90100000 0.50 0 -427000 0.20 2000000 0 -3629000 -4090000 1437000 13663000 1000000 13900000 100000000 100000000 60000000 60000000 40000000 40000000 10000000 1000000 P30D 20000000 125000000 47311000 100000000.0 50000000 350000000 50000000.0 306748 5 3 2 2 2 2 4 100 130575 1405 2312 25381 4550 3 43500000 14000 41000 14000 24000 750000 1012000 0 0.80 P2Y P1Y 10000000 10000000 60000000 0 0 P20Y 2100000 0.05 0.25 100000 200000 100000 75000 200000 250000000 P60D 0 -309000 20000000 8000000 P5Y 1000000 100000000 100000000 P30D 2702700 1176471 1176471 235294 235294 5055642 104167 100000 9911000 9941000 7274000 4226000 9378000 11988000 242000 153000 413901000 574316000 665000 1292000 657000 1319000 12006000 12006000 9646000 9646000 0 149000 54000 1200000 8000 0 358000 96000 2500000 34000 0 149000 0 1000000 178000 0 358000 0 2200000 275000 0 20000 0 20000 371000 515000 44000 73000 552000 88000 145000 1059000 44000 72000 545000 88000 145000 1090000 4300000 1100000 2200000 2500000 1100000 2200000 431613000 452521000 29700000 54746000 20429000 0 0 20429000 356000 0 85000 441000 20785000 0 85000 20870000 46784000 0 0 46784000 266000 0 57000 323000 47050000 0 57000 47107000 13700000 797081 1381346 309916 3000000 0.72 1 5.55 900000 0 25000000 38200000 10000000 29100000 2200000 6000000 10000000 300000000 9900000 9900000 9900000 53209000 14929000 3400000 12800000 0.20 0.1920 0.50 0.1221 0.50 0.1221 0.16 0.1221 1000000 16000000 800000 15400000 422000 391000 82398000 53681000 20429000 46784000 -28888000 26507000 0.01 0.01 0.25 0.01 0.01 8.50 8.50 8.50 8.50 1.52 2.61 2.61 8.77 9500000 9500000 9500000 9500000 9500000 12121210 8591794 2698662 2698662 4000000.0 35765538 3200 80000 306748 65892 10756281 182600 5397325 14819872 4153620 10000000.0 10000000.0 10000000.0 10000000.0 10000000.0 0.0001 0.0001 750000000 750000000 11260000 50882856 7568182 76540055 7568182 82903567 82903567 7568182 116240963 116240963 7568182 82903567 116240963 9000 12000 -13913000 -36915000 -74063000 -106525000 -552000 -1291000 -945000 -1919000 -14465000 -38206000 -75008000 -108444000 400000 300000 10000000 3864000 1878000 1600000 119287000 118247000 816000 1880000 1226000 2538000 18123000 46323000 32284000 71074000 910000 910000 32100000 12000000 12005000 2.26875 7.0125 2.26875 1600000 10000000 37849000 50000000 50000000 120500000 37848750 37848750 0.05 0.05 0.05 P1Y 12700000 9643000 9600000 21600000 44800000 21549000 44800000 -609000 600000 -450000 -500000 -121000 -100000 -118000 -100000 97000 98000 -3064000 -2253000 212000 243000 6015000 5926000 15535000 13281000 1100000 1900000 1300000 2600000 3188000 3931000 -0.20 -0.61 -0.73 -1.15 171000 -152000 0.075 0.021 0.21 4485000 6671000 0 P3Y0M0D 0 10800000 800000 1700000 4000000 36000000 500000 0.20 0.4 0.49 0.20 0.25 0.6 0.6 0.4 0.40 0.20 0.49 0.25 -2050000 -3027000 9800000 82300000 3100000 400000 1800000 27000 344000 2900000 100000000 10000000 369000 -331000 0 0 7800000 5500000 0 0 0 2200000 40000000 32999000 3700000 29972000 4500000 3500000 18200000 3800000 237008000 237000000 237008000 100000000 323000 10000000 750000 0 -13663000 -27000 51880000 54272000 84000 511000 2673000 1782000 1126000 16055000 57000 P19Y P15Y P19Y P5Y 4362000 709000 1091000 0 2562000 5685000 797000 1236000 0 3652000 50240000 1680000 5040000 5040000 3845000 3845000 75375000 3410000 1585000 37660000 32720000 75375000 3410000 1585000 37660000 32720000 71013000 2701000 494000 37660000 30158000 69690000 2613000 349000 37660000 29068000 P15Y 0 0 -586000 -569000 -4300000 9092000 20979000 11039000 21000000 38298000 38300000 38298000 1400000 0 0 0 0 0 0 0 0 0 -15035000 -39586000 -74081000 -107653000 276000 -1102000 -1000000 -2050000 -1500000 -73000 -2105000 -3100000 -3027000 -4700000 -1398000 -3100000 -3094000 -1377000 -2300000 -2325000 30000 15000 1715000 433000 -1063000 -326000 0 -2020000 1198000 -3049000 -4831000 -2115000 -181000 -1622000 -311000 2187000 -751000 99000 680000 -7000 44300000 1200000 2809000 45009000 46061000 1000000 2044000 1128000 232000 457000 6000 10000 10000000 225003000 193056000 431613000 452521000 78955000 39399000 0 0 0 0 54272000 54272000 54272000 54272000 0 0 0 0 16055000 16055000 16055000 16055000 75000000.0 25000000 16203000 37800000 16203000 0 0 1511000 40600000 16200000 38795000 1893000 1892000 1893000 1892000 946000 5211000 16203000 16203000 3250000 441000 323000 -450000 -118000 7042000 5094000 0.23 0.51 23116000 75404000 -10340000 -2812000 -41664000 -46085000 -14187000 -37251000 -73864000 -106436000 -552000 -1291000 -945000 -1919000 15465000 11308000 460123 20000000 1 -13458000 -36784000 -28371000 -60915000 3250000 2914000 274000 336000 336000 -199000 -89000 -89000 274000 336000 -199000 -89000 0 13744000 0 2340000 563000 44272000 2300000 38200000 11300000 1500000 0 22466000 557000 90100000 24500000 380000 557000 0 3000000 0 40000000 100.00 6783000 2812000 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 4904000 5002000 0 37849000 9600000 5000000 90100000 43100000 45628000 58273000 0 1586000 10000000 20000000 10000000 86500000 10000000 -21500000 0 0 20000000 0 162000 -14739000 -38542000 -1291000 -37251000 -74809000 -108355000 -1919000 -106436000 28723000 0 1035000 7327000 19868000 493000 31881000 292000 1077000 7460000 22573000 479000 19345000 19893000 P5Y P3Y 2211000 2204000 20000000 10000000 0 20000000 170000 340000 170000 340000 11179000 26062000 17925000 32554000 0 200000 0 0 -165120000 -270646000 4665000 2155000 2416000 883000 1187000 0 85000 94000 94000 9539000 4511000 4833000 2071000 2037000 0 403000 195000 195000 1700000 3913000 3793000 120000 895000 1231000 1667000 1700000 0 0 0 10159000 9919000 240000 2358000 3367000 3333000 3300000 861000 0 0 9000000 110000000 3000000 8700000 500000 110000000 2600000 1640000 648000 353000 5000000 P6M P1Y 2626000 2910000 281000 P1Y P1Y P4Y P2Y P4Y P2Y P4Y P2Y P4Y P2Y P4Y P2Y P3Y 0.00 0.00 0.00 0.64 0.81 0.77 0.65 0.0216 0.0252 0.0248 0.0242 8000 0 0 0 4000 52000 135000 1600000 1500000 800000 1300000 1000000 266835 600000 2900000 3600000 500000 1800000 1800000 2600000 1000000 1566200 5.20 7.39 6290000 19460000 6343400 88000 0 300000 500000 0 0 900000 3200 7616950 4.74 1.12 5.26 6.04 4.36 7.23 5.55 5.55 0.25 0.0208 P10Y P10Y P6Y1M6D P6Y1M6D P4Y P6Y1M6D P10Y P10Y P10Y P10Y P10Y P10Y 0 6000000 2626000 2626000 2910000 2939000 -29000 0 50000 1795011 797081 309916 1381346 1795011 22038565 22038565 9009005 8108108 8108108 1801802 1801802 25225221 208333 7838259 24855872 7786743 25815 25815 4246 11300000 1673000 1673000 2340000 2340000 13744000 13744000 11308000 11308000 0 50000000 49998000 2000 50000000 45000000 45000000 10000000 47500000 45598000 45595000 3000 900000 9600000 58273000 60200000 58272000 1000 162000 162000 30000 30000 0 199568000 254371000 86502000 -118000 303865000 6000 6465000 -174252000 -49464000 96196000 218000 353162000 9000 3774000 -211503000 -49464000 206610000 242000 413901000 9000 7042000 -165120000 -49464000 259465000 153000 574316000 12000 5094000 -270646000 -49464000 441000 750000 7568182 7568182 49464000 49464000 500000 400000 2800000 3900000 70302000 60650000 100563000 92795000 4375276 5932998 7616950 19528732 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost Method Investments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the aggregate carrying amount of the Company&#8217;s cost-method investments in non-publicly traded companies was </font><font style="font-family:inherit;font-size:10pt;">$237.0 million</font><font style="font-family:inherit;font-size:10pt;"> and included an ownership interest in NantCell, Inc. (&#8220;NantCell&#8221;), NantBioScience, Inc. (&#8220;NantBioScience&#8221;), Globavir Biosciences, Inc., Brink Biologics, Inc., Coneksis, Inc., and Celularity Inc. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company&#8217;s cost-method investments are assessed for impairment quarterly. The Company has determined that it is not practicable to estimate the fair value of its cost-method investments on a regular basis and does not reassess the fair value of cost-method investments if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investments.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> impairment losses were recorded during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;padding-left:0px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock reserved for future issuance consists of the following at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the underwriters agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the loan and security agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the Hercules securities agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,819,872</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under private placements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,153,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options outstanding under the Non-Employee Director Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized for future grant or issuance under the 2009 Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,756,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issuable upon the conversion of the 2018 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,397,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Issuable under assignment agreement based upon achievement of certain milestones</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,765,538</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition consideration payable relates to the Company&#8217;s acquisition of businesses and various other assets and is recorded on the Company&#8217;s condensed consolidated balance sheets at fair value and is re-measured at each balance sheet date until such contingent liabilities have been settled, with changes in fair value recorded as gain or loss on contingent liabilities. The Company estimates the fair value of contingent consideration based on level 3 inputs primarily driven by the probability of achieving certain financing or operating related milestones.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Going Concern</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically operated with working capital deficiencies and expects to operate in the future with working capital deficiencies and has incurred substantial net losses for the years ended December 31, 2017 and 2016, and anticipates that it will continue to do so for the foreseeable future as it continues to identify and invest in advancing product candidates, as well as expanding corporate infrastructure. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;"> of long term debt issued in a private placement (the "Private Placement") pursuant to a Securities Purchase Agreement, dated as of March 26, 2018, as amended by Amendment No. 1 thereto, dated as of June 13, 2018 (the &#8220;Securities Purchase Agreement&#8221;), among the Company and certain accredited investors (collectively, the &#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers (1) convertible promissory notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Notes&#8221;), which accrue simple interest at a rate equal to </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum and mature upon the earlier to occur of (a) June 13, 2023, and (b) the date of the closing of a change in control of the Company (the &#8220;Maturity Date&#8221;), and (2) warrants (the &#8220;Warrants&#8221;) to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the Notes provide that, upon the occurrence of an event of default, the Purchasers thereof may, by written notice to the Company, declare all of the outstanding principal and interest under such Notes immediately due and payable. For purposes of the Notes, an event of default includes, among other things, one or more events that have, or could reasonably be expected to have, a material adverse effect on (i) the Company&#8217;s ability to comply with its obligations under the Securities Purchase Agreement, the Notes or the Warrants or the registration rights agreement entered into with the Purchasers in connection with the Private Placement, or (ii) the rights of the Purchasers under the Notes. The Company believes that it is not probable that the material adverse event clause under the Notes will be exercised. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company&#8217;s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. Although management believes such plans, if executed as planned, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that the condensed consolidated financial statements are issued.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable, the Company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates. The Company may also seek collaborators for one or more of its current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements do not reflect any adjustments that might be necessary if the Company is unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Universal Shelf Registration</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, the Company filed a universal shelf registration statement on Form S-3 (the &#8220;2014 Shelf Registration Statement&#8221;) with the SEC, which was declared effective by the SEC in December 2014. This 2014 Shelf Registration Statement provided the Company with the ability to offer up to </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> of securities, including equity and other securities as described in the registration statement. Included in the 2014 shelf registration was a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock that could be issued and sold under a sales agreement with MLV &amp; Co. LLC (the &#8220;2014 ATM Facility&#8221;). During the twelve months ended December 31, 2017, the Company sold approximately </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of common stock under the 2014 ATM Facility. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, the Company completed a public offering of </font><font style="font-family:inherit;font-size:10pt;">$47.5 million</font><font style="font-family:inherit;font-size:10pt;"> of shares of common stock pursuant to the 2014 Shelf Registration Statement for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$43.1 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, the Company filed a universal shelf registration statement on Form S-3 (the &#8220;2017 Shelf Registration Statement&#8221;) with the SEC, which was declared effective by the SEC in December 2017. The 2014 Shelf Registration Statement expired on December 6, 2017 when the 2017 Shelf Registration was declared effective. The 2017 Shelf Registration Statement provides the Company with the ability to offer up to </font><font style="font-family:inherit;font-size:10pt;">$350 million</font><font style="font-family:inherit;font-size:10pt;"> of securities, including equity and other securities as described in the registration statement. Included in the 2017 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock that may be issued and sold under a sales agreement with B. Riley FBR, Inc. (the &#8220;ATM Facility&#8221;). During the twelve months ended December 31, 2017, the Company sold approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of common stock under the ATM Facility. During the three and six month periods ended June 30, 2018, the Company sold approximately </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$60.2 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of common stock, respectively, under the ATM Facility. The Company can offer up to approximately </font><font style="font-family:inherit;font-size:10pt;">$38.9 million</font><font style="font-family:inherit;font-size:10pt;"> of additional shares of common stock under the ATM Facility, subject to certain limitations. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the 2017 Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company&#8217;s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016 Private Investment in Public Entity Financing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2016, the Company entered into a Securities Purchase Agreement (the &#8220;ABG Purchase Agreement&#8221;) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, &#8220;Ally Bridge&#8221;), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers designated by Ally Bridge (collectively, the &#8220;ABG Purchasers&#8221;), in a private placement transaction (the &#8220;ABG Private Placement&#8221;), up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of the Company&#8217;s common stock and warrants to purchase shares of common stock. Upon the closing of the ABG Private Placement, the Company issued to the ABG Purchasers (1) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,009,005</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;ABG Shares&#8221;) of common stock,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">and (2) warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,702,700</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock (each, an &#8220;ABG Warrant&#8221;).&#160;&#160; Each ABG Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.50</font><font style="font-family:inherit;font-size:10pt;"> per share, was immediately exercisable upon issuance, has a term of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> and is exercisable on a cash or cashless exercise basis.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ABG Purchase Agreement, the Company was obligated to prepare and file with the SEC, within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of&#160;common stock issuable upon exercise of each ABG Warrant (the &#8220;ABG Warrant Shares&#8221;), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain &#8220;piggy-back&#8221; registration rights granted to the ABG Purchasers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the &#8220;Additional Purchase Agreements&#8221;) with each of Beijing Shijilongxin Investment Co., Ltd. (&#8220;Beijing Shijilongxin&#8221;), FREJOY Investment Management Co., Ltd. (&#8220;Frejoy&#8221;) and Yuhan Corporation (&#8220;Yuhan&#8221;), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, </font><font style="font-family:inherit;font-size:10pt;">8,108,108</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">1,176,471</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$45.0 million</font><font style="font-family:inherit;font-size:10pt;">; (2) to Frejoy, </font><font style="font-family:inherit;font-size:10pt;">8,108,108</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">1,176,471</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$45.0 million</font><font style="font-family:inherit;font-size:10pt;">; and (3) to Yuhan, </font><font style="font-family:inherit;font-size:10pt;">1,801,802</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">235,294</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">. The warrants issued pursuant to each of the Additional Purchase Agreements (collectively, the &#8220;Additional Warrants&#8221; and, together with each ABG Warrant, the &#8220;ABG Warrants&#8221;) have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.50</font><font style="font-family:inherit;font-size:10pt;"> per share, were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> and are exercisable on a cash or cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan had the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor&#8217;s shares of common stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of common stock issuable upon exercise of such investor&#8217;s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain &#8220;piggy-back&#8221; registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 2, 2016, the Company closed its private placement of common stock and warrants with Yuhan for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Yuhan purchased </font><font style="font-family:inherit;font-size:10pt;">1,801,802</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at </font><font style="font-family:inherit;font-size:10pt;">$5.55</font><font style="font-family:inherit;font-size:10pt;"> per share and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">235,294</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.&#160;&#160;The warrant is exercisable for </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.50</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between May 31, 2016 and June 7, 2016, the Company closed on the remainder of the </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> financing with the ABG Purchasers, Beijing Shijilongxin, and Frejoy. The ABG Purchasers led the financing and, together with&#160;Beijing Shijilongxin and Frejoy, collectively purchased&#160;</font><font style="font-family:inherit;font-size:10pt;">25,225,221</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at&#160;</font><font style="font-family:inherit;font-size:10pt;">$5.55</font><font style="font-family:inherit;font-size:10pt;">&#160;per share and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">5,055,642</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for total cash consideration of&#160;</font><font style="font-family:inherit;font-size:10pt;">$86.5 million</font><font style="font-family:inherit;font-size:10pt;"> and secured promissory notes (the &#8220;ABG Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$53.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2016, the Company entered into Warrant and Note Cancellation and Share Forfeiture Agreements (the &#8220;Cancellation and Forfeiture Agreements&#8221;) with certain investors (the &#8220;Investors&#8221;) that held an aggregate of </font><font style="font-family:inherit;font-size:10pt;">7,838,259</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and certain of the Warrants granting the right to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,137,316</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.&#160;&#160;Pursuant to the Cancellation and Forfeiture Agreements, effective December 31, 2016, the ABG Warrants held by the Investors and the ABG Notes, of which </font><font style="font-family:inherit;font-size:10pt;">$43.5 million</font><font style="font-family:inherit;font-size:10pt;"> was then outstanding, were cancelled and the shares of common stock held by the Investors were forfeited and returned to the Company.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Private Investment in Public Entity Financing </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 11, 2017, the Company entered into a Securities Purchase Agreement (the "December 2017 Securities Purchase Agreement") with certain accredited investors (collectively, the "December 2017 Purchasers"). Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, (1) convertible promissory notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$50,000,000</font><font style="font-family:inherit;font-size:10pt;"> (the "December 2017 Notes"), which accrued simple interest at a rate equal to </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum and would mature upon the earlier to occur of (a) December 21, 2022, and (b) the date of the closing of a change in control of the Company (the "December 2017 Warrant Maturity Date"), and (2) warrants (the "December 2017 Warrants") to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,121,210</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser&#8217;s December 2017 Note that was equal to or greater than the lesser of: (1) </font><font style="font-family:inherit;font-size:10pt;">$4,000,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$2.26875</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each December 2017 Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.61</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 17, 2018, the December 2017 Purchasers converted the full outstanding principal under the December 2017 Notes into </font><font style="font-family:inherit;font-size:10pt;">22,038,565</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of </font><font style="font-family:inherit;font-size:10pt;">$44.3 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized immediately at that date as interest expense.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 3 for discussion of the Company&#8217;s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$44.8 million</font><font style="font-family:inherit;font-size:10pt;">&#160;based on an allocation of proceeds to the Warrants of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and a beneficial conversion feature of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$32.1 million</font><font style="font-family:inherit;font-size:10pt;">, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Private Investment in Public Entity Financing </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, the Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$120,500,000</font><font style="font-family:inherit;font-size:10pt;"> and Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">8,591,794</font><font style="font-family:inherit;font-size:10pt;"> shares. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 13, 2018, the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;"> and that the aggregate number of shares of the common stock issuable upon exercise of the Warrants was reduced to </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;">, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;">, and (2) Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser&#8217;s Note that is equal to or greater than the lesser of: (1) </font><font style="font-family:inherit;font-size:10pt;">$4,000,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the then-outstanding principal amount of such Purchaser&#8217;s Note into shares of common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$7.0125</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. If a Purchaser elects to convert any of the principal amount of their Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Notes contain restrictive covenants and event of default provisions that are customary for transactions of this type.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.77</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company&#8217;s ability to operate its business.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Na</font><font style="font-family:inherit;font-size:10pt;">t</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ure of Operations and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the &#8220;Company&#8221;), is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. The Company&#8217;s primary focus is to transform cancer into a treatable or chronically manageable disease. The Company also has programs assessing the use of its technologies and products in auto-immune, inflammatory, neurodegenerative, infectious diseases and pain indications with high unmet medical needs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At its core, the Company is an antibody-centric company and leverages its proprietary G-MAB&#8482; library to identify, screen and validate fully human antibodies against high impact oncogenic targets and mutations, immune modulators and intracellular targets. To date, the Company has screened over </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> validated targets and generated a number of fully human antibodies against these targets which are at various stages of preclinical development. These include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (&#8220;ADCs&#8221;), bispecific approaches, as well as T-Cell Receptor (&#8220;TCR&#8221;)-like antibodies.&#160;&#160;With LA Cell, Inc. (&#8220;LA Cell&#8221;), the Company&#8217;s joint venture with City of Hope, the Company&#8217;s objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, the Company has acquired and is assessing the regulatory and strategic path forward for its portfolio of late stage biosimilar/biobetter antibodies based on Erbitux</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, Remicade</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, Xolair</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, and Simulect</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;"> as these may represent nearer term commercial opportunities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With each of its programs, the Company aims to tailor its therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape. In addition, the Company&#8217;s objective is to focus on tumors that are resistant to current treatments and where the Company can design focused trials based on a genetic signature or biomarker to ensure patients have the best chance of a durable and significant response. The Company has several immuno-oncology programs that are in or near to entering the clinic.&#160;&#160;These include cellular therapies, an oncolytic virus and a palliative care program targeted to treat intractable cancer pain.&#160;&#160;Finally, as part of its global aim to provide a wide range of therapeutic products to meet underserved therapeutic markets, the Company has made investments and developed a separate pain focused franchise which the Company believes will serve to provide short term upside to its core thesis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company&#8217;s subsidiaries.&#160;&#160;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.&#160;&#160;All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal, recurring and necessary for a fair statement of financial position, results of operations and cash flows. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Operating results for interim periods are not expected to be indicative of operating results for the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> fiscal year, or any subsequent period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Agreements and Contracts</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with Mabtech Limited</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2015, the Company entered into an exclusive licensing agreement to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from Mabtech Limited.&#160;&#160;Under the terms of the agreement, the Company will develop and market </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> mAbs for the North American, European and Japanese markets. The Company made an initial license payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> and in February 2016, paid an additional </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> license payment, both of which were recognized as acquired in-process research and development expense in the condensed consolidated statements of operations as the Company determined there was no alternative future use for the license.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company agreed to accelerate and pay a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone license payment which has been recognized as acquired in-process research and development expense in the condensed consolidated statements of operations, in exchange for the purchase by Mabtech Limited in June 2016, of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of shares of common stock and warrants.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company agreed to accelerate and, as a result, paid a </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone license payment, which has been recognized as acquired in-process research and development expense in the consolidated statements of operations for the year ended December 31, 2017. The amended agreement includes additional milestone payments totaling </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;"> payable following the completion of the technology transfer from Mabtech Limited and for payables to extend the license agreement. The remaining anniversary payments are due on December 31, 2018 and 2019, respectively. The Company is not obligated to extend the license agreement. Accordingly, the additional future milestone payments have not yet been accrued as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Immunotherapy Research Collaboration Agreement with Roger Williams Medical Center</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the Company entered into an immunotherapy research collaboration agreement with RWMC to provide certain clinical trial, research and manufacturing services. Under the terms of the agreement, RWMC will perform pre-clinical and clinical research related to the development and delivery of CAR-T immunotherapies. In exchange, the Company granted RWMC </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of TNK Class A Stock, subject to adjustment in certain circumstances, to be issued upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company determined the fair value of this obligation was </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of the April of 2016 agreement effective date, and the amount was recognized as prepaid expense and other and acquisition consideration payable in the condensed consolidated balance sheet.&#160;&#160;The Company will recognize the upfront payment over the expected performance period of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. During each of the quarters ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$170 thousand</font><font style="font-family:inherit;font-size:10pt;"> in pre-clinical research and development expense pursuant to the agreement. During each of the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$340 thousand</font><font style="font-family:inherit;font-size:10pt;"> in pre-clinical research and development expense pursuant to the agreement. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with NantCell</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the Company and NantCell entered into a license agreement. Under the terms of the agreement the Company granted an exclusive license to NantCell covering patent rights, know-how, and materials related to certain antibodies, ADCs and </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> CAR-TNK products.&#160;&#160;NantCell agreed to pay a royalty not to exceed five percent (</font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">) to the Company on any net sales of products (as defined) from the assets licensed by the Company to NantCell.&#160;&#160;In addition to the future royalties payable under this agreement, NantCell paid an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company and issued </font><font style="font-family:inherit;font-size:10pt;">10 million</font><font style="font-family:inherit;font-size:10pt;"> shares of NantCell common stock to the Company valued at </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on a recent equity sale of NantCell common stock to a third party.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had not yet provided all of the items noted in the agreement, including research services for and on behalf of NantCell, and therefore has recorded the entire upfront payment and value of the equity interest received as deferred revenue. Specifically, only a portion of the materials associated with the licensed assets have been delivered while the majority of the licensed assets remain undelivered and the related research activities are still to be performed. The Company will recognize the upfront payment and the value of the equity interest received over the period beginning with the commencement of the last item delivered. The Company&#8217;s ownership interest in NantCell does not provide the Company with control or the ability to exercise significant influence; therefore the </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment is carried at cost in the condensed consolidated balance sheets and evaluated for other-than-temporary impairment on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with The Scripps Research Institute</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2010, the Company entered into a license agreement (the &#8220;TSRI License&#8221;) with The Scripps Research Institute (&#8220;TSRI&#8221;). Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus ("</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">S. aureus</font><font style="font-family:inherit;font-size:10pt;">" or &#8220;Staph&#8221;) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i)&#160;issued TSRI a warrant for the purchase of common stock, (ii)&#160;agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved and (iii)&#160;agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;">&#8217; notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company&#8217;s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For each of the quarters ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$14 thousand</font><font style="font-family:inherit;font-size:10pt;"> in patent prosecution and maintenance costs associated with the TSRI License. For the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$24 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$41 thousand</font><font style="font-family:inherit;font-size:10pt;"> in patent prosecution and maintenance costs associated with the TSRI License, respectively. All such costs have been included in general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NIH Grants</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the NIAID awarded the Company a Phase II Small Business Technology Transfer (&#8220;STTR&#8221;) grant (the &#8220;Staph Grant III Award&#8221;) to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staph infections, including methicillin-resistant </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">S. aureus</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;MRSA&#8221;). The project period for the Staph Grant III Award covered a </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">-year period which commenced in June 2014, which was subsequently extended by </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">, with total funds available of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> per year for up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years. The Staph Grant III Award was not extended beyond June 30, 2017 and the remaining amounts for the award have been recorded as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. During each of the quarters ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$94 thousand</font><font style="font-family:inherit;font-size:10pt;"> of revenue associated with the Staph Grant III Award, respectively. During the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$195 thousand</font><font style="font-family:inherit;font-size:10pt;"> of revenue associated with the Staph Grant III Award, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Virttu Biologics Limited</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 27, 2017, the Company entered into a Share Purchase Agreement (the &#8220;Virttu Purchase Agreement&#8221;) with TNK Therapeutics, Inc., a majority-owned subsidiary of the Company (&#8220;TNK&#8221;), Virttu, the shareholders of Virttu (the &#8220;Virttu Shareholders&#8221;) and Dayspring Ventures Limited, as the representative of the Virttu Shareholders ("Dayspring"), pursuant to which, among other things, TNK acquired from the Virttu Shareholders </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding ordinary shares of Virttu (the &#8220;Virttu Acquisition&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Virttu focuses on the development of oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. Its lead oncolytic virus candidate, Seprehvir, infects and replicates in cancer cells selectively, leaving normal cells unharmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Virttu Purchase Agreement, the total amount of the consideration payable to the Virttu Shareholders in the Virttu Acquisition is equal to </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;">, less Virttu&#8217;s net debt (the &#8220;Virttu Base Consideration&#8221;). An additional </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> contingent consideration is payable upon the achievement of certain regulatory milestones (as described below) (the &#8220;Regulatory Approval Consideration&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the closing of the Virttu Acquisition (the &#8220;Closing&#8221;), the Company issued to the Virttu Shareholders consideration valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, which consisted primarily of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">797,081</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;Virttu Closing Shares&#8221;) and approximately </font><font style="font-family:inherit;font-size:10pt;">$557,000</font><font style="font-family:inherit;font-size:10pt;"> in cash (the &#8220;Cash Consideration&#8221;). The issuance of the Virttu Closing Shares and the payment of the Cash Consideration satisfied TNK&#8217;s obligation to pay </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of the Virttu Base Consideration at the Closing. Under the terms of the Virttu Purchase Agreement, the Company agreed to provide additional consideration to the Virttu Shareholders, as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> (a &#8220;Qualified Financing&#8221;), TNK would have issued to the Virttu Shareholders an aggregate number of shares of its capital stock (&#8220;TNK Capital Stock&#8221;) as is equal to the quotient obtained by dividing </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the Virttu Base Consideration by the lowest per share price paid by investors in the Qualified Financing (the &#8220;TNK Financing Consideration&#8221;); provided, however, that </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of the TNK Financing Consideration was held in escrow until April 27, 2018 (the &#8220;Financing Due Date&#8221;), to be used to, among other things, satisfy the indemnification obligations of the Virttu Shareholders. In the event that a Qualified Financing did not occur, then on the Financing Due Date, the Company would issue to the Virttu Shareholders an aggregate number of shares of the Company&#8217;s common stock as is equal to the quotient obtained by dividing </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the Virttu Base Consideration, by </font><font style="font-family:inherit;font-size:10pt;">$5.55</font><font style="font-family:inherit;font-size:10pt;"> (as adjusted, as appropriate, to reflect any stock splits or similar events affecting the Company&#8217;s common stock after the Closing).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Within </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;"> business days after Virttu becomes aware that certain governmental bodies in the United States, the European Union, the United Kingdom or Japan have approved for commercialization, on or before October 26, 2024, Seprehvir (or any enhancement, combination or derivative thereof) as a monotherapy or in combination with one or more other active components (each of the first two such approvals by a governmental body being a &#8220;Regulatory Approval&#8221;), TNK shall pay half of the Regulatory Approval Consideration to the Virttu Shareholders, in a combination of (a) up to </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash (the &#8220;Regulatory Approval Cash&#8221;) and/or (b) (i) such number of shares of the Company&#8217;s common stock as is equal to the quotient obtained by dividing </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> less the Regulatory Approval Cash (the &#8220;Regulatory Approval Share Value&#8221;) by the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> Day VWAP (as defined below) of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of the Company&#8217;s common stock; (ii) if TNK has completed its first public offering of TNK Capital Stock, the number of shares of TNK Capital Stock as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP of one share of TNK Capital Stock; or (iii) such number of shares of common stock of a publicly traded company as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the volume weighted average price of the relevant security, as reported on the Nasdaq Capital Market (or other principal stock exchange or securities market on which the shares are then listed or quoted) for the thirty trading days immediately following the receipt of Regulatory Approval (the &#8220;30 Day VWAP&#8221;), with the composition of the Regulatory Approval Consideration to be at TNK&#8217;s option. In order for a second regulatory approval to qualify as a Regulatory Approval under the Purchase Agreement, the second approval must be granted by a different governmental body in a different jurisdiction than that which granted the first Regulatory Approval.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At April 27, 2017, the </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the Virttu Base Consideration was valued at </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the Virttu Base Consideration is recorded as a current liability and will be adjusted quarterly for changes in fair value or as events and circumstances arise. At April 27, 2017, the contingent Regulatory Approval Consideration was valued at </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the contingent Regulatory Approval Consideration is recorded as a non-current liability within "Deferred rent and other" on the accompanying condensed consolidated balance sheet and will be adjusted quarterly for changes in fair value or as events and circumstances arise. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the preliminary results of operations from this transaction, which have been accounted for as a business combination, and require, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The final valuation of the acquired assets and liabilities resulted in the recognition of identifiable assets of approximately </font><font style="font-family:inherit;font-size:10pt;">$16.0 million</font><font style="font-family:inherit;font-size:10pt;"> comprised mainly of in-process research and development of approximately </font><font style="font-family:inherit;font-size:10pt;">$15.4 million</font><font style="font-family:inherit;font-size:10pt;">, deferred tax liabilities of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and goodwill of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. Various factors contributed to the establishment of goodwill, including an assembled workforce. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Virttu transaction, the Company recorded acquisition costs of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> in general and administrative expenses for the twelve months ended December 31, 2017, for legal and related costs. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> acquisition costs in connection with the Virttu transaction were recorded for the three and six months ended June 30, 2018. Acquisition costs are expensed as incurred.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TNK did not complete a Qualified Financing prior to the Financing Due Date and on April 27, 2018, the Company, TNK and Dayspring entered into the Amendment, pursuant to which, among other things, the Company agreed that the acquisition consideration, otherwise payable on April 27, 2018 to the Virttu Shareholders, shall be as follows: (1) an issuance of </font><font style="font-family:inherit;font-size:10pt;">1,795,011</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock to the Virttu Shareholders and (2) </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;"> payable in cash .</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,795,011</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock to the Virttu Shareholders on April 27, 2018 for a value of </font><font style="font-family:inherit;font-size:10pt;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;">. The approximately </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;"> payable in cash has not been paid as of the date of this filing.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Scilex Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;8, 2016, the Company entered into a Stock Purchase Agreement (the &#8220;Scilex Purchase Agreement&#8221;) with Scilex and a majority of the stockholders of Scilex (the &#8220;Scilex Stockholders&#8221;) pursuant to which, on November&#160;8, 2016, the Company acquired from the Scilex Stockholders, and the Scilex Stockholders sold to the Company, approximately </font><font style="font-family:inherit;font-size:10pt;">72%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding capital stock of Scilex (the &#8220;Scilex Acquisition&#8221;). The remainder of the outstanding capital stock of Scilex represents a noncontrolling interest of which approximately </font><font style="font-family:inherit;font-size:10pt;">23%</font><font style="font-family:inherit;font-size:10pt;"> continues to be held by ITOCHU CHEMICAL FRONTIER CORPORATION following the Scilex Acquisition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scilex focuses on the development and commercialization of specialty pharmaceutical products for the treatment of pain; its lead product, ZTlido</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;"> (lidocaine topical system 1.8%, is a branded lidocaine topical system formulation being developed for the treatment of chronic pain. ZTlido&#8482; (lidocaine topical system 1.8%) will be manufactured by a contract manufacturer.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Scilex Purchase Agreement, upon receipt of notice from the U.S. Food and Drug Administration (the "FDA") that the FDA has approved Scilex's new drug application for ZTlido&#8482; (lidocaine topical system 1.8%) for the treatment of postherpetic neuralgia (the "NDA") for commercialization, the Company was obligated to deliver to the Scilex Stockholders cash and shares of its common stock in such proportion to be determined in the Company&#8217;s sole discretion as a milestone payment. On February 28, 2018, the Company received notice from the FDA that the FDA had approved the NDA. As a result, the Company issued to the Scilex Stockholders consideration valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$38.2 million</font><font style="font-family:inherit;font-size:10pt;">, which included an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,381,346</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of approximately </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;">, cash payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">, which included a bridge loan of approximately </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> with B. Riley FBR to facilitate the timing of the cash payment and resulted in a change in fair value of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> since December 31, 2017, for the contingent consideration upon settlement. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquired In-process Research and Development of BDL</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the Company and TNK entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with BDL Products, Inc. (&#8220;BDL&#8221;) and the stockholders of BDL (&#8220;Stockholders&#8221;) pursuant to which the Stockholders sold all of their shares of capital stock in BDL to TNK for: (1)&#160;a cash payment of </font><font style="font-family:inherit;font-size:10pt;">$100.00</font><font style="font-family:inherit;font-size:10pt;">, and (2)&#160;</font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of TNK Class&#160;A Stock, subject to adjustment in certain circumstances, to be issued to the Stockholders upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> (a &#8220;Qualified Financing&#8221;).&#160;&#160;In accordance with subsequent amendments to the Stock Purchase Agreement, in the event a Qualified Financing does not occur by October 15, 2017 (which is subject to further extension as implied and based on previously amended dates) or TNK does not complete an initial public offering of shares of its capital stock by September 15, 2017, in lieu of receiving shares of TNK pursuant to the acquisition, the Stockholders shall receive an aggregate of </font><font style="font-family:inherit;font-size:10pt;">309,916</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, subject to adjustment in certain circumstances.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">TNK did not complete a Qualified Financing by the financing deadline and the Company issued </font><font style="font-family:inherit;font-size:10pt;">309,916</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock to the Stockholders on March 19, 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions and Intangibles</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. The Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Action Litigation</font></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 8, 2016, Yvonne Williams filed an action both derivatively and on behalf of a purported class of stockholders in the Court of Chancery of the State of Delaware (the "Court") against each of the members of the Henry Ji, William S. Marth, Kim D. Janda, Jaisim Shah, David H. Deming, and Douglas Ebersole (the &#8220;Prior Board&#8221;); George Ng, the Company&#8217;s Executive Vice President, Chief Administrative Officer, and Chief Legal Officer; Jeffrey Su, the Company&#8217;s Executive Vice President &amp; Chief Operating Officer; and the Company as nominal defendant, alleging: (1) breach of fiduciary duty with respect to the formation of, and certain options and warrants issued by, certain of the Company&#8217;s subsidiaries to Dr. Ji and members of the Prior Board; (2) breach of fiduciary duty with respect to the Company&#8217;s prior announcement that it had entered into a voting agreement with Yuhan Corporation in connection with a transaction through which it purchased </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of shares of the Company's common stock and warrants (the &#8220;Williams Action&#8221;). On November 14, 2016, the Company filed motions to dismiss or in the alternative stay the Williams Action. George Ng and Jeffrey Su were dismissed as defendants by plaintiff during the briefing on the motions. The Court denied the motions on June 28, 2017. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On October 25, 2017, Yvonne Williams filed a Supplemental and Amended Class Action and Derivative Complaint which re-added George Ng as a defendant, added Eragon Ventures, LLC as a defendant, and added certain claims challenging transactions whereby Eragon Ventures, LLC agreed to purchase certain stock in the Company&#8217;s subsidiary, LA Cell, Inc. Following a mediation held on November 16, 2017, the parties agreed that day to a term sheet reflecting a settlement of the Williams Action, which agreement was memorialized in a Stipulation and Agreement of Settlement executed on December 22, 2017 and filed with the Court. The settlement consisted of non-monetary consideration, such as the cancellation of certain subsidiary shares of stock that were obtained by defendants pursuant to options previously exercised by defendants. The settlement and plaintiff&#8217;s counsel&#8217;s request for an award of attorneys&#8217; fees were submitted to the Court for approval. On May 15, 2018, the Court held a hearing on the request for approval of the settlement and approved the settlement and awarded plaintiff&#8217;s counsel attorneys&#8217; fees of </font><font style="font-family:inherit;font-size:10pt;">$3.25 million</font><font style="font-family:inherit;font-size:10pt;">. This case was dismissed with prejudice. The Company has caused the attorneys&#8217; fees payment to be made, which payment was covered in large part, but not in whole, by insurance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Immunomedics Litigation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2015, Immunomedics, Inc. (&#8220;Immunomedics&#8221;) filed a complaint in the United States District Court for the District of New Jersey (the &#8220;New Jersey Case&#8221;) against the Board of Directors of RWMC, Dr. Richard P. Junghans, Dr. Steven C. Katz, the Office of the Board of Advisors of Tufts University School of Medicine, and one or more individuals or entities to be identified later. This complaint (the "Initial Complaint") alleged, among other things: (1) breach of contract; (2) breach of covenant of good faith and fair dealing; (3) tortious interference with prospective economic gain; (4) tortious interference with contracts; (5) misappropriation; (6) conversion; (7) bailment; (8) negligence; (9) vicarious liability; and (10) patent infringement. Overall, the allegations in the Initial Complaint were generally directed to an alleged material transfer agreement dated December 2008 and Immunomedics&#8217; alleged request for the return of certain alleged research material, as well as the alleged improper use and conversion of such research materials outside the scope of the material transfer agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2015, Immunomedics filed an amended complaint (the &#8220;First Amended Complaint&#8221;), which, among other things, no longer named the Board of Directors of RWMC and The Office of the Board of Advisors of Tufts University School of Medicine as defendants. RWMC and Tufts Medical Center were added as new defendants. On January 14, 2016, Immunomedics filed a second amended complaint (the "Second Amended Complaint"), which, among other things, no longer named Tufts Medical Center as a defendant. In addition, the Second Amended Complaint contained allegations directed to two additional alleged material transfer agreements dated September 1993 and May 2010, respectively, and also added an allegation of unjust enrichment. The Second Amended Complaint also no longer asserted claims for (1) breach of covenant of good faith and fair dealing; (2) misappropriation; (3) bailment; (4) negligence; and (5) vicarious liability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, Immunomedics filed a third amended complaint (the &#8220;Third Amended Complaint&#8221;), which added the Company, TNK, BDL and CARgenix as defendants. TNK is a subsidiary of the Company and purchased BDL and CARgenix in August 2015. The Third Amended Complaint included, among other things, allegations against the Company, TNK, BDL and CARgenix regarding (1) conversion; (2) tortious interference; and (3) unjust enrichment. On December 2, 2016, the Company, TNK, BDL, and CARgenix filed a motion to dismiss Immunomedics&#8217;s complaint against them for lack of personal jurisdiction. On January 25, 2017, the District of New Jersey granted this motion, and the Company, TNK, BDL and CARgenix were dismissed as defendants from the New Jersey Case. Under various agreements, TNK has certain indemnification obligations to RWMC, Dr. Richard P. Junghans and Dr. Steven C. Katz that may be implicated by the New Jersey Case. The New Jersey Case remains pending against defendants RWMC, Dr. Junghans, and Dr. Katz. A trial date has not yet been set.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 27, 2018, Immunomedics filed a complaint against the Company and TNK in San Diego Superior Court, Case No. 37-2018-00021006-CU-NP-CTL (the &#8220;San Diego Case&#8221;). The complaint includes, among other things, allegations against the Company and TNK regarding: (1) conversion; (2) tortious interference; and (3) inducing breach of contract. No trial date has yet been set in the San Diego Case.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that the New Jersey Case and the San Diego Case are without merit, and will vigorously defend itself in the litigation. However, should Immunomedics prevail against the Company, RWMC or other defendants, certain patent rights optioned, owned and/or licensed by the Company could be at risk of invalidity or enforceability, or the litigation could otherwise adversely impact the Company&#8217;s ownership or other rights in certain intellectual property.&#160;&#160;At this point in time, the Company is unable to determine whether any loss is probable or reasonably possible with respect to the New Jersey Case or the San Diego Case or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cantor Fitzgerald &amp; Co. Litigation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 25, 2018, Cantor Fitzgerald &amp; Co. (&#8220;CF&amp;Co.&#8221;) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, Index No. 652633/2018. The complaint includes, among other things, allegations against the Company for breach of contract arising out of a letter agreement whereby CF&amp;Co. was to supply certain services to the Company in exchange for a fee (the &#8220;CF &amp; Co. Litigation&#8221;). The Company has filed an Answer and Counterclaim for breach of contract against CF&amp;Co claiming that CF&amp;Co. did not perform under the letter agreement. The Company believes CF&amp;Co.&#8217;s claims against the Company are without merit and will vigorously defend itself in the litigation. At this point in time, the Company is unable to determine whether any loss is probable or reasonably possible with respect to the CF&amp;Co. Litigation or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently leases in San Diego, California approximately </font><font style="font-family:inherit;font-size:10pt;">130,575</font><font style="font-family:inherit;font-size:10pt;"> square feet of corporate office and laboratory space and approximately </font><font style="font-family:inherit;font-size:10pt;">1,405</font><font style="font-family:inherit;font-size:10pt;"> square feet of office space at a second location as well as approximately </font><font style="font-family:inherit;font-size:10pt;">36,400</font><font style="font-family:inherit;font-size:10pt;"> square feet for offices, facilities for cGMP fill and finish and storage space.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s lease agreements in San Diego, as amended, for its corporate office and laboratory space, its second laboratory and office space and its third office space, expire in </font><font style="font-family:inherit;font-size:10pt;">December 2026</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">November 2025</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">September 2020</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The Company also leases </font><font style="font-family:inherit;font-size:10pt;">25,381</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in Suzhou, China, which lease expires in </font><font style="font-family:inherit;font-size:10pt;">June 2018</font><font style="font-family:inherit;font-size:10pt;">. The Company leases </font><font style="font-family:inherit;font-size:10pt;">2,312</font><font style="font-family:inherit;font-size:10pt;"> square feet of office, laboratory, and storage space in Scotland, which lease expires in March 2021. The Company subleases in New York, New York for approximately </font><font style="font-family:inherit;font-size:10pt;">4,550</font><font style="font-family:inherit;font-size:10pt;"> square feet of additional corporate office space. The sublease began in July of 2017 and expires in December 2020.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is primarily comprised of net income (loss) and adjustments for the change in unrealized gains and losses on the Company&#8217;s investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its condensed consolidated statements of comprehensive income (loss).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loan and Security Agreement and Convertible Notes</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loan and Security Agreement with Hercules Capital, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;23, 2016, the Company and certain of its domestic subsidiaries (together with the Company, the &#8220;Borrowers&#8221;) entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), as a lender and agent for several banks and other financial institutions or entities from time to time party to the Loan Agreement (collectively, the &#8220;Lenders&#8221;) for a term loan of up to </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to funding in multiple tranches (the &#8220;Term Loan&#8221;). The Term Loan will mature on </font><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2020</font><font style="font-family:inherit;font-size:10pt;">. The proceeds of the Term Loan will be used for general corporate purposes and coincided with the repayment of the outstanding debt financing arrangement with Oxford Finance LLC and Silicon Valley Bank.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first tranche of </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> was funded upon execution of the Loan Agreement on November&#160;23, 2016. Under the terms of the Loan Agreement, the Borrowers may, but are not obligated to, request additional funds of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> which are available until </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, subject to approval by Hercules&#8217; Investment Committee. Pursuant to the terms of the third amendment to the Loan Agreement entered into on March 15, 2017, the Company paid Hercules </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> for a portion of the backend fee. Pursuant to the terms of the fourth amendment to the Loan Agreement entered into on March 23, 2017 (the &#8220;Fourth Amendment&#8221;), the Company repaid Hercules, without repayment penalty, </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding principal and unpaid interest accrued thereon on March 23, 2017.&#160;&#160;The Fourth Amendment also provided for the following: (1) Hercules reduced the minimum amount of unrestricted cash that the Company must maintain under the Loan Agreement, and (2) the parties agreed to change the date by which the Company must achieve a fundraising milestone.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties, including financial reporting obligations and significant limitations on dividends, indebtedness, liens (including a negative pledge on intellectual property and other assets), collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. Additionally, the Loan Agreement contains covenants requiring the Borrowers (i) to achieve certain fundraising requirements by certain dates and (ii) to maintain </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> of unrestricted cash prior to achieving its corporate and fundraising milestones. The Company's public offering for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$43.1 million</font><font style="font-family:inherit;font-size:10pt;"> satisfied the fundraising requirements and fundraising milestone. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the seventh amendment to the Loan Agreement entered into on November 6, 2017 (the &#8220;Seventh Amendment&#8221;), (i) the Company repaid Hercules, without repayment penalty, </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding principal and unpaid interest accrued thereon on November 6, 2017, and (ii) Hercules agreed to reduce the minimum amount of unrestricted cash that the Company must maintain under the Loan Agreement from </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 21, 2017, the Company paid off all obligations owing under, and terminated, the Loan Agreement. The secured interests were terminated in connection with the Company&#8217;s discharge of indebtedness thereunder.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Loan Agreement, the Company issued Hercules a warrant, dated November&#160;23, 2016 (the &#8220;Hercules Warrant&#8221;), to purchase up to </font><font style="font-family:inherit;font-size:10pt;">460,123</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$4.89</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment as provided in the Hercules Warrant. The Hercules Warrant is initially exercisable for </font><font style="font-family:inherit;font-size:10pt;">306,748</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and may automatically become exercisable for additional shares of common stock on such dates (if any) based upon the funding amounts of any additional tranches of the Term Loan that may be extended to the Borrowers. The Hercules Warrant will terminate, if not earlier exercised, on the earlier of </font><font style="font-family:inherit;font-size:10pt;">November&#160;23, 2023</font><font style="font-family:inherit;font-size:10pt;"> and the closing of certain merger or other transactions in which the consideration is cash, stock of a publicly-traded acquirer or a combination thereof.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the extinguishment of the Loan Agreement on December 21, 2017, a loss of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> on the extinguishment of debt was recorded representing the difference between the reacquisition price of debt and the net carrying amount of the loan as of December 21, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Chinese Yuan (&#8220;RMB&#8221;) Loan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In March 2018, the Company entered into a term loan in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> ("RMB </font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;">") with the Bank of China and the Agricultural Bank of China, which is guaranteed by Levena Suzhou Biopharma, Co. Ltd. This </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year bank facility was used for working capital purposes. The proceeds from the loan agreement are reflected as financing activities in the condensed consolidated statements of cash flows for the six months ended June 30, 2018. The outstanding balance is repayable from February 2018 to March 2019. The interest rate on this loan is </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Securities Purchase Agreement in Private Placement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 11, 2017, the Company entered into the December 2017 Securities Purchase Agreement with the December 2017 Purchasers. Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, the December 2017 Notes and the December 2017 Warrants.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser&#8217;s December 2017 Note that was equal to or greater than the lesser of: (1) </font><font style="font-family:inherit;font-size:10pt;">$4,000,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$2.26875</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each December 2017 Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.61</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 17, 2018, the December 2017 Purchasers converted in full the outstanding principal and accrued interest under the December 2017 Notes into </font><font style="font-family:inherit;font-size:10pt;">22,038,565</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of </font><font style="font-family:inherit;font-size:10pt;">$44.3 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized immediately at that date as interest expense.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 3 for discussion of the Company&#8217;s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately </font><font style="font-family:inherit;font-size:10pt;">$44.8 million</font><font style="font-family:inherit;font-size:10pt;"> based on an allocation of proceeds to the Warrants of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;"> and a beneficial conversion feature of approximately </font><font style="font-family:inherit;font-size:10pt;">$32.1 million</font><font style="font-family:inherit;font-size:10pt;">, before issuance costs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Securities Purchase Agreement in Private Placement </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, (1) the Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$120,500,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the Warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">8,591,794</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 13, 2018, the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;"> and that the aggregate number of shares of Common Stock issuable upon exercise of the Warrants was reduced to </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;">, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;">, and (2) Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser&#8217;s Note that is equal to or greater than the lesser of: (1) </font><font style="font-family:inherit;font-size:10pt;">$4,000,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the then-outstanding principal amount of such Purchaser&#8217;s Note into shares of common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$7.0125</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.77</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 3 for discussion of the Company&#8217;s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately </font><font style="font-family:inherit;font-size:10pt;">$21.6 million</font><font style="font-family:inherit;font-size:10pt;"> based on an allocation of proceeds to the Warrants of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> and a beneficial conversion feature of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;">, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Notes was estimated using a lattice model with Level 2 inputs including the stock price volatility, risk-free interest rate, and debt yield. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair value of the Notes was approximately </font><font style="font-family:inherit;font-size:10pt;">$40.6 million</font><font style="font-family:inherit;font-size:10pt;">, compared to the carrying value of </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;">, as a result of unamortized debt discount. A substantial portion of the market value of the Company's debt in excess of the outstanding principal amount relates to the conversion premium on the Notes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt and unamortized discount balances are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Face value of loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount - warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount - beneficial conversion feature</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt issuance costs and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands) as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.3170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ending December 31,</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,311</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unpaid interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,549</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized capitalized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum payment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,203</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt with Detachable Warrants </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt with detachable warrants are evaluated for the classification of warrants as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are first allocated to the debt and the warrants at their relative estimated fair values. The portion of the proceeds so allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of embedded derivatives and beneficial conversion features, are allocated to the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds, to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the amount allocated to the convertible debt results in an effective per share conversion price less than the fair value of the Company&#8217;s common stock on the commitment date, the intrinsic value of this beneficial conversion feature is recorded as a discount to the convertible debt with a corresponding increase to additional paid in capital. The beneficial conversion feature discount is equal to the difference between the effective conversion price and the fair value of the Company&#8217;s common stock at the commitment date, unless limited by the remaining proceeds allocated to the debt. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Liability</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liabilities are recorded on the Company&#8217;s condensed consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.&#160;&#160;The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows sales and service revenues disaggregated by product and services type for the three and six months ended June 30, 2018 and 2017 (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concortis sales and services</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Materials and supply agreements</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioserv sales and services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Joint development agreement</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,793</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the reconciliation of basic and diluted loss per share for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106,436</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for Basic and Diluted Loss Per Share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,302</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,795</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and Diluted Loss Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The potentially dilutive stock options that would have been excluded because the effect would have been antidilutive for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The potentially dilutive warrants that would have been excluded because the effect would have been antidilutive for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The potentially dilutive stock options that would have been excluded because the effect would have been antidilutive for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The potentially dilutive warrants that would have been excluded because the effect would have been antidilutive for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">2.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted per share amounts are computed independently in the consolidated statements of operations. Therefore, the sum of per share components may not equal the per share amounts presented.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Method Investments</font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NANTibody</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, the Company acquired IgDraSol Inc. (&#8220;IgDraSol&#8221;), a private company focused on the development of oncologic agents for the treatment of cancer, from a third party unrelated to the NantWorks, LLC (&#8220;NantWorks&#8221;) affiliated entities for </font><font style="font-family:inherit;font-size:10pt;">3.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock and </font><font style="font-family:inherit;font-size:10pt;">$380,000</font><font style="font-family:inherit;font-size:10pt;"> of cash for a total purchase price of </font><font style="font-family:inherit;font-size:10pt;">$29.1 million</font><font style="font-family:inherit;font-size:10pt;">. This transaction included the acquisition of IgDraSol&#8217;s lead compound, CynviloqTM, a micellar diblock copolymeric paclitaxel formulation drug product. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the Company entered into an agreement with NantPharma, LLC (&#8220;NantPharma&#8221;), a NantWorks company, pursuant to which the Company sold to NantPharma all of its equity interests in IgDraSol, which continued to hold the rights to CynviloqTM. Pursuant to the agreement, NantPharma paid the Company an upfront fee of </font><font style="font-family:inherit;font-size:10pt;">$90.1 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> was required to be used by the Company to fund </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> joint ventures, as described below. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the Company and NantCell, a subsidiary of NantWorks, a private company owned by Dr. Patrick Soon-Shiong, established a new entity called Immunotherapy NANTibody, LLC (&#8220;NANTibody&#8221;) as a stand-alone biotechnology company with </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> initial joint funding. NantCell owns </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> of the equity interest of NANTibody and agreed to contribute </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> to NANTibody. The Company owns </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of NANTibody and in July 2015, the Company had NantPharma, contribute its portion of the initial joint funding of </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> to NANTibody from the proceeds of the sale of IgDraSol. Additionally, the Company and NantCell were allowed to appoint </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> representatives, respectively, to NANTibody&#8217;s </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-member Board of Directors. NANTibody will focus on accelerating the development of multiple immuno-oncology mAbs for the treatment of cancer, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA4mAbs, and other immune-check point antibodies as well as ADCs and bispecific antibodies. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NANTibody had been formed to advance pre-clinical and clinical immunology assets contributed by the Company and NantCell. The Company continues to hold </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding equity of NANTibody and NantCell holds the remaining </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;">. Until July 2, 2017, NANTibody held approximately </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents, and the Company recorded its investment in NANTibody at approximately </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">. As an equity method investment, the Company's ratable portion of </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of money expended for the development of intellectual property assets held by NANTibody would be reflected within income (loss) on equity method investments in its statement of operations. As a result of limited spending at NANTibody, the cash on hand at NANTibody remained at approximately at </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> since the inception of the NANTibody joint venture until July 2, 2017. Further, the Company's equity method investment in NANTibody remained at approximately </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> until July 2, 2017. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements of NANTibody are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, NANTibody notified the Company that on July 2, 2017, NANTibody acquired all of the outstanding equity of IgDraSol in exchange for </font><font style="font-family:inherit;font-size:10pt;">$90.1 million</font><font style="font-family:inherit;font-size:10pt;"> in cash. NANTibody purchased IgDraSol from NantPharma, which is controlled by NantWorks, an entity with a controlling interest in NantCell and NantPharma. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company has had a designee serving on the Board of Directors of NANTibody since the formation of NANTibody in April 2015, and although the Company has held </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding equity of NANTibody since NANTibody&#8217;s formation, neither the Company nor its director designee was given any advance notice of NANTibody&#8217;s purchase of IgDraSol or of any board meeting or action to approve such purchase. As such, the Company's designee on NANTibody&#8217;s Board of Directors was not given an opportunity to consider or vote on the transaction as a director and the Company was not given an opportunity to consider or vote on the transaction in its position as a significant (</font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">) equity holder of NANTibody. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the July 2, 2017 purchase of IgDraSol, NANTibody&#8217;s cash and cash equivalents were reduced from </font><font style="font-family:inherit;font-size:10pt;">$99.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2017 to </font><font style="font-family:inherit;font-size:10pt;">$9.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2017, and NANTibody&#8217;s contributed capital was reduced from </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2017 to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2017, to effect the transfer of IgDraSol from NantPharma to NANTibody. No additional information was provided to the Company to explain why NANTibody&#8217;s total assets as of September 30, 2017 were reduced by approximately </font><font style="font-family:inherit;font-size:10pt;">$90.1 million</font><font style="font-family:inherit;font-size:10pt;">. The Company requested, but did not receive, additional information from NANTibody for purposes of supporting the value of IgDraSol, including any information regarding clinical advancements in the entity since the sale of IgDraSol by the Company in May 2015. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the communication of the transfer of IgDraSol from NantPharma to NANTibody, the Company relied on the cash and cash equivalents of NANTibody for purposes of determining the value of its investment in NANTibody, which capital was expended by NANTibody to acquire IgDraSol on July 2, 2017. As a result of the transfer of IgDraSol, the Company reassessed the recoverability of its equity method investment in NANTibody as of July 2, 2017. In doing so, the Company considered the expected outcomes for the intellectual property assets held by NANTibody as of July 2, 2017. As a result of the lack of evidence of any development activity associated with any of the assets held in NANTibody, given the passage of time since the formation of the joint venture, many competitive products from other drug developers worldwide have advanced and/or commercialized for the targeted disease indications of the assets held in NANTibody, and given the Company's minority interest in NANTibody (the investee), the Company concluded that it does not have the ability to recover the carrying amount of the investment and an other-than-temporary decline in the value of the investment had occurred. Accordingly, an impairment was recorded to the Company's equity method investment in NANTibody for the three and nine months ended September 30, 2017. The fair value of the Company&#8217;s investment in NANTibody was measured at fair value on July 2, 2017 using significant unobservable inputs (Level 3) due to the determination of fair value requiring significant judgment, including the potential outcomes of the intellectual property assets held by NANTibody. For these reasons, fair value was determined by applying the Company's </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> equity interest in NANTibody to the remaining cash and cash equivalents, which resulted in an impairment of </font><font style="font-family:inherit;font-size:10pt;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;">. The impairment resulted in a revised carrying value of the Company's investment in NANTibody of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> which approximates its ratable </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> ownership of the cash maintained by NANTibody expected to be used for future research and development. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the Company&#8217;s investment in NANTibody was approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NANTibody recorded net loss of </font><font style="font-family:inherit;font-size:10pt;">$73 thousand</font><font style="font-family:inherit;font-size:10pt;"> and net profit </font><font style="font-family:inherit;font-size:10pt;">$276 thousand</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2018 and 2017, respectively. The Company recorded its portion of loss from NANTibody in loss on equity method investments on its condensed consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;As of March 31, 2018, NANTibody had </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;"> in current assets and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> in current liabilities and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> noncurrent assets or noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NantStem </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company and NantBioScience, a wholly-owned subsidiary of NantWorks, established a new entity called NantCancerStemCell, LLC (&#8220;NantStem&#8221;) as a stand-alone biotechnology company with </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> initial joint funding.&#160;&#160;As initially organized, NantBioScience was obligated to make a </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> cash contribution to NantStem for a </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> equity interest in NantStem, and the Company was obligated to make a </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> cash contribution to NantStem for a </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> equity interest in NantStem.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Fifty</font><font style="font-family:inherit;font-size:10pt;"> percent of these contributions were funded in July 2015 and the remaining amounts were to be made by no later than September 30, 2015. The Company had NantPharma contribute its portion of the initial joint funding of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> to NantStem from the proceeds of the sale of IgDraSol.&#160;&#160;Pursuant to a Side Letter dated October 13, 2015, the NantStem joint venture agreement was amended to relieve the Company of the obligation to contribute the second </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment, and its ownership interest in NantStem was reduced to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;NantBioScience&#8217;s funding obligations were unchanged.&#160;&#160;The Side Letter was negotiated at the same time the Company issued a call option on shares of NantKwest that it owned to Cambridge Equities, L.P. (&#8220;Cambridge&#8221;), a related party to NantBioScience.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2015, the Company determined it had an other-than-temporary decline in the value of NantStem and recognized a loss of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> in loss on equity method investments on its condensed consolidated statement of operations for the year ended December 31, 2015. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> loss related to other-than-temporary impairment recognized for the equity investment for the year ended December&#8224;31, 2017. A loss related to other-than-temporary impairment of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized for the equity investment in NantStem for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is accounting for its interest in NantStem as an equity method investment, due to the significant influence the Company has over the operations of NantStem through its board representation and </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> voting interest.&#160;&#160;The Company&#8217;s investment in NantStem is reported in equity method investments on its condensed consolidated balance sheets and its share of NantStem&#8217;s loss is recorded in loss on equity method investments on its condensed consolidated statement of operations.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the Company&#8217;s investment in NantStem was approximately </font><font style="font-family:inherit;font-size:10pt;">$18.2 million</font><font style="font-family:inherit;font-size:10pt;">. The difference between the Company&#8217;s investment in NantStem and the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> interest in the net assets of Nantstem was approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements of NantStem are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NantStem recorded net loss of </font><font style="font-family:inherit;font-size:10pt;">$331 thousand</font><font style="font-family:inherit;font-size:10pt;"> and net profit of </font><font style="font-family:inherit;font-size:10pt;">$369 thousand</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2018 and 2017, respectively.&#160;&#160;The Company recorded its portion of loss from NantStem (in addition to the immaterial impairment) in loss on equity method investments on its condensed consolidated statement of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;As of March 31, 2018, NantStem had </font><font style="font-family:inherit;font-size:10pt;">$82.3 million</font><font style="font-family:inherit;font-size:10pt;"> in current assets and </font><font style="font-family:inherit;font-size:10pt;">$27 thousand</font><font style="font-family:inherit;font-size:10pt;"> in current liabilities and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> noncurrent assets or noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Yuhan Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the Company and Yuhan , a South Korea company, entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC (&#8220;ImmuneOncia&#8221;) to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.&#160;&#160;Under the terms of the joint venture agreement, Yuhan contributed an initial investment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> to ImmuneOncia, and the Company granted ImmuneOncia an exclusive license to one of its immune checkpoint antibodies for specified countries while retaining the rights for the U.S., European and Japanese markets, as well as global rights for ImmuneOncia to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional antibodies that will be selected by ImmuneOncia from a group of pre-specified antibodies from the Company&#8217;s immuno-oncology antibody portfolio. During October 2016, funding and operations of ImmuneOncia commenced. Yuhan owns </font><font style="font-family:inherit;font-size:10pt;">51%</font><font style="font-family:inherit;font-size:10pt;"> of ImmuneOncia, while the Company owns </font><font style="font-family:inherit;font-size:10pt;">49%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is accounting for its interest in ImmuneOncia as an equity method investment, due to the significant influence the Company has over the operations of ImmuneOncia through its board representation and </font><font style="font-family:inherit;font-size:10pt;">49%</font><font style="font-family:inherit;font-size:10pt;"> voting interest while not sharing joint control with Yuhan.&#160;&#160;The Company&#8217;s investment in ImmuneOncia is reported in equity method investments on its condensed consolidated balance sheets and its share of ImmuneOncia&#8217;s loss is recorded in loss on equity method investments on its condensed consolidated statement of operations.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the Company&#8217;s investment in ImmuneOncia was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">. The difference between the Company&#8217;s investment in ImmuneOncia and the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">49%</font><font style="font-family:inherit;font-size:10pt;"> interest in the net assets of ImmuneOncia was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ImmuneOncia recorded a net loss of </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017, respectively.&#160; ImmuneOncia recorded a net loss of </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, 2018 and 2017, respectively. The Company recorded its portion (</font><font style="font-family:inherit;font-size:10pt;">49%</font><font style="font-family:inherit;font-size:10pt;"> equity interest) of loss from ImmuneOncia in loss on equity method investments on its condensed consolidated statement of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, ImmuneOncia had </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> in current assets, </font><font style="font-family:inherit;font-size:10pt;">$344 thousand</font><font style="font-family:inherit;font-size:10pt;"> in current liabilities, </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> in noncurrent assets, and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> noncurrent liabilities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, Yuhan purchased </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of shares of common stock, and warrants as part of the Company&#8217;s private placement offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shanghai Three</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 7, 2016, TNK agreed to issue to SiniWest Holdings, Inc. (&#8220;SiniWest Holdings&#8221;) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of TNK Class A Stock, subject to certain circumstances, to be issued upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront cash payment in exchange for SiniWest Holdings transferring certain assets to TNK, including SiniWest Holdings&#8217; </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> interest in Shanghai Three, a China based company. The Company is accounting for its interest in Shanghai Three as an equity method investment, due to the significant influence the Company has over the operations of Shanghai Three through its </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> voting interest.&#160; The Company&#8217;s investment in Shanghai Three is reported in equity method investments on the condensed consolidated balance sheets and its share of Shanghai Three&#8217;s income or loss is recorded in income (loss) on equity method investments on the condensed consolidated statement of operations.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the Company&#8217;s investment in Shanghai Three was approximately </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements of Shanghai Three are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shanghai Three incurred </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> operating expenses or net loss for the three and six months ended March 31, 2018 and 2017.&#160; As of March 31, 2018, Shanghai Three had </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in current assets, </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> in current liabilities, </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> in noncurrent assets, and </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> in noncurrent liabilities.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Equity Method Investment </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company periodically evaluates the carrying value of its equity method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. The Company determines the fair value of its equity method investments to evaluate whether impairment losses shall be recorded using Level 3 inputs. These investments include the Company's holdings in privately held biotechnology companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values and unobservable inputs, including future cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes a summary of the Company&#8217;s contingent and financing liabilities, related inputs used to determine fair value, and the valuation methodologies used for the fair value measurements using significant unobservable inputs (Level&#160;3) at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation Methodology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(range, if applicable)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Virttu Contingent Consideration (Non-current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Probability of Regulatory Milestone</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.21%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concortis Contingent Consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent probabilities assigned to scenarios</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.20%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shanghai Three Contingent Consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent probabilities assigned to scenarios</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.21%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RWMC Contingent Consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent probabilities assigned to scenarios</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.21%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2&#8212;Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3&#8212;Unobservable inputs based on the Company's own assumptions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis.&#160;&#160;(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition consideration payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,870</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,785</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition consideration payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's financial assets and liabilities carried at fair value are comprised of cash and cash equivalents and acquisition consideration payable. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These investments are valued using inputs observable in active markets for identical securities. Marketable securities are valued using inputs observable in active markets for identical securities. The Company recorded contingent consideration as part of its investment in Shanghai Three Alliance Biotech Co. LTD (&#8220;Shanghai Three&#8221;), agreement with Roger Williams Medical Center (&#8220;RWMC&#8221;), and acquisitions of Concortis, Inc., (&#8220;Concortis&#8221;), and Virttu. The fair value of the contingent consideration is measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Contingent consideration is measured using the income approach and discounting to present value the contingent payments expected to be made based on assessment of the probability that the company would be required to make such future payment.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes a summary of the Company&#8217;s contingent consideration liabilities and acquisition consideration payables associated with acquisitions. The contingent consideration is measured at fair value using significant unobservable inputs (Level&#160;3) during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Re-measurement of Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,663</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of current year contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The payment of current year contingent consideration for the six months ended June 30, 2018 includes the settlement of Scilex and BDL liabilities for </font><font style="font-family:inherit;font-size:10pt;">$38.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and the </font><font style="font-family:inherit;font-size:10pt;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;"> partial settlement of the Virttu financing milestone in common shares of the Company (</font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;"> of the Virttu contingent liability remains to be paid in cash).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes a summary of the Company&#8217;s contingent and financing liabilities, related inputs used to determine fair value, and the valuation methodologies used for the fair value measurements using significant unobservable inputs (Level&#160;3) at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation Methodology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(range, if applicable)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Virttu Contingent Consideration (Non-current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Probability of Regulatory Milestone</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.21%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concortis Contingent Consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent probabilities assigned to scenarios</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.20%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shanghai Three Contingent Consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent probabilities assigned to scenarios</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.21%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RWMC Contingent Consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple outcome</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discounted cash flow</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent probabilities assigned to scenarios</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.21%</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal significant unobservable inputs used in the valuations of the contingent considerations are the discount rates and probabilities assigned to scenario outcomes. An increase in the discount rate or decrease in the probability of regulatory milestone achievement will cause a decrease in the fair value of the contingent consideration. Conversely, a decrease in the discount rate will cause an increase in the fair value of the contingent consideration. An increase in the probabilities assigned to certain scenarios will cause the fair value of contingent consideration to increase. Conversely, a decrease in the probabilities assigned to certain scenarios will cause the fair value of contingent considerations to decrease.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes a summary of the Company&#8217;s contingent consideration liabilities and acquisition consideration payables associated with acquisitions. The contingent consideration is measured at fair value using significant unobservable inputs (Level&#160;3) during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Re-measurement of Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,663</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of current year contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes a summary of the warrant measured at fair value using significant unobservable inputs (Level&#160;3) during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had recorded goodwill of </font><font style="font-family:inherit;font-size:10pt;">$38.3 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company performed a qualitative test for goodwill impairment as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Based upon the results of the qualitative testing the Company concluded that it is more-likely-than-not that the fair values of the Company&#8217;s goodwill was in excess of its carrying value and therefore performing the first step of the two-step impairment test was unnecessary. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> goodwill impairment was recognized for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;A summary of the Company's goodwill as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Goodwill Acquired from Acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s intangible assets, excluding goodwill, include acquired license and patent rights, core technologies, customer relationships and acquired in-process research and development. Amortization for the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives.&#160;&#160;A summary of the Company&#8217;s identifiable intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intangibles, net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,685</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intangibles, net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the remaining weighted average life for identifiable intangible assets is </font><font style="font-family:inherit;font-size:10pt;">15 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent rights are stated at cost and amortized on a straight-line basis over the estimated useful lives of the assets, determined to be approximately </font><font style="font-family:inherit;font-size:10pt;">fifteen years</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">nineteen years</font><font style="font-family:inherit;font-size:10pt;"> from the date of transfer of the rights to the Company. Amortization expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$545 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$552 thousand</font><font style="font-family:inherit;font-size:10pt;">, respectively, which has been included in intangible amortization on the condensed consolidated statement of operations. Amortization expense for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1,090 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,059 thousand</font><font style="font-family:inherit;font-size:10pt;">, respectively, which has been included in intangible amortization on the condensed consolidated statement of operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately </font><font style="font-family:inherit;font-size:10pt;">19 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of acquisition of the technology in December 2013. Amortization expense for each of the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$44 thousand</font><font style="font-family:inherit;font-size:10pt;">, which has been included in intangibles amortization on the condensed consolidated statement of operations. Amortization expense for each of the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$88 thousand</font><font style="font-family:inherit;font-size:10pt;">, which has been included in intangible amortization on the condensed consolidated statement of operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> from the date of acquisition. Amortization expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$72 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$73 thousand</font><font style="font-family:inherit;font-size:10pt;">, respectively, which has been included in intangibles amortization. Amortization expense for each of the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$145 thousand</font><font style="font-family:inherit;font-size:10pt;">, which has been included in intangible amortization on the condensed consolidated statement of operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired in-process research and development is stated at cost and may be immediately expensed if there is no alternative future use. The Company intends to begin amortization of acquired in-process research and development costs associated with the Scilex and Virttu business combinations upon commercialization of the respective products. The acquired in-process research and development is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated future amortization expense related to intangible assets at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Other Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, noting </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment. There have not been any triggering events indicating the potential for impairment through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development Expense</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired in-process research and development related to the business combinations of Virttu Biologics Limited ("Virttu") and Scilex Pharmaceuticals Inc. ("Scilex"), for which certain products are under development and expected to be commercialized in the future, was capitalized and recorded within &#8220;Intangibles, net&#8221; on the accompanying condensed consolidated balance sheet. The Company intends to commence amortization of acquired in-process research and development upon commercialization of the related products. Capitalized in-process research and development will be reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company's ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company's U.S. federal and state deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its Scilex subsidiary.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s income tax benefit of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;reflect effective tax rates of&#160;</font><font style="font-family:inherit;font-size:10pt;">2.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The difference between the expected statutory federal tax expense of&#160;</font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">&#160;and the </font><font style="font-family:inherit;font-size:10pt;">2.1%</font><font style="font-family:inherit;font-size:10pt;">&#160;effective tax expense for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> was primarily attributable to the valuation allowance against most of the Company&#8217;s deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to taxation in the U.S. and various state jurisdictions. The Company's tax years for 2007 and later are subject to examination by the U.S. and state tax authorities due to the existence of the NOL carryforwards.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> of</font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. For the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> expense was recorded related to interest and penalties. The Company believes that </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> significant amount of the liabilities for uncertain tax positions will expire within twelve months of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Tax Reform</font></div><div style="line-height:120%;padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;) was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, as well as making several other significant changes to the tax law, effective January 1, 2018. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), given the amount and complexity of the changes in tax law resulting from the Tax Act, the Company has not finalized the accounting for the income tax effects of the Tax Act. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to the Company's valuation allowance. The impact of the Tax Act may differ from this estimate, during the one-year measurement period due to, among other things, further refinement of the Company's calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Act. The Company is still analyzing certain aspects of the Tax Act and refining its calculations, which could potentially affect the analysis of the Company&#8217;s deferred tax assets and liabilities. Any subsequent adjustment is expected to be offset by a change in valuation allowance and have no impact on the Company&#8217;s financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of ASC Topic 740 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Income Taxes,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of each of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its investment in Scilex.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments in Other Entities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company&#8217;s share of earnings or losses reported in loss on equity method investments.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s cost method investments are included in cost method investments on the condensed consolidated balance sheets.&#160;&#160;The Company&#8217;s equity method investments are included in equity method investments on the condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: the magnitude of the impairment and length of time that the market value was below the cost basis; financial condition and business prospects of the investee; the Company&#8217;s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that the Company may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Realized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading securities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedoveX common shares and warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(427</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Realized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading securities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedoveX common shares and warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trading Securities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 5, 2016, the Company entered into a Unit Purchase Agreement (the &#8220;Unit Purchase Agreement&#8221;) with MedoveX Corporation (&#8220;MedoveX&#8221;). Pursuant to the terms of the Unit Purchase Agreement, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> Units for </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Each Unit had a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> and consisted of (i) </font><font style="font-family:inherit;font-size:10pt;">208,333</font><font style="font-family:inherit;font-size:10pt;"> shares of MedoveX common stock (the &#8220;MedoveX Common Stock&#8221;), and (ii) a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">104,167</font><font style="font-family:inherit;font-size:10pt;"> shares of MedoveX Common Stock&#160;(the &#8220;MedoveX Warrant&#8221;).&#160;&#160;The MedoveX Warrant has an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.52</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment, and is initially exercisable six months following the date of issuance for a period of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> from the date of issuance.&#160;&#160;In addition, the Company entered into a Registration Rights Agreement with MedoveX pursuant to which MedoveX was required to file a registration statement registering for resale all shares of MedoveX Common Stock and shares of MedoveX Common Stock issuable pursuant to the MedoveX Warrant issued as part of the Units.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a loss of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, on trading securities. For the the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a loss of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> on trading securities, respectively. The Company&#8217;s investment in MedoveX will be revalued on each balance sheet date.&#160;&#160;The fair value of the Company&#8217;s holding in MedoveX Common Stock at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is a Level 1 measurement.&#160;&#160;The fair value of the Company&#8217;s holdings in the MedoveX Warrant was estimated using the Black-Scholes option-pricing method. The risk-free rate was derived from the U.S. Treasury yield curve, matching the MedoveX Warrant&#8217;s term, in effect at the measurement date. The volatility factor was determined based on MedoveX&#8217;s historical stock prices. The warrant valuation is a Level 3 measurement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes a summary of the warrant measured at fair value using significant unobservable inputs (Level&#160;3) during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are designated either as trading or available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations and are classified as short-term available-for-sale securities are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Marketable securities that are not trading securities and are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities that are classified as trading are carried at fair value, with changes to fair value reported as a component of income. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary.&#160;For the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> other-than-temporary impairment charges were recorded.</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU No. 2014-09 was originally effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard for annual reporting periods beginning after December 15, 2017, and interim periods thereafter. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, January 1, 2018 under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of January 1, 2018 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. The ASU amends the guidance in GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. ASU No. 2016-01 is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Leases</font><font style="font-family:inherit;font-size:10pt;">. ASU No. 2016-02 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU No. 2016-20 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-02 will have on its consolidated financial position, results of operations and cash flows. The Company's leases are discussed in Note 14. The Company currently expects to record right-of-use assets and lease liabilities with regard to its leases in the consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font><font style="font-family:inherit;font-size:10pt;"> to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The ASU also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#8217;s portfolio. The ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application will be permitted for all organizations for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2016-13 will have on its consolidated financial position, results of operations and cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">, to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. The ASU requires that (1) debt extinguishment costs be classified as cash outflows for financing activities and provides additional classification guidance for the statement of cash flows, (2) the classification of cash receipts and payments that have aspects of more than one class of cash flows to be determined by applying specific guidance under generally accepted accounting principles, and (3) each separately identifiable source or use within the cash receipts and payments be classified on the basis of their nature in financing, investing or operating activities. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:inherit;font-size:10pt;">, to clarify the definition of a business to add guidance for evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Specifically, this ASU provides a screen to assist entities in determining when a set should not be considered a business, which screen provides that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar assets, the set is not a business. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Test for Goodwill Impairment (Topic 350)</font><font style="font-family:inherit;font-size:10pt;">. This standard eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#8217;s fair value. This guidance is effective for interim and annual goodwill impairment tests in fiscal years beginning after December 15, 2019 with early adoption permitted. This guidance must be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of ASU No. 2017-04 will have on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:inherit;font-size:10pt;">, to provide clarity and reduce both the diversity in practice and cost of complexity when applying the guidance. Specifically, the ASU provides additional modification conditions in determining whether or not modification accounting should be applied. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">, to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and improves the usefulness of information reported to financial statement users. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2018-07 will have on the Company&#8217;s consolidated financial position, results of operations or cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Operations and Business Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Na</font><font style="font-family:inherit;font-size:10pt;">t</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ure of Operations and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the &#8220;Company&#8221;), is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. The Company&#8217;s primary focus is to transform cancer into a treatable or chronically manageable disease. The Company also has programs assessing the use of its technologies and products in auto-immune, inflammatory, neurodegenerative, infectious diseases and pain indications with high unmet medical needs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At its core, the Company is an antibody-centric company and leverages its proprietary G-MAB&#8482; library to identify, screen and validate fully human antibodies against high impact oncogenic targets and mutations, immune modulators and intracellular targets. To date, the Company has screened over </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> validated targets and generated a number of fully human antibodies against these targets which are at various stages of preclinical development. These include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (&#8220;ADCs&#8221;), bispecific approaches, as well as T-Cell Receptor (&#8220;TCR&#8221;)-like antibodies.&#160;&#160;With LA Cell, Inc. (&#8220;LA Cell&#8221;), the Company&#8217;s joint venture with City of Hope, the Company&#8217;s objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, the Company has acquired and is assessing the regulatory and strategic path forward for its portfolio of late stage biosimilar/biobetter antibodies based on Erbitux</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, Remicade</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, Xolair</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, and Simulect</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;"> as these may represent nearer term commercial opportunities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With each of its programs, the Company aims to tailor its therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape. In addition, the Company&#8217;s objective is to focus on tumors that are resistant to current treatments and where the Company can design focused trials based on a genetic signature or biomarker to ensure patients have the best chance of a durable and significant response. The Company has several immuno-oncology programs that are in or near to entering the clinic.&#160;&#160;These include cellular therapies, an oncolytic virus and a palliative care program targeted to treat intractable cancer pain.&#160;&#160;Finally, as part of its global aim to provide a wide range of therapeutic products to meet underserved therapeutic markets, the Company has made investments and developed a separate pain focused franchise which the Company believes will serve to provide short term upside to its core thesis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company&#8217;s subsidiaries.&#160;&#160;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.&#160;&#160;All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal, recurring and necessary for a fair statement of financial position, results of operations and cash flows. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Operating results for interim periods are not expected to be indicative of operating results for the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> fiscal year, or any subsequent period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,868</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,881</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,723</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and 2017 was </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Depreciation expense for the six months ended June 30, 2018 and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,868</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,881</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,723</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Grants and Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants receivable at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> represent amounts due under&#160;several federal contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a division of the National Institutes of Health (&#8220;NIH&#8221;). The Company considers the grants receivable to be fully collectible; accordingly, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> consist of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2015, the Company entered into a joint venture called NANTibody, with NantCell, a subsidiary of NantWorks.&#160;&#160;In July 2015, the Company contributed its portion of the initial joint funding of </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the NANTibody joint venture.&#160;&#160;The Company and NantCell have also entered into a license agreement pursuant to which the Company received a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront license payment and </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> of vested NantCell common stock.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2015, the Company entered into a joint venture called NantStem, with NantBioScience, a wholly-owned subsidiary of NantWorks.&#160;&#160;In connection with negotiated changes to the structure of NantStem the Company issued a call option on shares of NantKwest that it owned to Cambridge, a related party to the Company and to NantBioScience.&#160;&#160;In April 2015, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of NantBioScience common stock for </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the Company and Yuhan entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the Company&#8217;s investment in ImmuneOncia Therapeutics, LLC was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">. During the three months ended June 30, 2016, Yuhan purchased </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of common stock and warrants.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 15, 2017, the transactions contemplated by that certain Contribution Agreement, dated June 12, 2017, by and among the Company, TNK and Celularity Inc. (&#8220;Celularity&#8221;), pursuant to which, among other things, the Company and TNK agreed to contribute certain intellectual property rights related to their proprietary chimeric antigen receptor constructs and related CARs to Celularity in exchange for shares of Celularity&#8217;s Series A Preferred Stock equal to </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of Celularity&#8217;s outstanding shares of capital stock, calculated on a fully-diluted basis closed. Dr. Henry Ji, the Company's Chairman of the Board, President and Chief Executive Officer, Jaisim Shah, a member of the Company&#8217;s Board of Directors and David Deming, a member of the Company&#8217;s Board of Directors, were previously appointed as members of the board of directors of Celularity.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 8, 2016, the Company entered into the Scilex Purchase Agreement, pursuant to which the Company acquired from the Scilex Stockholders approximately </font><font style="font-family:inherit;font-size:10pt;">72%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding capital stock of Scilex. Dr. Henry Ji, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and George K. Ng, the Company&#8217;s Vice President, Chief Administrative Officer and Chief Legal Officer, were stockholders of Scilex prior to the acquisition transaction.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs and Collaborations</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concortis Biosystems Corporation (&#8220;Concortis&#8221;)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Contract manufacturing associated with sales of customized reagents for Concortis operations relate to providing synthetic expertise to customers&#8217; synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers which are recognized upon the transfer of control, which is generally upon shipment given the short contract terms which are generally three months or less. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Materials and Supply Agreements</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from the sale of materials associated with our research and development arrangements are recognized upon the transfer of control, which is generally, upon shipment. Outstanding performance obligations related to materials and supply agreements was </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the Company expects to fulfill such obligations during the remainder of 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bioserv Corporation (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bioserv</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturing services associated with the Company's Bioserv operations related to finish and fill activities for drug products and reagents are recognized ratably over the contract term based on a time-based measure which reflects the transfer of services to the customer because the manufactured products are highly customized and do not have an alternative use to the Company</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Sales and Services Revenues</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and services revenues are comprised of contract manufacturing associated with sales of customized reagents at Concortis Biosystems Corporation, materials and supply agreements, contract manufacturing services at BioServ Corporation, and the Company&#8217;s joint development agreement with Celularity Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. The Company applied the practical expedient in ASC Topic 606-10-50-14 to the revenue contracts for our Concortis Biosystems Corporation sales and services and materials and supply agreements due to the short-term length of such contracts.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenues are generated from various NIH grant awards, license fees, the sale of customized reagents and other materials, and the provision of contract manufacturing and other services. The Company does not have significant costs associated with costs to obtain contracts with its customers. Substantially all of the Company&#8217;s grants and accounts receivable result from contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Grant Revenues</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Royalty and License Revenues</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period, with the exception of license agreements with no remaining performance obligations or undelivered obligations. The Company applies judgment in determining the timing of revenue recognition related to contracts that include multiple performance obligations. The total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. For goods or services for which observable standalone selling prices are not available, the Company develops an estimated standalone selling price of each performance obligation. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes Bioserv sales and services revenue expected to be recognized in the future related to performance obligations that are undelivered or partially delivered at the end of the reporting period and do not include contracts with original durations of one year or less (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remainder of 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020 and thereafter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturing services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$353</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These outstanding securities consist of the following:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:37px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,616,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,375,276</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,528,732</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,932,998</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt and unamortized discount balances are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Face value of loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount - warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount - beneficial conversion feature</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt issuance costs and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the reconciliation of basic and diluted loss per share for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106,436</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,251</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for Basic and Diluted Loss Per Share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,302</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,795</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and Diluted Loss Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis.&#160;&#160;(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition consideration payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,870</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,785</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition consideration payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s identifiable intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intangibles, net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,685</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intangibles, net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's goodwill as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Goodwill Acquired from Acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands) as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.3170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ending December 31,</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,311</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unpaid interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,549</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized capitalized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum payment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,203</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and the changes for the period then ended (dollar values in thousands, other than weighted-average exercise price):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,343,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,566,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(266,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,616,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of employee stock options was estimated at the grant date using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average grant date fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.52</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated future amortization expense related to intangible assets at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for stock-based compensation in accordance with ASC Topic 718 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation,</font><font style="font-family:inherit;font-size:10pt;">&#8221; which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Incentive Plans</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2009 Non-Employee Director Grants</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company&#8217;s Board of Directors approved the reservation and issuance of </font><font style="font-family:inherit;font-size:10pt;">8,000</font><font style="font-family:inherit;font-size:10pt;"> non-statutory stock options to the Company&#8217;s non-employee directors. The options vested on the </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;"> anniversary of the vesting commencement date in October 2010, and are exercisable for up to </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;"> from the grant date. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> further shares may be granted under this plan and, as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">3,200</font><font style="font-family:inherit;font-size:10pt;"> options with a weighted-average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.12</font><font style="font-family:inherit;font-size:10pt;"> were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2009 Stock Incentive Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2009, the Company&#8217;s stockholders approved the 2009 Stock Incentive Plan. In July 2017, the Company&#8217;s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan (as amended and restated, the &#8220;Stock Plan&#8221;) to increase the number of shares of the Company&#8217;s common stock authorized to be issued pursuant to the Stock Plan to </font><font style="font-family:inherit;font-size:10pt;">11,260,000</font><font style="font-family:inherit;font-size:10pt;">. Such shares of the Company&#8217;s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Employee option grants generally vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company&#8217;s Compensation Committee. Stock options are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and the changes for the period then ended (dollar values in thousands, other than weighted-average exercise price):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,343,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,566,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(266,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,616,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options exercised during the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$4 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The aggregate intrinsic value of options exercised during the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$52 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of employee stock options was estimated at the grant date using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average grant date fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.52</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumed dividend yield was based on the Company&#8217;s expectation of not paying dividends in the foreseeable future. Due to the Company&#8217;s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total employee and director stock-based compensation recorded as operating expenses was </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;for the six months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total unrecognized compensation cost related to unvested employee and director stock option grants as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;"> and the weighted average period over which these grants are expected to vest is </font><font style="font-family:inherit;font-size:10pt;">3.0 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was </font><font style="font-family:inherit;font-size:10pt;">$178 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8 thousand</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$275 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$34 thousand</font><font style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, 2018 and 2017, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Reserved for Future Issuance</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;padding-left:0px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock reserved for future issuance consists of the following at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the underwriters agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the loan and security agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the Hercules securities agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under the convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,819,872</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants outstanding under private placements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,153,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options outstanding under the Non-Employee Director Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized for future grant or issuance under the 2009 Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,756,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issuable upon the conversion of the 2018 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,397,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Issuable under assignment agreement based upon achievement of certain milestones</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,765,538</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017 Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, the Company&#8217;s subsidiary, Scilex, adopted the Scilex 2017 Equity Incentive Plan, reserved </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Scilex common stock and awarded </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">0.5 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">options were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015 Stock Option Plans</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the Company&#8217;s subsidiary, TNK, adopted the TNK 2015 Stock Option Plan, reserved </font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of TNK class A common stock and awarded </font><font style="font-family:inherit;font-size:10pt;">3.6 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel, directors and consultants under such plan. In November 2015, TNK awarded </font><font style="font-family:inherit;font-size:10pt;">0.5 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel.&#160;&#160;Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> or monthly over four years from the grant date and have a contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Effective August 29, 2017, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. Effective May 16, 2018, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">0.9 million</font><font style="font-family:inherit;font-size:10pt;"> options were outstanding. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, TNK granted a warrant to the Company&#8217;s CEO to purchase </font><font style="font-family:inherit;font-size:10pt;">9.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of TNK class B common stock, which have </font><font style="font-family:inherit;font-size:10pt;">10 to 1</font><font style="font-family:inherit;font-size:10pt;"> voting rights.&#160;&#160;Warrant shares totaling </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;"> were exercisable evenly over </font><font style="font-family:inherit;font-size:10pt;">forty months</font><font style="font-family:inherit;font-size:10pt;"> and the remaining warrant shares were exercisable if certain defined events occur within </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from date of issuance at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;This warrant was canceled in its entirety effective August 29, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the Company&#8217;s subsidiary, LA Cell, adopted the LA Cell 2015 Stock Option Plan reserved </font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of LA Cell class A common stock and awarded </font><font style="font-family:inherit;font-size:10pt;">2.9 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> or monthly over four years from the grant date and have a contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Effective August 29, 2017, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. Effective May 16, 2018, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">0.3 million</font><font style="font-family:inherit;font-size:10pt;"> options were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, LA Cell granted a warrant to the Company&#8217;s CEO to purchase </font><font style="font-family:inherit;font-size:10pt;">9.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of LA Cell class B common stock, which have </font><font style="font-family:inherit;font-size:10pt;">10 to 1</font><font style="font-family:inherit;font-size:10pt;"> voting rights.&#160;&#160;Warrant shares totaling </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;"> were exercisable evenly over </font><font style="font-family:inherit;font-size:10pt;">forty months</font><font style="font-family:inherit;font-size:10pt;"> and the remaining warrant shares were exercisable if certain defined events occur within </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from date of issuance at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;This warrant was canceled in its entirety effective August 29, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, the Company&#8217;s subsidiary, Concortis Biosystems, Corp. (&#8220;CBC&#8221;), adopted the CBC 2015 Stock Option Plan and reserved </font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of CBC class A common stock and awarded </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> or monthly over </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from the grant date and have a contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Effective August 29, 2017, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. Effective May 16, 2018, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, CBC granted a warrant to the Company&#8217;s CEO to purchase </font><font style="font-family:inherit;font-size:10pt;">9.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of CBC class B common stock, which have </font><font style="font-family:inherit;font-size:10pt;">10 to 1</font><font style="font-family:inherit;font-size:10pt;"> voting rights.&#160;&#160;Warrant shares totaling </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;"> were exercisable evenly over </font><font style="font-family:inherit;font-size:10pt;">forty months</font><font style="font-family:inherit;font-size:10pt;"> and the remaining warrant shares were exercisable if certain defined events occur within </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from date of issuance at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;This warrant was canceled in its entirety effective August 29, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, the Company&#8217;s subsidiary, Scintilla, adopted the Scintilla 2015 Stock Option Plan, reserved </font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Scintilla class A common stock and awarded </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel, directors and consultants under such plan.&#160;&#160; Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> or monthly over </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from the grant date and have a contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Effective August 29, 2017, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. Effective May 16, 2018, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, Scintilla granted a warrant to the Company&#8217;s CEO to purchase </font><font style="font-family:inherit;font-size:10pt;">9.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Scintilla class B common stock, which have </font><font style="font-family:inherit;font-size:10pt;">10 to 1</font><font style="font-family:inherit;font-size:10pt;"> voting rights.&#160;&#160;Warrant shares totaling </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;"> were exercisable evenly over </font><font style="font-family:inherit;font-size:10pt;">forty months</font><font style="font-family:inherit;font-size:10pt;"> and the remaining warrant shares were exercisable if certain defined events occur within </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from date of issuance at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;This warrant was canceled in its entirety effective August 29, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, the Company&#8217;s subsidiary, Sorrento Biologics, Inc. (&#8220;Biologics&#8221;), adopted the Biologics 2015 Stock Option Plan, reserved </font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Biologics class A common stock and awarded </font><font style="font-family:inherit;font-size:10pt;">2.6 million</font><font style="font-family:inherit;font-size:10pt;"> options to certain Company personnel, directors and consultants under such plan.&#160;&#160;Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> or monthly over </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from the grant date and have a contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Effective August 29, 2017, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. Effective May 16, 2018, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">75,000</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">options were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, Biologics granted a warrant to the Company&#8217;s CEO to purchase </font><font style="font-family:inherit;font-size:10pt;">9.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Biologics class B common stock which have </font><font style="font-family:inherit;font-size:10pt;">10 to 1</font><font style="font-family:inherit;font-size:10pt;"> voting rights.&#160;&#160;Warrant shares totaling </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;"> were exercisable evenly over </font><font style="font-family:inherit;font-size:10pt;">forty months</font><font style="font-family:inherit;font-size:10pt;"> and the remaining warrant shares were exercisable if certain defined events occur within </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> from date of issuance at an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;This warrant was canceled in its entirety effective August 29, 2017.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 29, 2017, the options and warrants were canceled in accordance with the terms of a settlement agreement with Wildcat Liquid Alpha, LLC and, as a result, unrecognized compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$281 thousand</font><font style="font-family:inherit;font-size:10pt;"> associated with these previously issued shares was accelerated and recognized upon cancellation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total director stock-based compensation recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$54 thousand</font><font style="font-family:inherit;font-size:10pt;">, respectively and was&#160;</font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$96 thousand</font><font style="font-family:inherit;font-size:10pt;">&#160;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> unrecognized stock-based compensation expense related to unvested director stock option and warrant grants remained for these entities as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest.&#160;&#160;Stock based compensation expense related to non-employee consultants recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics was </font><font style="font-family:inherit;font-size:10pt;">$149 thousand</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">for each of the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and was&#160;</font><font style="font-family:inherit;font-size:10pt;">$358 thousand</font><font style="font-family:inherit;font-size:10pt;">&#160;for each of the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average assumptions used in the Black-Scholes option and warrant pricing model used by TNK, LA Cell, CBC, Scintilla and Biologics to determine the fair value of stock option grants for directors and non-employee consultants for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows: expected dividend yield &#8211; </font><font style="font-family:inherit;font-size:10pt;">0%</font><font style="font-family:inherit;font-size:10pt;">, risk-free interest rate &#8211;</font><font style="font-family:inherit;font-size:10pt;">2.42%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.48%</font><font style="font-family:inherit;font-size:10pt;">, expected volatility &#8211; </font><font style="font-family:inherit;font-size:10pt;">65%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">77%</font><font style="font-family:inherit;font-size:10pt;">, and expected term of </font><font style="font-family:inherit;font-size:10pt;">4.0</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">6.1 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014 Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Company&#8217;s subsidiary, Ark Animal Health, Inc. (&#8220;Ark&#8221;), adopted the Ark 2014 Stock Option Plan and reserved and awarded </font><font style="font-family:inherit;font-size:10pt;">600,000</font><font style="font-family:inherit;font-size:10pt;"> options to certain directors and consultants under such plan. Stock options granted under such plan typically vest a portion immediately upon grant and the remaining options over </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;"> from the grant date and have a contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Effective August 29, 2017, options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">135,000</font><font style="font-family:inherit;font-size:10pt;"> shares were canceled. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">88,000</font><font style="font-family:inherit;font-size:10pt;"> options were outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total director and consultant stock-based compensation recorded as operating expenses by the Company for Ark was </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> for each of the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> unrecognized stock-based compensation expense remains related to stock option grants as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period.&#160;Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are designated either as trading or available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations and are classified as short-term available-for-sale securities are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Marketable securities that are not trading securities and are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities that are classified as trading are carried at fair value, with changes to fair value reported as a component of income. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary.&#160;For the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> other-than-temporary impairment charges were recorded.</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Grants and Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants receivable at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> represent amounts due under&#160;several federal contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a division of the National Institutes of Health (&#8220;NIH&#8221;). The Company considers the grants receivable to be fully collectible; accordingly, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> consist of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of each of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$20 thousand</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions and Intangibles</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Other Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, noting </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment. There have not been any triggering events indicating the potential for impairment through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition consideration payable relates to the Company&#8217;s acquisition of businesses and various other assets and is recorded on the Company&#8217;s condensed consolidated balance sheets at fair value and is re-measured at each balance sheet date until such contingent liabilities have been settled, with changes in fair value recorded as gain or loss on contingent liabilities. The Company estimates the fair value of contingent consideration based on level 3 inputs primarily driven by the probability of achieving certain financing or operating related milestones.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt with Detachable Warrants </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt with detachable warrants are evaluated for the classification of warrants as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are first allocated to the debt and the warrants at their relative estimated fair values. The portion of the proceeds so allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of embedded derivatives and beneficial conversion features, are allocated to the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds, to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the amount allocated to the convertible debt results in an effective per share conversion price less than the fair value of the Company&#8217;s common stock on the commitment date, the intrinsic value of this beneficial conversion feature is recorded as a discount to the convertible debt with a corresponding increase to additional paid in capital. The beneficial conversion feature discount is equal to the difference between the effective conversion price and the fair value of the Company&#8217;s common stock at the commitment date, unless limited by the remaining proceeds allocated to the debt. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Liability</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liabilities are recorded on the Company&#8217;s condensed consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.&#160;&#160;The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments in Other Entities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company&#8217;s share of earnings or losses reported in loss on equity method investments.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s cost method investments are included in cost method investments on the condensed consolidated balance sheets.&#160;&#160;The Company&#8217;s equity method investments are included in equity method investments on the condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: the magnitude of the impairment and length of time that the market value was below the cost basis; financial condition and business prospects of the investee; the Company&#8217;s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that the Company may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs and Collaborations</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development Expense</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired in-process research and development related to the business combinations of Virttu Biologics Limited ("Virttu") and Scilex Pharmaceuticals Inc. ("Scilex"), for which certain products are under development and expected to be commercialized in the future, was capitalized and recorded within &#8220;Intangibles, net&#8221; on the accompanying condensed consolidated balance sheet. The Company intends to commence amortization of acquired in-process research and development upon commercialization of the related products. Capitalized in-process research and development will be reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of ASC Topic 740 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Income Taxes,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of each of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its investment in Scilex.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenues are generated from various NIH grant awards, license fees, the sale of customized reagents and other materials, and the provision of contract manufacturing and other services. The Company does not have significant costs associated with costs to obtain contracts with its customers. Substantially all of the Company&#8217;s grants and accounts receivable result from contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Grant Revenues</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Royalty and License Revenues</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period, with the exception of license agreements with no remaining performance obligations or undelivered obligations. The Company applies judgment in determining the timing of revenue recognition related to contracts that include multiple performance obligations. The total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. For goods or services for which observable standalone selling prices are not available, the Company develops an estimated standalone selling price of each performance obligation. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the future performance obligations for royalty and license revenues relate to the ImmuneOncia Therapeutics, LLC (&#8220;ImmuneOncia&#8221;) and NantCell, Inc. (&#8220;NantCell&#8221;) license agreements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total consideration for the ImmuneOncia license performance obligation, effective September 1, 2016, represented </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;">. The estimated revenue expected to be recognized for future performance obligations, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company expects to recognize license revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> of the remaining performance obligation annually through the remaining term. The Company applied judgment in estimating the </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">-year contract term, analogous to the expected life of the patent, over which revenue is recognized over time given the ongoing performance obligation related to the Company's participation on a steering committee for the technologies under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the NantCell license agreement, effective April 21, 2015, represented </font><font style="font-family:inherit;font-size:10pt;">$110 million</font><font style="font-family:inherit;font-size:10pt;"> of contract liabilities reflected in long-term deferred revenue. See Note 11 for additional information regarding the remaining performance obligation for the significant agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Sales and Services Revenues</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and services revenues are comprised of contract manufacturing associated with sales of customized reagents at Concortis Biosystems Corporation, materials and supply agreements, contract manufacturing services at BioServ Corporation, and the Company&#8217;s joint development agreement with Celularity Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. The Company applied the practical expedient in ASC Topic 606-10-50-14 to the revenue contracts for our Concortis Biosystems Corporation sales and services and materials and supply agreements due to the short-term length of such contracts.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows sales and service revenues disaggregated by product and services type for the three and six months ended June 30, 2018 and 2017 (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concortis sales and services</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Materials and supply agreements</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioserv sales and services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Joint development agreement</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,793</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concortis Biosystems Corporation (&#8220;Concortis&#8221;)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Contract manufacturing associated with sales of customized reagents for Concortis operations relate to providing synthetic expertise to customers&#8217; synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers which are recognized upon the transfer of control, which is generally upon shipment given the short contract terms which are generally three months or less. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Materials and Supply Agreements</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from the sale of materials associated with our research and development arrangements are recognized upon the transfer of control, which is generally, upon shipment. Outstanding performance obligations related to materials and supply agreements was </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the Company expects to fulfill such obligations during the remainder of 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bioserv Corporation (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bioserv</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturing services associated with the Company's Bioserv operations related to finish and fill activities for drug products and reagents are recognized ratably over the contract term based on a time-based measure which reflects the transfer of services to the customer because the manufactured products are highly customized and do not have an alternative use to the Company. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of unbilled accounts receivable for which revenue has been recognized but not billed at the reporting date, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of upfront payments related to its contract manufacturing services included in deferred revenue, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the estimated revenue expected to be recognized for future performance obligations associated with contract manufacturing services was approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company expects to recognize revenue on approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> of these remaining performance obligations over the next twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes Bioserv sales and services revenue expected to be recognized in the future related to performance obligations that are undelivered or partially delivered at the end of the reporting period and do not include contracts with original durations of one year or less (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remainder of 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020 and thereafter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturing services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$353</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Joint Development Agreement</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On September 26, 2017, the Company entered into a joint development agreement with Celularity Inc. whereby the Company agreed to provide research services to Celularity Inc. through June 30, 2018 in exchange for an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">. The revenue related to the joint development agreement of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> will be recognized over the length of the service agreement as services are performed. The Company recorded sales and services revenues under the joint development agreement of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for stock-based compensation in accordance with ASC Topic 718 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation,</font><font style="font-family:inherit;font-size:10pt;">&#8221; which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is primarily comprised of net income (loss) and adjustments for the change in unrealized gains and losses on the Company&#8217;s investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its condensed consolidated statements of comprehensive income (loss).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These outstanding securities consist of the following:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:37px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,616,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,375,276</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,528,732</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,932,998</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU No. 2014-09 was originally effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard for annual reporting periods beginning after December 15, 2017, and interim periods thereafter. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, January 1, 2018 under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of January 1, 2018 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. The ASU amends the guidance in GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. ASU No. 2016-01 is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Leases</font><font style="font-family:inherit;font-size:10pt;">. ASU No. 2016-02 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU No. 2016-20 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-02 will have on its consolidated financial position, results of operations and cash flows. The Company's leases are discussed in Note 14. The Company currently expects to record right-of-use assets and lease liabilities with regard to its leases in the consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font><font style="font-family:inherit;font-size:10pt;"> to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The ASU also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#8217;s portfolio. The ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application will be permitted for all organizations for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2016-13 will have on its consolidated financial position, results of operations and cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">, to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. The ASU requires that (1) debt extinguishment costs be classified as cash outflows for financing activities and provides additional classification guidance for the statement of cash flows, (2) the classification of cash receipts and payments that have aspects of more than one class of cash flows to be determined by applying specific guidance under generally accepted accounting principles, and (3) each separately identifiable source or use within the cash receipts and payments be classified on the basis of their nature in financing, investing or operating activities. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:inherit;font-size:10pt;">, to clarify the definition of a business to add guidance for evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Specifically, this ASU provides a screen to assist entities in determining when a set should not be considered a business, which screen provides that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar assets, the set is not a business. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Test for Goodwill Impairment (Topic 350)</font><font style="font-family:inherit;font-size:10pt;">. This standard eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#8217;s fair value. This guidance is effective for interim and annual goodwill impairment tests in fiscal years beginning after December 15, 2019 with early adoption permitted. This guidance must be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of ASU No. 2017-04 will have on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:inherit;font-size:10pt;">, to provide clarity and reduce both the diversity in practice and cost of complexity when applying the guidance. Specifically, the ASU provides additional modification conditions in determining whether or not modification accounting should be applied. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">, to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and improves the usefulness of information reported to financial statement users. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2018-07 will have on the Company&#8217;s consolidated financial position, results of operations or cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sofusa</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Acquisition</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 2, 2018, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Kimberly-Clark Corporation (&#8220;KCC&#8221;); Kimberly-Clark Global Sales, LLC (&#8220;KCCGS&#8221;); and Kimberly-Clark Worldwide, Inc. (&#8220;KCCW&#8221; and together with KCC and KCCGS, &#8220;Kimberly-Clark&#8221;) pursuant to which, among other things, the Company acquired certain of Kimberly-Clark&#8217;s assets related to microneedle drug delivery systems, including the Sofusa</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;"> platform (the &#8220;Assets&#8221;), and assumed certain of Kimberly-Clark&#8217;s liabilities related to the Assets (the &#8220;Acquisition&#8221;).&#160; The closing of the Acquisition (the &#8220;Closing&#8221;) occurred on July 2, 2018. At the Closing, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> and agreed to pay additional consideration to Kimberly-Clark upon the achievement of certain regulatory and net sales milestones, as well as a percentage in the low double-digits of any non-royalty amounts received by the Company in connection with any license, sale or other grant of rights by the Company to develop or commercialize the Assets (all such additional consideration, the &#8220;Contingent Consideration&#8221;). Under the Purchase Agreement, the aggregate amount of the Contingent Consideration payable by the Company will not exceed </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160; The Company also agreed to pay Kimberly-Clark a low single-digit royalty on all net sales with respect to the first five products developed by the Company or its licensees that utilizes intellectual property included in the Assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Going Concern</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically operated with working capital deficiencies and expects to operate in the future with working capital deficiencies and has incurred substantial net losses for the years ended December 31, 2017 and 2016, and anticipates that it will continue to do so for the foreseeable future as it continues to identify and invest in advancing product candidates, as well as expanding corporate infrastructure. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$37.8 million</font><font style="font-family:inherit;font-size:10pt;"> of long term debt issued in a private placement (the "Private Placement") pursuant to a Securities Purchase Agreement, dated as of March 26, 2018, as amended by Amendment No. 1 thereto, dated as of June 13, 2018 (the &#8220;Securities Purchase Agreement&#8221;), among the Company and certain accredited investors (collectively, the &#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers (1) convertible promissory notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Notes&#8221;), which accrue simple interest at a rate equal to </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum and mature upon the earlier to occur of (a) June 13, 2023, and (b) the date of the closing of a change in control of the Company (the &#8220;Maturity Date&#8221;), and (2) warrants (the &#8220;Warrants&#8221;) to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the Notes provide that, upon the occurrence of an event of default, the Purchasers thereof may, by written notice to the Company, declare all of the outstanding principal and interest under such Notes immediately due and payable. For purposes of the Notes, an event of default includes, among other things, one or more events that have, or could reasonably be expected to have, a material adverse effect on (i) the Company&#8217;s ability to comply with its obligations under the Securities Purchase Agreement, the Notes or the Warrants or the registration rights agreement entered into with the Purchasers in connection with the Private Placement, or (ii) the rights of the Purchasers under the Notes. The Company believes that it is not probable that the material adverse event clause under the Notes will be exercised. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company&#8217;s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. Although management believes such plans, if executed as planned, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that the condensed consolidated financial statements are issued.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable, the Company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates. The Company may also seek collaborators for one or more of its current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements do not reflect any adjustments that might be necessary if the Company is unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Universal Shelf Registration</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, the Company filed a universal shelf registration statement on Form S-3 (the &#8220;2014 Shelf Registration Statement&#8221;) with the SEC, which was declared effective by the SEC in December 2014. This 2014 Shelf Registration Statement provided the Company with the ability to offer up to </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> of securities, including equity and other securities as described in the registration statement. Included in the 2014 shelf registration was a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock that could be issued and sold under a sales agreement with MLV &amp; Co. LLC (the &#8220;2014 ATM Facility&#8221;). During the twelve months ended December 31, 2017, the Company sold approximately </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of common stock under the 2014 ATM Facility. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, the Company completed a public offering of </font><font style="font-family:inherit;font-size:10pt;">$47.5 million</font><font style="font-family:inherit;font-size:10pt;"> of shares of common stock pursuant to the 2014 Shelf Registration Statement for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$43.1 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, the Company filed a universal shelf registration statement on Form S-3 (the &#8220;2017 Shelf Registration Statement&#8221;) with the SEC, which was declared effective by the SEC in December 2017. The 2014 Shelf Registration Statement expired on December 6, 2017 when the 2017 Shelf Registration was declared effective. The 2017 Shelf Registration Statement provides the Company with the ability to offer up to </font><font style="font-family:inherit;font-size:10pt;">$350 million</font><font style="font-family:inherit;font-size:10pt;"> of securities, including equity and other securities as described in the registration statement. Included in the 2017 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock that may be issued and sold under a sales agreement with B. Riley FBR, Inc. (the &#8220;ATM Facility&#8221;). During the twelve months ended December 31, 2017, the Company sold approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of common stock under the ATM Facility. During the three and six month periods ended June 30, 2018, the Company sold approximately </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$60.2 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of common stock, respectively, under the ATM Facility. The Company can offer up to approximately </font><font style="font-family:inherit;font-size:10pt;">$38.9 million</font><font style="font-family:inherit;font-size:10pt;"> of additional shares of common stock under the ATM Facility, subject to certain limitations. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the 2017 Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company&#8217;s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016 Private Investment in Public Entity Financing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2016, the Company entered into a Securities Purchase Agreement (the &#8220;ABG Purchase Agreement&#8221;) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, &#8220;Ally Bridge&#8221;), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers designated by Ally Bridge (collectively, the &#8220;ABG Purchasers&#8221;), in a private placement transaction (the &#8220;ABG Private Placement&#8221;), up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of the Company&#8217;s common stock and warrants to purchase shares of common stock. Upon the closing of the ABG Private Placement, the Company issued to the ABG Purchasers (1) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,009,005</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;ABG Shares&#8221;) of common stock,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">and (2) warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,702,700</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock (each, an &#8220;ABG Warrant&#8221;).&#160;&#160; Each ABG Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.50</font><font style="font-family:inherit;font-size:10pt;"> per share, was immediately exercisable upon issuance, has a term of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> and is exercisable on a cash or cashless exercise basis.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ABG Purchase Agreement, the Company was obligated to prepare and file with the SEC, within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of&#160;common stock issuable upon exercise of each ABG Warrant (the &#8220;ABG Warrant Shares&#8221;), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain &#8220;piggy-back&#8221; registration rights granted to the ABG Purchasers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the &#8220;Additional Purchase Agreements&#8221;) with each of Beijing Shijilongxin Investment Co., Ltd. (&#8220;Beijing Shijilongxin&#8221;), FREJOY Investment Management Co., Ltd. (&#8220;Frejoy&#8221;) and Yuhan Corporation (&#8220;Yuhan&#8221;), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, </font><font style="font-family:inherit;font-size:10pt;">8,108,108</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">1,176,471</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$45.0 million</font><font style="font-family:inherit;font-size:10pt;">; (2) to Frejoy, </font><font style="font-family:inherit;font-size:10pt;">8,108,108</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">1,176,471</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$45.0 million</font><font style="font-family:inherit;font-size:10pt;">; and (3) to Yuhan, </font><font style="font-family:inherit;font-size:10pt;">1,801,802</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">235,294</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">. The warrants issued pursuant to each of the Additional Purchase Agreements (collectively, the &#8220;Additional Warrants&#8221; and, together with each ABG Warrant, the &#8220;ABG Warrants&#8221;) have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.50</font><font style="font-family:inherit;font-size:10pt;"> per share, were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> and are exercisable on a cash or cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan had the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor&#8217;s shares of common stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of common stock issuable upon exercise of such investor&#8217;s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain &#8220;piggy-back&#8221; registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 2, 2016, the Company closed its private placement of common stock and warrants with Yuhan for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Yuhan purchased </font><font style="font-family:inherit;font-size:10pt;">1,801,802</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at </font><font style="font-family:inherit;font-size:10pt;">$5.55</font><font style="font-family:inherit;font-size:10pt;"> per share and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">235,294</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.&#160;&#160;The warrant is exercisable for </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.50</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between May 31, 2016 and June 7, 2016, the Company closed on the remainder of the </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> financing with the ABG Purchasers, Beijing Shijilongxin, and Frejoy. The ABG Purchasers led the financing and, together with&#160;Beijing Shijilongxin and Frejoy, collectively purchased&#160;</font><font style="font-family:inherit;font-size:10pt;">25,225,221</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at&#160;</font><font style="font-family:inherit;font-size:10pt;">$5.55</font><font style="font-family:inherit;font-size:10pt;">&#160;per share and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">5,055,642</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for total cash consideration of&#160;</font><font style="font-family:inherit;font-size:10pt;">$86.5 million</font><font style="font-family:inherit;font-size:10pt;"> and secured promissory notes (the &#8220;ABG Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$53.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2016, the Company entered into Warrant and Note Cancellation and Share Forfeiture Agreements (the &#8220;Cancellation and Forfeiture Agreements&#8221;) with certain investors (the &#8220;Investors&#8221;) that held an aggregate of </font><font style="font-family:inherit;font-size:10pt;">7,838,259</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and certain of the Warrants granting the right to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,137,316</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.&#160;&#160;Pursuant to the Cancellation and Forfeiture Agreements, effective December 31, 2016, the ABG Warrants held by the Investors and the ABG Notes, of which </font><font style="font-family:inherit;font-size:10pt;">$43.5 million</font><font style="font-family:inherit;font-size:10pt;"> was then outstanding, were cancelled and the shares of common stock held by the Investors were forfeited and returned to the Company.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Private Investment in Public Entity Financing </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 11, 2017, the Company entered into a Securities Purchase Agreement (the "December 2017 Securities Purchase Agreement") with certain accredited investors (collectively, the "December 2017 Purchasers"). Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, (1) convertible promissory notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$50,000,000</font><font style="font-family:inherit;font-size:10pt;"> (the "December 2017 Notes"), which accrued simple interest at a rate equal to </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum and would mature upon the earlier to occur of (a) December 21, 2022, and (b) the date of the closing of a change in control of the Company (the "December 2017 Warrant Maturity Date"), and (2) warrants (the "December 2017 Warrants") to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,121,210</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser&#8217;s December 2017 Note that was equal to or greater than the lesser of: (1) </font><font style="font-family:inherit;font-size:10pt;">$4,000,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$2.26875</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each December 2017 Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.61</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 17, 2018, the December 2017 Purchasers converted the full outstanding principal under the December 2017 Notes into </font><font style="font-family:inherit;font-size:10pt;">22,038,565</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of </font><font style="font-family:inherit;font-size:10pt;">$44.3 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized immediately at that date as interest expense.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 3 for discussion of the Company&#8217;s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$44.8 million</font><font style="font-family:inherit;font-size:10pt;">&#160;based on an allocation of proceeds to the Warrants of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and a beneficial conversion feature of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$32.1 million</font><font style="font-family:inherit;font-size:10pt;">, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Private Investment in Public Entity Financing </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, the Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$120,500,000</font><font style="font-family:inherit;font-size:10pt;"> and Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">8,591,794</font><font style="font-family:inherit;font-size:10pt;"> shares. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 13, 2018, the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;"> and that the aggregate number of shares of the common stock issuable upon exercise of the Warrants was reduced to </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;">, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$37,848,750</font><font style="font-family:inherit;font-size:10pt;">, and (2) Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,698,662</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser&#8217;s Note that is equal to or greater than the lesser of: (1) </font><font style="font-family:inherit;font-size:10pt;">$4,000,000</font><font style="font-family:inherit;font-size:10pt;">, and (2) the then-outstanding principal amount of such Purchaser&#8217;s Note into shares of common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$7.0125</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. If a Purchaser elects to convert any of the principal amount of their Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Notes contain restrictive covenants and event of default provisions that are customary for transactions of this type.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.77</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company&#8217;s ability to operate its business.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Realized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading securities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedoveX common shares and warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(427</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Realized Gains (Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading securities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedoveX common shares and warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period.&#160;Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</font></div></div> EX-101.SCH 7 srne-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Acquisitions - Acquired In-process Research and Development of BDL and Cargenix (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Acquisitions - Acquisition of Scilex Pharmaceuticals Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Acquisitions - Acquisition of Virttu Biologics Limited (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Cost Method Investments link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Cost Method Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Equity Method Investments link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Equity Method Investments - NANTibody (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Equity Method Investments - NantStem (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Equity Method Investments - Shanghai Three (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Equity Method Investments - Yuhan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Fair Value Measurements - Summary of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Fair Value Measurements - Summary of Inputs and the Valuation Methodologies used for Fair Value Measurements Using Significant Unobservable Inputs Level 3 (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Liquidity and Going Concern - 2016 Private Investment in Public Entity Financing (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Liquidity and Going Concern - 2017 Private Investment in Public Entity Financing (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Liquidity and Going Concern - 2018 Private Investment in Public Entity Financing (Details) link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Liquidity and Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Liquidity and Going Concern - Universal Shelf Registration (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Loan and Security Agreement and Convertible Notes link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Loan and Security Agreement and Convertible Notes - 2017 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Loan and Security Agreement and Convertible Notes - 2018 Chinese Yuan Loan (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Loan and Security Agreement and Convertible Notes - 2018 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Loan and Security Agreement and Convertible Notes - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Loan and Security Agreement and Convertible Notes - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Loan and Security Agreement and Convertible Notes - Hercules Capital, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Loan and Security Agreement and Convertible Notes - Schedule of Long-Term Debt and Unamortized Discount Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Loan and Security Agreement and Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Marketable Securities - Summary of Warrant Measured at Fair Value Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Operations and Business Activities link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Nature of Operations and Business Activities (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Related Party Agreements link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Related Party Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Significant Accounting Policies - Narrative - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Significant Accounting Policies - Schedule of Outstanding Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Significant Accounting Policies - Schedule of Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Significant Accounting Policies - Schedule of Revenues by Category (Details) link:presentationLink link:calculationLink link:definitionLink 2304302 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Significant Agreements and Contracts link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Significant Agreements and Contracts - Immunotherapy Research Collaboration Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Significant Agreements and Contracts - License Agreement with Mabtech Limited (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Significant Agreements and Contracts - License Agreement with NantCell (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Significant Agreements and Contracts - License Agreement with The Scripps Research Institute (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Significant Agreements and Contracts - NIH Grants (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Stock Incentive Plans link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Stock Incentive Plans - Fair Value of Employee Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Stock Incentive Plans - Narrative: 2009 Non-Employee Director Grants (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Stock Incentive Plans - Narrative: 2009 Stock Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Stock Incentive Plans - Narrative: 2014 Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Stock Incentive Plans - Narrative: 2015 Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Stock Incentive Plans - Narrative: 2017 Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Stock Incentive Plans - Summary of Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Stock Incentive Plans - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Stock Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 srne-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 srne-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 srne-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Earnings Per Share [Abstract] Net Loss Net Income (Loss) Attributable to Parent Denominator for Basic and Diluted Loss Per Share Weighted Average Number of Shares Outstanding, Basic and Diluted Dilutive Earnings Per Share (in dollars per share) Earnings Per Share, Basic and Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Employee Stock Option [Member] Employee Stock Option [Member] Warrant [Member] Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Comprehensive Income [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Sorrento Comprehensive Income (Loss), Net of Tax, Attributable to Parent Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2009 Stock Incentive Plan Two Thousand Nine Stock Incentive Plan [Member] 2009 stock incentive plan. Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Employee and Director Employee And Director [Member] Employee and director. Non Employee Consultants [Member] Non Employee Consultants [Member] Non-Employee consultants. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Options exercisable period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Employee option grants vested (percent) Share Based Compensation Employee Option Grants Vesting Rate Share based compensation employee option grants vesting rate. Options vesting anniversary period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Aggregate intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Stock-based compensation Allocated Share-based Compensation Expense Unrecognized compensation cost related to unvested stock option grants Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Period for recognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Grant Grant [Member] Royalty and license Royalty And License [Member] Royalty And License [Member] Sales and services Product And Service [Member] Product And Service [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Total revenues Revenue from Contract with Customer, Including Assessed Tax Operating costs and expenses: Operating Costs and Expenses [Abstract] Costs of revenues Cost of Revenue Research and development Research and Development Expense (Excluding Acquired in Process Cost) Acquired in-process research and development Research and Development in Process General and administrative General and Administrative Expense Intangible amortization Amortization Loss (gain) on contingent liabilities and acquisition consideration payable Gain Loss On Contingent Liabilities Gain loss on contingent liabilities. Total operating costs and expenses Costs and Expenses Loss from operations Operating Income (Loss) Loss on trading securities Debt Securities, Trading, Realized Gain (Loss) Loss on foreign currency exchange Foreign Currency Transaction Gain (Loss), before Tax Interest expense Interest Expense Interest income Investment Income, Interest Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Loss on equity method investments Income (Loss) from Equity Method Investments Net loss Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to Sorrento Net loss per share - basic and diluted per share attributable to Sorrento (in dollars per share) Weighted-average shares used during period - basic and diluted per share attributable to Sorrento (in shares) Fair Value Disclosures [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Discount Rate Measurement Input, Discount Rate [Member] Default Rate Measurement Input, Default Rate [Member] Liability Class Liability Class [Axis] Fair Value by Liability Class Fair Value by Liability Class [Domain] Contingent liabilities [Member] Contingent Liabilities [Member] Contingent liabilities. Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Virttu Biologics Limited [Member] Virttu Biologics Limited [Member] Virttu Biologics Limited. Concortis [Member] Concortis [Member] Concortis. Shanghai Three [Member] Shanghai Three [Member] Shanghai three. RWMC [Member] R W M C [Member] RWMC. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Significant Unobservable Inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Weighted Average [Member] Weighted Average [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31) Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Discount Rate Business Combination, Contingent Consideration, Liability, Measurement Input Stockholders' Equity Note [Abstract] Weighted-average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations and Business Activities Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Investments, Debt and Equity Securities [Abstract] Schedule of Marketable Securities Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Milestones achievement [Member] Milestones Achievement [Member] Milestones Achievement [Member] Sofusa [Member] Sofusa [Member] Sofusa [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Purchase consideration Business Combination, Consideration Transferred Business combination additional consideration transferred Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Fair Value Measurements Fair Value Disclosures [Text Block] Equity [Abstract] Summary of Stock Option Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Fair Value of Employee Stock Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Common Stock Reserved for Future Issuance Common Stock Reserved For Future Issuance Table [Text Block] Common stock reserved for future issuance. Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Quoted Prices in Active Markets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Acquisition consideration payable - Current [Member] Contingent Consideration, Current [Member] Contingent Consideration, Current Asset Class Asset Class [Axis] Asset Class Asset Class [Domain] Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Marketable securities [Member] Investments [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value assets disclosure Assets, Fair Value Disclosure Fair value liabilities disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Equity Method Investments and Joint Ventures [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] NantBioScience, Inc. [Member] Nant Bio Science Inc [Member] NantBioScience, Inc. Nant Cell [Member] Nant Cell [Member] Nant cell. Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Nant Cancer Stem LLC [Member] Nant Cancer Stem L L C [Member] Nant cancer stem LLC. ImmuneOncia Therapeutics, LLC [Member] Immune Oncia Therapeutics L L C [Member] ImmuneOncia Therapeutics, LLC Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Initial joint funding Initial Joint Funding Initial joint funding. Initial joint funding contributed Initial Joint Funding Contributed Initial joint funding contributed. Equity method investment ownership percentage Equity Method Investment, Ownership Percentage Percentage of contribution made Equity Method Investments, Percentage of Contribution made Equity Method Investments, Percentage of Contribution made Joint venture agreement second payment contribution Joint Venture Agreement Second Payment Contribution Joint Venture Agreement Second Payment Contribution. Loss on equity investments Equity Method Investment, Other than Temporary Impairment Equity method investments Equity Method Investments Difference between carrying amount and underlying equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Net income (loss) in equity method investments Equity Method Investment, Summarized Financial Information, Net Income (Loss) Equity method investment current assets Equity Method Investment, Summarized Financial Information, Current Assets Equity method investment current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Equity method investment noncurrent assets Equity Method Investment, Summarized Financial Information, Noncurrent Assets Equity method investment noncurrent liabilities Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Reported Value Measurement [Member] Reported Value Measurement [Member] Fair Value, Inputs, Level 2 [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private Placement [Member] Private Placement [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] March 2018 Warrant [Member] March 2018 Warrant [Member] March 2018 Warrant [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Debt [Member] Convertible Debt [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] March 2018 Notes [Member] March 2018 Notes [Member] March 2018 Notes [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Term of warrants Class Of Warrant Or Right, Period In Which Warrants Or Rights Exercisable Class Of Warrant Or Right, Period In Which Warrants Or Rights Exercisable Face value of loan Debt Instrument, Face Amount Number of securities called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Interest rate Debt Instrument, Interest Rate, Stated Percentage Debt instrument term Debt Instrument, Term If converted - outstanding principal threshold amount Debt Instrument, Convertible, If-Converted, Outstanding Principal Amount Threshold Debt Instrument, Convertible, If-Converted, Outstanding Principal Amount Threshold Debt conversion price Debt Instrument, Convertible, Conversion Price Warrant exercise price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Debt discount allocated to warrant Debt Instrument, Unamortized Discount Debt beneficial conversion feature Debt Instrument, Convertible, Beneficial Conversion Feature Long-term debt, fair value disclosure Long-term Debt, Fair Value Income Tax Disclosure [Abstract] Income tax benefit Effective income tax rate Effective Income Tax Rate Reconciliation, Percent U.S federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Unrecognized tax benefits that if recognized would impact effective income tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Related interest and penalty Related Interest And Penalty Related interest and penalty. Significant change in uncertain tax positions in the next 12 months Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Schedule of Goodwill Schedule of Goodwill [Table Text Block] Summary of Company's Identifiable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Estimated Future Amortization Expense Related to Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Liquidity and Going Concern Substantial Doubt about Going Concern [Text Block] Related Party Transactions [Abstract] Related Party Agreements Related Party Transactions Disclosure [Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Significant Agreements and Contracts Significant Agreements And Contracts [Text Block] Significant agreements and contracts. Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Stock Conversion Description [Axis] Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Underwriters Agreement [Member] Underwriters Agreement [Member] Underwriters agreement. Loan and Security Agreement [Member] Loan And Security Agreement [Member] Loan and security agreement. Hercules Securities Agreement [Member] Hercules Securities Agreement [Member] Hercules securities agreement. Convertible Notes [Member] Convertible Debt Securities [Member] Non-Employee Director Plan [Member] Non Employee Director Plan [Member] Non employee director plan. Virttu Acquisition Agreement [Member] Virttu Acquisition Agreement [Member] Virttu Acquisition Agreement [Member] Assignment Agreement [Member] Assignment Agreement [Member] Assignment agreement. Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Accounting Policies [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Weighted average number of securities outstanding Weighted Average Number of Shares Outstanding, Basic Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Non-cash interest expense Paid-in-Kind Interest Loss on trading securities Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss Amortization of debt issuance costs and debt discount Amortization of Debt Issuance Costs Stock-based compensation Share-based Compensation Loss on equity method investments Equity Method Investment, Realized Gain (Loss) on Disposal Loss (gain) on contingent liabilities and acquisition consideration payable Deferred tax provision Deferred Income Tax Expense (Benefit) Changes in operating assets and liabilities, excluding effect of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Grants and other receivables Increase (Decrease) in Receivables Accrued payroll Increase (Decrease) in Employee Related Liabilities Prepaid expenses and other Increase (Decrease) in Prepaid Expense and Other Assets Deposits and other assets Increase (Decrease) in Deposit Assets Accounts payable Increase (Decrease) in Accounts Payable Deferred revenue Increase (Decrease) in Contract with Customer, Liability Deferred rent and other Deferred Rent And Other Period Increase (Decrease) Deferred rent and other period increase (decrease). Acquisition consideration payable for Scilex Increase (Decrease) in Accrued Liabilities Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net cash used for operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Investment in Celularity Payments to Acquire Equity Method Investments Purchase of business, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from bridge loan for Scilex regulatory milestone Proceeds from Short-term Debt Repayment of bridge loan for Scilex regulatory milestone Repayments of Short-term Debt Repayment under the amended loan and security agreement Proceeds from (Repayments of) Debt Proceeds from loan agreement Proceeds from Issuance of Debt Payments under deferred compensation arrangements Payments For Repurchase Of Common Stock For Deferred Compensation Obligations Payments for repurchase of common stock for deferred compensation obligations. Scilex consideration for regulatory milestone Payments of Stock Issuance Costs Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance of convertible notes Proceeds from Convertible Debt Proceeds from exercise of stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net change in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental disclosures: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Income Taxes And Interest Paid Net [Abstract] Income taxes and interest paid net. Income taxes Income Taxes Paid, Net Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Supplemental disclosures of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Virttu acquisition non-cash consideration Noncash or Part Noncash Acquisition, Intangible Assets Acquired BDL non-cash consideration Other Significant Noncash Transaction, Value of Consideration Received Property and equipment costs incurred but not paid Capital Expenditures Incurred but Not yet Paid Scilex non-cash consideration for regulatory milestone Other Significant Noncash Transaction, Value of Consideration Given Investment in Celularity Financing Receivable Issued Financing Receivable Issued Conversion of convertible notes Stock Issued Commitment Contingency And Related Party Transactions [Abstract] Commitment Contingency And Related Party Transactions. Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Yuhan Corporation [Member] Yuhan Corporation [Member] Yuhan corporation. Celularity Inc [Member] Celularity Inc [Member] Celularity Inc. Scilex Pharmaceuticals, Inc [Member] Scilex Pharmaceuticals Inc [Member] Scilex Pharmaceuticals, Inc. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Payments to acquire interest in joint venture Payments to Acquire Interest in Joint Venture Non-refundable up-front payment Proceeds from License Fees Received Vested equity received Vested Equity Received Under Agreement Vested equity received under agreement. Number of common stock shares acquired Investment In Affiliates Number Of Common Stock Shares Acquired Investment in affiliates, number of common stock shares acquired Cost method investments Equity Securities, FV-NI Gross proceeds of common stock and warrants Proceed From Issuance Of Common Stock And Warrants Proceed from issuance of common stock and warrants. Business acquisition, percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Goodwill and intangible assets. Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Patents [Member] Acquired technology [Member] Acquired Technology [Member] Acquired technology. Customer relationships [Member] Customer Relationships [Member] Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items] Disclosure Goodwill And Intangible Assets Additional Information Detail [Line Items] Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items] Goodwill Goodwill Goodwill impairment Goodwill, Impairment Loss Identifiable intangible assets, weighted average life Finite-Lived Intangible Assets, Remaining Amortization Period Estimated useful life of intangible asset Finite-Lived Intangible Asset, Useful Life Amortization expense Amortization of Intangible Assets Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Initial investment Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Number of monoclonal antibodies Number Of Monoclonal Antibodies Number of monoclonal antibodies. Ownership percentage by Parent Noncontrolling Interest, Ownership Percentage by Parent Income (loss) on equity method investments Gross proceeds of common stock and warrants Debt discount - warrant Debt discount - beneficial conversion feature Capitalized debt issuance costs Debt Issuance Costs, Net Accretion of debt issuance costs and other Accretion Of Debt Issuance Costs And Other Accretion of debt issuance costs and other. Accretion of debt discount Standardized Measure of Discounted Future Net Cash Flow Relating to Proved Oil and Gas Reserves, Accretion of Discount Balance at June 30, 2018 Long-term Debt Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] MedoveX common shares and warrants [Member] Medove X Common Shares And Warrants [Member] MedoveX common shares and warrants. Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Trading securities, Cost Equity Securities, FV-NI, Cost Gross Unrealized Gains (Losses) Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss) Before Tax Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss) Before Tax Gross Realized Gains (Losses) Equity Securities, FV-NI, Accumulated Gross Realized Gain(Loss) Before Tax Equity Securities, FV-NI, Accumulated Gross Realized Gain(Loss) Before Tax Fair Value Trading Securities, Cost Trading Securities, Cost Gross Unrealized Gains (Losses) Trading Securities Accumulated Gross Unrealized Gain Loss Before Tax Trading securities Accumulated Gross Unrealized Gain Loss Before Tax. Gross Realized Gains (Losses) Trading Securities Accumulated Gross Realized Gain Loss Before Tax Trading Securities Accumulated Gross Realized Gain Loss Before Tax. Fair Value Debt Securities, Trading, and Equity Securities, FV-NI Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Concortis sales and services [Member] Sale And Service, Customized Reagents [Member] Sale And Service, Customized Reagents Materials and supply [Member] Sale And Service, Material Supply [Member] Sale And Service, Material Supply [Member] Bioserve sale and services [Member] Sale And Service, Drug and Reagents [Member] Sale And Service, Drug and Reagents Joint development sale and service [Member] Sale And Service, Joint Development [Member] Sale And Service, Joint Development [Member] Product And Service [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Common Stock [Member] Common Stock [Member] 2017 Warrants [Member] 2017 Warrants [Member] 2017 Warrants [Member] Promissory Notes, Due 2022 [Member] Promissory Notes, Due 2022 [Member] Promissory Notes, Due 2022 Debt discount Debt Instrument, Unamortized Discount (Premium), Net Issuance of common stock for conversion of notes payable (shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Interest expense Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] MedoveX [Member] Medove X Corporation [Member] MedoveX corporation. Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Unit Purchase Agreement [Member] Unit Purchase Agreement [Member] Unit purchase agreement. Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Number of units purchased Number Of Units Purchased Number of units purchased. Payment for purchase of units Payment For Purchase Of Units Payment for purchase of units. Aggregate purchase price of common stock warrants Aggregate Purchase Price Of Common Stock Warrants Aggregate purchase price of common stock warrants. Common stock agreed to issue and sell Stock Issued During Period, Shares, New Issues Warrants to purchase common stock Warrants To Purchase Common Stock Warrants to purchase common stock. Warrant exercisable period Class Of Warrant Exercisable Term Class of warrant exercisable term. Loss on trading securities Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Regulatory Approval Consideration [Member] Regulatory Approval Consideration [Member] Regulatory Approval Consideration [Member] In Process Research and Development [Member] In Process Research and Development [Member] TNK Therapeutics, Inc. [Member] T N K Therapeutics Inc [Member] TNK Therapeutics Inc. Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General and administrative expenses [Member] General and Administrative Expense [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Business combination additional contingent consideration payable Business acquisition, common stock consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Issuance of common stock upon acquisition, shares Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Cash consideration to equity holders Payments to Acquire Businesses, Gross Percentage of base consideration due at closing Business Combination, Percentage of Consideration Due at Closing Business Combination, Percentage of Consideration Due at Closing Financial support for equity interest per business combination agreement Business Combination, Financing Agreement, Financial Support For Equity Interest Business Combination, Financing Agreement, Financial Support for Equity Interest Percentage of adjusted base consideration payable in cash Percentage Of Adjusted Base Consideration Payable In Cash Percentage of adjusted base consideration payable in cash. Escrow shares percentage Escrow Shares Percentage Escrow shares percentage. Share price of common stock purchased Business Acquisition, Share Price Number of business days to satisfy 50% of regulatory approval contingent consideration payment Business Combination, Contingent Consideration, Number of Business Days to Satisfy One Half Payment Upon Achievement of Regulatory Approval Business Combination, Contingent Consideration, Number of Business Days to Satisfy One Half Payment Upon Achievement of Regulatory Approval Contingent consideration payment option one, maximum cash payment Business Combination, Contingent Consideration, Payment Option One, Cash Business Combination, Contingent Consideration, Payment Option One, Cash Contingent consideration payment option two, share value less any cash payment Business Combination, Contingent Consideration, Payment Option Two, Share Value Business Combination, Contingent Consideration, Payment Option Two, Share Value Contingent consideration option two calculation in put, 30 days VWAP Volume Weighted Average Price Period Volume-weighted average price period. Contingent liability in a business combination Business Combination, Contingent Consideration, Liability Issuance of common stock related to acquisitions settlement (in shares) Stock Issued During Period, Shares, Acquisitions Issuance of common stock related to acquisitions settlement Stock Issued During Period, Value, Acquisitions Acquisition consideration payable Business Combination, Contingent Consideration, Liability, Current Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business acquisition costs Business Combination, Acquisition Related Costs Schedule of Revenues by Category Disaggregation of Revenue [Table Text Block] Schedule of Remaining Performance Obligation Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Components of Outstanding Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] First year Share-based Compensation Award, Tranche One [Member] Quarterly Share-based Compensation Award, Tranche Two [Member] 2017 Stock Options Plans 2017 Stock Options Plans [Member] 2017 Stock Options Plans [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Common stock reserved for issuance (in shares) Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Option outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number B D L Products Inc [Member] B D L Products Inc [Member] BDL Products, Inc Payments for previous acquisition Payments for Previous Acquisition Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Inputs and the Valuation Methodologies used for Fair Value Measurements Using Significant Unobservable Inputs Level 3 Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] FDA Approval For Commercialization [Member] FDA Approval For Commercialization [Member] FDA Approval For Commercialization [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Itochu Chemical Frontier Corporation [Member] Itochu Chemical Frontier Corporation [Member] Itochu chemical frontier corporation. Receivable Type [Axis] Receivable Type [Axis] Receivable [Domain] Receivable [Domain] Loans Receivable [Member] Loans Receivable [Member] Noncontrolling interest ownership percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Amount of stock issued in acquisition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Bridge loan issued Notes Issued Change in fair value for contingent consideration upon settlement Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Loan and Security Agreement and Convertible Notes Debt Disclosure [Text Block] Chief Executive Officer [Member] Chief Executive Officer [Member] Director [Member] Director [Member] Directors and Non Employee Consultants [Member] Directors And Non Employee Consultants [Member] Directors and non-employee consultants. L A Cell [Member] L A Cell [Member] LA Cell. Concortis Biosystems Corporation [Member] Concortis Biosystems Corporation [Member] Concortis Biosystems Corporation. Scintilla Pharmaceuticals Inc [Member] Scintilla Pharmaceuticals Inc [Member] Scintilla Pharmaceuticals, Inc Sorrento Biologics Inc [Member] Sorrento Biologics Inc [Member] Sorrento Biologics, Inc. 2015 Stock Incentive Plan [Member] Two Thousand Fifteen Stock Option Plan [Member] Two thousand fifteen stock option plan. Common Class B [Member] Common Class B [Member] Stock options, contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Number of shares canceled during period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of options canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled Warrant granted to purchase common stock (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Warrant shares exercisable (in shares) Class Of Warrant Or Right Exercisable Number Class of warrant or right exercisable number. Number of shares per vote Common Stock Voting Rights, Number of Shares Per Vote Common Stock Voting Rights, Number of Shares Per Vote Accelerated compensation expense Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Unrecognized compensation cost related to unvested stock option and warrant grants Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Amended Loan And Security Agreement [Member] Amended Loan And Security Agreement [Member] Amended Loan And Security Agreement [Member] Term Loan [Member] Term Loan [Member] Term loan. Term Loan Tranche One [Member] Term Loan Tranche One [Member] Term loan tranche one Term Loan Tranche Two [Member] Term Loan Tranche Two [Member] Term loan tranche two Amended and restated principal amount of loan agreement Line of Credit Facility, Maximum Borrowing Capacity Face value of loan amount Available of borrowing amount Line of Credit Facility, Remaining Borrowing Capacity Payment of backend fee Payments of Debt Issuance Costs Repayment of loan Repayments of Long-term Debt Unrestricted cash covenant requirement for long term debt Unrestricted Cash Covenant Requirement For Long Term Debt Unrestricted cash covenant requirement for long term debt. Warrant received to purchase aggregate of common stock - shares Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued Warrant received to purchase aggregate of common stock - exercise price Investment Warrants, Exercise Price Warrants exercisable Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Exercisable Noncash or part noncash acquisition noncash financial or equity instrument consideration warrants exercisable. Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Statement of Stockholders' Equity [Abstract] Treasury Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Accumulated Deficit [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, shares Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Adoption impact of ASC 606 Cumulative Effect of New Accounting Principle in Period of Adoption Issuance of common stock with exercise of stock options, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock for public placement and investments, net (shares) Issuance of common stock for public placement and investments, net Stock Issued During Period, Value, New Issues Issuance of common stock related to conversion of notes payable Stock Issued During Period, Value, Conversion of Convertible Securities Beneficial conversion feature recorded on convertible notes Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Warrants issued in connection with convertible notes Adjustments to Additional Paid in Capital, Warrant Issued Scilex acquisition adjustments Adjustments To Additional Paid In Capital Acquisition Adjustments Adjustments to additional paid in capital acquisition adjustments. Issuance of common stock for private placement and investments, net (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Issuance of common stock for private placement and investments, net Stock Issued During Period, Value, Treasury Stock Reissued Stock-based compensation Stock Granted, Value, Share-based Compensation, Gross Balance Balance, shares Document And Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Amendment Description Amendment Description Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Depreciation expense Depreciation Schedule of Long-Term Debt and Unamortized Discount Balances Schedule of Long-term Debt Instruments [Table Text Block] Future Minimum Payments under Amended and Restated Loan and Security Agreement Schedule of Maturities of Long-term Debt [Table Text Block] Liquidity And Going Concern [Table] Liquidity And Going Concern [Table] Liquidity and going concern. Beijing Shijilongxin Investment Co Ltd [Member] Beijing Shijilongxin Investment Co Ltd [Member] Beijing Shijilongxin Co Ltd. FREJOY Investment Management Co Ltd [Member] F R E J O Y Investment Management Co Ltd [Member] Frejoy investment management co ltd. Investor [Member] Investor [Member] ABG Purchase Agreement [Member] A B G Purchase Agreement [Member] ABG purchase agreement. Additional Purchase Agreements [Member] Additional Purchase Agreements [Member] Additional purchase agreements. ABG Purchasers, Beijing Shijilongxin, and Frejoy [Member] A B G Purchasers Beijing Shijilongxin And Frejoy [Member] Domain member used to indicate actual financial results. Cancellation and Forfeiture Agreements [Member] Cancellation And Forfeiture Agreements [Member] Cancellation and forfeiture agreements. Secured Promissory Notes [Member] Secured Promissory Notes [Member] Secured promissory notes. Liquidity And Going Concern [Line Items] Liquidity And Going Concern [Line Items] Liquidity and going concern. Aggregate purchase price of common stock & warrants Issuance of securities for resale, period Issuance Of Securities For Resale Period Issuance of securities for resale period. Gross proceeds of common stock and warrants Proceeds from Issuance or Sale of Equity Common stock price per share Share Price Closed consideration of common stock and warrants Closed Financing Consideration Of Common Stock And Warrants Closed financing consideration of common stock and warrants. Aggregate principal amount Consideration Received In Form Of Shares Value Consideration received in the form of shares value. Common stock shares forfeited Common Stock Shares Forfeited Common stock shares forfeited. Outstanding balance of promissory note forfeited Outstanding Balance Of Promissory Note Forfeited Outstanding balance of promissory note forfeited. Loss Per Share Earnings Per Share [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Intangibles, net Finite-Lived Intangible Assets, Net Promissory Note, Due 2023 [Member] Promissory Note, Due 2023 [Member] Promissory Note, Due 2023 [Member] Long-term debt Stock Incentive Plans Shareholders' Equity and Share-based Payments [Text Block] Investments [Abstract] Cost method investments, impairment losses Equity Securities, FV-NI, Gain (Loss) Cost Method Investments Investment [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] IgDraSol Inc [Member] IgDraSol Inc [Member] IgDraSol Inc [Member] Equity Method Investments [Member] Equity Method Investments [Member] NANTibody [Member] N A N Tibody [Member] NANTibody. Cash consideration in a purchase Proceeds from divestiture of business Proceeds from Divestiture of Businesses Amount of proceeds restricted to funding joint ventures Proceeds From Divestiture Of Businesses, Restricted To Funding Joint Ventures Proceeds From Divestiture Of Businesses, Restricted To Funding Joint Ventures Number of joint ventures to be funded Number Of Joint Ventures To Be Funded Number Of Joint Ventures To Be Funded Number of board members Number Of Board Members Number Of Board Members Cash and cash equivalents held by equity method investment Equity Method Investment, Summarized Financial Information, Cash And Cash Equivalents Equity Method Investment, Summarized Financial Information, Cash And Cash Equivalents Equity of equity method investment Equity Method Investment Summarized Financial Information, Equity Decrease in cash and cash equivalent of equity method investment Equity Method Investment Summarized Financial Information, Increase (Decrease) In Cash And Cash Equivalents Equity Method Investment Summarized Financial Information, Increase (Decrease) In Cash And Cash Equivalents Nature of Operations and Basis of Presentation Nature Of Operations And Basis Of Presentation Policy [Text Block] Nature of operations and basis of presentation. Liquidity and Going Concern Liquidity Disclosure Policy [Policy Text Block] Liquidity Disclosure. Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Grants and Accounts Receivable Receivables, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Acquisitions and Intangibles Business Combinations Policy [Policy Text Block] Goodwill and Other Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities Contingent Consideration Policy [Policy Text Block] Contingent consideration. Debt with Detachable Warrants Debt, Policy [Policy Text Block] Derivative Liability Derivatives, Policy [Policy Text Block] Investments in Other Entities Investment, Policy [Policy Text Block] Research and Development Costs and Collaborations Research and Development Expense, Policy [Policy Text Block] Acquired In-Process Research and Development Expense In Process Research and Development, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Stock-based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Acquisitions Business Combination Disclosure [Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Roger Williams Medical Center [Member] Roger Williams Medical Center [Member] Roger Williams Medical Center. Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Shares granted value Gross proceed from shares issued Fair value of the obligation Upfront payment period for recognition Upfront Payment Period For Recognition Upfront payment period for recognition. Acquired in-process research and development Research and Development Expense Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Number of screened and validated targets Number Of Screened And Validated Targets Number of screened and validated targets. Goodwill [Roll Forward] Goodwill [Roll Forward] Balance at December 31, 2017 Goodwill Acquired from Acquisitions Goodwill, Acquired During Period Balance at June 30, 2018 Subsequent Events Subsequent Events [Text Block] Chinese Yuan Term Loan [Member] Chinese Yuan Term Loan [Member] Chinese Yuan Term Loan [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Current portion of deferred revenue Contract with Customer, Liability, Current Proceeds from Customers Proceeds from Customers Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Revenue recognized during period Estimated license contract term based on expected life of patent Revenue, Performance Obligation Satisfied Over Time, Period Revenue, Performance Obligation Satisfied Over Time, Period Unbilled contracts receivable Unbilled Contracts Receivable Deferred revenue Contract with Customer, Liability Remaining performance obligation expected to be recognized in the next twelve months Revenue, Remaining Performance Obligation, Amount Expected To Be Recognized In The Next Twelve Months Revenue, Remaining Performance Obligation, Amount Expected To Be Recognized In The Next Twelve Months Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Grants Receivable [Member] Grants Receivable [Member] Information by grants receivable. Trade Accounts Receivable [Member] Trade Accounts Receivable [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Other-than-temporary impairment charges Other than Temporary Impairment Losses, Investments Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Estimated useful life of fixed asset Property, Plant and Equipment, Useful Life Impairment losses of long-lived assets Impairment of Long-Lived Assets Held-for-use Number of operating segments Number of Operating Segments Upfront payment received for contract development services Upfront payment received from customers Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Royalty And License [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Warrants and Rights Note Disclosure [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Beginning balance Change in fair value of warrant Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Ending balance Schedule of Basic and Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] TSRI License [Member] T S R I License [Member] TSRI license. Terminate notice of license Terminate Notice Of License Period Terminate notice of license. Patent prosecution and maintenance costs Patent Prosecution And Maintenance Costs Patent prosecution and maintenance costs. Acquired In Progress Research And Development Expense [Member] Acquired In Progress Research And Development Expense [Member] Acquired in progress research and development expense. Mabtech Limited [Member] Mabtech Limited [Member] Mabtech limited. Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] CHINA CHINA Initial payment for license agreement Initial Payment For Licensing Agreement Initial payment for licensing agreement. Additional payment for license agreement Additional Payment For Licensing Agreement Additional payment for licensing agreement. Licensing agreement, additional amounts payable License Fees Payable License Fees Payable Directors and Consultants [Member] Directors And Consultants [Member] Directors and consultants. Ark Animal Health Inc [Member] Ark Animal Health Inc [Member] Ark Animal Health, Inc. 2014 Stock Option Plan [Member] Two Thousand Fourteen Employee Stock Option Plan [Member] Two thousand fourteen employee stock option plan. Non Employee Directors Non Employee Directors [Member] Non employee director. 2009 Non-Employee Director Grants Two Thousand Nine Non Employee Director Grants [Member] 2009 Non-employee director grants. Common stock reserved for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Weighted-average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Staph Grant III Award [Member] Staph Grant Three Award [Member] Staph grant three award. Period of grant Period Of Grant Period of grant. Period of grant subsequently extended Period Of Grant Subsequently Extended Period of grant subsequently extended. Amount of grant awards Grants From Governmental Entities Amount Of Grant Award Grants from governmental entities amount of grant award. Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Marketable securities Marketable Securities, Current Grants and accounts receivables, net Receivables, Net, Current Income tax receivable Income Taxes Receivable, Current Prepaid expenses and other, net Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangibles, net Other, net Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued payroll and related benefits Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Current portion of deferred rent Deferred Rent Credit, Current Current portion of debt Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Long-term debt Long-term Debt, Excluding Current Maturities Deferred tax liabilities Deferred Tax Liabilities, Net Deferred revenue Contract with Customer, Liability, Noncurrent Deferred rent and other Deferred Rent Credit, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding Preferred Stock, Value, Issued Common stock, $0.0001 par value; 750,000,000 shares authorized and 116,240,963 and 82,903,567 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Treasury stock, 7,568,182 shares at cost at June 30, 2018, and December 31, 2017, respectively Treasury Stock, Value Total Sorrento Therapeutics, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Total liabilities and stockholders' equity Liabilities and Equity 2018 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Other Commitments [Table] Other Commitments [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Yuhan agreement claim [Member] Yuhan Agreement Claim [Member] Yuhan agreement claim. Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled litigation [Member] Settled Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Property, Plant and Equipment, Type Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type Property, Plant and Equipment, Type [Domain] Corporate office and laboratory space [Member] Office And Laboratory Space [Member] Office and laboratory space. Office space [Member] Office Space [Member] Office space. Offices, facilities for cGMP fill and finish and storage space [Member] Office And Storage Space [Member] Office and storage space. San Diego, California [Member] San Diego California [Member] San Diego, California. Suzhou, China [Member] Suzhou China [Member] Suzhou china. Scotland [Member] Scotland [Member] Scotland [Member] New York [Member] NEW YORK Other Commitments [Line Items] Other Commitments [Line Items] Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Leased office space Number Of Square Feet Of Leased Office Number of square feet of leased office. Additional, leased office space Additional Number Of Square Feet Of Leased Office additional number of square feet of leased office. Contingent Consideration Liabilities [Member] Contingent Consideration Liabilities [Member] Contingent consideration liabilities. Re-measurement of Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Payment of current year contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Common stock to be issued, value Common Stock Value To Be Issued Common stock value to be issued. Upfront cash payment Upfront Payments Received Upfront Payments Received Operating expenses of an equity method investment Equity Method Investment Operating Expenses Equity method investment, operating expenses. Significant Accounting Policies Significant Accounting Policies [Text Block] Amount due in 2018 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year Amount due in 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two Amount due in 2020 Long-term Debt, Maturities, Repayments of Principal in Year Three Amount due in 2021 Long-term Debt, Maturities, Repayments of Principal in Year Four Amount due in 2022 Long-term Debt, Maturities, Repayments of Principal in Year Five Amount due in 2023 Long-term Debt, Maturities, Repayments of Principal after Year Five Total future minimum payments Long Term Debt Maturities Repayments Of Principal Amount Long term debt maturities repayments of principal amount. Unamortized interest Debt Instrument Unamortized Interest On Debt Debt instrument unamortized interest on debt. Debt discount Total minimum payment Current portion Income Taxes Income Tax Disclosure [Text Block] Investment Contract Counterparty [Axis] Investment Contract Counterparty [Axis] Investment Contract Counterparty [Domain] Investment Contract Counterparty [Domain] Stock Purchase Agreement [Member] Stock Purchase Agreement [Member] Stock purchase agreement. Cash payment Payments to Acquire Interest in Subsidiaries and Affiliates Minimum qualified financing Minimum Qualified Financing Amount Minimum qualified financing amount. Aggregate common stock to be issued, shares Aggregate Shares Of Common Stock To Be Issued Aggregate shares of common stock to be issued. Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Option Outstanding Beginning Balance (in shares) Options Canceled (in shares) Options Exercised (in shares) Option Outstanding Ending Balance (in shares) Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price, Beginning Balance (in dollars per share) Options Granted, Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options Canceled, Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options Exercised, Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Ending Balance (in dollars per share) Aggregate Intrinsic Value, Beginning Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value ATM Facility [Member] ATM Facility [Member] ATM Facility [Member] Registration Payment Arrangement by Arrangement [Axis] Registration Payment Arrangement by Arrangement [Axis] Registration Payment Arrangement, Arrangement [Domain] Registration Payment Arrangement, Arrangement [Domain] November 2014 Registration [Member] November Two Thousand Fourteen Registration [Member] November two thousand fourteen registration. November 2017 Registration [Member] November 2017 Registration [Member] November 2017 Registration [Member] Maximum amount of equity and other securities authorized to offer Shelf Registration Statement Amount Maximum Shelf registration statement amount maximum. Remaining amount of equity and other securities authorized to offer Maximum Amount Registered For Future Issuance Of Securities Maximum amount registered for future issuance of securities. Common stock issued and sold under sales agreement Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock. Maximum aggregate offering amount authorized Maximum Aggregate Offering Amount Authorized Maximum Aggregate Offering Amount Authorized Value of additional shares of common stock authorized Common Stock, Additional Offering Authorized Common Stock, Additional Offering Authorized Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Furniture and Fixtures [Member] Furniture and Fixtures [Member] Office Equipment [Member] Office Equipment [Member] Machinery and Equipment [Member] Machinery and Equipment [Member] Leasehold Improvements [Member] Leasehold Improvements [Member] Construction in Progress [Member] Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, total Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Number of CARs for cellular therapy Number Of C A Rs For Cellular Therapy Number of CARs for cellular therapy. Royalty rate percent of net sales Royalty Receivable As Percentage On Net Sales Royalty receivable as percentage on net sales. Common stock received Common Stock Shares Received Common stock shares received. EX-101.PRE 11 srne-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2018
Aug. 06, 2018
Document And Entity Information [Abstract]    
Entity Registrant Name Sorrento Therapeutics, Inc.  
Entity Central Index Key 0000850261  
Trading Symbol SRNE  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Jun. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Amendment Description  
Entity Common Stock, Shares Outstanding   116,732,276
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 46,784 $ 20,429
Marketable securities 323 441
Grants and accounts receivables, net 2,204 2,211
Income tax receivable 433 1,715
Prepaid expenses and other, net 5,002 4,904
Total current assets 54,746 29,700
Property and equipment, net 19,893 19,345
Intangibles, net 69,690 71,013
Goodwill 38,298 38,298
Cost method investments 237,008 237,008
Equity method investments 29,972 32,999
Other, net 2,914 3,250
Total assets 452,521 431,613
Current liabilities:    
Accounts payable 9,941 9,911
Accrued payroll and related benefits 6,671 4,485
Accrued expenses 4,226 7,274
Current portion of deferred revenue 1,878 3,864
Current portion of deferred rent 243 212
Acquisition consideration payable 14,929 53,209
Current portion of debt 1,511 0
Total current liabilities 39,399 78,955
Long-term debt 16,203 5,211
Deferred tax liabilities 13,281 15,535
Deferred revenue 118,247 119,287
Deferred rent and other 5,926 6,015
Total liabilities 193,056 225,003
Commitments and contingencies
Equity:    
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding 0 0
Common stock, $0.0001 par value; 750,000,000 shares authorized and 116,240,963 and 82,903,567 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively 12 9
Additional paid-in capital 574,316 413,901
Accumulated other comprehensive income (loss) 153 242
Accumulated deficit (270,646) (165,120)
Treasury stock, 7,568,182 shares at cost at June 30, 2018, and December 31, 2017, respectively (49,464) (49,464)
Total Sorrento Therapeutics, Inc. stockholders' equity 254,371 199,568
Noncontrolling interests 5,094 7,042
Total equity 259,465 206,610
Total liabilities and stockholders' equity $ 452,521 $ 431,613
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 100,000,000 100,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 116,240,963 82,903,567
Common stock, shares outstanding (in shares) 116,240,963 82,903,567
Treasury stock, shares (in shares) 7,568,182 7,568,182
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenues:        
Total revenues $ 3,913 $ 4,665 $ 10,159 $ 9,539
Operating costs and expenses:        
Costs of revenues 1,226 816 2,538 1,880
Research and development 17,925 11,179 32,554 26,062
Acquired in-process research and development 0 0 0 200
General and administrative 11,039 9,092 21,000 20,979
Intangible amortization 657 665 1,319 1,292
Loss (gain) on contingent liabilities and acquisition consideration payable 1,437 (3,629) 13,663 (4,090)
Total operating costs and expenses 32,284 18,123 71,074 46,323
Loss from operations (28,371) (13,458) (60,915) (36,784)
Loss on trading securities (121) (609) (118) (450)
Loss on foreign currency exchange (586) 0 (569) 0
Interest expense (45,009) (1,200) (46,061) (2,809)
Interest income 6 232 10 457
Loss before income tax (74,081) (15,035) (107,653) (39,586)
Income tax benefit (1,377) (1,398) (2,325) (3,094)
Loss on equity method investments (2,105) (1,102) (3,027) (2,050)
Net loss (74,809) (14,739) (108,355) (38,542)
Net loss attributable to noncontrolling interests (945) (552) (1,919) (1,291)
Net loss attributable to Sorrento $ (73,864) $ (14,187) $ (106,436) $ (37,251)
Net loss per share - basic and diluted per share attributable to Sorrento (in dollars per share) $ (0.73) $ (0.20) $ (1.15) $ (0.61)
Weighted-average shares used during period - basic and diluted per share attributable to Sorrento (in shares) 100,563 70,302 92,795 60,650
Grant        
Revenues:        
Total revenues $ 0 $ 94 $ 0 $ 195
Royalty and license        
Revenues:        
Total revenues 120 2,416 240 4,833
Sales and services        
Revenues:        
Total revenues $ 3,793 $ 2,155 $ 9,919 $ 4,511
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net loss $ (74,809) $ (14,739) $ (108,355) $ (38,542)
Other comprehensive income:        
Foreign currency translation adjustments (199) 274 (89) 336
Total other comprehensive income (loss) (199) 274 (89) 336
Comprehensive loss (75,008) (14,465) (108,444) (38,206)
Comprehensive loss attributable to noncontrolling interests (945) (552) (1,919) (1,291)
Comprehensive loss attributable to Sorrento $ (74,063) $ (13,913) $ (106,525) $ (36,915)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
B D L Products Inc [Member]
B D L Products Inc [Member]
Common Stock [Member]
B D L Products Inc [Member]
Additional Paid-in Capital [Member]
Scilex Pharmaceuticals, Inc [Member]
Scilex Pharmaceuticals, Inc [Member]
Common Stock [Member]
Scilex Pharmaceuticals, Inc [Member]
Additional Paid-in Capital [Member]
Virttu Biologics Limited [Member]
Virttu Biologics Limited [Member]
Common Stock [Member]
Virttu Biologics Limited [Member]
Additional Paid-in Capital [Member]
Balance, shares at Dec. 31, 2016   50,882,856 7,568,182                          
Balance at Dec. 31, 2016 $ 86,502 $ 6 $ (49,464) $ 303,865 $ (118) $ (174,252) $ 6,465                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock related to acquisitions settlement (in shares)   797,081                            
Issuance of common stock related to acquisitions settlement 1,673     1,673                        
Issuance of common stock for public placement and investments, net (shares)   24,855,872                            
Issuance of common stock for public placement and investments, net 45,598 $ 3   45,595                        
Scilex acquisition adjustments (2,027)     (627)     (1,400)                  
Issuance of common stock for private placement and investments, net (in shares)   4,246                            
Issuance of common stock for private placement and investments, net 30 $ 0   30                        
Stock-based compensation 2,626     2,626                        
Foreign currency translation adjustments 336       336                      
Net loss (38,542)         (37,251) (1,291)                  
Balance at Jun. 30, 2017 96,196 $ 9 $ (49,464) 353,162 218 (211,503) 3,774                  
Balance, shares at Jun. 30, 2017   76,540,055 7,568,182                          
Balance, shares at Dec. 31, 2016   50,882,856 7,568,182                          
Balance at Dec. 31, 2016 86,502 $ 6 $ (49,464) 303,865 (118) (174,252) 6,465                  
Balance at Dec. 31, 2017 $ 206,610 $ 9 $ (49,464) 413,901 242 (165,120) 7,042                  
Balance, shares at Dec. 31, 2017 82,903,567 82,903,567 7,568,182                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Adoption impact of ASC 606 $ 910         910                    
Issuance of common stock with exercise of stock options, shares   25,815                            
Issuance of common stock upon exercise of stock options 162     162                        
Issuance of common stock related to acquisitions settlement (in shares)                 309,916     1,381,346     1,795,011  
Issuance of common stock related to acquisitions settlement               $ 2,340   $ 2,340 $ 13,744   $ 13,744 $ 11,308 $ 0 $ 11,308
Issuance of common stock for public placement and investments, net (shares)   7,786,743                            
Issuance of common stock for public placement and investments, net 58,273 $ 1   58,272                        
Issuance of common stock for conversion of notes payable (shares)   22,038,565                            
Issuance of common stock related to conversion of notes payable 50,000 $ 2   49,998                        
Beneficial conversion feature recorded on convertible notes 12,006     12,006                        
Warrants issued in connection with convertible notes 9,646     9,646                        
Stock-based compensation 2,910     2,939     (29)                  
Foreign currency translation adjustments (89)       (89)                      
Net loss (108,355)         (106,436) (1,919)                  
Balance at Jun. 30, 2018 $ 259,465 $ 12 $ (49,464) $ 574,316 $ 153 $ (270,646) $ 5,094                  
Balance, shares at Jun. 30, 2018 116,240,963 116,240,963 7,568,182                          
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Operating activities    
Net income (loss) $ (108,355,000) $ (38,542,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,931,000 3,188,000
Non-cash interest expense 44,272,000 563,000
Loss on trading securities 118,000 450,000
Amortization of debt issuance costs and debt discount 515,000 371,000
Stock-based compensation 2,910,000 2,626,000
Loss on equity method investments 3,027,000 2,050,000
Loss (gain) on contingent liabilities and acquisition consideration payable 13,663,000 (4,090,000)
Deferred tax provision (2,253,000) (3,064,000)
Changes in operating assets and liabilities, excluding effect of acquisitions:    
Grants and other receivables 7,000 (680,000)
Accrued payroll 2,187,000 (311,000)
Prepaid expenses and other (99,000) 751,000
Deposits and other assets 1,622,000 181,000
Accounts payable (326,000) (1,063,000)
Deferred revenue (2,115,000) (4,831,000)
Deferred rent and other (120,000) (461,000)
Acquisition consideration payable for Scilex (2,020,000) 0
Accrued expenses and other liabilities (3,049,000) 1,198,000
Net cash used for operating activities (46,085,000) (41,664,000)
Investing activities    
Purchases of property and equipment (2,812,000) (6,783,000)
Investment in Celularity 0 (3,000,000)
Purchase of business, net of cash acquired 0 (557,000)
Net cash used in investing activities (2,812,000) (10,340,000)
Financing activities    
Proceeds from bridge loan for Scilex regulatory milestone 20,000,000 0
Repayment of bridge loan for Scilex regulatory milestone (20,000,000) 0
Repayment under the amended loan and security agreement 0 (21,500,000)
Proceeds from loan agreement 1,586,000 0
Payments under deferred compensation arrangements 0 (1,012,000)
Scilex consideration for regulatory milestone (22,466,000) 0
Proceeds from issuance of common stock, net of issuance costs 58,273,000 45,628,000
Proceeds from issuance of convertible notes 37,849,000 0
Proceeds from exercise of stock options 162,000 0
Net cash provided by financing activities 75,404,000 23,116,000
Net change in cash and cash equivalents 26,507,000 (28,888,000)
Net effect of exchange rate changes on cash (152,000) 171,000
Cash and cash equivalents at beginning of period 20,429,000 82,398,000
Cash and cash equivalents at end of period 46,784,000 53,681,000
Cash paid during the period for:    
Income taxes 15,000 30,000
Interest paid 1,128,000 2,044,000
Supplemental disclosures of non-cash investing and financing activities:    
Virttu acquisition non-cash consideration 11,308,000 15,465,000
BDL non-cash consideration 2,340,000 0
Property and equipment costs incurred but not paid 391,000 422,000
Scilex non-cash consideration for regulatory milestone 13,744,000 0
Investment in Celularity 0 2,000,000
Conversion of convertible notes $ 50,000 $ 0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations and Business Activities
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Business Activities
Nature of Operations and Business Activities
Nature of Operations and Basis of Presentation
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the “Company”), is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. The Company’s primary focus is to transform cancer into a treatable or chronically manageable disease. The Company also has programs assessing the use of its technologies and products in auto-immune, inflammatory, neurodegenerative, infectious diseases and pain indications with high unmet medical needs.
At its core, the Company is an antibody-centric company and leverages its proprietary G-MAB™ library to identify, screen and validate fully human antibodies against high impact oncogenic targets and mutations, immune modulators and intracellular targets. To date, the Company has screened over 100 validated targets and generated a number of fully human antibodies against these targets which are at various stages of preclinical development. These include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.
The Company’s vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as T-Cell Receptor (“TCR”)-like antibodies.  With LA Cell, Inc. (“LA Cell”), the Company’s joint venture with City of Hope, the Company’s objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, the Company has acquired and is assessing the regulatory and strategic path forward for its portfolio of late stage biosimilar/biobetter antibodies based on Erbitux®, Remicade®, Xolair®, and Simulect® as these may represent nearer term commercial opportunities.
With each of its programs, the Company aims to tailor its therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape. In addition, the Company’s objective is to focus on tumors that are resistant to current treatments and where the Company can design focused trials based on a genetic signature or biomarker to ensure patients have the best chance of a durable and significant response. The Company has several immuno-oncology programs that are in or near to entering the clinic.  These include cellular therapies, an oncolytic virus and a palliative care program targeted to treat intractable cancer pain.  Finally, as part of its global aim to provide a wide range of therapeutic products to meet underserved therapeutic markets, the Company has made investments and developed a separate pain focused franchise which the Company believes will serve to provide short term upside to its core thesis.
Through June 30, 2018, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure.  
The accompanying condensed consolidated financial statements include the accounts of the Company’s subsidiaries.  For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.  All intercompany balances and transactions have been eliminated in consolidation.
In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal, recurring and necessary for a fair statement of financial position, results of operations and cash flows. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2018 fiscal year, or any subsequent period.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity and Going Concern
Liquidity and Going Concern
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically operated with working capital deficiencies and expects to operate in the future with working capital deficiencies and has incurred substantial net losses for the years ended December 31, 2017 and 2016, and anticipates that it will continue to do so for the foreseeable future as it continues to identify and invest in advancing product candidates, as well as expanding corporate infrastructure. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.
As of June 30, 2018, the Company had $37.8 million of long term debt issued in a private placement (the "Private Placement") pursuant to a Securities Purchase Agreement, dated as of March 26, 2018, as amended by Amendment No. 1 thereto, dated as of June 13, 2018 (the “Securities Purchase Agreement”), among the Company and certain accredited investors (collectively, the “Purchasers”). Pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers (1) convertible promissory notes in an aggregate principal amount of $37,848,750 (the “Notes”), which accrue simple interest at a rate equal to 5.0% per annum and mature upon the earlier to occur of (a) June 13, 2023, and (b) the date of the closing of a change in control of the Company (the “Maturity Date”), and (2) warrants (the “Warrants”) to purchase an aggregate of 2,698,662 shares of the common stock of the Company.
Each of the Notes provide that, upon the occurrence of an event of default, the Purchasers thereof may, by written notice to the Company, declare all of the outstanding principal and interest under such Notes immediately due and payable. For purposes of the Notes, an event of default includes, among other things, one or more events that have, or could reasonably be expected to have, a material adverse effect on (i) the Company’s ability to comply with its obligations under the Securities Purchase Agreement, the Notes or the Warrants or the registration rights agreement entered into with the Purchasers in connection with the Private Placement, or (ii) the rights of the Purchasers under the Notes. The Company believes that it is not probable that the material adverse event clause under the Notes will be exercised.
The Company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company’s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. Although management believes such plans, if executed as planned, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company’s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that the condensed consolidated financial statements are issued.
If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable, the Company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates. The Company may also seek collaborators for one or more of its current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available.
The condensed consolidated financial statements do not reflect any adjustments that might be necessary if the Company is unable to continue as a going concern.
Universal Shelf Registration
In November 2014, the Company filed a universal shelf registration statement on Form S-3 (the “2014 Shelf Registration Statement”) with the SEC, which was declared effective by the SEC in December 2014. This 2014 Shelf Registration Statement provided the Company with the ability to offer up to $250 million of securities, including equity and other securities as described in the registration statement. Included in the 2014 shelf registration was a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that could be issued and sold under a sales agreement with MLV & Co. LLC (the “2014 ATM Facility”). During the twelve months ended December 31, 2017, the Company sold approximately $13.9 million in shares of common stock under the 2014 ATM Facility.
In April 2017, the Company completed a public offering of $47.5 million of shares of common stock pursuant to the 2014 Shelf Registration Statement for net proceeds of approximately $43.1 million.
In November 2017, the Company filed a universal shelf registration statement on Form S-3 (the “2017 Shelf Registration Statement”) with the SEC, which was declared effective by the SEC in December 2017. The 2014 Shelf Registration Statement expired on December 6, 2017 when the 2017 Shelf Registration was declared effective. The 2017 Shelf Registration Statement provides the Company with the ability to offer up to $350 million of securities, including equity and other securities as described in the registration statement. Included in the 2017 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $100.0 million of the Company’s common stock that may be issued and sold under a sales agreement with B. Riley FBR, Inc. (the “ATM Facility”). During the twelve months ended December 31, 2017, the Company sold approximately $0.9 million in shares of common stock under the ATM Facility. During the three and six month periods ended June 30, 2018, the Company sold approximately $9.6 million and $60.2 million in shares of common stock, respectively, under the ATM Facility. The Company can offer up to approximately $38.9 million of additional shares of common stock under the ATM Facility, subject to certain limitations.
Pursuant to the 2017 Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all.
2016 Private Investment in Public Entity Financing
On April 3, 2016, the Company entered into a Securities Purchase Agreement (the “ABG Purchase Agreement”) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, “Ally Bridge”), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers designated by Ally Bridge (collectively, the “ABG Purchasers”), in a private placement transaction (the “ABG Private Placement”), up to $50.0 million in shares of the Company’s common stock and warrants to purchase shares of common stock. Upon the closing of the ABG Private Placement, the Company issued to the ABG Purchasers (1) an aggregate of 9,009,005 shares (the “ABG Shares”) of common stock, and (2) warrants to purchase an aggregate of 2,702,700 shares of common stock (each, an “ABG Warrant”).   Each ABG Warrant has an exercise price of $8.50 per share, was immediately exercisable upon issuance, has a term of three years and is exercisable on a cash or cashless exercise basis. 
Under the terms of the ABG Purchase Agreement, the Company was obligated to prepare and file with the SEC, within 30 days of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of common stock issuable upon exercise of each ABG Warrant (the “ABG Warrant Shares”), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain “piggy-back” registration rights granted to the ABG Purchasers.
On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the “Additional Purchase Agreements”) with each of Beijing Shijilongxin Investment Co., Ltd. (“Beijing Shijilongxin”), FREJOY Investment Management Co., Ltd. (“Frejoy”) and Yuhan Corporation (“Yuhan”), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, 8,108,108 shares of common stock, and a warrant to purchase 1,176,471 shares of common stock, for an aggregate purchase price of $45.0 million; (2) to Frejoy, 8,108,108 shares of common stock, and a warrant to purchase 1,176,471 shares of common stock, for an aggregate purchase price of $45.0 million; and (3) to Yuhan, 1,801,802 shares of common stock, and a warrant to purchase 235,294 shares of common stock, for an aggregate purchase price of $10.0 million. The warrants issued pursuant to each of the Additional Purchase Agreements (collectively, the “Additional Warrants” and, together with each ABG Warrant, the “ABG Warrants”) have an exercise price of $8.50 per share, were immediately exercisable upon issuance, have a term of three years and are exercisable on a cash or cashless exercise basis.
Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan had the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor’s shares of common stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of common stock issuable upon exercise of such investor’s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain “piggy-back” registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan.
On May 2, 2016, the Company closed its private placement of common stock and warrants with Yuhan for gross proceeds of $10.0 million.  Yuhan purchased 1,801,802 shares of common stock at $5.55 per share and a warrant to purchase 235,294 shares of common stock.  The warrant is exercisable for three years at an exercise price of $8.50 per share.
Between May 31, 2016 and June 7, 2016, the Company closed on the remainder of the $150.0 million financing with the ABG Purchasers, Beijing Shijilongxin, and Frejoy. The ABG Purchasers led the financing and, together with Beijing Shijilongxin and Frejoy, collectively purchased 25,225,221 shares of common stock at $5.55 per share and warrants to purchase 5,055,642 shares of common stock for total cash consideration of $86.5 million and secured promissory notes (the “ABG Notes”) in an aggregate principal amount of $53.5 million.
On December 31, 2016, the Company entered into Warrant and Note Cancellation and Share Forfeiture Agreements (the “Cancellation and Forfeiture Agreements”) with certain investors (the “Investors”) that held an aggregate of 7,838,259 shares of common stock and certain of the Warrants granting the right to purchase an aggregate of 1,137,316 shares of common stock.  Pursuant to the Cancellation and Forfeiture Agreements, effective December 31, 2016, the ABG Warrants held by the Investors and the ABG Notes, of which $43.5 million was then outstanding, were cancelled and the shares of common stock held by the Investors were forfeited and returned to the Company.
2017 Private Investment in Public Entity Financing
On December 11, 2017, the Company entered into a Securities Purchase Agreement (the "December 2017 Securities Purchase Agreement") with certain accredited investors (collectively, the "December 2017 Purchasers"). Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, (1) convertible promissory notes in an aggregate principal amount of $50,000,000 (the "December 2017 Notes"), which accrued simple interest at a rate equal to 5.0% per annum and would mature upon the earlier to occur of (a) December 21, 2022, and (b) the date of the closing of a change in control of the Company (the "December 2017 Warrant Maturity Date"), and (2) warrants (the "December 2017 Warrants") to purchase an aggregate of 12,121,210 shares of the common stock of the Company.
At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser’s December 2017 Note that was equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of $2.26875, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.
Each December 2017 Warrant has an exercise price of $2.61 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.
On May 17, 2018, the December 2017 Purchasers converted the full outstanding principal under the December 2017 Notes into 22,038,565 shares of the Company's common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of $1.0 million in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of $44.3 million was recognized immediately at that date as interest expense.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $44.8 million based on an allocation of proceeds to the Warrants of approximately $12.7 million and a beneficial conversion feature of approximately $32.1 million, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.
2018 Private Investment in Public Entity Financing
On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, the Notes in an aggregate principal amount of $120,500,000 and Warrants to purchase an aggregate of 8,591,794 shares.
On June 13, 2018, the Company entered into an amendment (the “Amendment”) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of the common stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of the common stock of the Company.
At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser’s Note that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such Purchaser’s Note into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. If a Purchaser elects to convert any of the principal amount of their Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Notes contain restrictive covenants and event of default provisions that are customary for transactions of this type.
Each Warrant has an exercise price of $8.77 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.
If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments
The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:
•
Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
•
Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.
•
Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.
The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities.
Marketable Securities
Marketable securities are designated either as trading or available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations and are classified as short-term available-for-sale securities are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Marketable securities that are not trading securities and are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying condensed consolidated balance sheets.
Securities that are classified as trading are carried at fair value, with changes to fair value reported as a component of income. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method.
All of the Company’s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. For the three and six months ended June 30, 2018 and 2017, no other-than-temporary impairment charges were recorded. 
Grants and Accounts Receivable
Grants receivable at June 30, 2018 and December 31, 2017 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a division of the National Institutes of Health (“NIH”). The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
Accounts receivable at June 30, 2018 and December 31, 2017 consist of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of each of June 30, 2018 and December 31, 2017, the allowance for doubtful accounts was $20 thousand.  
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
Acquisitions and Intangibles
The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
Goodwill and Other Long-Lived Assets
Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2017, noting no impairment. There have not been any triggering events indicating the potential for impairment through June 30, 2018.
The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through June 30, 2018.
Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities
Acquisition consideration payable relates to the Company’s acquisition of businesses and various other assets and is recorded on the Company’s condensed consolidated balance sheets at fair value and is re-measured at each balance sheet date until such contingent liabilities have been settled, with changes in fair value recorded as gain or loss on contingent liabilities. The Company estimates the fair value of contingent consideration based on level 3 inputs primarily driven by the probability of achieving certain financing or operating related milestones.  
Debt with Detachable Warrants
Debt with detachable warrants are evaluated for the classification of warrants as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are first allocated to the debt and the warrants at their relative estimated fair values. The portion of the proceeds so allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of embedded derivatives and beneficial conversion features, are allocated to the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds, to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815.
If the amount allocated to the convertible debt results in an effective per share conversion price less than the fair value of the Company’s common stock on the commitment date, the intrinsic value of this beneficial conversion feature is recorded as a discount to the convertible debt with a corresponding increase to additional paid in capital. The beneficial conversion feature discount is equal to the difference between the effective conversion price and the fair value of the Company’s common stock at the commitment date, unless limited by the remaining proceeds allocated to the debt.
Derivative Liability
Derivative liabilities are recorded on the Company’s condensed consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.  The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model.
Investments in Other Entities
The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company’s share of earnings or losses reported in loss on equity method investments.
The Company’s cost method investments are included in cost method investments on the condensed consolidated balance sheets.  The Company’s equity method investments are included in equity method investments on the condensed consolidated balance sheets.
All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: the magnitude of the impairment and length of time that the market value was below the cost basis; financial condition and business prospects of the investee; the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that the Company may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so.
Research and Development Costs and Collaborations
All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
Acquired In-Process Research and Development Expense
The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired in-process research and development related to the business combinations of Virttu Biologics Limited ("Virttu") and Scilex Pharmaceuticals Inc. ("Scilex"), for which certain products are under development and expected to be commercialized in the future, was capitalized and recorded within “Intangibles, net” on the accompanying condensed consolidated balance sheet. The Company intends to commence amortization of acquired in-process research and development upon commercialization of the related products. Capitalized in-process research and development will be reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.
Income Taxes
The provisions of ASC Topic 740 “Income Taxes,” addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions.
The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of each of December 31, 2017 and June 30, 2018, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its investment in Scilex.
Revenue Recognition
The Company’s revenues are generated from various NIH grant awards, license fees, the sale of customized reagents and other materials, and the provision of contract manufacturing and other services. The Company does not have significant costs associated with costs to obtain contracts with its customers. Substantially all of the Company’s grants and accounts receivable result from contracts with customers.
Grant Revenues
The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
Royalty and License Revenues
License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period, with the exception of license agreements with no remaining performance obligations or undelivered obligations. The Company applies judgment in determining the timing of revenue recognition related to contracts that include multiple performance obligations. The total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. For goods or services for which observable standalone selling prices are not available, the Company develops an estimated standalone selling price of each performance obligation.
As of December 31, 2017 and June 30, 2018, the future performance obligations for royalty and license revenues relate to the ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) and NantCell, Inc. (“NantCell”) license agreements.
The total consideration for the ImmuneOncia license performance obligation, effective September 1, 2016, represented $9.6 million. The estimated revenue expected to be recognized for future performance obligations, as of December 31, 2017 and June 30, 2018, was approximately $9.0 million and $8.7 million, respectively. The Company expects to recognize license revenue of approximately $0.5 million of the remaining performance obligation annually through the remaining term. The Company applied judgment in estimating the 20-year contract term, analogous to the expected life of the patent, over which revenue is recognized over time given the ongoing performance obligation related to the Company's participation on a steering committee for the technologies under the agreement.
As of December 31, 2017 and June 30, 2018, the NantCell license agreement, effective April 21, 2015, represented $110 million of contract liabilities reflected in long-term deferred revenue. See Note 11 for additional information regarding the remaining performance obligation for the significant agreement.
Sales and Services Revenues
Sales and services revenues are comprised of contract manufacturing associated with sales of customized reagents at Concortis Biosystems Corporation, materials and supply agreements, contract manufacturing services at BioServ Corporation, and the Company’s joint development agreement with Celularity Inc.
The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. The Company applied the practical expedient in ASC Topic 606-10-50-14 to the revenue contracts for our Concortis Biosystems Corporation sales and services and materials and supply agreements due to the short-term length of such contracts.
The following table shows sales and service revenues disaggregated by product and services type for the three and six months ended June 30, 2018 and 2017 (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Concortis sales and services
895

 
883

 
2,358

 
2,071

Materials and supply agreements
—

 
85

 
861

 
403

Bioserv sales and services
1,231

 
1,187

 
3,367

 
2,037

Joint development agreement
1,667

 
—

 
3,333

 
—

 
$
3,793

 
$
2,155

 
$
9,919

 
$
4,511


The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
Concortis Biosystems Corporation (“Concortis”)
Contract manufacturing associated with sales of customized reagents for Concortis operations relate to providing synthetic expertise to customers’ synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers which are recognized upon the transfer of control, which is generally upon shipment given the short contract terms which are generally three months or less.
Materials and Supply Agreements
Revenues from the sale of materials associated with our research and development arrangements are recognized upon the transfer of control, which is generally, upon shipment. Outstanding performance obligations related to materials and supply agreements was $1.6 million as of June 30, 2018, and the Company expects to fulfill such obligations during the remainder of 2018.
Bioserv Corporation (“Bioserv”)
Contract manufacturing services associated with the Company's Bioserv operations related to finish and fill activities for drug products and reagents are recognized ratably over the contract term based on a time-based measure which reflects the transfer of services to the customer because the manufactured products are highly customized and do not have an alternative use to the Company. As of December 31, 2017 and June 30, 2018, the Company had approximately $0.5 million and $0.4 million of unbilled accounts receivable for which revenue has been recognized but not billed at the reporting date, respectively. As of December 31, 2017 and June 30, 2018, the Company had approximately $0.4 million and $0.3 million of upfront payments related to its contract manufacturing services included in deferred revenue, respectively.
As of December 31, 2017 and June 30, 2018, the estimated revenue expected to be recognized for future performance obligations associated with contract manufacturing services was approximately $3.0 million and $2.6 million, respectively. The Company expects to recognize revenue on approximately $2.1 million of these remaining performance obligations over the next twelve months.
The following table includes Bioserv sales and services revenue expected to be recognized in the future related to performance obligations that are undelivered or partially delivered at the end of the reporting period and do not include contracts with original durations of one year or less (in thousands):
 
 
Remainder of 2018
 
2019
 
2020 and thereafter
Contract manufacturing services
 
$1,640
 
$648
 
$353


Joint Development Agreement
On September 26, 2017, the Company entered into a joint development agreement with Celularity Inc. whereby the Company agreed to provide research services to Celularity Inc. through June 30, 2018 in exchange for an upfront payment of $5.0 million. The revenue related to the joint development agreement of $5.0 million will be recognized over the length of the service agreement as services are performed. The Company recorded sales and services revenues under the joint development agreement of $1.7 million and $3.3 million for the three and six months ended June 30, 2018, respectively, and $1.7 million for the year ended December 31, 2017.
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC Topic 718 “Compensation – Stock Compensation,” which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date.
Comprehensive Income (Loss)
Comprehensive income (loss) is primarily comprised of net income (loss) and adjustments for the change in unrealized gains and losses on the Company’s investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its condensed consolidated statements of comprehensive income (loss).
Net Loss per Share
Basic net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.
These outstanding securities consist of the following:
 
Quarters Ended June 30,
 
2018
 
2017
Outstanding options
7,616,950
 
4,375,276
Outstanding warrants
19,528,732
 
5,932,998

Segment Information
The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in one operating segment.
Recent Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU No. 2014-09 was originally effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard for annual reporting periods beginning after December 15, 2017, and interim periods thereafter. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, January 1, 2018 under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of January 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends the guidance in GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. ASU No. 2016-01 is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU No. 2016-02 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU No. 2016-20 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-02 will have on its consolidated financial position, results of operations and cash flows. The Company's leases are discussed in Note 14. The Company currently expects to record right-of-use assets and lease liabilities with regard to its leases in the consolidated balance sheets.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The ASU also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. The ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application will be permitted for all organizations for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2016-13 will have on its consolidated financial position, results of operations and cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. The ASU requires that (1) debt extinguishment costs be classified as cash outflows for financing activities and provides additional classification guidance for the statement of cash flows, (2) the classification of cash receipts and payments that have aspects of more than one class of cash flows to be determined by applying specific guidance under generally accepted accounting principles, and (3) each separately identifiable source or use within the cash receipts and payments be classified on the basis of their nature in financing, investing or operating activities. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, to clarify the definition of a business to add guidance for evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Specifically, this ASU provides a screen to assist entities in determining when a set should not be considered a business, which screen provides that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar assets, the set is not a business. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350). This standard eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit’s fair value. This guidance is effective for interim and annual goodwill impairment tests in fiscal years beginning after December 15, 2019 with early adoption permitted. This guidance must be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of ASU No. 2017-04 will have on the Company’s consolidated financial position, results of operations or cash flows.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, to provide clarity and reduce both the diversity in practice and cost of complexity when applying the guidance. Specifically, the ASU provides additional modification conditions in determining whether or not modification accounting should be applied. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and improves the usefulness of information reported to financial statement users. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2018-07 will have on the Company’s consolidated financial position, results of operations or cash flows.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions
 6 Months Ended
Jun. 30, 2018
Business Combinations [Abstract]  
Acquisitions
Acquisitions
Acquisition of Virttu Biologics Limited
On April 27, 2017, the Company entered into a Share Purchase Agreement (the “Virttu Purchase Agreement”) with TNK Therapeutics, Inc., a majority-owned subsidiary of the Company (“TNK”), Virttu, the shareholders of Virttu (the “Virttu Shareholders”) and Dayspring Ventures Limited, as the representative of the Virttu Shareholders ("Dayspring"), pursuant to which, among other things, TNK acquired from the Virttu Shareholders 100% of the outstanding ordinary shares of Virttu (the “Virttu Acquisition”).
Virttu focuses on the development of oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. Its lead oncolytic virus candidate, Seprehvir, infects and replicates in cancer cells selectively, leaving normal cells unharmed.
Under the Virttu Purchase Agreement, the total amount of the consideration payable to the Virttu Shareholders in the Virttu Acquisition is equal to $25 million, less Virttu’s net debt (the “Virttu Base Consideration”). An additional $10 million contingent consideration is payable upon the achievement of certain regulatory milestones (as described below) (the “Regulatory Approval Consideration”).
At the closing of the Virttu Acquisition (the “Closing”), the Company issued to the Virttu Shareholders consideration valued at approximately $2.2 million, which consisted primarily of an aggregate of 797,081 shares (the “Virttu Closing Shares”) and approximately $557,000 in cash (the “Cash Consideration”). The issuance of the Virttu Closing Shares and the payment of the Cash Consideration satisfied TNK’s obligation to pay 20% of the Virttu Base Consideration at the Closing. Under the terms of the Virttu Purchase Agreement, the Company agreed to provide additional consideration to the Virttu Shareholders, as follows:
(1) Upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $50.0 million (a “Qualified Financing”), TNK would have issued to the Virttu Shareholders an aggregate number of shares of its capital stock (“TNK Capital Stock”) as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration by the lowest per share price paid by investors in the Qualified Financing (the “TNK Financing Consideration”); provided, however, that 20% of the TNK Financing Consideration was held in escrow until April 27, 2018 (the “Financing Due Date”), to be used to, among other things, satisfy the indemnification obligations of the Virttu Shareholders. In the event that a Qualified Financing did not occur, then on the Financing Due Date, the Company would issue to the Virttu Shareholders an aggregate number of shares of the Company’s common stock as is equal to the quotient obtained by dividing 80% of the Virttu Base Consideration, by $5.55 (as adjusted, as appropriate, to reflect any stock splits or similar events affecting the Company’s common stock after the Closing).
(2) Within 45 business days after Virttu becomes aware that certain governmental bodies in the United States, the European Union, the United Kingdom or Japan have approved for commercialization, on or before October 26, 2024, Seprehvir (or any enhancement, combination or derivative thereof) as a monotherapy or in combination with one or more other active components (each of the first two such approvals by a governmental body being a “Regulatory Approval”), TNK shall pay half of the Regulatory Approval Consideration to the Virttu Shareholders, in a combination of (a) up to $5.0 million in cash (the “Regulatory Approval Cash”) and/or (b) (i) such number of shares of the Company’s common stock as is equal to the quotient obtained by dividing $5.0 million less the Regulatory Approval Cash (the “Regulatory Approval Share Value”) by the 30 Day VWAP (as defined below) of one share of the Company’s common stock; (ii) if TNK has completed its first public offering of TNK Capital Stock, the number of shares of TNK Capital Stock as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the 30 Day VWAP of one share of TNK Capital Stock; or (iii) such number of shares of common stock of a publicly traded company as is equal to the quotient obtained by dividing the Regulatory Approval Share Value by the volume weighted average price of the relevant security, as reported on the Nasdaq Capital Market (or other principal stock exchange or securities market on which the shares are then listed or quoted) for the thirty trading days immediately following the receipt of Regulatory Approval (the “30 Day VWAP”), with the composition of the Regulatory Approval Consideration to be at TNK’s option. In order for a second regulatory approval to qualify as a Regulatory Approval under the Purchase Agreement, the second approval must be granted by a different governmental body in a different jurisdiction than that which granted the first Regulatory Approval.
At April 27, 2017, the 80% of the Virttu Base Consideration was valued at $12.8 million. The fair value of the 80% of the Virttu Base Consideration is recorded as a current liability and will be adjusted quarterly for changes in fair value or as events and circumstances arise. At April 27, 2017, the contingent Regulatory Approval Consideration was valued at $1.0 million. The fair value of the contingent Regulatory Approval Consideration is recorded as a non-current liability within "Deferred rent and other" on the accompanying condensed consolidated balance sheet and will be adjusted quarterly for changes in fair value or as events and circumstances arise.
The consolidated financial statements include the preliminary results of operations from this transaction, which have been accounted for as a business combination, and require, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The final valuation of the acquired assets and liabilities resulted in the recognition of identifiable assets of approximately $16.0 million comprised mainly of in-process research and development of approximately $15.4 million, deferred tax liabilities of $0.8 million and goodwill of approximately $1.4 million. Various factors contributed to the establishment of goodwill, including an assembled workforce.
In connection with the Virttu transaction, the Company recorded acquisition costs of approximately $0.9 million in general and administrative expenses for the twelve months ended December 31, 2017, for legal and related costs. No acquisition costs in connection with the Virttu transaction were recorded for the three and six months ended June 30, 2018. Acquisition costs are expensed as incurred.
TNK did not complete a Qualified Financing prior to the Financing Due Date and on April 27, 2018, the Company, TNK and Dayspring entered into the Amendment, pursuant to which, among other things, the Company agreed that the acquisition consideration, otherwise payable on April 27, 2018 to the Virttu Shareholders, shall be as follows: (1) an issuance of 1,795,011 shares of its common stock to the Virttu Shareholders and (2) $9.9 million payable in cash .
The Company issued an aggregate of 1,795,011 shares of its common stock to the Virttu Shareholders on April 27, 2018 for a value of $11.3 million. The approximately $9.9 million payable in cash has not been paid as of the date of this filing.
Acquisition of Scilex Pharmaceuticals Inc.
On November 8, 2016, the Company entered into a Stock Purchase Agreement (the “Scilex Purchase Agreement”) with Scilex and a majority of the stockholders of Scilex (the “Scilex Stockholders”) pursuant to which, on November 8, 2016, the Company acquired from the Scilex Stockholders, and the Scilex Stockholders sold to the Company, approximately 72% of the outstanding capital stock of Scilex (the “Scilex Acquisition”). The remainder of the outstanding capital stock of Scilex represents a noncontrolling interest of which approximately 23% continues to be held by ITOCHU CHEMICAL FRONTIER CORPORATION following the Scilex Acquisition.
Scilex focuses on the development and commercialization of specialty pharmaceutical products for the treatment of pain; its lead product, ZTlidoTM (lidocaine topical system 1.8%, is a branded lidocaine topical system formulation being developed for the treatment of chronic pain. ZTlido™ (lidocaine topical system 1.8%) will be manufactured by a contract manufacturer.
Under the terms of the Scilex Purchase Agreement, upon receipt of notice from the U.S. Food and Drug Administration (the "FDA") that the FDA has approved Scilex's new drug application for ZTlido™ (lidocaine topical system 1.8%) for the treatment of postherpetic neuralgia (the "NDA") for commercialization, the Company was obligated to deliver to the Scilex Stockholders cash and shares of its common stock in such proportion to be determined in the Company’s sole discretion as a milestone payment. On February 28, 2018, the Company received notice from the FDA that the FDA had approved the NDA. As a result, the Company issued to the Scilex Stockholders consideration valued at approximately $38.2 million, which included an aggregate of 1,381,346 shares of common stock of approximately $13.7 million, cash payment of approximately $24.5 million, which included a bridge loan of approximately $20.0 million with B. Riley FBR to facilitate the timing of the cash payment and resulted in a change in fair value of $6.0 million since December 31, 2017, for the contingent consideration upon settlement.
Acquired In-process Research and Development of BDL
In August 2015, the Company and TNK entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with BDL Products, Inc. (“BDL”) and the stockholders of BDL (“Stockholders”) pursuant to which the Stockholders sold all of their shares of capital stock in BDL to TNK for: (1) a cash payment of $100.00, and (2) $6.0 million in shares of TNK Class A Stock, subject to adjustment in certain circumstances, to be issued to the Stockholders upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $50.0 million (a “Qualified Financing”).  In accordance with subsequent amendments to the Stock Purchase Agreement, in the event a Qualified Financing does not occur by October 15, 2017 (which is subject to further extension as implied and based on previously amended dates) or TNK does not complete an initial public offering of shares of its capital stock by September 15, 2017, in lieu of receiving shares of TNK pursuant to the acquisition, the Stockholders shall receive an aggregate of 309,916 shares of the Company’s common stock, subject to adjustment in certain circumstances. TNK did not complete a Qualified Financing by the financing deadline and the Company issued 309,916 shares of its common stock to the Stockholders on March 19, 2018.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
 6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements 
Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.
Level 3—Unobservable inputs based on the Company's own assumptions.
The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis.  (in thousands):
 
Fair Value Measurements at June 30, 2018
 
Balance
 
Quoted Prices in Active Markets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
46,784

 
$
46,784

 
$
—

 
$
—

Marketable securities
$
323

 
$
266

 
$
—

 
$
57

Total assets
$
47,107

 
$
47,050

 
$
—

 
$
57

Liabilities:
 

 
 

 
 

 
 

Acquisition consideration payable
$
16,055

 
$
—

 
$
—

 
$
16,055

Total liabilities
$
16,055

 
$
—

 
$
—

 
$
16,055

 
 
 
 
 
 
 
 
 
Fair Value Measurements at December 31, 2017
 
Balance
 
Quoted Prices in Active Markets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
20,429

 
$
20,429

 
$
—

 
$
—

Marketable securities
$
441

 
$
356

 
$
—

 
$
85

Total assets
$
20,870

 
$
20,785

 
$
—

 
$
85

Liabilities:
 

 
 

 
 

 
 

Acquisition consideration payable
$
54,272

 
$
—

 
$
—

 
$
54,272

Total liabilities
$
54,272

 
$
—

 
$
—

 
$
54,272


The Company's financial assets and liabilities carried at fair value are comprised of cash and cash equivalents and acquisition consideration payable. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These investments are valued using inputs observable in active markets for identical securities. Marketable securities are valued using inputs observable in active markets for identical securities. The Company recorded contingent consideration as part of its investment in Shanghai Three Alliance Biotech Co. LTD (“Shanghai Three”), agreement with Roger Williams Medical Center (“RWMC”), and acquisitions of Concortis, Inc., (“Concortis”), and Virttu. The fair value of the contingent consideration is measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Contingent consideration is measured using the income approach and discounting to present value the contingent payments expected to be made based on assessment of the probability that the company would be required to make such future payment.
The following table includes a summary of the Company’s contingent consideration liabilities and acquisition consideration payables associated with acquisitions. The contingent consideration is measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018:
(in thousands)
 
Fair Value
Beginning Balance at December 31, 2017
 
54,272

Re-measurement of Fair Value
 
13,663

Payment of current year contingent consideration
 
(51,880
)
Ending Balance at June 30, 2018
 
$
16,055


The payment of current year contingent consideration for the six months ended June 30, 2018 includes the settlement of Scilex and BDL liabilities for $38.2 million and $2.3 million, respectively, and the $11.3 million partial settlement of the Virttu financing milestone in common shares of the Company ($9.9 million of the Virttu contingent liability remains to be paid in cash).
The following table includes a summary of the Company’s contingent and financing liabilities, related inputs used to determine fair value, and the valuation methodologies used for the fair value measurements using significant unobservable inputs (Level 3) at June 30, 2018: 
(in thousands)
 
Fair Value Measurements at June 30, 2018
 
Valuation Methodology
 
Significant Unobservable Input
 
Weighted Average
(range, if applicable)
Virttu Contingent Consideration (Non-current)
 
$
1,126

 
Multiple outcome
discounted cash flow
 
Discount Rate
Probability of Regulatory Milestone
 
12.21%
16%
Concortis Contingent Consideration
 
$
511

 
Multiple outcome
discounted cash flow
 
Discount Rate
Percent probabilities assigned to scenarios
 
19.20%
20%
Shanghai Three Contingent Consideration
 
$
1,782

 
Multiple outcome
discounted cash flow
 
Discount Rate
Percent probabilities assigned to scenarios
 
12.21%
50%
RWMC Contingent Consideration
 
$
2,673

 
Multiple outcome
discounted cash flow
 
Discount Rate,
Percent probabilities assigned to scenarios
 
12.21%
50%
 
The principal significant unobservable inputs used in the valuations of the contingent considerations are the discount rates and probabilities assigned to scenario outcomes. An increase in the discount rate or decrease in the probability of regulatory milestone achievement will cause a decrease in the fair value of the contingent consideration. Conversely, a decrease in the discount rate will cause an increase in the fair value of the contingent consideration. An increase in the probabilities assigned to certain scenarios will cause the fair value of contingent consideration to increase. Conversely, a decrease in the probabilities assigned to certain scenarios will cause the fair value of contingent considerations to decrease.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities
 6 Months Ended
Jun. 30, 2018
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
Marketable Securities
Marketable securities consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
Cost
 
Gross Unrealized Gains (Losses)
 
Gross Realized Gains (Losses)
 
Fair Value
Trading securities:
 

 
 

 
 

 
 

MedoveX common shares and warrants
$
750

 
$
(427
)
 
$
—

 
$
323

 
December 31, 2017
 
Cost
 
Gross Unrealized Gains (Losses)
 
Gross Realized Gains (Losses)
 
Fair Value
Trading securities:
 

 
 

 
 

 
 

MedoveX common shares and warrants
$
750

 
$
(309
)
 
$
—

 
$
441


Trading Securities
On August 5, 2016, the Company entered into a Unit Purchase Agreement (the “Unit Purchase Agreement”) with MedoveX Corporation (“MedoveX”). Pursuant to the terms of the Unit Purchase Agreement, the Company purchased three Units for $750,000.  Each Unit had a purchase price of $250,000 and consisted of (i) 208,333 shares of MedoveX common stock (the “MedoveX Common Stock”), and (ii) a warrant to purchase 104,167 shares of MedoveX Common Stock (the “MedoveX Warrant”).  The MedoveX Warrant has an initial exercise price of $1.52 per share, subject to adjustment, and is initially exercisable six months following the date of issuance for a period of five years from the date of issuance.  In addition, the Company entered into a Registration Rights Agreement with MedoveX pursuant to which MedoveX was required to file a registration statement registering for resale all shares of MedoveX Common Stock and shares of MedoveX Common Stock issuable pursuant to the MedoveX Warrant issued as part of the Units. 
For the three months ended June 30, 2018 and 2017, the Company recorded a loss of $0.1 million and $0.6 million, respectively, on trading securities. For the the six months ended June 30, 2018 and 2017, the Company recorded a loss of $0.1 million and $0.5 million on trading securities, respectively. The Company’s investment in MedoveX will be revalued on each balance sheet date.  The fair value of the Company’s holding in MedoveX Common Stock at June 30, 2018 is a Level 1 measurement.  The fair value of the Company’s holdings in the MedoveX Warrant was estimated using the Black-Scholes option-pricing method. The risk-free rate was derived from the U.S. Treasury yield curve, matching the MedoveX Warrant’s term, in effect at the measurement date. The volatility factor was determined based on MedoveX’s historical stock prices. The warrant valuation is a Level 3 measurement.
The following table includes a summary of the warrant measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018 (in thousands):
 
Total
Beginning balance at December 31, 2017
$
84

Change in fair value of warrant
(27
)
Ending balance at June 30, 2018
$
57
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment
 6 Months Ended
Jun. 30, 2018
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment
Property and equipment consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
December 31, 2017
Furniture and fixtures
1,077

 
1,035

Office equipment
479

 
493

Machinery and lab equipment
22,573

 
19,868

Leasehold improvements
7,460

 
7,327

Construction in progress
292

 
—

 
31,881

 
28,723

Less accumulated depreciation
(11,988
)
 
(9,378
)
 
$
19,893

 
$
19,345


Depreciation expense for the three months ended June 30, 2018 and 2017 was $1.3 million and $1.1 million, respectively. Depreciation expense for the six months ended June 30, 2018 and 2017 was $2.6 million and $1.9 million, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cost Method Investments
 6 Months Ended
Jun. 30, 2018
Investments [Abstract]  
Cost Method Investments
Cost Method Investments
As of June 30, 2018 and December 31, 2017, the aggregate carrying amount of the Company’s cost-method investments in non-publicly traded companies was $237.0 million and included an ownership interest in NantCell, Inc. (“NantCell”), NantBioScience, Inc. (“NantBioScience”), Globavir Biosciences, Inc., Brink Biologics, Inc., Coneksis, Inc., and Celularity Inc.
The Company’s cost-method investments are assessed for impairment quarterly. The Company has determined that it is not practicable to estimate the fair value of its cost-method investments on a regular basis and does not reassess the fair value of cost-method investments if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investments.  No impairment losses were recorded during the six months ended June 30, 2018.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Method Investments
 6 Months Ended
Jun. 30, 2018
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments
Equity Method Investments 
NANTibody
In 2013, the Company acquired IgDraSol Inc. (“IgDraSol”), a private company focused on the development of oncologic agents for the treatment of cancer, from a third party unrelated to the NantWorks, LLC (“NantWorks”) affiliated entities for 3.0 million shares of the Company's common stock and $380,000 of cash for a total purchase price of $29.1 million. This transaction included the acquisition of IgDraSol’s lead compound, CynviloqTM, a micellar diblock copolymeric paclitaxel formulation drug product.
In May 2015, the Company entered into an agreement with NantPharma, LLC (“NantPharma”), a NantWorks company, pursuant to which the Company sold to NantPharma all of its equity interests in IgDraSol, which continued to hold the rights to CynviloqTM. Pursuant to the agreement, NantPharma paid the Company an upfront fee of $90.1 million, of which $60.0 million was required to be used by the Company to fund two joint ventures, as described below.
In April 2015, the Company and NantCell, a subsidiary of NantWorks, a private company owned by Dr. Patrick Soon-Shiong, established a new entity called Immunotherapy NANTibody, LLC (“NANTibody”) as a stand-alone biotechnology company with $100.0 million initial joint funding. NantCell owns 60% of the equity interest of NANTibody and agreed to contribute $60.0 million to NANTibody. The Company owns 40% of NANTibody and in July 2015, the Company had NantPharma, contribute its portion of the initial joint funding of $40.0 million to NANTibody from the proceeds of the sale of IgDraSol. Additionally, the Company and NantCell were allowed to appoint two and three representatives, respectively, to NANTibody’s five-member Board of Directors. NANTibody will focus on accelerating the development of multiple immuno-oncology mAbs for the treatment of cancer, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA4mAbs, and other immune-check point antibodies as well as ADCs and bispecific antibodies.
NANTibody had been formed to advance pre-clinical and clinical immunology assets contributed by the Company and NantCell. The Company continues to hold 40% of the outstanding equity of NANTibody and NantCell holds the remaining 60%. Until July 2, 2017, NANTibody held approximately $100.0 million of cash and cash equivalents, and the Company recorded its investment in NANTibody at approximately $40.0 million. As an equity method investment, the Company's ratable portion of 40% of money expended for the development of intellectual property assets held by NANTibody would be reflected within income (loss) on equity method investments in its statement of operations. As a result of limited spending at NANTibody, the cash on hand at NANTibody remained at approximately at $100.0 million since the inception of the NANTibody joint venture until July 2, 2017. Further, the Company's equity method investment in NANTibody remained at approximately $40.0 million until July 2, 2017.
The financial statements of NANTibody are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag.
In February 2018, NANTibody notified the Company that on July 2, 2017, NANTibody acquired all of the outstanding equity of IgDraSol in exchange for $90.1 million in cash. NANTibody purchased IgDraSol from NantPharma, which is controlled by NantWorks, an entity with a controlling interest in NantCell and NantPharma.
Although the Company has had a designee serving on the Board of Directors of NANTibody since the formation of NANTibody in April 2015, and although the Company has held 40% of the outstanding equity of NANTibody since NANTibody’s formation, neither the Company nor its director designee was given any advance notice of NANTibody’s purchase of IgDraSol or of any board meeting or action to approve such purchase. As such, the Company's designee on NANTibody’s Board of Directors was not given an opportunity to consider or vote on the transaction as a director and the Company was not given an opportunity to consider or vote on the transaction in its position as a significant (40%) equity holder of NANTibody.
As a result of the July 2, 2017 purchase of IgDraSol, NANTibody’s cash and cash equivalents were reduced from $99.6 million as of June 30, 2017 to $9.5 million as of September 30, 2017, and NANTibody’s contributed capital was reduced from $100.0 million as of June 30, 2017 to $10.0 million as of September 30, 2017, to effect the transfer of IgDraSol from NantPharma to NANTibody. No additional information was provided to the Company to explain why NANTibody’s total assets as of September 30, 2017 were reduced by approximately $90.1 million. The Company requested, but did not receive, additional information from NANTibody for purposes of supporting the value of IgDraSol, including any information regarding clinical advancements in the entity since the sale of IgDraSol by the Company in May 2015.
Prior to the communication of the transfer of IgDraSol from NantPharma to NANTibody, the Company relied on the cash and cash equivalents of NANTibody for purposes of determining the value of its investment in NANTibody, which capital was expended by NANTibody to acquire IgDraSol on July 2, 2017. As a result of the transfer of IgDraSol, the Company reassessed the recoverability of its equity method investment in NANTibody as of July 2, 2017. In doing so, the Company considered the expected outcomes for the intellectual property assets held by NANTibody as of July 2, 2017. As a result of the lack of evidence of any development activity associated with any of the assets held in NANTibody, given the passage of time since the formation of the joint venture, many competitive products from other drug developers worldwide have advanced and/or commercialized for the targeted disease indications of the assets held in NANTibody, and given the Company's minority interest in NANTibody (the investee), the Company concluded that it does not have the ability to recover the carrying amount of the investment and an other-than-temporary decline in the value of the investment had occurred. Accordingly, an impairment was recorded to the Company's equity method investment in NANTibody for the three and nine months ended September 30, 2017. The fair value of the Company’s investment in NANTibody was measured at fair value on July 2, 2017 using significant unobservable inputs (Level 3) due to the determination of fair value requiring significant judgment, including the potential outcomes of the intellectual property assets held by NANTibody. For these reasons, fair value was determined by applying the Company's 40% equity interest in NANTibody to the remaining cash and cash equivalents, which resulted in an impairment of $36.0 million. The impairment resulted in a revised carrying value of the Company's investment in NANTibody of $3.7 million which approximates its ratable 40% ownership of the cash maintained by NANTibody expected to be used for future research and development. As of June 30, 2018, the carrying value of the Company’s investment in NANTibody was approximately $3.5 million.
NANTibody recorded net loss of $73 thousand and net profit $276 thousand for the three months ended March 31, 2018 and 2017, respectively. The Company recorded its portion of loss from NANTibody in loss on equity method investments on its condensed consolidated statement of operations for the six months ended June 30, 2018 and 2017.  As of March 31, 2018, NANTibody had $9.8 million in current assets and $1.8 million in current liabilities and no noncurrent assets or noncurrent liabilities.
NantStem
In July 2015, the Company and NantBioScience, a wholly-owned subsidiary of NantWorks, established a new entity called NantCancerStemCell, LLC (“NantStem”) as a stand-alone biotechnology company with $100.0 million initial joint funding.  As initially organized, NantBioScience was obligated to make a $60.0 million cash contribution to NantStem for a 60% equity interest in NantStem, and the Company was obligated to make a $40.0 million cash contribution to NantStem for a 40% equity interest in NantStem.  Fifty percent of these contributions were funded in July 2015 and the remaining amounts were to be made by no later than September 30, 2015. The Company had NantPharma contribute its portion of the initial joint funding of $20.0 million to NantStem from the proceeds of the sale of IgDraSol.  Pursuant to a Side Letter dated October 13, 2015, the NantStem joint venture agreement was amended to relieve the Company of the obligation to contribute the second $20.0 million payment, and its ownership interest in NantStem was reduced to 20%.  NantBioScience’s funding obligations were unchanged.  The Side Letter was negotiated at the same time the Company issued a call option on shares of NantKwest that it owned to Cambridge Equities, L.P. (“Cambridge”), a related party to NantBioScience.  
In the fourth quarter of 2015, the Company determined it had an other-than-temporary decline in the value of NantStem and recognized a loss of $4.0 million in loss on equity method investments on its condensed consolidated statement of operations for the year ended December 31, 2015. There was no loss related to other-than-temporary impairment recognized for the equity investment for the year ended December†31, 2017. A loss related to other-than-temporary impairment of $0.5 million was recognized for the equity investment in NantStem for the three months ended June 30, 2018.
The Company is accounting for its interest in NantStem as an equity method investment, due to the significant influence the Company has over the operations of NantStem through its board representation and 20% voting interest.  The Company’s investment in NantStem is reported in equity method investments on its condensed consolidated balance sheets and its share of NantStem’s loss is recorded in loss on equity method investments on its condensed consolidated statement of operations.  As of June 30, 2018, the carrying value of the Company’s investment in NantStem was approximately $18.2 million. The difference between the Company’s investment in NantStem and the Company’s 20% interest in the net assets of Nantstem was approximately $1.7 million at June 30, 2018.
The financial statements of NantStem are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag.
NantStem recorded net loss of $331 thousand and net profit of $369 thousand for the three months ended March 31, 2018 and 2017, respectively.  The Company recorded its portion of loss from NantStem (in addition to the immaterial impairment) in loss on equity method investments on its condensed consolidated statement of operations for the three and six months ended June 30, 2018 and 2017.  As of March 31, 2018, NantStem had $82.3 million in current assets and $27 thousand in current liabilities and no noncurrent assets or noncurrent liabilities.
Yuhan Agreement
In March 2016, the Company and Yuhan , a South Korea company, entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.  Under the terms of the joint venture agreement, Yuhan contributed an initial investment of $10.0 million to ImmuneOncia, and the Company granted ImmuneOncia an exclusive license to one of its immune checkpoint antibodies for specified countries while retaining the rights for the U.S., European and Japanese markets, as well as global rights for ImmuneOncia to two additional antibodies that will be selected by ImmuneOncia from a group of pre-specified antibodies from the Company’s immuno-oncology antibody portfolio. During October 2016, funding and operations of ImmuneOncia commenced. Yuhan owns 51% of ImmuneOncia, while the Company owns 49%.
The Company is accounting for its interest in ImmuneOncia as an equity method investment, due to the significant influence the Company has over the operations of ImmuneOncia through its board representation and 49% voting interest while not sharing joint control with Yuhan.  The Company’s investment in ImmuneOncia is reported in equity method investments on its condensed consolidated balance sheets and its share of ImmuneOncia’s loss is recorded in loss on equity method investments on its condensed consolidated statement of operations.  As of June 30, 2018, the carrying value of the Company’s investment in ImmuneOncia was approximately $4.5 million. The difference between the Company’s investment in ImmuneOncia and the Company’s 49% interest in the net assets of ImmuneOncia was approximately $0.8 million at June 30, 2018.
ImmuneOncia recorded a net loss of $3.1 million and $1.0 million for the three months ended June 30, 2018 and 2017, respectively.  ImmuneOncia recorded a net loss of $4.7 million and $1.5 million for the six months ended June 30, 2018 and 2017, respectively. The Company recorded its portion (49% equity interest) of loss from ImmuneOncia in loss on equity method investments on its condensed consolidated statement of operations for the three and six months ended June 30, 2018 and 2017.  As of June 30, 2018, ImmuneOncia had $3.1 million in current assets, $344 thousand in current liabilities, $7.8 million in noncurrent assets, and no noncurrent liabilities.
In April 2016, Yuhan purchased $10.0 million of shares of common stock, and warrants as part of the Company’s private placement offering.
Shanghai Three
On March 7, 2016, TNK agreed to issue to SiniWest Holdings, Inc. (“SiniWest Holdings”) $4.0 million in shares of TNK Class A Stock, subject to certain circumstances, to be issued upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $10.0 million and a $1.0 million upfront cash payment in exchange for SiniWest Holdings transferring certain assets to TNK, including SiniWest Holdings’ 25% interest in Shanghai Three, a China based company. The Company is accounting for its interest in Shanghai Three as an equity method investment, due to the significant influence the Company has over the operations of Shanghai Three through its 25% voting interest.  The Company’s investment in Shanghai Three is reported in equity method investments on the condensed consolidated balance sheets and its share of Shanghai Three’s income or loss is recorded in income (loss) on equity method investments on the condensed consolidated statement of operations.  As of June 30, 2018, the carrying value of the Company’s investment in Shanghai Three was approximately $3.8 million.
The financial statements of Shanghai Three are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag. 
Shanghai Three incurred no operating expenses or net loss for the three and six months ended March 31, 2018 and 2017.  As of March 31, 2018, Shanghai Three had $0.4 million in current assets, $2.9 million in current liabilities, $5.5 million in noncurrent assets, and $2.2 million in noncurrent liabilities. 
Fair Value of Equity Method Investment
The Company periodically evaluates the carrying value of its equity method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. The Company determines the fair value of its equity method investments to evaluate whether impairment losses shall be recorded using Level 3 inputs. These investments include the Company's holdings in privately held biotechnology companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values and unobservable inputs, including future cash flows.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets
 6 Months Ended
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Goodwill and Intangible Assets
 At June 30, 2018 and December 31, 2017, the Company had recorded goodwill of $38.3 million.  The Company performed a qualitative test for goodwill impairment as of December 31, 2017. Based upon the results of the qualitative testing the Company concluded that it is more-likely-than-not that the fair values of the Company’s goodwill was in excess of its carrying value and therefore performing the first step of the two-step impairment test was unnecessary. No goodwill impairment was recognized for the three and six months ended June 30, 2018 and 2017. A summary of the Company's goodwill as of June 30, 2018 is as follows (in thousands):
 
Total
Balance at December 31, 2017
$
38,298

    Goodwill Acquired from Acquisitions
—

Balance at June 30, 2018
$
38,298


The Company’s intangible assets, excluding goodwill, include acquired license and patent rights, core technologies, customer relationships and acquired in-process research and development. Amortization for the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives.  A summary of the Company’s identifiable intangible assets as of June 30, 2018 and December 31, 2017 is as follows (in thousands):
 
June 30, 2018
 
Gross Carrying Amount
 
Accumulated Amortization
 
Intangibles, net
Customer relationships
$
1,585

 
$
1,236

 
$
349

Acquired technology
3,410

 
797

 
2,613

Acquired in-process research and development
37,660

 
—

 
37,660

Patent rights
32,720

 
3,652

 
29,068

Total intangible assets
$
75,375

 
$
5,685

 
$
69,690

 
December 31, 2017
 
Gross Carrying Amount
 
Accumulated Amortization
 
Intangibles, net
Customer relationships
$
1,585

 
$
1,091

 
$
494

Acquired technology
3,410

 
709

 
2,701

Acquired in-process research and development
37,660

 
—

 
37,660

Patent rights
32,720

 
2,562

 
30,158

Total intangible assets
$
75,375

 
$
4,362

 
$
71,013


As of June 30, 2018, the remaining weighted average life for identifiable intangible assets is 15 years.
Patent rights are stated at cost and amortized on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years or nineteen years from the date of transfer of the rights to the Company. Amortization expense for the three months ended June 30, 2018 and 2017 was $545 thousand and $552 thousand, respectively, which has been included in intangible amortization on the condensed consolidated statement of operations. Amortization expense for the six months ended June 30, 2018 and 2017 was $1,090 thousand and $1,059 thousand, respectively, which has been included in intangible amortization on the condensed consolidated statement of operations.
Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately 19 years from the date of acquisition of the technology in December 2013. Amortization expense for each of the three months ended June 30, 2018 and 2017 was $44 thousand, which has been included in intangibles amortization on the condensed consolidated statement of operations. Amortization expense for each of the six months ended June 30, 2018 and 2017 was $88 thousand, which has been included in intangible amortization on the condensed consolidated statement of operations.
Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition. Amortization expense for the three months ended June 30, 2018 and 2017, was $72 thousand and $73 thousand, respectively, which has been included in intangibles amortization. Amortization expense for each of the six months ended June 30, 2018 and 2017 was $145 thousand, which has been included in intangible amortization on the condensed consolidated statement of operations.
Acquired in-process research and development is stated at cost and may be immediately expensed if there is no alternative future use. The Company intends to begin amortization of acquired in-process research and development costs associated with the Scilex and Virttu business combinations upon commercialization of the respective products. The acquired in-process research and development is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.
Estimated future amortization expense related to intangible assets at June 30, 2018 is as follows (in thousands):
Years Ending December 31,
 
Amount
2018
 
$
1,680

2019
 
3,845

2020
 
3,845

2021
 
5,040

2022
 
5,040

Thereafter
 
50,240

Total
 
$
69,690
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements and Contracts
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Significant Agreements and Contracts
Significant Agreements and Contracts
License Agreement with Mabtech Limited
In August 2015, the Company entered into an exclusive licensing agreement to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from Mabtech Limited.  Under the terms of the agreement, the Company will develop and market four mAbs for the North American, European and Japanese markets. The Company made an initial license payment of $10.0 million and in February 2016, paid an additional $10.0 million license payment, both of which were recognized as acquired in-process research and development expense in the condensed consolidated statements of operations as the Company determined there was no alternative future use for the license.  
In June 2016, the Company agreed to accelerate and pay a $30.0 million milestone license payment which has been recognized as acquired in-process research and development expense in the condensed consolidated statements of operations, in exchange for the purchase by Mabtech Limited in June 2016, of $10.0 million of shares of common stock and warrants. 
In December 2017, the Company agreed to accelerate and, as a result, paid a $25.0 million milestone license payment, which has been recognized as acquired in-process research and development expense in the consolidated statements of operations for the year ended December 31, 2017. The amended agreement includes additional milestone payments totaling $125.0 million payable following the completion of the technology transfer from Mabtech Limited and for payables to extend the license agreement. The remaining anniversary payments are due on December 31, 2018 and 2019, respectively. The Company is not obligated to extend the license agreement. Accordingly, the additional future milestone payments have not yet been accrued as of June 30, 2018.
Immunotherapy Research Collaboration Agreement with Roger Williams Medical Center
In April 2016, the Company entered into an immunotherapy research collaboration agreement with RWMC to provide certain clinical trial, research and manufacturing services. Under the terms of the agreement, RWMC will perform pre-clinical and clinical research related to the development and delivery of CAR-T immunotherapies. In exchange, the Company granted RWMC $6.0 million in shares of TNK Class A Stock, subject to adjustment in certain circumstances, to be issued upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $20.0 million.  The Company determined the fair value of this obligation was $3.4 million as of the April of 2016 agreement effective date, and the amount was recognized as prepaid expense and other and acquisition consideration payable in the condensed consolidated balance sheet.  The Company will recognize the upfront payment over the expected performance period of five years. During each of the quarters ended June 30, 2018 and 2017, the Company recognized approximately $170 thousand in pre-clinical research and development expense pursuant to the agreement. During each of the six months ended June 30, 2018 and 2017, the Company recognized approximately $340 thousand in pre-clinical research and development expense pursuant to the agreement.
License Agreement with NantCell
In April 2015, the Company and NantCell entered into a license agreement. Under the terms of the agreement the Company granted an exclusive license to NantCell covering patent rights, know-how, and materials related to certain antibodies, ADCs and two CAR-TNK products.  NantCell agreed to pay a royalty not to exceed five percent (5%) to the Company on any net sales of products (as defined) from the assets licensed by the Company to NantCell.  In addition to the future royalties payable under this agreement, NantCell paid an upfront payment of $10.0 million to the Company and issued 10 million shares of NantCell common stock to the Company valued at $100.0 million based on a recent equity sale of NantCell common stock to a third party.  As of June 30, 2018, the Company had not yet provided all of the items noted in the agreement, including research services for and on behalf of NantCell, and therefore has recorded the entire upfront payment and value of the equity interest received as deferred revenue. Specifically, only a portion of the materials associated with the licensed assets have been delivered while the majority of the licensed assets remain undelivered and the related research activities are still to be performed. The Company will recognize the upfront payment and the value of the equity interest received over the period beginning with the commencement of the last item delivered. The Company’s ownership interest in NantCell does not provide the Company with control or the ability to exercise significant influence; therefore the $100.0 million investment is carried at cost in the condensed consolidated balance sheets and evaluated for other-than-temporary impairment on a quarterly basis.
License Agreement with The Scripps Research Institute
In January 2010, the Company entered into a license agreement (the “TSRI License”) with The Scripps Research Institute (“TSRI”). Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus ("S. aureus" or “Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved and (iii) agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days’ notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For each of the quarters ended June 30, 2018 and 2017, the Company recorded $14 thousand in patent prosecution and maintenance costs associated with the TSRI License. For the six months ended June 30, 2018 and 2017, the Company recorded $24 thousand and $41 thousand in patent prosecution and maintenance costs associated with the TSRI License, respectively. All such costs have been included in general and administrative expenses.
NIH Grants
In June 2014, the NIAID awarded the Company a Phase II Small Business Technology Transfer (“STTR”) grant (the “Staph Grant III Award”) to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staph infections, including methicillin-resistant S. aureus (“MRSA”). The project period for the Staph Grant III Award covered a two-year period which commenced in June 2014, which was subsequently extended by one year, with total funds available of approximately $1.0 million per year for up to two years. The Staph Grant III Award was not extended beyond June 30, 2017 and the remaining amounts for the award have been recorded as of June 30, 2018. During each of the quarters ended June 30, 2018 and 2017, the Company recorded $0 and $94 thousand of revenue associated with the Staph Grant III Award, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded $0 and $195 thousand of revenue associated with the Staph Grant III Award, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Loan and Security Agreement and Convertible Notes
Loan and Security Agreement and Convertible Notes
Loan and Security Agreement with Hercules Capital, Inc.
On November 23, 2016, the Company and certain of its domestic subsidiaries (together with the Company, the “Borrowers”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), as a lender and agent for several banks and other financial institutions or entities from time to time party to the Loan Agreement (collectively, the “Lenders”) for a term loan of up to $75.0 million, subject to funding in multiple tranches (the “Term Loan”). The Term Loan will mature on December 1, 2020. The proceeds of the Term Loan will be used for general corporate purposes and coincided with the repayment of the outstanding debt financing arrangement with Oxford Finance LLC and Silicon Valley Bank.
The first tranche of $50.0 million was funded upon execution of the Loan Agreement on November 23, 2016. Under the terms of the Loan Agreement, the Borrowers may, but are not obligated to, request additional funds of up to $25.0 million which are available until June 30, 2018, subject to approval by Hercules’ Investment Committee. Pursuant to the terms of the third amendment to the Loan Agreement entered into on March 15, 2017, the Company paid Hercules $1.5 million for a portion of the backend fee. Pursuant to the terms of the fourth amendment to the Loan Agreement entered into on March 23, 2017 (the “Fourth Amendment”), the Company repaid Hercules, without repayment penalty, $20.0 million of the outstanding principal and unpaid interest accrued thereon on March 23, 2017.  The Fourth Amendment also provided for the following: (1) Hercules reduced the minimum amount of unrestricted cash that the Company must maintain under the Loan Agreement, and (2) the parties agreed to change the date by which the Company must achieve a fundraising milestone.
The Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties, including financial reporting obligations and significant limitations on dividends, indebtedness, liens (including a negative pledge on intellectual property and other assets), collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. Additionally, the Loan Agreement contains covenants requiring the Borrowers (i) to achieve certain fundraising requirements by certain dates and (ii) to maintain $20.0 million of unrestricted cash prior to achieving its corporate and fundraising milestones. The Company's public offering for net proceeds of $43.1 million satisfied the fundraising requirements and fundraising milestone.
Pursuant to the terms of the seventh amendment to the Loan Agreement entered into on November 6, 2017 (the “Seventh Amendment”), (i) the Company repaid Hercules, without repayment penalty, $10.0 million of the outstanding principal and unpaid interest accrued thereon on November 6, 2017, and (ii) Hercules agreed to reduce the minimum amount of unrestricted cash that the Company must maintain under the Loan Agreement from $20.0 million to $8.0 million.
On December 21, 2017, the Company paid off all obligations owing under, and terminated, the Loan Agreement. The secured interests were terminated in connection with the Company’s discharge of indebtedness thereunder.
In connection with the Loan Agreement, the Company issued Hercules a warrant, dated November 23, 2016 (the “Hercules Warrant”), to purchase up to 460,123 shares of common stock, at an initial exercise price of $4.89, subject to adjustment as provided in the Hercules Warrant. The Hercules Warrant is initially exercisable for 306,748 shares of common stock, and may automatically become exercisable for additional shares of common stock on such dates (if any) based upon the funding amounts of any additional tranches of the Term Loan that may be extended to the Borrowers. The Hercules Warrant will terminate, if not earlier exercised, on the earlier of November 23, 2023 and the closing of certain merger or other transactions in which the consideration is cash, stock of a publicly-traded acquirer or a combination thereof.
In connection with the extinguishment of the Loan Agreement on December 21, 2017, a loss of $4.3 million on the extinguishment of debt was recorded representing the difference between the reacquisition price of debt and the net carrying amount of the loan as of December 21, 2017.
2018 Chinese Yuan (“RMB”) Loan
In March 2018, the Company entered into a term loan in the aggregate principal amount of $1.6 million ("RMB 10.0 million") with the Bank of China and the Agricultural Bank of China, which is guaranteed by Levena Suzhou Biopharma, Co. Ltd. This one year bank facility was used for working capital purposes. The proceeds from the loan agreement are reflected as financing activities in the condensed consolidated statements of cash flows for the six months ended June 30, 2018. The outstanding balance is repayable from February 2018 to March 2019. The interest rate on this loan is 5%.
2017 Securities Purchase Agreement in Private Placement
On December 11, 2017, the Company entered into the December 2017 Securities Purchase Agreement with the December 2017 Purchasers. Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, the December 2017 Notes and the December 2017 Warrants.
At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser’s December 2017 Note that was equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of $2.26875, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.
Each December 2017 Warrant has an exercise price of $2.61 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.
On May 17, 2018, the December 2017 Purchasers converted in full the outstanding principal and accrued interest under the December 2017 Notes into 22,038,565 shares of the Company’s common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of $1.0 million in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of $44.3 million was recognized immediately at that date as interest expense.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $44.8 million based on an allocation of proceeds to the Warrants of approximately $12.7 million and a beneficial conversion feature of approximately $32.1 million, before issuance costs.
2018 Securities Purchase Agreement in Private Placement
On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, (1) the Notes in an aggregate principal amount of $120,500,000, and (2) the Warrants to purchase 8,591,794 shares of the common stock of the Company.
On June 13, 2018, the Company entered into an amendment (the “Amendment”) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of Common Stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of Common Stock.
At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser’s Note that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such Purchaser’s Note into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018.
Each Warrant has an exercise price of $8.77 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $21.6 million based on an allocation of proceeds to the Warrants of approximately $9.6 million and a beneficial conversion feature of approximately $12.0 million, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.
The fair value of the Notes was estimated using a lattice model with Level 2 inputs including the stock price volatility, risk-free interest rate, and debt yield. As of June 30, 2018, the estimated fair value of the Notes was approximately $40.6 million, compared to the carrying value of $16.2 million, as a result of unamortized debt discount. A substantial portion of the market value of the Company's debt in excess of the outstanding principal amount relates to the conversion premium on the Notes.
Convertible debt and unamortized discount balances are as follows (in thousands):
Face value of loan
$
37,849

Debt discount - warrant
(9,643
)
Debt discount - beneficial conversion feature
(12,005
)
Capitalized debt issuance costs
(98
)
Accretion of debt issuance costs and other
—

Accretion of debt discount
100

Balance at June 30, 2018
16,203


Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands) as of June 30, 2018:
Years Ending December 31,
 
2018
946

2019
1,892

2020
1,893

2021
1,892

2022
1,893

2023
38,795

Total future minimum payments
47,311

Unpaid interest
(9,462
)
Unamortized debt discount
(21,549
)
Unamortized capitalized debt issuance costs
(97
)
Total minimum payment
16,203

Current portion
—

Long-term debt
$
16,203
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans
 6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Stock Incentive Plans
Stock Incentive Plans
2009 Non-Employee Director Grants
In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved the reservation and issuance of 8,000 non-statutory stock options to the Company’s non-employee directors. The options vested on the one year anniversary of the vesting commencement date in October 2010, and are exercisable for up to ten years from the grant date. No further shares may be granted under this plan and, as of June 30, 2018, 3,200 options with a weighted-average exercise price of $1.12 were outstanding.
2009 Stock Incentive Plan
In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan. In July 2017, the Company’s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan (as amended and restated, the “Stock Plan”) to increase the number of shares of the Company’s common stock authorized to be issued pursuant to the Stock Plan to 11,260,000. Such shares of the Company’s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. Stock options are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement.
The following table summarizes stock option activity as of June 30, 2018 and the changes for the period then ended (dollar values in thousands, other than weighted-average exercise price):
 
Options
Outstanding
 
Weighted-
Average
Exercise Price
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2017
6,343,400

 
$
4.74

 
$
6,290

Options Granted
1,566,200

 
$
7.23

 
 

Options Canceled
(266,835
)
 
$
4.36

 
 

Options Exercised
(25,815
)
 
$
6.04

 
 

Outstanding at June 30, 2018
7,616,950

 
$
5.26

 
$
19,460


The aggregate intrinsic value of options exercised during the three months ended June 30, 2018 and 2017 was $4 thousand and $0, respectively.  The aggregate intrinsic value of options exercised during the six months ended June 30, 2018 and 2017 was $52 thousand and $0, respectively. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of employee stock options was estimated at the grant date using the following assumptions:
 
Six Months Ended June 30,
 
2018
 
2017
Weighted-average grant date fair value
$
7.39

 
$
5.20

Dividend yield
—
%
 
—
%
Volatility
81
%
 
64
%
Risk-free interest rate
2.52
%
 
2.16
%
Expected life of options
6.1 years

 
6.1 years


The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.
The total employee and director stock-based compensation recorded as operating expenses was $1.0 million and $1.2 million for the three months ended June 30, 2018 and 2017, respectively, and $2.2 million and $2.5 million for the six months ended June 30, 2018 and 2017, respectively.
The total unrecognized compensation cost related to unvested employee and director stock option grants as of June 30, 2018 was $10.8 million and the weighted average period over which these grants are expected to vest is 3.0 years.
The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $178 thousand and $8 thousand for the three months ended June 30, 2018 and 2017, respectively, and $275 thousand and $34 thousand for the six months ended June 30, 2018 and 2017, respectively.
Common Stock Reserved for Future Issuance
Common stock reserved for future issuance consists of the following at June 30, 2018:
Common stock warrants outstanding under the underwriters agreement
182,600

Common stock warrants outstanding under the loan and security agreement
65,892

Common stock warrants outstanding under the Hercules securities agreement
306,748

Common stock warrants outstanding under the convertible notes
14,819,872

Common stock warrants outstanding under private placements
4,153,620

Common stock options outstanding under the Non-Employee Director Plan
3,200

Authorized for future grant or issuance under the 2009 Stock Incentive Plan
10,756,281

Shares issuable upon the conversion of the 2018 Notes
5,397,325

Issuable under assignment agreement based upon achievement of certain milestones
80,000

 
35,765,538

 
2017 Equity Incentive Plan
In June 2017, the Company’s subsidiary, Scilex, adopted the Scilex 2017 Equity Incentive Plan, reserved 4.0 million shares of Scilex common stock and awarded 1.0 million options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. As of June 30, 2018, 0.5 million options were outstanding.
2015 Stock Option Plans
In May 2015, the Company’s subsidiary, TNK, adopted the TNK 2015 Stock Option Plan, reserved 10.0 million shares of TNK class A common stock and awarded 3.6 million options to certain Company personnel, directors and consultants under such plan. In November 2015, TNK awarded 0.5 million options to certain Company personnel.  Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.0 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.2 million shares were canceled. As of June 30, 2018, 0.9 million options were outstanding.
In May 2015, TNK granted a warrant to the Company’s CEO to purchase 9.5 million shares of TNK class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
In May 2015, the Company’s subsidiary, LA Cell, adopted the LA Cell 2015 Stock Option Plan reserved 10.0 million shares of LA Cell class A common stock and awarded 2.9 million options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.5 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.2 million shares were canceled. As of June 30, 2018, 0.3 million options were outstanding.
In May 2015, LA Cell granted a warrant to the Company’s CEO to purchase 9.5 million shares of LA Cell class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
In October 2015, the Company’s subsidiary, Concortis Biosystems, Corp. (“CBC”), adopted the CBC 2015 Stock Option Plan and reserved 10.0 million shares of CBC class A common stock and awarded 1.8 million options to certain Company personnel, directors and consultants under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.6 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.1 million shares were canceled. As of June 30, 2018, no options were outstanding.
In October 2015, CBC granted a warrant to the Company’s CEO to purchase 9.5 million shares of CBC class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.25 per share.  This warrant was canceled in its entirety effective August 29, 2017.
In October 2015, the Company’s subsidiary, Scintilla, adopted the Scintilla 2015 Stock Option Plan, reserved 10.0 million shares of Scintilla class A common stock and awarded 1.8 million options to certain Company personnel, directors and consultants under such plan.   Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 0.8 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 0.1 million shares were canceled. As of June 30, 2018, no options were outstanding.
In October 2015, Scintilla granted a warrant to the Company’s CEO to purchase 9.5 million shares of Scintilla class B common stock, which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
In October 2015, the Company’s subsidiary, Sorrento Biologics, Inc. (“Biologics”), adopted the Biologics 2015 Stock Option Plan, reserved 10.0 million shares of Biologics class A common stock and awarded 2.6 million options to certain Company personnel, directors and consultants under such plan.  Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 1.3 million shares were canceled. Effective May 16, 2018, options to purchase an aggregate of 75,000 shares were canceled. As of June 30, 2018, no options were outstanding.
In October 2015, Biologics granted a warrant to the Company’s CEO to purchase 9.5 million shares of Biologics class B common stock which have 10 to 1 voting rights.  Warrant shares totaling 4.0 million were exercisable evenly over forty months and the remaining warrant shares were exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. This warrant was canceled in its entirety effective August 29, 2017.
On August 29, 2017, the options and warrants were canceled in accordance with the terms of a settlement agreement with Wildcat Liquid Alpha, LLC and, as a result, unrecognized compensation expense of $281 thousand associated with these previously issued shares was accelerated and recognized upon cancellation.
The total director stock-based compensation recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics for the three months ended June 30, 2018 and 2017 was $0 and $54 thousand, respectively and was $0 and $96 thousand for the six months ended June 30, 2018 and 2017, respectively. No unrecognized stock-based compensation expense related to unvested director stock option and warrant grants remained for these entities as of June 30, 2018.  The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest.  Stock based compensation expense related to non-employee consultants recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics was $149 thousand for each of the three months ended June 30, 2018 and 2017, and was $358 thousand for each of the six months ended June 30, 2018 and 2017.
The weighted-average assumptions used in the Black-Scholes option and warrant pricing model used by TNK, LA Cell, CBC, Scintilla and Biologics to determine the fair value of stock option grants for directors and non-employee consultants for the six months ended June 30, 2018 were as follows: expected dividend yield – 0%, risk-free interest rate –2.42% to 2.48%, expected volatility – 65% to 77%, and expected term of 4.0 to 6.1 years.
2014 Stock Option Plan
In May 2014, the Company’s subsidiary, Ark Animal Health, Inc. (“Ark”), adopted the Ark 2014 Stock Option Plan and reserved and awarded 600,000 options to certain directors and consultants under such plan. Stock options granted under such plan typically vest a portion immediately upon grant and the remaining options over one year from the grant date and have a contractual term of ten years. Effective August 29, 2017, options to purchase an aggregate of 135,000 shares were canceled. As of June 30, 2018, 88,000 options were outstanding.
The total director and consultant stock-based compensation recorded as operating expenses by the Company for Ark was $0 for each of the three and six months ended June 30, 2018 and 2017. No unrecognized stock-based compensation expense remains related to stock option grants as of June 30, 2018.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Litigation
In the normal course of business, the Company may be named as a defendant in one or more lawsuits. The Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.
Derivative Action Litigation
On September 8, 2016, Yvonne Williams filed an action both derivatively and on behalf of a purported class of stockholders in the Court of Chancery of the State of Delaware (the "Court") against each of the members of the Henry Ji, William S. Marth, Kim D. Janda, Jaisim Shah, David H. Deming, and Douglas Ebersole (the “Prior Board”); George Ng, the Company’s Executive Vice President, Chief Administrative Officer, and Chief Legal Officer; Jeffrey Su, the Company’s Executive Vice President & Chief Operating Officer; and the Company as nominal defendant, alleging: (1) breach of fiduciary duty with respect to the formation of, and certain options and warrants issued by, certain of the Company’s subsidiaries to Dr. Ji and members of the Prior Board; (2) breach of fiduciary duty with respect to the Company’s prior announcement that it had entered into a voting agreement with Yuhan Corporation in connection with a transaction through which it purchased $10 million of shares of the Company's common stock and warrants (the “Williams Action”). On November 14, 2016, the Company filed motions to dismiss or in the alternative stay the Williams Action. George Ng and Jeffrey Su were dismissed as defendants by plaintiff during the briefing on the motions. The Court denied the motions on June 28, 2017.
On October 25, 2017, Yvonne Williams filed a Supplemental and Amended Class Action and Derivative Complaint which re-added George Ng as a defendant, added Eragon Ventures, LLC as a defendant, and added certain claims challenging transactions whereby Eragon Ventures, LLC agreed to purchase certain stock in the Company’s subsidiary, LA Cell, Inc. Following a mediation held on November 16, 2017, the parties agreed that day to a term sheet reflecting a settlement of the Williams Action, which agreement was memorialized in a Stipulation and Agreement of Settlement executed on December 22, 2017 and filed with the Court. The settlement consisted of non-monetary consideration, such as the cancellation of certain subsidiary shares of stock that were obtained by defendants pursuant to options previously exercised by defendants. The settlement and plaintiff’s counsel’s request for an award of attorneys’ fees were submitted to the Court for approval. On May 15, 2018, the Court held a hearing on the request for approval of the settlement and approved the settlement and awarded plaintiff’s counsel attorneys’ fees of $3.25 million. This case was dismissed with prejudice. The Company has caused the attorneys’ fees payment to be made, which payment was covered in large part, but not in whole, by insurance.
Immunomedics Litigation
On June 26, 2015, Immunomedics, Inc. (“Immunomedics”) filed a complaint in the United States District Court for the District of New Jersey (the “New Jersey Case”) against the Board of Directors of RWMC, Dr. Richard P. Junghans, Dr. Steven C. Katz, the Office of the Board of Advisors of Tufts University School of Medicine, and one or more individuals or entities to be identified later. This complaint (the "Initial Complaint") alleged, among other things: (1) breach of contract; (2) breach of covenant of good faith and fair dealing; (3) tortious interference with prospective economic gain; (4) tortious interference with contracts; (5) misappropriation; (6) conversion; (7) bailment; (8) negligence; (9) vicarious liability; and (10) patent infringement. Overall, the allegations in the Initial Complaint were generally directed to an alleged material transfer agreement dated December 2008 and Immunomedics’ alleged request for the return of certain alleged research material, as well as the alleged improper use and conversion of such research materials outside the scope of the material transfer agreement.
On October 22, 2015, Immunomedics filed an amended complaint (the “First Amended Complaint”), which, among other things, no longer named the Board of Directors of RWMC and The Office of the Board of Advisors of Tufts University School of Medicine as defendants. RWMC and Tufts Medical Center were added as new defendants. On January 14, 2016, Immunomedics filed a second amended complaint (the "Second Amended Complaint"), which, among other things, no longer named Tufts Medical Center as a defendant. In addition, the Second Amended Complaint contained allegations directed to two additional alleged material transfer agreements dated September 1993 and May 2010, respectively, and also added an allegation of unjust enrichment. The Second Amended Complaint also no longer asserted claims for (1) breach of covenant of good faith and fair dealing; (2) misappropriation; (3) bailment; (4) negligence; and (5) vicarious liability.
On October 12, 2016, Immunomedics filed a third amended complaint (the “Third Amended Complaint”), which added the Company, TNK, BDL and CARgenix as defendants. TNK is a subsidiary of the Company and purchased BDL and CARgenix in August 2015. The Third Amended Complaint included, among other things, allegations against the Company, TNK, BDL and CARgenix regarding (1) conversion; (2) tortious interference; and (3) unjust enrichment. On December 2, 2016, the Company, TNK, BDL, and CARgenix filed a motion to dismiss Immunomedics’s complaint against them for lack of personal jurisdiction. On January 25, 2017, the District of New Jersey granted this motion, and the Company, TNK, BDL and CARgenix were dismissed as defendants from the New Jersey Case. Under various agreements, TNK has certain indemnification obligations to RWMC, Dr. Richard P. Junghans and Dr. Steven C. Katz that may be implicated by the New Jersey Case. The New Jersey Case remains pending against defendants RWMC, Dr. Junghans, and Dr. Katz. A trial date has not yet been set.
On April 27, 2018, Immunomedics filed a complaint against the Company and TNK in San Diego Superior Court, Case No. 37-2018-00021006-CU-NP-CTL (the “San Diego Case”). The complaint includes, among other things, allegations against the Company and TNK regarding: (1) conversion; (2) tortious interference; and (3) inducing breach of contract. No trial date has yet been set in the San Diego Case.

The Company believes that the New Jersey Case and the San Diego Case are without merit, and will vigorously defend itself in the litigation. However, should Immunomedics prevail against the Company, RWMC or other defendants, certain patent rights optioned, owned and/or licensed by the Company could be at risk of invalidity or enforceability, or the litigation could otherwise adversely impact the Company’s ownership or other rights in certain intellectual property.  At this point in time, the Company is unable to determine whether any loss is probable or reasonably possible with respect to the New Jersey Case or the San Diego Case or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.

Cantor Fitzgerald & Co. Litigation

On May 25, 2018, Cantor Fitzgerald & Co. (“CF&Co.”) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, Index No. 652633/2018. The complaint includes, among other things, allegations against the Company for breach of contract arising out of a letter agreement whereby CF&Co. was to supply certain services to the Company in exchange for a fee (the “CF & Co. Litigation”). The Company has filed an Answer and Counterclaim for breach of contract against CF&Co claiming that CF&Co. did not perform under the letter agreement. The Company believes CF&Co.’s claims against the Company are without merit and will vigorously defend itself in the litigation. At this point in time, the Company is unable to determine whether any loss is probable or reasonably possible with respect to the CF&Co. Litigation or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q.
Operating Leases
The Company currently leases in San Diego, California approximately 130,575 square feet of corporate office and laboratory space and approximately 1,405 square feet of office space at a second location as well as approximately 36,400 square feet for offices, facilities for cGMP fill and finish and storage space.
The Company’s lease agreements in San Diego, as amended, for its corporate office and laboratory space, its second laboratory and office space and its third office space, expire in December 2026, November 2025 and September 2020, respectively.  The Company also leases 25,381 square feet of office and laboratory space in Suzhou, China, which lease expires in June 2018. The Company leases 2,312 square feet of office, laboratory, and storage space in Scotland, which lease expires in March 2021. The Company subleases in New York, New York for approximately 4,550 square feet of additional corporate office space. The sublease began in July of 2017 and expires in December 2020.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 6 Months Ended
Jun. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company's ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company's U.S. federal and state deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its Scilex subsidiary.
The Company’s income tax benefit of $2.3 million and $3.1 million reflect effective tax rates of 2.1% and 7.5% for the six months ended June 30, 2018 and 2017, respectively.
The difference between the expected statutory federal tax expense of 21% and the 2.1% effective tax expense for the six months ended June 30, 2018 was primarily attributable to the valuation allowance against most of the Company’s deferred tax assets.
The Company is subject to taxation in the U.S. and various state jurisdictions. The Company's tax years for 2007 and later are subject to examination by the U.S. and state tax authorities due to the existence of the NOL carryforwards.
As of June 30, 2018, the Company had approximately $3.9 million of unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance. As of June 30, 2017, the Company had approximately $2.8 million of unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance.
The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. For the six months ended June 30, 2018 and 2017, no expense was recorded related to interest and penalties. The Company believes that no significant amount of the liabilities for uncertain tax positions will expire within twelve months of June 30, 2018.
U.S. Tax Reform

The Tax Cuts and Jobs Act (“Tax Act”) was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, as well as making several other significant changes to the tax law, effective January 1, 2018. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), given the amount and complexity of the changes in tax law resulting from the Tax Act, the Company has not finalized the accounting for the income tax effects of the Tax Act. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to the Company's valuation allowance. The impact of the Tax Act may differ from this estimate, during the one-year measurement period due to, among other things, further refinement of the Company's calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Act. The Company is still analyzing certain aspects of the Tax Act and refining its calculations, which could potentially affect the analysis of the Company’s deferred tax assets and liabilities. Any subsequent adjustment is expected to be offset by a change in valuation allowance and have no impact on the Company’s financial position or results of operations.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Agreements
 6 Months Ended
Jun. 30, 2018
Related Party Transactions [Abstract]  
Related Party Agreements
Related Party Agreements
During the year ended December 31, 2015, the Company entered into a joint venture called NANTibody, with NantCell, a subsidiary of NantWorks.  In July 2015, the Company contributed its portion of the initial joint funding of $40.0 million to the NANTibody joint venture.  The Company and NantCell have also entered into a license agreement pursuant to which the Company received a $10.0 million upfront license payment and $100.0 million of vested NantCell common stock.  
During the year ended December 31, 2015, the Company entered into a joint venture called NantStem, with NantBioScience, a wholly-owned subsidiary of NantWorks.  In connection with negotiated changes to the structure of NantStem the Company issued a call option on shares of NantKwest that it owned to Cambridge, a related party to the Company and to NantBioScience.  In April 2015, the Company purchased 1.0 million shares of NantBioScience common stock for $10.0 million.  
In March 2016, the Company and Yuhan entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.  As of June 30, 2018, the carrying value of the Company’s investment in ImmuneOncia Therapeutics, LLC was approximately $4.5 million. During the three months ended June 30, 2016, Yuhan purchased $10.0 million of common stock and warrants.
On August 15, 2017, the transactions contemplated by that certain Contribution Agreement, dated June 12, 2017, by and among the Company, TNK and Celularity Inc. (“Celularity”), pursuant to which, among other things, the Company and TNK agreed to contribute certain intellectual property rights related to their proprietary chimeric antigen receptor constructs and related CARs to Celularity in exchange for shares of Celularity’s Series A Preferred Stock equal to 25% of Celularity’s outstanding shares of capital stock, calculated on a fully-diluted basis closed. Dr. Henry Ji, the Company's Chairman of the Board, President and Chief Executive Officer, Jaisim Shah, a member of the Company’s Board of Directors and David Deming, a member of the Company’s Board of Directors, were previously appointed as members of the board of directors of Celularity.
On November 8, 2016, the Company entered into the Scilex Purchase Agreement, pursuant to which the Company acquired from the Scilex Stockholders approximately 72% of the outstanding capital stock of Scilex. Dr. Henry Ji, the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and George K. Ng, the Company’s Vice President, Chief Administrative Officer and Chief Legal Officer, were stockholders of Scilex prior to the acquisition transaction.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loss Per Share
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Loss Per Share
Loss Per Share
For the three and six months ended June 30, 2018 and 2017, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.
The following table sets forth the reconciliation of basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 (in thousands):
 
Three Months Ended June 30,
Six Months Ended June 30,
 
2018
 
2017
2018
 
2017
Basic and Diluted


 


 
 
 
Net loss
$
(73,864
)
 
$
(14,187
)
$
(106,436
)
 
$
(37,251
)
 
 
 
 
 
 
 
Denominator for Basic and Diluted Loss Per Share
100,563

 
70,302

92,795

 
60,650

Basic and Diluted Loss Per Share
$
(0.73
)
 
$
(0.20
)
$
(1.15
)
 
$
(0.61
)

The potentially dilutive stock options that would have been excluded because the effect would have been antidilutive for the three months ended June 30, 2018 and 2017 were 2.5 million and 4.3 million, respectively. The potentially dilutive warrants that would have been excluded because the effect would have been antidilutive for the three months ended June 30, 2018 and 2017 were 1.1 million and 1.1 million, respectively.

The potentially dilutive stock options that would have been excluded because the effect would have been antidilutive for the six months ended June 30, 2018 and 2017 were 2.5 million and 4.3 million, respectively. The potentially dilutive warrants that would have been excluded because the effect would have been antidilutive for the six months ended June 30, 2018 and 2017 were 2.2 million and 2.2 million, respectively.
    
Basic and diluted per share amounts are computed independently in the consolidated statements of operations. Therefore, the sum of per share components may not equal the per share amounts presented.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
SofusaTM Acquisition
On July 2, 2018, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Kimberly-Clark Corporation (“KCC”); Kimberly-Clark Global Sales, LLC (“KCCGS”); and Kimberly-Clark Worldwide, Inc. (“KCCW” and together with KCC and KCCGS, “Kimberly-Clark”) pursuant to which, among other things, the Company acquired certain of Kimberly-Clark’s assets related to microneedle drug delivery systems, including the SofusaTM platform (the “Assets”), and assumed certain of Kimberly-Clark’s liabilities related to the Assets (the “Acquisition”).  The closing of the Acquisition (the “Closing”) occurred on July 2, 2018. At the Closing, the Company paid $10 million and agreed to pay additional consideration to Kimberly-Clark upon the achievement of certain regulatory and net sales milestones, as well as a percentage in the low double-digits of any non-royalty amounts received by the Company in connection with any license, sale or other grant of rights by the Company to develop or commercialize the Assets (all such additional consideration, the “Contingent Consideration”). Under the Purchase Agreement, the aggregate amount of the Contingent Consideration payable by the Company will not exceed $300.0 million.  The Company also agreed to pay Kimberly-Clark a low single-digit royalty on all net sales with respect to the first five products developed by the Company or its licensees that utilizes intellectual property included in the Assets.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Nature of Operations and Basis of Presentation
Nature of Operations and Basis of Presentation
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the “Company”), is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. The Company’s primary focus is to transform cancer into a treatable or chronically manageable disease. The Company also has programs assessing the use of its technologies and products in auto-immune, inflammatory, neurodegenerative, infectious diseases and pain indications with high unmet medical needs.
At its core, the Company is an antibody-centric company and leverages its proprietary G-MAB™ library to identify, screen and validate fully human antibodies against high impact oncogenic targets and mutations, immune modulators and intracellular targets. To date, the Company has screened over 100 validated targets and generated a number of fully human antibodies against these targets which are at various stages of preclinical development. These include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.
The Company’s vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as T-Cell Receptor (“TCR”)-like antibodies.  With LA Cell, Inc. (“LA Cell”), the Company’s joint venture with City of Hope, the Company’s objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, the Company has acquired and is assessing the regulatory and strategic path forward for its portfolio of late stage biosimilar/biobetter antibodies based on Erbitux®, Remicade®, Xolair®, and Simulect® as these may represent nearer term commercial opportunities.
With each of its programs, the Company aims to tailor its therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape. In addition, the Company’s objective is to focus on tumors that are resistant to current treatments and where the Company can design focused trials based on a genetic signature or biomarker to ensure patients have the best chance of a durable and significant response. The Company has several immuno-oncology programs that are in or near to entering the clinic.  These include cellular therapies, an oncolytic virus and a palliative care program targeted to treat intractable cancer pain.  Finally, as part of its global aim to provide a wide range of therapeutic products to meet underserved therapeutic markets, the Company has made investments and developed a separate pain focused franchise which the Company believes will serve to provide short term upside to its core thesis.
Through June 30, 2018, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure.  
The accompanying condensed consolidated financial statements include the accounts of the Company’s subsidiaries.  For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.  All intercompany balances and transactions have been eliminated in consolidation.
In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal, recurring and necessary for a fair statement of financial position, results of operations and cash flows. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2018 fiscal year, or any subsequent period.
Liquidity and Going Concern
Liquidity and Going Concern
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically operated with working capital deficiencies and expects to operate in the future with working capital deficiencies and has incurred substantial net losses for the years ended December 31, 2017 and 2016, and anticipates that it will continue to do so for the foreseeable future as it continues to identify and invest in advancing product candidates, as well as expanding corporate infrastructure. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.
As of June 30, 2018, the Company had $37.8 million of long term debt issued in a private placement (the "Private Placement") pursuant to a Securities Purchase Agreement, dated as of March 26, 2018, as amended by Amendment No. 1 thereto, dated as of June 13, 2018 (the “Securities Purchase Agreement”), among the Company and certain accredited investors (collectively, the “Purchasers”). Pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers (1) convertible promissory notes in an aggregate principal amount of $37,848,750 (the “Notes”), which accrue simple interest at a rate equal to 5.0% per annum and mature upon the earlier to occur of (a) June 13, 2023, and (b) the date of the closing of a change in control of the Company (the “Maturity Date”), and (2) warrants (the “Warrants”) to purchase an aggregate of 2,698,662 shares of the common stock of the Company.
Each of the Notes provide that, upon the occurrence of an event of default, the Purchasers thereof may, by written notice to the Company, declare all of the outstanding principal and interest under such Notes immediately due and payable. For purposes of the Notes, an event of default includes, among other things, one or more events that have, or could reasonably be expected to have, a material adverse effect on (i) the Company’s ability to comply with its obligations under the Securities Purchase Agreement, the Notes or the Warrants or the registration rights agreement entered into with the Purchasers in connection with the Private Placement, or (ii) the rights of the Purchasers under the Notes. The Company believes that it is not probable that the material adverse event clause under the Notes will be exercised.
The Company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company’s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. Although management believes such plans, if executed as planned, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company’s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that the condensed consolidated financial statements are issued.
If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable, the Company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates. The Company may also seek collaborators for one or more of its current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available.
The condensed consolidated financial statements do not reflect any adjustments that might be necessary if the Company is unable to continue as a going concern.
Universal Shelf Registration
In November 2014, the Company filed a universal shelf registration statement on Form S-3 (the “2014 Shelf Registration Statement”) with the SEC, which was declared effective by the SEC in December 2014. This 2014 Shelf Registration Statement provided the Company with the ability to offer up to $250 million of securities, including equity and other securities as described in the registration statement. Included in the 2014 shelf registration was a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that could be issued and sold under a sales agreement with MLV & Co. LLC (the “2014 ATM Facility”). During the twelve months ended December 31, 2017, the Company sold approximately $13.9 million in shares of common stock under the 2014 ATM Facility.
In April 2017, the Company completed a public offering of $47.5 million of shares of common stock pursuant to the 2014 Shelf Registration Statement for net proceeds of approximately $43.1 million.
In November 2017, the Company filed a universal shelf registration statement on Form S-3 (the “2017 Shelf Registration Statement”) with the SEC, which was declared effective by the SEC in December 2017. The 2014 Shelf Registration Statement expired on December 6, 2017 when the 2017 Shelf Registration was declared effective. The 2017 Shelf Registration Statement provides the Company with the ability to offer up to $350 million of securities, including equity and other securities as described in the registration statement. Included in the 2017 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $100.0 million of the Company’s common stock that may be issued and sold under a sales agreement with B. Riley FBR, Inc. (the “ATM Facility”). During the twelve months ended December 31, 2017, the Company sold approximately $0.9 million in shares of common stock under the ATM Facility. During the three and six month periods ended June 30, 2018, the Company sold approximately $9.6 million and $60.2 million in shares of common stock, respectively, under the ATM Facility. The Company can offer up to approximately $38.9 million of additional shares of common stock under the ATM Facility, subject to certain limitations.
Pursuant to the 2017 Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all.
2016 Private Investment in Public Entity Financing
On April 3, 2016, the Company entered into a Securities Purchase Agreement (the “ABG Purchase Agreement”) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, “Ally Bridge”), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers designated by Ally Bridge (collectively, the “ABG Purchasers”), in a private placement transaction (the “ABG Private Placement”), up to $50.0 million in shares of the Company’s common stock and warrants to purchase shares of common stock. Upon the closing of the ABG Private Placement, the Company issued to the ABG Purchasers (1) an aggregate of 9,009,005 shares (the “ABG Shares”) of common stock, and (2) warrants to purchase an aggregate of 2,702,700 shares of common stock (each, an “ABG Warrant”).   Each ABG Warrant has an exercise price of $8.50 per share, was immediately exercisable upon issuance, has a term of three years and is exercisable on a cash or cashless exercise basis. 
Under the terms of the ABG Purchase Agreement, the Company was obligated to prepare and file with the SEC, within 30 days of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of common stock issuable upon exercise of each ABG Warrant (the “ABG Warrant Shares”), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain “piggy-back” registration rights granted to the ABG Purchasers.
On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the “Additional Purchase Agreements”) with each of Beijing Shijilongxin Investment Co., Ltd. (“Beijing Shijilongxin”), FREJOY Investment Management Co., Ltd. (“Frejoy”) and Yuhan Corporation (“Yuhan”), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, 8,108,108 shares of common stock, and a warrant to purchase 1,176,471 shares of common stock, for an aggregate purchase price of $45.0 million; (2) to Frejoy, 8,108,108 shares of common stock, and a warrant to purchase 1,176,471 shares of common stock, for an aggregate purchase price of $45.0 million; and (3) to Yuhan, 1,801,802 shares of common stock, and a warrant to purchase 235,294 shares of common stock, for an aggregate purchase price of $10.0 million. The warrants issued pursuant to each of the Additional Purchase Agreements (collectively, the “Additional Warrants” and, together with each ABG Warrant, the “ABG Warrants”) have an exercise price of $8.50 per share, were immediately exercisable upon issuance, have a term of three years and are exercisable on a cash or cashless exercise basis.
Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan had the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor’s shares of common stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of common stock issuable upon exercise of such investor’s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain “piggy-back” registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan.
On May 2, 2016, the Company closed its private placement of common stock and warrants with Yuhan for gross proceeds of $10.0 million.  Yuhan purchased 1,801,802 shares of common stock at $5.55 per share and a warrant to purchase 235,294 shares of common stock.  The warrant is exercisable for three years at an exercise price of $8.50 per share.
Between May 31, 2016 and June 7, 2016, the Company closed on the remainder of the $150.0 million financing with the ABG Purchasers, Beijing Shijilongxin, and Frejoy. The ABG Purchasers led the financing and, together with Beijing Shijilongxin and Frejoy, collectively purchased 25,225,221 shares of common stock at $5.55 per share and warrants to purchase 5,055,642 shares of common stock for total cash consideration of $86.5 million and secured promissory notes (the “ABG Notes”) in an aggregate principal amount of $53.5 million.
On December 31, 2016, the Company entered into Warrant and Note Cancellation and Share Forfeiture Agreements (the “Cancellation and Forfeiture Agreements”) with certain investors (the “Investors”) that held an aggregate of 7,838,259 shares of common stock and certain of the Warrants granting the right to purchase an aggregate of 1,137,316 shares of common stock.  Pursuant to the Cancellation and Forfeiture Agreements, effective December 31, 2016, the ABG Warrants held by the Investors and the ABG Notes, of which $43.5 million was then outstanding, were cancelled and the shares of common stock held by the Investors were forfeited and returned to the Company.
2017 Private Investment in Public Entity Financing
On December 11, 2017, the Company entered into a Securities Purchase Agreement (the "December 2017 Securities Purchase Agreement") with certain accredited investors (collectively, the "December 2017 Purchasers"). Pursuant to the December 2017 Securities Purchase Agreement, on December 21, 2017, the Company issued and sold to the December 2017 Purchasers, in a private placement transaction, (1) convertible promissory notes in an aggregate principal amount of $50,000,000 (the "December 2017 Notes"), which accrued simple interest at a rate equal to 5.0% per annum and would mature upon the earlier to occur of (a) December 21, 2022, and (b) the date of the closing of a change in control of the Company (the "December 2017 Warrant Maturity Date"), and (2) warrants (the "December 2017 Warrants") to purchase an aggregate of 12,121,210 shares of the common stock of the Company.
At any time and from time to time before the December 2017 Warrant Maturity Date, each December 2017 Purchaser had the option to convert any portion of the outstanding principal amount of such December 2017 Purchaser’s December 2017 Note that was equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such December 2017 Purchaser's December 2017 Note into shares of common stock at a price per share of $2.26875, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the December 2017 Notes was to be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with the year ending December 31, 2018.
Each December 2017 Warrant has an exercise price of $2.61 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, became exercisable on June 20, 2018, has a term of five and a half years and is exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the December 2017 Warrants, in which case the December 2017 Warrants shall also be exercisable on a cashless exercise basis.
On May 17, 2018, the December 2017 Purchasers converted the full outstanding principal under the December 2017 Notes into 22,038,565 shares of the Company's common stock, and the Company paid to the December 2017 Purchasers cash in an aggregate amount of $1.0 million in accrued but unpaid interest. The unamortized discount remaining at the date of conversion of $44.3 million was recognized immediately at that date as interest expense.
See Note 3 for discussion of the Company’s policies for accounting for debt with detachable warrants. In connection with the issuance of the Notes and Warrants, the Company recorded a debt discount of approximately $44.8 million based on an allocation of proceeds to the Warrants of approximately $12.7 million and a beneficial conversion feature of approximately $32.1 million, before issuance costs. The Company accounts for the debt at amortized cost and amortizes the debt discount to interest expense using the effective interest method over the expected term of the Notes.
2018 Private Investment in Public Entity Financing
On March 26, 2018, the Company entered into the Securities Purchase Agreement with the Purchasers. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in the Private Placement, the Notes in an aggregate principal amount of $120,500,000 and Warrants to purchase an aggregate of 8,591,794 shares.
On June 13, 2018, the Company entered into an amendment (the “Amendment”) to the Securities Purchase Agreement. Under the terms of the Amendment, the Company and the Purchasers agreed that the aggregate principal amount of the Notes was reduced to $37,848,750 and that the aggregate number of shares of the common stock issuable upon exercise of the Warrants was reduced to 2,698,662, and also agreed to certain other adjustments to the threshold principal amount of the Notes required to remain outstanding in order for certain rights and obligations to apply to the Notes.

On June 13, 2018, pursuant to the Securities Purchase Agreement, the Company issued and sold to the Purchasers, in the Private Placement (1) Notes in an aggregate principal amount of $37,848,750, and (2) Warrants to purchase an aggregate of 2,698,662 shares of the common stock of the Company.
At any time and from time to time before the Maturity Date, each Purchaser shall have the option to convert any portion of the outstanding principal amount of such Purchaser’s Note that is equal to or greater than the lesser of: (1) $4,000,000, and (2) the then-outstanding principal amount of such Purchaser’s Note into shares of common stock at a price per share of $7.0125, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Accrued but unpaid interest on the Notes shall be paid in cash semi-annually in arrears on or prior to the 30th day of June and 31st day of December of each calendar year commencing with December 31, 2018. If a Purchaser elects to convert any of the principal amount of their Note, then all accrued but unpaid interest on such portion of the principal amount shall become due and payable in cash. The Notes contain restrictive covenants and event of default provisions that are customary for transactions of this type.
Each Warrant has an exercise price of $8.77 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, will become exercisable on December 11, 2018, has a term of five and a half years from the date of issuance and will be exercisable on a cash basis, unless there is not an effective registration statement covering the resale of the shares issuable upon exercise of the Warrants, in which case the Warrants shall also be exercisable on a cashless exercise basis.
If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:
•
Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
•
Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.
•
Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.
The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities.
Marketable Securities
Marketable Securities
Marketable securities are designated either as trading or available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations and are classified as short-term available-for-sale securities are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Marketable securities that are not trading securities and are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying condensed consolidated balance sheets.
Securities that are classified as trading are carried at fair value, with changes to fair value reported as a component of income. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method.
All of the Company’s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. For the three and six months ended June 30, 2018 and 2017, no other-than-temporary impairment charges were recorded. 
Grants and Accounts Receivable
Grants and Accounts Receivable
Grants receivable at June 30, 2018 and December 31, 2017 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a division of the National Institutes of Health (“NIH”). The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
Accounts receivable at June 30, 2018 and December 31, 2017 consist of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
Property and Equipment
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
Acquisitions and Intangibles
Acquisitions and Intangibles
The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
Goodwill and Other Long-Lived Assets
Goodwill and Other Long-Lived Assets
Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2017, noting no impairment. There have not been any triggering events indicating the potential for impairment through June 30, 2018.
The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through June 30, 2018.
Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities
Acquisition Consideration Payable - Gain or Loss on Contingent Liabilities
Acquisition consideration payable relates to the Company’s acquisition of businesses and various other assets and is recorded on the Company’s condensed consolidated balance sheets at fair value and is re-measured at each balance sheet date until such contingent liabilities have been settled, with changes in fair value recorded as gain or loss on contingent liabilities. The Company estimates the fair value of contingent consideration based on level 3 inputs primarily driven by the probability of achieving certain financing or operating related milestones.  
Debt with Detachable Warrants
Debt with Detachable Warrants
Debt with detachable warrants are evaluated for the classification of warrants as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are first allocated to the debt and the warrants at their relative estimated fair values. The portion of the proceeds so allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of embedded derivatives and beneficial conversion features, are allocated to the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds, to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815.
If the amount allocated to the convertible debt results in an effective per share conversion price less than the fair value of the Company’s common stock on the commitment date, the intrinsic value of this beneficial conversion feature is recorded as a discount to the convertible debt with a corresponding increase to additional paid in capital. The beneficial conversion feature discount is equal to the difference between the effective conversion price and the fair value of the Company’s common stock at the commitment date, unless limited by the remaining proceeds allocated to the debt.
Derivative Liability
Derivative Liability
Derivative liabilities are recorded on the Company’s condensed consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.  The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model.
Investments in Other Entities
Investments in Other Entities
The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company’s share of earnings or losses reported in loss on equity method investments.
The Company’s cost method investments are included in cost method investments on the condensed consolidated balance sheets.  The Company’s equity method investments are included in equity method investments on the condensed consolidated balance sheets.
All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: the magnitude of the impairment and length of time that the market value was below the cost basis; financial condition and business prospects of the investee; the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that the Company may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so.
Research and Development Costs and Collaborations
Research and Development Costs and Collaborations
All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
Acquired In-Process Research and Development Expense
Acquired In-Process Research and Development Expense
The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired in-process research and development related to the business combinations of Virttu Biologics Limited ("Virttu") and Scilex Pharmaceuticals Inc. ("Scilex"), for which certain products are under development and expected to be commercialized in the future, was capitalized and recorded within “Intangibles, net” on the accompanying condensed consolidated balance sheet. The Company intends to commence amortization of acquired in-process research and development upon commercialization of the related products. Capitalized in-process research and development will be reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.
Income Taxes
Income Taxes
The provisions of ASC Topic 740 “Income Taxes,” addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions.
The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of each of December 31, 2017 and June 30, 2018, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, an amount equal to its alternative minimum tax credits and state research and development tax credits for which there is no expiration and the deferred tax assets related to its investment in Scilex.
Revenue Recognition
The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
Concortis Biosystems Corporation (“Concortis”)
Contract manufacturing associated with sales of customized reagents for Concortis operations relate to providing synthetic expertise to customers’ synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers which are recognized upon the transfer of control, which is generally upon shipment given the short contract terms which are generally three months or less.
Materials and Supply Agreements
Revenues from the sale of materials associated with our research and development arrangements are recognized upon the transfer of control, which is generally, upon shipment. Outstanding performance obligations related to materials and supply agreements was $1.6 million as of June 30, 2018, and the Company expects to fulfill such obligations during the remainder of 2018.
Bioserv Corporation (“Bioserv”)
Contract manufacturing services associated with the Company's Bioserv operations related to finish and fill activities for drug products and reagents are recognized ratably over the contract term based on a time-based measure which reflects the transfer of services to the customer because the manufactured products are highly customized and do not have an alternative use to the Company
Sales and Services Revenues
Sales and services revenues are comprised of contract manufacturing associated with sales of customized reagents at Concortis Biosystems Corporation, materials and supply agreements, contract manufacturing services at BioServ Corporation, and the Company’s joint development agreement with Celularity Inc.
The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. The Company applied the practical expedient in ASC Topic 606-10-50-14 to the revenue contracts for our Concortis Biosystems Corporation sales and services and materials and supply agreements due to the short-term length of such contracts.
Revenue Recognition
The Company’s revenues are generated from various NIH grant awards, license fees, the sale of customized reagents and other materials, and the provision of contract manufacturing and other services. The Company does not have significant costs associated with costs to obtain contracts with its customers. Substantially all of the Company’s grants and accounts receivable result from contracts with customers.
Grant Revenues
The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
Royalty and License Revenues
License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period, with the exception of license agreements with no remaining performance obligations or undelivered obligations. The Company applies judgment in determining the timing of revenue recognition related to contracts that include multiple performance obligations. The total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. For goods or services for which observable standalone selling prices are not available, the Company develops an estimated standalone selling price of each performance obligation.
Stock-based Compensation
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC Topic 718 “Compensation – Stock Compensation,” which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date.
Comprehensive Income (Loss)
Comprehensive Income (Loss)
Comprehensive income (loss) is primarily comprised of net income (loss) and adjustments for the change in unrealized gains and losses on the Company’s investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its condensed consolidated statements of comprehensive income (loss).
Net Loss per Share
Net Loss per Share
Basic net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.
Segment Information
Segment Information
The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in one operating segment.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU No. 2014-09 was originally effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard for annual reporting periods beginning after December 15, 2017, and interim periods thereafter. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, January 1, 2018 under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of January 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends the guidance in GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. ASU No. 2016-01 is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU No. 2016-02 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU No. 2016-20 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-02 will have on its consolidated financial position, results of operations and cash flows. The Company's leases are discussed in Note 14. The Company currently expects to record right-of-use assets and lease liabilities with regard to its leases in the consolidated balance sheets.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The ASU also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. The ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application will be permitted for all organizations for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2016-13 will have on its consolidated financial position, results of operations and cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. The ASU requires that (1) debt extinguishment costs be classified as cash outflows for financing activities and provides additional classification guidance for the statement of cash flows, (2) the classification of cash receipts and payments that have aspects of more than one class of cash flows to be determined by applying specific guidance under generally accepted accounting principles, and (3) each separately identifiable source or use within the cash receipts and payments be classified on the basis of their nature in financing, investing or operating activities. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, to clarify the definition of a business to add guidance for evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Specifically, this ASU provides a screen to assist entities in determining when a set should not be considered a business, which screen provides that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar assets, the set is not a business. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350). This standard eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit’s fair value. This guidance is effective for interim and annual goodwill impairment tests in fiscal years beginning after December 15, 2019 with early adoption permitted. This guidance must be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of ASU No. 2017-04 will have on the Company’s consolidated financial position, results of operations or cash flows.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, to provide clarity and reduce both the diversity in practice and cost of complexity when applying the guidance. Specifically, the ASU provides additional modification conditions in determining whether or not modification accounting should be applied. The ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and improves the usefulness of information reported to financial statement users. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2018-07 will have on the Company’s consolidated financial position, results of operations or cash flows.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Schedule of Revenues by Category
The following table shows sales and service revenues disaggregated by product and services type for the three and six months ended June 30, 2018 and 2017 (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Concortis sales and services
895

 
883

 
2,358

 
2,071

Materials and supply agreements
—

 
85

 
861

 
403

Bioserv sales and services
1,231

 
1,187

 
3,367

 
2,037

Joint development agreement
1,667

 
—

 
3,333

 
—

 
$
3,793

 
$
2,155

 
$
9,919

 
$
4,511
Schedule of Remaining Performance Obligation
The following table includes Bioserv sales and services revenue expected to be recognized in the future related to performance obligations that are undelivered or partially delivered at the end of the reporting period and do not include contracts with original durations of one year or less (in thousands):
 
 
Remainder of 2018
 
2019
 
2020 and thereafter
Contract manufacturing services
 
$1,640
 
$648
 
$353
Components of Outstanding Securities
These outstanding securities consist of the following:
 
Quarters Ended June 30,
 
2018
 
2017
Outstanding options
7,616,950
 
4,375,276
Outstanding warrants
19,528,732
 
5,932,998
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis.  (in thousands):
 
Fair Value Measurements at June 30, 2018
 
Balance
 
Quoted Prices in Active Markets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
46,784

 
$
46,784

 
$
—

 
$
—

Marketable securities
$
323

 
$
266

 
$
—

 
$
57

Total assets
$
47,107

 
$
47,050

 
$
—

 
$
57

Liabilities:
 

 
 

 
 

 
 

Acquisition consideration payable
$
16,055

 
$
—

 
$
—

 
$
16,055

Total liabilities
$
16,055

 
$
—

 
$
—

 
$
16,055

 
 
 
 
 
 
 
 
 
Fair Value Measurements at December 31, 2017
 
Balance
 
Quoted Prices in Active Markets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
20,429

 
$
20,429

 
$
—

 
$
—

Marketable securities
$
441

 
$
356

 
$
—

 
$
85

Total assets
$
20,870

 
$
20,785

 
$
—

 
$
85

Liabilities:
 

 
 

 
 

 
 

Acquisition consideration payable
$
54,272

 
$
—

 
$
—

 
$
54,272

Total liabilities
$
54,272

 
$
—

 
$
—

 
$
54,272
Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
The following table includes a summary of the Company’s contingent consideration liabilities and acquisition consideration payables associated with acquisitions. The contingent consideration is measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018:
(in thousands)
 
Fair Value
Beginning Balance at December 31, 2017
 
54,272

Re-measurement of Fair Value
 
13,663

Payment of current year contingent consideration
 
(51,880
)
Ending Balance at June 30, 2018
 
$
16,055

The following table includes a summary of the warrant measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018 (in thousands):
 
Total
Beginning balance at December 31, 2017
$
84

Change in fair value of warrant
(27
)
Ending balance at June 30, 2018
$
57
Summary of Inputs and the Valuation Methodologies used for Fair Value Measurements Using Significant Unobservable Inputs Level 3
The following table includes a summary of the Company’s contingent and financing liabilities, related inputs used to determine fair value, and the valuation methodologies used for the fair value measurements using significant unobservable inputs (Level 3) at June 30, 2018: 
(in thousands)
 
Fair Value Measurements at June 30, 2018
 
Valuation Methodology
 
Significant Unobservable Input
 
Weighted Average
(range, if applicable)
Virttu Contingent Consideration (Non-current)
 
$
1,126

 
Multiple outcome
discounted cash flow
 
Discount Rate
Probability of Regulatory Milestone
 
12.21%
16%
Concortis Contingent Consideration
 
$
511

 
Multiple outcome
discounted cash flow
 
Discount Rate
Percent probabilities assigned to scenarios
 
19.20%
20%
Shanghai Three Contingent Consideration
 
$
1,782

 
Multiple outcome
discounted cash flow
 
Discount Rate
Percent probabilities assigned to scenarios
 
12.21%
50%
RWMC Contingent Consideration
 
$
2,673

 
Multiple outcome
discounted cash flow
 
Discount Rate,
Percent probabilities assigned to scenarios
 
12.21%
50%
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities (Tables)
 6 Months Ended
Jun. 30, 2018
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Securities
Marketable securities consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
Cost
 
Gross Unrealized Gains (Losses)
 
Gross Realized Gains (Losses)
 
Fair Value
Trading securities:
 

 
 

 
 

 
 

MedoveX common shares and warrants
$
750

 
$
(427
)
 
$
—

 
$
323

 
December 31, 2017
 
Cost
 
Gross Unrealized Gains (Losses)
 
Gross Realized Gains (Losses)
 
Fair Value
Trading securities:
 

 
 

 
 

 
 

MedoveX common shares and warrants
$
750

 
$
(309
)
 
$
—

 
$
441
Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
The following table includes a summary of the Company’s contingent consideration liabilities and acquisition consideration payables associated with acquisitions. The contingent consideration is measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018:
(in thousands)
 
Fair Value
Beginning Balance at December 31, 2017
 
54,272

Re-measurement of Fair Value
 
13,663

Payment of current year contingent consideration
 
(51,880
)
Ending Balance at June 30, 2018
 
$
16,055

The following table includes a summary of the warrant measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2018 (in thousands):
 
Total
Beginning balance at December 31, 2017
$
84

Change in fair value of warrant
(27
)
Ending balance at June 30, 2018
$
57
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Tables)
 6 Months Ended
Jun. 30, 2018
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment
Property and equipment consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
December 31, 2017
Furniture and fixtures
1,077

 
1,035

Office equipment
479

 
493

Machinery and lab equipment
22,573

 
19,868

Leasehold improvements
7,460

 
7,327

Construction in progress
292

 
—

 
31,881

 
28,723

Less accumulated depreciation
(11,988
)
 
(9,378
)
 
$
19,893

 
$
19,345
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets (Tables)
 6 Months Ended
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
A summary of the Company's goodwill as of June 30, 2018 is as follows (in thousands):
 
Total
Balance at December 31, 2017
$
38,298

    Goodwill Acquired from Acquisitions
—

Balance at June 30, 2018
$
38,298
Summary of Company's Identifiable Intangible Assets
A summary of the Company’s identifiable intangible assets as of June 30, 2018 and December 31, 2017 is as follows (in thousands):
 
June 30, 2018
 
Gross Carrying Amount
 
Accumulated Amortization
 
Intangibles, net
Customer relationships
$
1,585

 
$
1,236

 
$
349

Acquired technology
3,410

 
797

 
2,613

Acquired in-process research and development
37,660

 
—

 
37,660

Patent rights
32,720

 
3,652

 
29,068

Total intangible assets
$
75,375

 
$
5,685

 
$
69,690

 
December 31, 2017
 
Gross Carrying Amount
 
Accumulated Amortization
 
Intangibles, net
Customer relationships
$
1,585

 
$
1,091

 
$
494

Acquired technology
3,410

 
709

 
2,701

Acquired in-process research and development
37,660

 
—

 
37,660

Patent rights
32,720

 
2,562

 
30,158

Total intangible assets
$
75,375

 
$
4,362

 
$
71,013
Schedule of Estimated Future Amortization Expense Related to Intangible Assets
Estimated future amortization expense related to intangible assets at June 30, 2018 is as follows (in thousands):
Years Ending December 31,
 
Amount
2018
 
$
1,680

2019
 
3,845

2020
 
3,845

2021
 
5,040

2022
 
5,040

Thereafter
 
50,240

Total
 
$
69,690
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes (Tables)
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt and Unamortized Discount Balances
Convertible debt and unamortized discount balances are as follows (in thousands):
Face value of loan
$
37,849

Debt discount - warrant
(9,643
)
Debt discount - beneficial conversion feature
(12,005
)
Capitalized debt issuance costs
(98
)
Accretion of debt issuance costs and other
—

Accretion of debt discount
100

Balance at June 30, 2018
16,203
Future Minimum Payments under Amended and Restated Loan and Security Agreement
Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands) as of June 30, 2018:
Years Ending December 31,
 
2018
946

2019
1,892

2020
1,893

2021
1,892

2022
1,893

2023
38,795

Total future minimum payments
47,311

Unpaid interest
(9,462
)
Unamortized debt discount
(21,549
)
Unamortized capitalized debt issuance costs
(97
)
Total minimum payment
16,203

Current portion
—

Long-term debt
$
16,203
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans (Tables)
 6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Summary of Stock Option Activity
The following table summarizes stock option activity as of June 30, 2018 and the changes for the period then ended (dollar values in thousands, other than weighted-average exercise price):
 
Options
Outstanding
 
Weighted-
Average
Exercise Price
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2017
6,343,400

 
$
4.74

 
$
6,290

Options Granted
1,566,200

 
$
7.23

 
 

Options Canceled
(266,835
)
 
$
4.36

 
 

Options Exercised
(25,815
)
 
$
6.04

 
 

Outstanding at June 30, 2018
7,616,950

 
$
5.26

 
$
19,460
Fair Value of Employee Stock Options
The fair value of employee stock options was estimated at the grant date using the following assumptions:
 
Six Months Ended June 30,
 
2018
 
2017
Weighted-average grant date fair value
$
7.39

 
$
5.20

Dividend yield
—
%
 
—
%
Volatility
81
%
 
64
%
Risk-free interest rate
2.52
%
 
2.16
%
Expected life of options
6.1 years

 
6.1 years
Summary of Common Stock Reserved for Future Issuance
Common stock reserved for future issuance consists of the following at June 30, 2018:
Common stock warrants outstanding under the underwriters agreement
182,600

Common stock warrants outstanding under the loan and security agreement
65,892

Common stock warrants outstanding under the Hercules securities agreement
306,748

Common stock warrants outstanding under the convertible notes
14,819,872

Common stock warrants outstanding under private placements
4,153,620

Common stock options outstanding under the Non-Employee Director Plan
3,200

Authorized for future grant or issuance under the 2009 Stock Incentive Plan
10,756,281

Shares issuable upon the conversion of the 2018 Notes
5,397,325

Issuable under assignment agreement based upon achievement of certain milestones
80,000

 
35,765,538
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loss Per Share (Tables)
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings per Share
The following table sets forth the reconciliation of basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 (in thousands):
 
Three Months Ended June 30,
Six Months Ended June 30,
 
2018
 
2017
2018
 
2017
Basic and Diluted


 


 
 
 
Net loss
$
(73,864
)
 
$
(14,187
)
$
(106,436
)
 
$
(37,251
)
 
 
 
 
 
 
 
Denominator for Basic and Diluted Loss Per Share
100,563

 
70,302

92,795

 
60,650

Basic and Diluted Loss Per Share
$
(0.73
)
 
$
(0.20
)
$
(1.15
)
 
$
(0.61
)
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations and Business Activities (Details)
 6 Months Ended
Jun. 30, 2018
target
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of screened and validated targets 100
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern (Details) - USD ($)
Jun. 30, 2018
Jun. 13, 2018
Mar. 26, 2018
Dec. 31, 2017
Dec. 21, 2017
Convertible Debt [Member]          
Liquidity And Going Concern [Line Items]          
Long-term debt $ 16,203,000     $ 16,203,000  
Face value of loan 37,849,000        
2017 Warrants [Member]          
Liquidity And Going Concern [Line Items]          
Number of securities called by warrants   2,698,662      
Promissory Note, Due 2023 [Member] | Convertible Debt [Member]          
Liquidity And Going Concern [Line Items]          
Face value of loan   $ 37,848,750      
Interest rate   5.00%      
Promissory Notes, Due 2022 [Member] | Convertible Debt [Member]          
Liquidity And Going Concern [Line Items]          
Face value of loan         $ 50,000,000
Interest rate         5.00%
March 2018 Notes [Member] | Convertible Debt [Member]          
Liquidity And Going Concern [Line Items]          
Face value of loan   $ 37,848,750 $ 120,500,000    
Loan and Security Agreement [Member]          
Liquidity And Going Concern [Line Items]          
Long-term debt $ 37,800,000        
Private Placement [Member] | 2017 Warrants [Member]          
Liquidity And Going Concern [Line Items]          
Number of securities called by warrants         12,121,210
Private Placement [Member] | March 2018 Warrant [Member]          
Liquidity And Going Concern [Line Items]          
Number of securities called by warrants   2,698,662 8,591,794    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern - Universal Shelf Registration (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2017
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Nov. 30, 2017
Dec. 31, 2014
Liquidity And Going Concern [Line Items]              
Maximum amount of equity and other securities authorized to offer             $ 250,000,000
Remaining amount of equity and other securities authorized to offer             $ 50,000,000
Issuance of common stock for public placement and investments, net     $ 58,273,000 $ 45,598,000      
Proceeds from issuance of common stock, net of issuance costs     58,273,000 $ 45,628,000      
November 2014 Registration [Member]              
Liquidity And Going Concern [Line Items]              
Common stock issued and sold under sales agreement         $ 13,900,000    
November 2017 Registration [Member]              
Liquidity And Going Concern [Line Items]              
Remaining amount of equity and other securities authorized to offer           $ 350,000,000  
Common Stock [Member]              
Liquidity And Going Concern [Line Items]              
Issuance of common stock for public placement and investments, net $ 47,500,000            
Proceeds from issuance of common stock, net of issuance costs $ 43,100,000            
ATM Facility [Member] | November 2017 Registration [Member]              
Liquidity And Going Concern [Line Items]              
Maximum aggregate offering amount authorized           $ 100,000,000.0  
Value of additional shares of common stock authorized   $ 38,900,000 38,900,000        
ATM Facility [Member] | Common Stock [Member] | November 2017 Registration [Member]              
Liquidity And Going Concern [Line Items]              
Issuance of common stock for public placement and investments, net   $ 9,600,000 $ 60,200,000   $ 900,000    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern - 2016 Private Investment in Public Entity Financing (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Dec. 31, 2016
Jun. 07, 2016
May 02, 2016
Apr. 03, 2016
Jun. 30, 2018
Jun. 30, 2017
Liquidity And Going Concern [Line Items]            
Aggregate purchase price of common stock & warrants         $ 58,273 $ 45,598
ABG Purchasers, Beijing Shijilongxin, and Frejoy [Member]            
Liquidity And Going Concern [Line Items]            
Issuance of common stock for public placement and investments, net (shares)   25,225,221        
Warrants to purchase common stock   5,055,642        
Gross proceeds of common stock and warrants   $ 86,500        
Common stock price per share   $ 5.55        
Closed consideration of common stock and warrants   $ 150,000        
Aggregate principal amount   $ 53,500        
Private Placement [Member] | ABG Purchase Agreement [Member]            
Liquidity And Going Concern [Line Items]            
Aggregate purchase price of common stock & warrants       $ 50,000    
Issuance of common stock for public placement and investments, net (shares)       9,009,005    
Warrants to purchase common stock       2,702,700    
Warrant exercise price per share       $ 8.50    
Warrant exercisable period       3 years    
Private Placement [Member] | Maximum [Member] | ABG Purchase Agreement [Member]            
Liquidity And Going Concern [Line Items]            
Issuance of securities for resale, period       30 days    
Beijing Shijilongxin Investment Co Ltd [Member] | Private Placement [Member] | Additional Purchase Agreements [Member]            
Liquidity And Going Concern [Line Items]            
Aggregate purchase price of common stock & warrants       $ 45,000    
Issuance of common stock for public placement and investments, net (shares)       8,108,108    
Warrants to purchase common stock       1,176,471    
Warrant exercise price per share       $ 8.50    
Warrant exercisable period       3 years    
FREJOY Investment Management Co Ltd [Member] | Private Placement [Member] | Additional Purchase Agreements [Member]            
Liquidity And Going Concern [Line Items]            
Aggregate purchase price of common stock & warrants       $ 45,000    
Issuance of common stock for public placement and investments, net (shares)       8,108,108    
Warrants to purchase common stock       1,176,471    
Warrant exercise price per share       $ 8.50    
Warrant exercisable period       3 years    
Yuhan Corporation [Member] | Private Placement [Member]            
Liquidity And Going Concern [Line Items]            
Issuance of common stock for public placement and investments, net (shares)     1,801,802      
Warrants to purchase common stock     235,294      
Warrant exercise price per share     $ 8.50      
Warrant exercisable period     3 years      
Gross proceeds of common stock and warrants     $ 10,000      
Common stock price per share     $ 5.55      
Yuhan Corporation [Member] | Private Placement [Member] | Additional Purchase Agreements [Member]            
Liquidity And Going Concern [Line Items]            
Aggregate purchase price of common stock & warrants       $ 10,000    
Issuance of common stock for public placement and investments, net (shares)       1,801,802    
Warrants to purchase common stock       235,294    
Investor [Member] | Cancellation and Forfeiture Agreements [Member]            
Liquidity And Going Concern [Line Items]            
Issuance of common stock for public placement and investments, net (shares) 7,838,259          
Common stock shares forfeited 1,137,316          
Investor [Member] | Cancellation and Forfeiture Agreements [Member] | Secured Promissory Notes [Member]            
Liquidity And Going Concern [Line Items]            
Outstanding balance of promissory note forfeited $ 43,500          
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern - 2017 Private Investment in Public Entity Financing (Details) - USD ($)
 3 Months Ended 6 Months Ended
May 17, 2018
Dec. 21, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 13, 2018
Dec. 31, 2017
Debt Instrument [Line Items]                
Interest paid         $ 1,128,000 $ 2,044,000    
Interest expense     $ 45,009,000 $ 1,200,000 46,061,000 $ 2,809,000    
Debt discount   $ 44,800,000           $ 44,800,000
Debt discount allocated to warrant               12,700,000
Debt beneficial conversion feature   $ 32,100,000            
2017 Warrants [Member]                
Debt Instrument [Line Items]                
Number of securities called by warrants             2,698,662  
2017 Warrants [Member] | Private Placement [Member]                
Debt Instrument [Line Items]                
Number of securities called by warrants   12,121,210            
Warrant exercise price per share   $ 2.61            
Term of warrants   5 years 6 months            
Convertible Debt [Member]                
Debt Instrument [Line Items]                
Face value of loan amount     37,849,000   37,849,000      
Debt discount               $ 21,549,000
Debt discount allocated to warrant     $ 9,643,000   9,643,000      
Debt beneficial conversion feature         $ 12,005,000      
Promissory Notes, Due 2022 [Member] | Convertible Debt [Member]                
Debt Instrument [Line Items]                
Face value of loan amount   $ 50,000,000            
Interest rate   5.00%            
If converted - outstanding principal threshold amount   $ 4,000,000            
Debt conversion price $ 2.26875              
Interest paid $ 1,000,000              
Interest expense $ 44,300,000              
Promissory Notes, Due 2022 [Member] | Convertible Debt [Member] | Private Placement [Member]                
Debt Instrument [Line Items]                
If converted - outstanding principal threshold amount   $ 4,000,000            
Debt conversion price   $ 2.26875            
Common Stock [Member]                
Debt Instrument [Line Items]                
Issuance of common stock for conversion of notes payable (shares) 22,038,565       22,038,565      
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern - 2018 Private Investment in Public Entity Financing (Details) - USD ($)
Mar. 26, 2018
Jun. 30, 2018
Jun. 13, 2018
Convertible Debt [Member]      
Debt Instrument [Line Items]      
Face value of loan   $ 37,849,000  
March 2018 Notes [Member] | Convertible Debt [Member]      
Debt Instrument [Line Items]      
Face value of loan $ 120,500,000   $ 37,848,750
If converted - outstanding principal threshold amount $ 4,000,000    
Debt conversion price $ 7.0125    
Private Placement [Member] | March 2018 Warrant [Member]      
Debt Instrument [Line Items]      
Number of securities called by warrants 8,591,794   2,698,662
Warrant exercise price per share $ 8.77    
Term of warrants 5 years 6 months    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies - Narrative (Details)
 3 Months Ended 6 Months Ended
Sep. 26, 2017
USD ($)
Sep. 01, 2016
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
segment
Jun. 30, 2017
USD ($)
Significant Accounting Policies [Line Items]              
Other-than-temporary impairment charges     $ 0   $ 0    
Goodwill impairment     0 $ 0 $ 0 $ 0 $ 0
Impairment losses of long-lived assets           $ 0  
Number of operating segments | segment           1  
Minimum [Member]              
Significant Accounting Policies [Line Items]              
Estimated useful life of fixed asset           3 years  
Maximum [Member]              
Significant Accounting Policies [Line Items]              
Estimated useful life of fixed asset           5 years  
Grants Receivable [Member]              
Significant Accounting Policies [Line Items]              
Allowance for doubtful accounts     0 0   $ 0  
Trade Accounts Receivable [Member]              
Significant Accounting Policies [Line Items]              
Allowance for doubtful accounts     20,000 20,000   20,000  
Bioserve sale and services [Member]              
Significant Accounting Policies [Line Items]              
Unbilled contracts receivable     400,000 500,000   400,000  
Upfront payment received for contract development services     $ 300,000 $ 400,000   $ 300,000  
Joint development sale and service [Member]              
Significant Accounting Policies [Line Items]              
Upfront payment received from customers $ 5,000,000            
ImmuneOncia Therapeutics, LLC [Member] | Royalty and license              
Significant Accounting Policies [Line Items]              
Upfront payment received from customers   $ 9,600,000          
Estimated license contract term based on expected life of patent           20 years  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies - Schedule of Revenues by Category (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Disaggregation of Revenue [Line Items]          
Total revenues $ 3,913 $ 4,665 $ 10,159 $ 9,539  
Concortis sales and services [Member]          
Disaggregation of Revenue [Line Items]          
Total revenues 895 883 2,358 2,071  
Materials and supply [Member]          
Disaggregation of Revenue [Line Items]          
Total revenues 0 85 861 403  
Bioserve sale and services [Member]          
Disaggregation of Revenue [Line Items]          
Total revenues 1,231 1,187 3,367 2,037  
Joint development sale and service [Member]          
Disaggregation of Revenue [Line Items]          
Total revenues 1,667 0 3,333 0 $ 1,700
Product And Service [Member]          
Disaggregation of Revenue [Line Items]          
Total revenues $ 3,793 $ 2,155 $ 9,919 $ 4,511  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies - Schedule of Remaining Performance Obligations (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Bioserve sale and services [Member]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation $ 2,600 $ 3,000
ImmuneOncia Therapeutics, LLC [Member] | Royalty And License [Member]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation 8,700 $ 9,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01 | Bioserve sale and services [Member]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation $ 1,640  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 6 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Bioserve sale and services [Member]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation $ 648  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil) | Bioserve sale and services [Member]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation $ 353  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil) | ImmuneOncia Therapeutics, LLC [Member] | Royalty And License [Member]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation $ 500  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies - Schedule of Outstanding Securities (Details) - shares
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Employee Stock Option [Member]    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Weighted average number of securities outstanding 7,616,950 4,375,276
Warrant [Member]    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Weighted average number of securities outstanding 19,528,732 5,932,998
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies - Narrative - Revenue Recognition (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 26, 2017
Sep. 01, 2016
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Current portion of deferred revenue     $ 1,878   $ 1,878   $ 3,864
Revenue recognized during period     3,913 $ 4,665 10,159 $ 9,539  
Royalty and license              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Revenue recognized during period     120 2,416 240 4,833  
Materials and supply [Member]              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Current portion of deferred revenue     1,600   1,600    
Revenue recognized during period     0 85 861 403  
Bioserve sale and services [Member]              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Remaining performance obligation     2,600   2,600   3,000
Revenue recognized during period     1,231 1,187 3,367 2,037  
Unbilled contracts receivable     400   400   500
Deferred revenue     300   300   400
Remaining performance obligation expected to be recognized in the next twelve months     2,100   2,100    
Joint development sale and service [Member]              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Proceeds from Customers $ 5,000            
Remaining performance obligation $ 5,000            
Revenue recognized during period     1,667 $ 0 3,333 $ 0 1,700
ImmuneOncia Therapeutics, LLC [Member] | Royalty and license              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Proceeds from Customers   $ 9,600          
Remaining performance obligation     8,700   $ 8,700   9,000
Estimated license contract term based on expected life of patent         20 years    
Nant Cell [Member] | Royalty and license              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]              
Remaining performance obligation     $ 110,000   $ 110,000   $ 110,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions - Acquisition of Virttu Biologics Limited (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 27, 2018
USD ($)
shares
Apr. 27, 2017
USD ($)
day
$ / shares
shares
Mar. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]            
Issuance of common stock related to acquisitions settlement         $ 1,673  
Acquisition consideration payable       $ 14,929   $ 53,209
Goodwill       38,298   38,298
Virttu Biologics Limited [Member]            
Business Acquisition [Line Items]            
Issuance of common stock related to acquisitions settlement       11,308    
TNK Therapeutics, Inc. [Member] | Virttu Biologics Limited [Member]            
Business Acquisition [Line Items]            
Business acquisition, percentage of voting interests acquired   100.00%        
Purchase consideration   $ 25,000        
Business acquisition, common stock consideration   $ 2,200        
Issuance of common stock upon acquisition, shares | shares   797,081        
Cash consideration to equity holders   $ 557        
Percentage of base consideration due at closing   20.00%        
Percentage of adjusted base consideration payable in cash   80.00%        
Escrow shares percentage   20.00%        
Share price of common stock purchased | $ / shares   $ 5.55        
Contingent liability in a business combination $ 9,900     $ 9,900    
Issuance of common stock related to acquisitions settlement (in shares) | shares 1,795,011          
Issuance of common stock related to acquisitions settlement $ 11,300          
Acquisition consideration payable   $ 12,800        
Contingent consideration   1,000        
Identifiable assets acquired   16,000        
Deferred tax liabilities   800        
Goodwill   1,400        
TNK Therapeutics, Inc. [Member] | Virttu Biologics Limited [Member] | General and administrative expenses [Member]            
Business Acquisition [Line Items]            
Business acquisition costs     $ 0     $ 900
In Process Research and Development [Member] | TNK Therapeutics, Inc. [Member] | Virttu Biologics Limited [Member]            
Business Acquisition [Line Items]            
Intangible assets acquired   15,400        
Minimum [Member] | TNK Therapeutics, Inc. [Member] | Virttu Biologics Limited [Member]            
Business Acquisition [Line Items]            
Financial support for equity interest per business combination agreement   50,000        
Regulatory Approval Consideration [Member] | TNK Therapeutics, Inc. [Member] | Virttu Biologics Limited [Member]            
Business Acquisition [Line Items]            
Business combination additional contingent consideration payable   $ 10,000        
Number of business days to satisfy 50% of regulatory approval contingent consideration payment | day   45        
Contingent consideration payment option two, share value less any cash payment   $ 5,000        
Contingent consideration option two calculation in put, 30 days VWAP   30 days        
Regulatory Approval Consideration [Member] | Maximum [Member] | TNK Therapeutics, Inc. [Member] | Virttu Biologics Limited [Member]            
Business Acquisition [Line Items]            
Contingent consideration payment option one, maximum cash payment   $ 5,000        
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions - Acquisition of Scilex Pharmaceuticals Inc. (Details) - USD ($)
$ in Millions
Feb. 28, 2018
Nov. 08, 2016
Scilex Pharmaceuticals, Inc [Member]    
Business Acquisition [Line Items]    
Business acquisition, percentage of voting interests acquired   72.00%
Itochu Chemical Frontier Corporation [Member]    
Business Acquisition [Line Items]    
Noncontrolling interest ownership percentage   23.00%
FDA Approval For Commercialization [Member] | Scilex Pharmaceuticals, Inc [Member]    
Business Acquisition [Line Items]    
Purchase consideration $ 38.2  
Issuance of common stock upon acquisition, shares 1,381,346  
Amount of stock issued in acquisition $ 13.7  
Cash consideration to equity holders 24.5  
Change in fair value for contingent consideration upon settlement 6.0  
FDA Approval For Commercialization [Member] | Scilex Pharmaceuticals, Inc [Member] | Loans Receivable [Member]    
Business Acquisition [Line Items]    
Bridge loan issued $ 20.0  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions - Acquired In-process Research and Development of BDL and Cargenix (Details) - B D L Products Inc [Member] - Stock Purchase Agreement [Member] - USD ($)
 1 Months Ended
Mar. 19, 2018
Aug. 31, 2015
Business Acquisition [Line Items]    
Cash payment   $ 100.00
Minimum qualified financing   $ 50,000,000.0
Aggregate common stock to be issued, shares   309,916
Issuance of common stock upon acquisition, shares 309,916  
Common Class A [Member]    
Business Acquisition [Line Items]    
Common stock to be issued, value   $ 6,000,000
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure $ 47,107 $ 20,870
Fair value liabilities disclosure 16,055 54,272
Cash and Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 46,784 20,429
Marketable securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 323 441
Acquisition consideration payable - Current [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value liabilities disclosure 16,055 54,272
Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 47,050 20,785
Fair value liabilities disclosure 0 0
Quoted Prices in Active Markets (Level 1) [Member] | Cash and Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 46,784 20,429
Quoted Prices in Active Markets (Level 1) [Member] | Marketable securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 266 356
Quoted Prices in Active Markets (Level 1) [Member] | Acquisition consideration payable - Current [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value liabilities disclosure 0 0
Significant Other Observable Inputs (Level 2) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 0 0
Fair value liabilities disclosure 0 0
Significant Other Observable Inputs (Level 2) [Member] | Cash and Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 0 0
Significant Other Observable Inputs (Level 2) [Member] | Marketable securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 0 0
Significant Other Observable Inputs (Level 2) [Member] | Acquisition consideration payable - Current [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value liabilities disclosure 0 0
Significant Unobservable Inputs (Level 3) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 57 85
Fair value liabilities disclosure 16,055 54,272
Significant Unobservable Inputs (Level 3) [Member] | Cash and Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 0 0
Significant Unobservable Inputs (Level 3) [Member] | Marketable securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value assets disclosure 57 85
Significant Unobservable Inputs (Level 3) [Member] | Acquisition consideration payable - Current [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value liabilities disclosure $ 16,055 $ 54,272
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Summary of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) - Contingent Consideration Liabilities [Member]
$ in Thousands
 6 Months Ended
Jun. 30, 2018
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance $ 54,272
Re-measurement of Fair Value 13,663
Payment of current year contingent consideration (51,880)
Ending balance $ 16,055
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Summary of Inputs and the Valuation Methodologies used for Fair Value Measurements Using Significant Unobservable Inputs Level 3 (Details) - Contingent liabilities [Member] - Significant Unobservable Inputs (Level 3) [Member]
$ in Thousands
Jun. 30, 2018
USD ($)
Virttu Biologics Limited [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Fair Value $ 1,126
Concortis [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Fair Value 511
Shanghai Three [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Fair Value 1,782
RWMC [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Fair Value $ 2,673
Discount Rate | Virttu Biologics Limited [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.1221
Discount Rate | Concortis [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.1920
Discount Rate | Shanghai Three [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.1221
Discount Rate | RWMC [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.1221
Default Rate | Virttu Biologics Limited [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.16
Default Rate | Concortis [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.20
Default Rate | Shanghai Three [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.50
Default Rate | RWMC [Member] | Weighted Average [Member]  
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)  
Discount Rate 0.50
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Narrative (Details) - Milestones achievement [Member]
$ in Millions
 6 Months Ended
Jun. 30, 2018
USD ($)
Scilex Pharmaceuticals, Inc [Member]  
Business Acquisition [Line Items]  
Payments for previous acquisition $ 38.2
B D L Products Inc [Member]  
Business Acquisition [Line Items]  
Payments for previous acquisition 2.3
Virttu Biologics Limited [Member]  
Business Acquisition [Line Items]  
Payments for previous acquisition 11.3
Contingent liability in a business combination $ 9.9
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 237,008 $ 237,008
MedoveX common shares and warrants [Member]    
Debt Securities, Available-for-sale [Line Items]    
Trading securities, Cost 750  
Gross Unrealized Gains (Losses) (427)  
Gross Realized Gains (Losses) 0  
Fair Value $ 323  
Trading Securities, Cost   750
Gross Unrealized Gains (Losses)   (309)
Gross Realized Gains (Losses)   0
Fair Value   $ 441
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities - Additional Information (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Aug. 05, 2016
USD ($)
unit
$ / shares
shares
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Debt and Equity Securities, FV-NI [Line Items]          
Loss on trading securities   $ 121 $ 609 $ 118 $ 450
MedoveX common shares and warrants [Member]          
Debt and Equity Securities, FV-NI [Line Items]          
Loss on trading securities   $ 100 $ (600) $ 100 $ 500
MedoveX [Member] | Unit Purchase Agreement [Member]          
Debt and Equity Securities, FV-NI [Line Items]          
Number of units purchased | unit 3        
Payment for purchase of units $ 750        
Aggregate purchase price of common stock warrants $ 250        
Common stock agreed to issue and sell | shares 208,333        
Warrants to purchase common stock | shares 104,167        
Warrant exercise price per share | $ / shares $ 1.52        
Warrant exercisable period 5 years        
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities - Summary of Warrant Measured at Fair Value Using Significant Unobservable Inputs (Details) - Warrant [Member]
$ in Thousands
 6 Months Ended
Jun. 30, 2018
USD ($)
Class of Warrant or Right [Line Items]  
Beginning balance $ 84
Change in fair value of warrant (27)
Ending balance $ 57
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]    
Property and equipment, total $ 31,881 $ 28,723
Less accumulated depreciation (11,988) (9,378)
Property, Plant and Equipment, Net 19,893 19,345
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total 1,077 1,035
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total 479 493
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total 22,573 19,868
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total 7,460 7,327
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total $ 292 $ 0
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 1.3 $ 1.1 $ 2.6 $ 1.9
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cost Method Investments - Additional Information (Details) - USD ($)
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Investments [Abstract]    
Cost method investments $ 237,008,000 $ 237,008,000
Cost method investments, impairment losses $ 0  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Method Investments - NANTibody (Details)
shares in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 02, 2017
USD ($)
May 31, 2015
USD ($)
joint_venture
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2013
USD ($)
shares
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jul. 31, 2015
USD ($)
board_member
Apr. 30, 2015
USD ($)
Schedule of Equity Method Investments [Line Items]                            
Number of joint ventures to be funded | joint_venture   2                        
Equity method investments     $ 29,972,000         $ 29,972,000     $ 32,999,000      
Income (loss) on equity method investments     (2,105,000)     $ (1,102,000)   (3,027,000) $ (2,050,000)          
NANTibody [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Initial joint funding                           $ 100,000,000
Equity method investment ownership percentage                     40.00%     40.00%
Initial joint funding contributed                         $ 40,000,000  
Number of board members | board_member                         2  
Cash and cash equivalents held by equity method investment         $ 9,500,000 99,600,000     99,600,000     $ 100,000,000    
Equity method investments     $ 3,500,000     40,000,000   $ 3,500,000 40,000,000   $ 3,700,000      
Equity of equity method investment         10,000,000 $ 100,000,000     $ 100,000,000          
Decrease in cash and cash equivalent of equity method investment         90,100,000                  
Loss on equity investments         $ 36,000,000                  
Income (loss) on equity method investments       $ (73,000)     $ 276,000              
Equity method investment current assets       9,800,000                    
Equity method investment current liabilities       1,800,000                    
Equity method investment noncurrent assets       0                    
Equity method investment noncurrent liabilities       $ 0                    
NANTibody [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Number of board members | board_member                         5  
Nant Cell [Member] | NANTibody [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment ownership percentage                           60.00%
Initial joint funding contributed                           $ 60,000,000
Number of board members | board_member                         3  
Equity Method Investments [Member] | NANTibody [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Cash consideration in a purchase $ 90,100,000                          
IgDraSol Inc [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Issuance of common stock upon acquisition, shares | shares                   3.0        
Cash consideration in a purchase                   $ 380,000        
Purchase consideration                   $ 29,100,000        
IgDraSol Inc [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Proceeds from divestiture of business   $ 90,100,000                        
Amount of proceeds restricted to funding joint ventures   $ 60,000,000                        
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Method Investments - NantStem (Details) - USD ($)
 1 Months Ended 3 Months Ended
Oct. 13, 2015
Jul. 31, 2015
Jun. 30, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2015
Dec. 31, 2017
Jun. 30, 2017
Oct. 31, 2016
Apr. 30, 2015
Schedule of Equity Method Investments [Line Items]                    
Equity method investments     $ 29,972,000       $ 32,999,000      
Nant Cancer Stem LLC [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Initial joint funding   $ 100,000,000                
Initial joint funding contributed   $ 40,000,000                
Equity method investment ownership percentage 20.00% 40.00% 20.00%         20.00%    
Percentage of contribution made   50.00%                
Joint venture agreement second payment contribution $ 20,000,000                  
Loss on equity investments     $ 500,000     $ 4,000,000        
Equity method investments     18,200,000              
Difference between carrying amount and underlying equity     $ 1,700,000              
Net income (loss) in equity method investments       $ (331,000) $ 369,000          
Equity method investment current assets       82,300,000            
Equity method investment current liabilities       27,000            
Equity method investment noncurrent assets       0            
Equity method investment noncurrent liabilities       $ 0            
ImmuneOncia Therapeutics, LLC [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Equity method investment ownership percentage     49.00%           49.00%  
Equity method investments     $ 4,500,000              
Difference between carrying amount and underlying equity     800,000              
Equity method investment current assets     3,100,000              
Equity method investment current liabilities     344,000              
Equity method investment noncurrent assets     7,800,000              
Equity method investment noncurrent liabilities     $ 0              
NantBioScience, Inc. [Member] | Nant Cancer Stem LLC [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Initial joint funding contributed   $ 60,000,000                
Nant Cell [Member] | Nant Cancer Stem LLC [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Equity method investment ownership percentage                   60.00%
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Method Investments - Yuhan Agreement (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2016
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Oct. 31, 2016
Mar. 31, 2016
USD ($)
antibody
Schedule of Equity Method Investments [Line Items]                
Equity method investments   $ 29,972,000   $ 29,972,000   $ 32,999,000    
Income (loss) on equity method investments   $ (2,105,000) $ (1,102,000) $ (3,027,000) $ (2,050,000)      
ImmuneOncia Therapeutics, LLC [Member]                
Schedule of Equity Method Investments [Line Items]                
Number of monoclonal antibodies | antibody               2
Equity method investment ownership percentage   49.00%   49.00%     49.00%  
Equity method investments   $ 4,500,000   $ 4,500,000        
Difference between carrying amount and underlying equity   800,000   800,000        
Income (loss) on equity method investments   (3,100,000) $ (1,000,000) (4,700,000) $ (1,500,000)      
Equity method investment current assets   3,100,000   3,100,000        
Equity method investment current liabilities   344,000   344,000        
Equity method investment noncurrent assets   7,800,000   7,800,000        
Equity method investment noncurrent liabilities   $ 0   $ 0        
Yuhan Corporation [Member] | ImmuneOncia Therapeutics, LLC [Member]                
Schedule of Equity Method Investments [Line Items]                
Initial investment               $ 10,000,000
Ownership percentage by Parent             51.00%  
Private Placement [Member] | Yuhan Corporation [Member]                
Schedule of Equity Method Investments [Line Items]                
Gross proceeds of common stock and warrants $ 10,000,000              
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Method Investments - Shanghai Three (Details) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 07, 2016
Jun. 30, 2018
Jun. 30, 2017
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]            
Equity method investments   $ 29,972,000       $ 32,999,000
Shanghai Three [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity method investment ownership percentage   25.00%        
Equity method investments   $ 3,800,000        
Operating expenses of an equity method investment   0 $ 0 $ 0 $ 0  
Equity method investment current assets   400,000        
Equity method investment current liabilities   2,900,000        
Equity method investment noncurrent assets   5,500,000        
Equity method investment noncurrent liabilities   $ 2,200,000        
TNK Therapeutics, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Gross proceed from shares issued $ 10,000,000          
Upfront cash payment 1,000,000          
Common Class A [Member] | TNK Therapeutics, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Common stock to be issued, value $ 4,000,000          
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Goodwill $ 38,298,000 $ 38,298,000   $ 38,298,000  
Goodwill impairment 0 $ 0 $ 0 0 $ 0
Patents [Member]          
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Amortization expense 545,000   552,000 $ 1,090,000 1,059,000
Acquired technology [Member]          
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Estimated useful life of intangible asset       19 years  
Amortization expense 44,000   44,000 $ 88,000 88,000
Customer relationships [Member]          
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Estimated useful life of intangible asset       5 years  
Amortization expense $ 72,000   $ 73,000 $ 145,000 $ 145,000
Weighted Average [Member]          
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Identifiable intangible assets, weighted average life       15 years  
Minimum [Member] | Patents [Member]          
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Estimated useful life of intangible asset       15 years  
Maximum [Member] | Patents [Member]          
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]          
Estimated useful life of intangible asset       19 years  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets - Schedule of Goodwill (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
USD ($)
Goodwill [Roll Forward]  
Balance at December 31, 2017 $ 38,298
Goodwill Acquired from Acquisitions 0
Balance at June 30, 2018 $ 38,298
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 75,375 $ 75,375
Accumulated Amortization 5,685 4,362
Intangibles, net 69,690 71,013
Customer relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 1,585 1,585
Accumulated Amortization 1,236 1,091
Intangibles, net 349 494
Acquired technology [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 3,410 3,410
Accumulated Amortization 797 709
Intangibles, net 2,613 2,701
In Process Research and Development [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 37,660 37,660
Accumulated Amortization 0 0
Intangibles, net 37,660 37,660
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 32,720 32,720
Accumulated Amortization 3,652 2,562
Intangibles, net $ 29,068 $ 30,158
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]    
2018 $ 1,680  
2019 3,845  
2020 3,845  
2021 5,040  
2022 5,040  
Thereafter 50,240  
Intangibles, net $ 69,690 $ 71,013
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements and Contracts - License Agreement with Mabtech Limited (Details) - Mabtech Limited [Member]
$ in Millions
 1 Months Ended
Dec. 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
Feb. 29, 2016
USD ($)
Aug. 31, 2015
USD ($)
antibody
CHINA        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Number of monoclonal antibodies | antibody       4
Additional payment for license agreement     $ 10.0  
Aggregate purchase price of common stock warrants   $ 10.0    
Licensing agreement, additional amounts payable $ 125.0      
Acquired In Progress Research And Development Expense [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Additional payment for license agreement $ 25.0      
Acquired In Progress Research And Development Expense [Member] | CHINA        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Initial payment for license agreement       $ 10.0
Additional payment for license agreement   $ 30.0    
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements and Contracts - Immunotherapy Research Collaboration Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Mar. 07, 2016
Apr. 30, 2016
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Shares granted value         $ 2,910 $ 2,626  
Fair value of the obligation     $ 14,929   14,929   $ 53,209
TNK Therapeutics, Inc. [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Gross proceed from shares issued $ 10,000            
Roger Williams Medical Center [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment period for recognition   5 years          
Acquired in-process research and development     $ 170 $ 170 $ 340 $ 340  
Common Class A [Member] | Roger Williams Medical Center [Member] | TNK Therapeutics, Inc. [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Shares granted value   $ 6,000          
Gross proceed from shares issued   20,000          
Fair value of the obligation   $ 3,400          
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements and Contracts - License Agreement with NantCell (Details)
$ in Thousands, shares in Millions
 1 Months Ended
Apr. 30, 2015
USD ($)
CAR
shares
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Cost method investments   $ 237,008 $ 237,008
Nant Cell [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Number of CARs for cellular therapy | CAR 2    
Deferred revenue $ 10,000    
Common stock received | shares 10    
Vested equity received $ 100,000    
Cost method investments   $ 100,000  
Maximum [Member] | Nant Cell [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Royalty rate percent of net sales 5.00%    
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements and Contracts - License Agreement with The Scripps Research Institute (Details) - TSRI License [Member] - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2010
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Terminate notice of license 60 days        
General and administrative expenses [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Patent prosecution and maintenance costs   $ 14,000 $ 14,000 $ 24,000 $ 41,000
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements and Contracts - NIH Grants (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue recognized during period   $ 3,913,000 $ 4,665,000 $ 10,159,000 $ 9,539,000
Staph Grant III Award [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Period of grant 2 years        
Period of grant subsequently extended 1 year        
Amount of grant awards $ 1,000,000        
Grant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue recognized during period   0 94,000 0 195,000
Grant | Staph Grant III Award [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue recognized during period   $ 0 $ 94,000 $ 0 $ 195,000
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes - Hercules Capital, Inc. (Details) - USD ($)
 1 Months Ended 6 Months Ended
Dec. 21, 2017
Nov. 06, 2017
Mar. 23, 2017
Mar. 15, 2017
Nov. 23, 2016
Apr. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Debt Instrument [Line Items]                
Proceeds from issuance of common stock, net of issuance costs             $ 58,273,000 $ 45,628,000
Warrant received to purchase aggregate of common stock - shares         460,123      
Warrant received to purchase aggregate of common stock - exercise price         $ 4.89      
Warrants exercisable         306,748      
Loss on extinguishment of debt $ 4,300,000              
Term Loan [Member]                
Debt Instrument [Line Items]                
Amended and restated principal amount of loan agreement         $ 75,000,000.0      
Repayment of loan   $ 10,000,000 $ 20,000,000          
Term Loan Tranche One [Member]                
Debt Instrument [Line Items]                
Face value of loan amount         50,000,000      
Payment of backend fee       $ 1,500,000        
Term Loan Tranche Two [Member]                
Debt Instrument [Line Items]                
Available of borrowing amount         $ 25,000,000      
Loan and Security Agreement [Member]                
Debt Instrument [Line Items]                
Unrestricted cash covenant requirement for long term debt     $ 20,000,000          
Amended Loan And Security Agreement [Member]                
Debt Instrument [Line Items]                
Unrestricted cash covenant requirement for long term debt   $ 8,000,000            
Common Stock [Member]                
Debt Instrument [Line Items]                
Proceeds from issuance of common stock, net of issuance costs           $ 43,100,000    
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes - 2018 Chinese Yuan Loan (Details) - Chinese Yuan Term Loan [Member]
¥ in Millions, $ in Millions
 1 Months Ended
Mar. 31, 2018
USD ($)
Mar. 31, 2018
CNY (¥)
Debt Instrument [Line Items]    
Face value of loan $ 1.6 ¥ 10.0
Debt instrument term 1 year  
Interest rate 5.00% 5.00%
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes - 2017 Private Placement (Details) - USD ($)
 3 Months Ended 6 Months Ended
May 17, 2018
Dec. 21, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 13, 2018
Dec. 31, 2017
Debt Instrument [Line Items]                
Debt discount   $ 44,800,000           $ 44,800,000
Debt discount allocated to warrant               12,700,000
Debt beneficial conversion feature   $ 32,100,000            
Interest paid         $ 1,128,000 $ 2,044,000    
Interest expense     $ 45,009,000 $ 1,200,000 46,061,000 $ 2,809,000    
Convertible Debt [Member]                
Debt Instrument [Line Items]                
Debt discount               $ 21,549,000
Debt discount allocated to warrant     $ 9,643,000   9,643,000      
Debt beneficial conversion feature         $ 12,005,000      
Convertible Debt [Member] | Promissory Notes, Due 2022 [Member]                
Debt Instrument [Line Items]                
Interest rate   5.00%            
If converted - outstanding principal threshold amount   $ 4,000,000            
Debt conversion price $ 2.26875              
Interest paid $ 1,000,000              
Interest expense $ 44,300,000              
Private Placement [Member] | Convertible Debt [Member] | Promissory Notes, Due 2022 [Member]                
Debt Instrument [Line Items]                
If converted - outstanding principal threshold amount   $ 4,000,000            
Debt conversion price   $ 2.26875            
2017 Warrants [Member]                
Debt Instrument [Line Items]                
Number of securities called by warrants             2,698,662  
2017 Warrants [Member] | Private Placement [Member]                
Debt Instrument [Line Items]                
Number of securities called by warrants   12,121,210            
Warrant exercise price per share   $ 2.61            
Term of warrants   5 years 6 months            
Common Stock [Member]                
Debt Instrument [Line Items]                
Issuance of common stock for conversion of notes payable (shares) 22,038,565       22,038,565      
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes - 2018 Private Placement (Details) - USD ($)
 6 Months Ended
Jun. 13, 2018
Mar. 26, 2018
Dec. 21, 2017
Jun. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]          
Debt discount allocated to warrant         $ 12,700,000
Debt beneficial conversion feature     $ 32,100,000    
Convertible Debt [Member]          
Debt Instrument [Line Items]          
Face value of loan       $ 37,849,000  
Debt discount allocated to warrant       9,643,000  
Debt beneficial conversion feature       12,005,000  
Convertible Debt [Member] | March 2018 Notes [Member]          
Debt Instrument [Line Items]          
Face value of loan $ 37,848,750 $ 120,500,000      
If converted - outstanding principal threshold amount   $ 4,000,000      
Debt conversion price   $ 7.0125      
Debt discount allocated to warrant 21,600,000        
Debt beneficial conversion feature 12,000,000        
March 2018 Warrant [Member] | Convertible Debt [Member] | March 2018 Notes [Member]          
Debt Instrument [Line Items]          
Debt discount allocated to warrant $ 9,600,000        
Private Placement [Member] | March 2018 Warrant [Member]          
Debt Instrument [Line Items]          
Term of warrants   5 years 6 months      
Number of securities called by warrants 2,698,662 8,591,794      
Warrant exercise price per share   $ 8.77      
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]          
Debt Instrument [Line Items]          
Long-term debt, fair value disclosure       40,600,000  
Reported Value Measurement [Member]          
Debt Instrument [Line Items]          
Long-term debt, fair value disclosure       $ 16,200,000  
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes - Schedule of Long-Term Debt and Unamortized Discount Balances (Details) - USD ($)
 6 Months Ended
Dec. 21, 2017
Jun. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]      
Debt discount - warrant     $ (12,700,000)
Debt discount - beneficial conversion feature $ (32,100,000)    
Convertible Debt [Member]      
Debt Instrument [Line Items]      
Face value of loan   $ 37,849,000  
Debt discount - warrant   (9,643,000)  
Debt discount - beneficial conversion feature   (12,005,000)  
Capitalized debt issuance costs   (98,000) (97,000)
Accretion of debt issuance costs and other   0  
Accretion of debt discount   100,000  
Balance at June 30, 2018   $ 16,203,000 $ 16,203,000
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loan and Security Agreement and Convertible Notes - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Dec. 21, 2017
Debt Instrument [Line Items]      
Debt discount   $ (44,800) $ (44,800)
Current portion $ (1,511) 0  
Long-term debt 16,203 5,211  
Convertible Debt [Member]      
Debt Instrument [Line Items]      
Amount due in 2018   946  
Amount due in 2019   1,892  
Amount due in 2020   1,893  
Amount due in 2021   1,892  
Amount due in 2022   1,893  
Amount due in 2023   38,795  
Total future minimum payments   47,311  
Unamortized interest   (9,462)  
Debt discount   (21,549)  
Capitalized debt issuance costs (98) (97)  
Total minimum payment $ 16,203 16,203  
Current portion   0  
Long-term debt   $ 16,203  
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Narrative: 2009 Non-Employee Director Grants (Details) - Non Employee Directors - 2009 Non-Employee Director Grants - $ / shares
Sep. 30, 2009
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 8,000  
Options vesting anniversary period 1 year  
Shares available for grant (in shares)   0
Option outstanding (in shares)   3,200
Weighted-average exercise price (in dollars per share)   $ 1.12
Maximum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options exercisable period 10 years  
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Narrative: 2009 Stock Incentive Plan (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock, shares authorized (in shares)   750,000,000   750,000,000   750,000,000
2009 Stock Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock, shares authorized (in shares) 11,260,000          
Aggregate intrinsic value of options exercised   $ 4,000 $ 0 $ 52,000 $ 0  
Unrecognized compensation cost related to unvested stock option grants   10,800,000   $ 10,800,000    
Period for recognized compensation cost       3 years    
2009 Stock Incentive Plan | Employee and Director            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock-based compensation   1,000,000 1,200,000 $ 2,200,000 2,500,000  
2009 Stock Incentive Plan | Non Employee Consultants [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock-based compensation   $ 178,000 $ 8,000 $ 275,000 $ 34,000  
2009 Stock Incentive Plan | Employee Stock Option [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options exercisable period 10 years          
Employee option grants vested (percent) 25.00%          
Options vesting anniversary period 3 years          
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Summary of Stock Option Activity (Details) - 2009 Stock Incentive Plan - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Options Outstanding    
Option Outstanding Beginning Balance (in shares) 6,343,400  
Options granted (in shares) 1,566,200  
Options Canceled (in shares) (266,835)  
Options Exercised (in shares) (25,815)  
Option Outstanding Ending Balance (in shares) 7,616,950  
Weighted- Average Exercise Price    
Weighted Average Exercise Price, Beginning Balance (in dollars per share) $ 4.74  
Options Granted, Weighted Average Exercise Price (in dollars per share) 7.23  
Options Canceled, Weighted Average Exercise Price (in dollars per share) 4.36  
Options Exercised, Weighted Average Exercise Price (in dollars per share) 6.04  
Weighted Average Exercise Price, Ending Balance (in dollars per share) $ 5.26  
Aggregate Intrinsic Value, Beginning Balance (in dollars per share) $ 19,460 $ 6,290
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Fair Value of Employee Stock Options (Details) - Employee Stock Option [Member] - $ / shares
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted-average grant date fair value (in dollars per share) $ 7.39 $ 5.20
Dividend yield 0.00% 0.00%
Volatility 81.00% 64.00%
Risk-free interest rate 2.52% 2.16%
Expected life of options 6 years 1 month 6 days 6 years 1 month 6 days
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Summary of Common Stock Reserved for Future Issuance (Details)
Jun. 30, 2018
shares
Class of Stock [Line Items]  
Common stock reserved for future issuance 35,765,538
Private Placement [Member] | Warrant [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 4,153,620
Underwriters Agreement [Member] | Warrant [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 182,600
Loan and Security Agreement [Member] | Warrant [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 65,892
Hercules Securities Agreement [Member] | Warrant [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 306,748
Convertible Notes [Member] | Warrant [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 14,819,872
Non-Employee Director Plan [Member] | Employee Stock Option [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 3,200
2009 Stock Incentive Plan  
Class of Stock [Line Items]  
Common stock reserved for future issuance 10,756,281
Virttu Acquisition Agreement [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 5,397,325
Assignment Agreement [Member]  
Class of Stock [Line Items]  
Common stock reserved for future issuance 80,000
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Narrative: 2017 Equity Incentive Plan (Details) - shares
 1 Months Ended
Jun. 30, 2017
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares)   35,765,538
Scilex Pharmaceuticals, Inc [Member] | 2017 Stock Options Plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares) 1,000,000  
Option outstanding (in shares)   500,000
Scilex Pharmaceuticals, Inc [Member] | 2017 Stock Options Plans | Common Class A [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 4,000,000.0  
First year | Scilex Pharmaceuticals, Inc [Member] | 2017 Stock Options Plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting percentage 25.00%  
Quarterly | Scilex Pharmaceuticals, Inc [Member] | 2017 Stock Options Plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting percentage 2.08%  
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Narrative: 2015 Stock Option Plans (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 16, 2018
Aug. 29, 2017
Nov. 30, 2015
Oct. 31, 2015
May 31, 2015
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock reserved for issuance (in shares)           35,765,538   35,765,538    
2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Accelerated compensation expense   $ 281,000                
TNK Therapeutics, Inc. [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options granted (in shares)     500,000   3,600,000          
Stock options, contractual term         10 years          
Number of shares canceled during period   1,000,000                
Number of options canceled (in shares) 200,000                  
Option outstanding (in shares)           900,000   900,000    
Warrant shares exercisable (in shares)         4,000,000          
Warrant exercise price per share         $ 0.01          
TNK Therapeutics, Inc. [Member] | 2015 Stock Incentive Plan [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period         2 years          
Term of warrants         40 months          
TNK Therapeutics, Inc. [Member] | 2015 Stock Incentive Plan [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period         4 years          
Term of warrants         4 years          
TNK Therapeutics, Inc. [Member] | 2015 Stock Incentive Plan [Member] | Common Class A [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock reserved for issuance (in shares)         10,000,000.0          
L A Cell [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options granted (in shares)         2,900,000          
Stock options, contractual term         10 years          
Number of shares canceled during period   1,500,000                
Number of options canceled (in shares) 200,000                  
Option outstanding (in shares)           300,000   300,000    
Warrant shares exercisable (in shares)         4,000,000          
Warrant exercise price per share         $ 0.01          
L A Cell [Member] | 2015 Stock Incentive Plan [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period         2 years          
Term of warrants         40 months          
L A Cell [Member] | 2015 Stock Incentive Plan [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period         4 years          
Term of warrants         4 years          
L A Cell [Member] | 2015 Stock Incentive Plan [Member] | Common Class A [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock reserved for issuance (in shares)         10,000,000.0          
Concortis Biosystems Corporation [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options granted (in shares)       1,800,000            
Stock options, contractual term       10 years            
Number of shares canceled during period   1,600,000                
Number of options canceled (in shares) 100,000                  
Option outstanding (in shares)           0   0    
Warrant shares exercisable (in shares)       4,000,000            
Warrant exercise price per share       $ 0.25            
Concortis Biosystems Corporation [Member] | 2015 Stock Incentive Plan [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period       2 years            
Term of warrants       40 months            
Concortis Biosystems Corporation [Member] | 2015 Stock Incentive Plan [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period       4 years            
Term of warrants       4 years            
Concortis Biosystems Corporation [Member] | 2015 Stock Incentive Plan [Member] | Common Class A [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock reserved for issuance (in shares)       10,000,000.0            
Scintilla Pharmaceuticals Inc [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Stock options, contractual term       10 years            
Number of shares canceled during period   800,000                
Number of options canceled (in shares) 100,000                  
Option outstanding (in shares)           0   0    
Warrant shares exercisable (in shares)       4,000,000            
Warrant exercise price per share       $ 0.01            
Scintilla Pharmaceuticals Inc [Member] | 2015 Stock Incentive Plan [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period       2 years            
Term of warrants       40 months            
Scintilla Pharmaceuticals Inc [Member] | 2015 Stock Incentive Plan [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period       4 years            
Term of warrants       4 years            
Scintilla Pharmaceuticals Inc [Member] | 2015 Stock Incentive Plan [Member] | Common Class A [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock reserved for issuance (in shares)       10,000,000.0            
Options granted (in shares)       1,800,000            
Sorrento Biologics Inc [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Stock options, contractual term       10 years            
Number of shares canceled during period   1,300,000                
Number of options canceled (in shares) 75,000                  
Option outstanding (in shares)           0   0    
Warrant shares exercisable (in shares)       4,000,000            
Warrant exercise price per share       $ 0.01            
Sorrento Biologics Inc [Member] | 2015 Stock Incentive Plan [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period       2 years            
Term of warrants       40 months            
Sorrento Biologics Inc [Member] | 2015 Stock Incentive Plan [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options vesting anniversary period       4 years            
Term of warrants       4 years            
Sorrento Biologics Inc [Member] | 2015 Stock Incentive Plan [Member] | Common Class A [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock reserved for issuance (in shares)       10,000,000.0            
Options granted (in shares)       2,600,000            
Chief Executive Officer [Member] | TNK Therapeutics, Inc. [Member] | 2015 Stock Incentive Plan [Member] | Common Class B [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Warrant granted to purchase common stock (in shares)         9,500,000          
Number of shares per vote         10          
Chief Executive Officer [Member] | L A Cell [Member] | 2015 Stock Incentive Plan [Member] | Common Class B [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Warrant granted to purchase common stock (in shares)         9,500,000          
Number of shares per vote         10          
Chief Executive Officer [Member] | Concortis Biosystems Corporation [Member] | 2015 Stock Incentive Plan [Member] | Common Class B [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Warrant granted to purchase common stock (in shares)       9,500,000            
Number of shares per vote       10            
Chief Executive Officer [Member] | Scintilla Pharmaceuticals Inc [Member] | 2015 Stock Incentive Plan [Member] | Common Class B [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Warrant granted to purchase common stock (in shares)       9,500,000            
Number of shares per vote       10            
Chief Executive Officer [Member] | Sorrento Biologics Inc [Member] | 2015 Stock Incentive Plan [Member] | Common Class B [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Warrant granted to purchase common stock (in shares)       9,500,000            
Number of shares per vote       10            
Director [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Unrecognized compensation cost related to unvested stock option and warrant grants                   $ 0
Stock-based compensation           $ 0 $ 54,000 $ 0 $ 96,000  
Non Employee Consultants [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Stock-based compensation           $ 149,000 $ 149,000 $ 358,000 $ 358,000  
Directors and Non Employee Consultants [Member] | 2015 Stock Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Dividend yield               0.00%    
Risk-free interest rate, minimum               2.42%    
Risk-free interest rate, maximum               2.48%    
Expected volatility, minimum               65.00%    
Expected volatility, maximum               77.00%    
Directors and Non Employee Consultants [Member] | 2015 Stock Incentive Plan [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Expected life of options               4 years    
Directors and Non Employee Consultants [Member] | 2015 Stock Incentive Plan [Member] | Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Expected life of options               6 years 1 month 6 days    
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Narrative: 2014 Stock Option Plans (Details) - Directors and Consultants [Member] - Ark Animal Health Inc [Member] - 2014 Stock Option Plan [Member] - USD ($)
shares in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 29, 2017
May 31, 2014
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options granted (in shares)   600        
Options vesting anniversary period   1 year        
Stock options, contractual term   10 years        
Number of shares canceled during period 135          
Option outstanding (in shares)     88   88  
Stock-based compensation     $ 0 $ 0 $ 0 $ 0
Unrecognized compensation cost related to unvested stock option grants     $ 0   $ 0  
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details)
$ in Thousands
May 15, 2018
USD ($)
Sep. 08, 2016
USD ($)
Jun. 30, 2018
ft²
Jul. 31, 2017
ft²
Corporate office and laboratory space [Member] | San Diego, California [Member]        
Other Commitments [Line Items]        
Leased office space     130,575  
Corporate office and laboratory space [Member] | Suzhou, China [Member]        
Other Commitments [Line Items]        
Leased office space     25,381  
Corporate office and laboratory space [Member] | Scotland [Member]        
Other Commitments [Line Items]        
Leased office space     2,312  
Office space [Member] | San Diego, California [Member]        
Other Commitments [Line Items]        
Leased office space     1,405  
Office space [Member] | New York [Member]        
Other Commitments [Line Items]        
Leased office space       4,550
Offices, facilities for cGMP fill and finish and storage space [Member] | San Diego, California [Member]        
Other Commitments [Line Items]        
Additional, leased office space     36,400  
Settled litigation [Member] | Yuhan agreement claim [Member]        
Other Commitments [Line Items]        
Loss Contingency, Damages Awarded, Value | $ $ 3,250      
Yuhan agreement claim [Member]        
Other Commitments [Line Items]        
Aggregate purchase price of common stock warrants | $   $ 10,000    
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Tax Disclosure [Abstract]        
Income tax benefit $ 1,377,000 $ 1,398,000 $ 2,325,000 $ 3,094,000
Effective income tax rate     2.10% 7.50%
U.S federal statutory tax rate     21.00%  
Unrecognized tax benefits that if recognized would impact effective income tax rate 3,900,000 $ 2,800,000 $ 3,900,000 $ 2,800,000
Related interest and penalty     0 $ 0
Significant change in uncertain tax positions in the next 12 months $ 0   $ 0  
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Agreements - Narrative (Details) - USD ($)
$ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended
Jul. 31, 2015
Jun. 30, 2016
Jun. 30, 2018
Dec. 31, 2017
Jun. 12, 2017
Nov. 08, 2016
Oct. 31, 2016
Apr. 30, 2015
Related Party Transaction [Line Items]                
Cost method investments     $ 237,008 $ 237,008        
Equity method investments     29,972 $ 32,999        
Scilex Pharmaceuticals, Inc [Member]                
Related Party Transaction [Line Items]                
Business acquisition, percentage of voting interests acquired           72.00%    
ImmuneOncia Therapeutics, LLC [Member]                
Related Party Transaction [Line Items]                
Equity method investments     $ 4,500          
Equity method investment ownership percentage     49.00%       49.00%  
Celularity Inc [Member]                
Related Party Transaction [Line Items]                
Equity method investment ownership percentage         25.00%      
NantBioScience, Inc. [Member]                
Related Party Transaction [Line Items]                
Number of common stock shares acquired               1.0
Cost method investments               $ 10,000
Nant Cell [Member]                
Related Party Transaction [Line Items]                
Payments to acquire interest in joint venture $ 40,000              
Non-refundable up-front payment 10,000              
Vested equity received $ 100,000              
Yuhan Corporation [Member]                
Related Party Transaction [Line Items]                
Gross proceeds of common stock and warrants   $ 10,000            
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Earnings Per Share [Abstract]        
Net Loss $ (73,864) $ (14,187) $ (106,436) $ (37,251)
Denominator for Basic and Diluted Loss Per Share 100,563 70,302 92,795 60,650
Dilutive Earnings Per Share (in dollars per share) $ (0.73) $ (0.20) $ (1.15) $ (0.61)
Employee Stock Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of EPS 2,500 4,300    
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of EPS 1,100 1,100 2,200 2,200
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details) - Sofusa [Member] - Subsequent event [Member]
$ in Millions
Jul. 03, 2018
USD ($)
Subsequent Event [Line Items]  
Purchase consideration $ 10.0
Milestones achievement [Member]  
Subsequent Event [Line Items]  
Business combination additional consideration transferred $ 300.0
EXCEL 102 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 103 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 104 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 106 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 480 409 1 false 154 0 false 14 false false R1.htm 0002000 - Document - Document and Entity Information Sheet http://www.sorrentotherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.sorrentotherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.sorrentotherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.sorrentotherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.sorrentotherapeutics.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.sorrentotherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sorrentotherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - Nature of Operations and Business Activities Sheet http://www.sorrentotherapeutics.com/role/NatureOfOperationsAndBusinessActivities Nature of Operations and Business Activities Notes 8 false false R9.htm 2102100 - Disclosure - Liquidity and Going Concern Sheet http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 9 false false R10.htm 2104100 - Disclosure - Significant Accounting Policies Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 2105100 - Disclosure - Acquisitions Sheet http://www.sorrentotherapeutics.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.sorrentotherapeutics.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2108100 - Disclosure - Marketable Securities Sheet http://www.sorrentotherapeutics.com/role/MarketableSecurities Marketable Securities Notes 13 false false R14.htm 2109100 - Disclosure - Property and Equipment Sheet http://www.sorrentotherapeutics.com/role/PropertyAndEquipment Property and Equipment Notes 14 false false R15.htm 2110100 - Disclosure - Cost Method Investments Sheet http://www.sorrentotherapeutics.com/role/CostMethodInvestments Cost Method Investments Notes 15 false false R16.htm 2111100 - Disclosure - Equity Method Investments Sheet http://www.sorrentotherapeutics.com/role/EquityMethodInvestments Equity Method Investments Notes 16 false false R17.htm 2112100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 17 false false R18.htm 2113100 - Disclosure - Significant Agreements and Contracts Sheet http://www.sorrentotherapeutics.com/role/SignificantAgreementsAndContracts Significant Agreements and Contracts Notes 18 false false R19.htm 2114100 - Disclosure - Loan and Security Agreement and Convertible Notes Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotes Loan and Security Agreement and Convertible Notes Notes 19 false false R20.htm 2115100 - Disclosure - Stock Incentive Plans Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlans Stock Incentive Plans Notes 20 false false R21.htm 2117100 - Disclosure - Commitments and Contingencies Sheet http://www.sorrentotherapeutics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 2118100 - Disclosure - Income Taxes Sheet http://www.sorrentotherapeutics.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2119100 - Disclosure - Related Party Agreements Sheet http://www.sorrentotherapeutics.com/role/RelatedPartyAgreements Related Party Agreements Notes 23 false false R24.htm 2120100 - Disclosure - Loss Per Share Sheet http://www.sorrentotherapeutics.com/role/LossPerShare Loss Per Share Notes 24 false false R25.htm 2121100 - Disclosure - Subsequent Events Sheet http://www.sorrentotherapeutics.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 2204201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.sorrentotherapeutics.com/role/SignificantAccountingPolicies 26 false false R27.htm 2304302 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.sorrentotherapeutics.com/role/SignificantAccountingPolicies 27 false false R28.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.sorrentotherapeutics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.sorrentotherapeutics.com/role/FairValueMeasurements 28 false false R29.htm 2308301 - Disclosure - Marketable Securities (Tables) Sheet http://www.sorrentotherapeutics.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.sorrentotherapeutics.com/role/MarketableSecurities 29 false false R30.htm 2309301 - Disclosure - Property and Equipment (Tables) Sheet http://www.sorrentotherapeutics.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.sorrentotherapeutics.com/role/PropertyAndEquipment 30 false false R31.htm 2312301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssets 31 false false R32.htm 2314301 - Disclosure - Loan and Security Agreement and Convertible Notes (Tables) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotesTables Loan and Security Agreement and Convertible Notes (Tables) Tables http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotes 32 false false R33.htm 2315301 - Disclosure - Stock Incentive Plans (Tables) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansTables Stock Incentive Plans (Tables) Tables http://www.sorrentotherapeutics.com/role/StockIncentivePlans 33 false false R34.htm 2320301 - Disclosure - Loss Per Share (Tables) Sheet http://www.sorrentotherapeutics.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.sorrentotherapeutics.com/role/LossPerShare 34 false false R35.htm 2401401 - Disclosure - Nature of Operations and Business Activities (Details) Sheet http://www.sorrentotherapeutics.com/role/NatureOfOperationsAndBusinessActivitiesDetails Nature of Operations and Business Activities (Details) Details http://www.sorrentotherapeutics.com/role/NatureOfOperationsAndBusinessActivities 35 false false R36.htm 2402401 - Disclosure - Liquidity and Going Concern (Details) Sheet http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcernDetails Liquidity and Going Concern (Details) Details http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcern 36 false false R37.htm 2402402 - Disclosure - Liquidity and Going Concern - Universal Shelf Registration (Details) Sheet http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcernUniversalShelfRegistrationDetails Liquidity and Going Concern - Universal Shelf Registration (Details) Details 37 false false R38.htm 2402403 - Disclosure - Liquidity and Going Concern - 2016 Private Investment in Public Entity Financing (Details) Sheet http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcern2016PrivateInvestmentInPublicEntityFinancingDetails Liquidity and Going Concern - 2016 Private Investment in Public Entity Financing (Details) Details 38 false false R39.htm 2402404 - Disclosure - Liquidity and Going Concern - 2017 Private Investment in Public Entity Financing (Details) Sheet http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcern2017PrivateInvestmentInPublicEntityFinancingDetails Liquidity and Going Concern - 2017 Private Investment in Public Entity Financing (Details) Details 39 false false R40.htm 2402405 - Disclosure - Liquidity and Going Concern - 2018 Private Investment in Public Entity Financing (Details) Sheet http://www.sorrentotherapeutics.com/role/LiquidityAndGoingConcern2018PrivateInvestmentInPublicEntityFinancingDetails Liquidity and Going Concern - 2018 Private Investment in Public Entity Financing (Details) Details 40 false false R41.htm 2404403 - Disclosure - Significant Accounting Policies - Narrative (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails Significant Accounting Policies - Narrative (Details) Details 41 false false R42.htm 2404404 - Disclosure - Significant Accounting Policies - Schedule of Revenues by Category (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails Significant Accounting Policies - Schedule of Revenues by Category (Details) Details 42 false false R43.htm 2404405 - Disclosure - Significant Accounting Policies - Schedule of Remaining Performance Obligations (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesScheduleOfRemainingPerformanceObligationsDetails Significant Accounting Policies - Schedule of Remaining Performance Obligations (Details) Details 43 false false R44.htm 2404406 - Disclosure - Significant Accounting Policies - Schedule of Outstanding Securities (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesScheduleOfOutstandingSecuritiesDetails Significant Accounting Policies - Schedule of Outstanding Securities (Details) Details 44 false false R45.htm 2404407 - Disclosure - Significant Accounting Policies - Narrative - Revenue Recognition (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAccountingPoliciesNarrativeRevenueRecognitionDetails Significant Accounting Policies - Narrative - Revenue Recognition (Details) Details 45 false false R46.htm 2405401 - Disclosure - Acquisitions - Acquisition of Virttu Biologics Limited (Details) Sheet http://www.sorrentotherapeutics.com/role/AcquisitionsAcquisitionOfVirttuBiologicsLimitedDetails Acquisitions - Acquisition of Virttu Biologics Limited (Details) Details 46 false false R47.htm 2405402 - Disclosure - Acquisitions - Acquisition of Scilex Pharmaceuticals Inc. (Details) Sheet http://www.sorrentotherapeutics.com/role/AcquisitionsAcquisitionOfScilexPharmaceuticalsIncDetails Acquisitions - Acquisition of Scilex Pharmaceuticals Inc. (Details) Details 47 false false R48.htm 2405403 - Disclosure - Acquisitions - Acquired In-process Research and Development of BDL and Cargenix (Details) Sheet http://www.sorrentotherapeutics.com/role/AcquisitionsAcquiredInProcessResearchAndDevelopmentOfBdlAndCargenixDetails Acquisitions - Acquired In-process Research and Development of BDL and Cargenix (Details) Details 48 false false R49.htm 2406402 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.sorrentotherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 49 false false R50.htm 2406403 - Disclosure - Fair Value Measurements - Summary of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) Sheet http://www.sorrentotherapeutics.com/role/FairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details Fair Value Measurements - Summary of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) Details 50 false false R51.htm 2406404 - Disclosure - Fair Value Measurements - Summary of Inputs and the Valuation Methodologies used for Fair Value Measurements Using Significant Unobservable Inputs Level 3 (Details) Sheet http://www.sorrentotherapeutics.com/role/FairValueMeasurementsSummaryOfInputsAndValuationMethodologiesUsedForFairValueMeasurementsUsingSignificantUnobservableInputsLevel3Details Fair Value Measurements - Summary of Inputs and the Valuation Methodologies used for Fair Value Measurements Using Significant Unobservable Inputs Level 3 (Details) Details 51 false false R52.htm 2406406 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.sorrentotherapeutics.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 52 false false R53.htm 2408402 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details) Sheet http://www.sorrentotherapeutics.com/role/MarketableSecuritiesScheduleOfMarketableSecuritiesDetails Marketable Securities - Schedule of Marketable Securities (Details) Details 53 false false R54.htm 2408403 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://www.sorrentotherapeutics.com/role/MarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 54 false false R55.htm 2408404 - Disclosure - Marketable Securities - Summary of Warrant Measured at Fair Value Using Significant Unobservable Inputs (Details) Sheet http://www.sorrentotherapeutics.com/role/MarketableSecuritiesSummaryOfWarrantMeasuredAtFairValueUsingSignificantUnobservableInputsDetails Marketable Securities - Summary of Warrant Measured at Fair Value Using Significant Unobservable Inputs (Details) Details 55 false false R56.htm 2409402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://www.sorrentotherapeutics.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Property and Equipment - Summary of Property and Equipment (Details) Details 56 false false R57.htm 2409403 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://www.sorrentotherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 57 false false R58.htm 2410401 - Disclosure - Cost Method Investments - Additional Information (Details) Sheet http://www.sorrentotherapeutics.com/role/CostMethodInvestmentsAdditionalInformationDetails Cost Method Investments - Additional Information (Details) Details 58 false false R59.htm 2411401 - Disclosure - Equity Method Investments - NANTibody (Details) Sheet http://www.sorrentotherapeutics.com/role/EquityMethodInvestmentsNantibodyDetails Equity Method Investments - NANTibody (Details) Details 59 false false R60.htm 2411402 - Disclosure - Equity Method Investments - NantStem (Details) Sheet http://www.sorrentotherapeutics.com/role/EquityMethodInvestmentsNantstemDetails Equity Method Investments - NantStem (Details) Details 60 false false R61.htm 2411403 - Disclosure - Equity Method Investments - Yuhan Agreement (Details) Sheet http://www.sorrentotherapeutics.com/role/EquityMethodInvestmentsYuhanAgreementDetails Equity Method Investments - Yuhan Agreement (Details) Details 61 false false R62.htm 2411405 - Disclosure - Equity Method Investments - Shanghai Three (Details) Sheet http://www.sorrentotherapeutics.com/role/EquityMethodInvestmentsShanghaiThreeDetails Equity Method Investments - Shanghai Three (Details) Details 62 false false R63.htm 2412402 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) Sheet http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails Goodwill and Intangible Assets - Additional Information (Details) Details 63 false false R64.htm 2412403 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details) Sheet http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillDetails Goodwill and Intangible Assets - Schedule of Goodwill (Details) Details 64 false false R65.htm 2412404 - Disclosure - Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Detail) Sheet http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssetsSummaryOfCompanysIdentifiableIntangibleAssetsDetail Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Detail) Details 65 false false R66.htm 2412405 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Detail) Sheet http://www.sorrentotherapeutics.com/role/GoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Detail) Details 66 false false R67.htm 2413402 - Disclosure - Significant Agreements and Contracts - License Agreement with Mabtech Limited (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAgreementsAndContractsLicenseAgreementWithMabtechLimitedDetails Significant Agreements and Contracts - License Agreement with Mabtech Limited (Details) Details 67 false false R68.htm 2413403 - Disclosure - Significant Agreements and Contracts - Immunotherapy Research Collaboration Agreement (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAgreementsAndContractsImmunotherapyResearchCollaborationAgreementDetails Significant Agreements and Contracts - Immunotherapy Research Collaboration Agreement (Details) Details 68 false false R69.htm 2413404 - Disclosure - Significant Agreements and Contracts - License Agreement with NantCell (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAgreementsAndContractsLicenseAgreementWithNantcellDetails Significant Agreements and Contracts - License Agreement with NantCell (Details) Details 69 false false R70.htm 2413405 - Disclosure - Significant Agreements and Contracts - License Agreement with The Scripps Research Institute (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAgreementsAndContractsLicenseAgreementWithScrippsResearchInstituteDetails Significant Agreements and Contracts - License Agreement with The Scripps Research Institute (Details) Details 70 false false R71.htm 2413406 - Disclosure - Significant Agreements and Contracts - NIH Grants (Details) Sheet http://www.sorrentotherapeutics.com/role/SignificantAgreementsAndContractsNihGrantsDetails Significant Agreements and Contracts - NIH Grants (Details) Details 71 false false R72.htm 2414402 - Disclosure - Loan and Security Agreement and Convertible Notes - Hercules Capital, Inc. (Details) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotesHerculesCapitalIncDetails Loan and Security Agreement and Convertible Notes - Hercules Capital, Inc. (Details) Details 72 false false R73.htm 2414403 - Disclosure - Loan and Security Agreement and Convertible Notes - 2018 Chinese Yuan Loan (Details) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotes2018ChineseYuanLoanDetails Loan and Security Agreement and Convertible Notes - 2018 Chinese Yuan Loan (Details) Details 73 false false R74.htm 2414404 - Disclosure - Loan and Security Agreement and Convertible Notes - 2017 Private Placement (Details) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotes2017PrivatePlacementDetails Loan and Security Agreement and Convertible Notes - 2017 Private Placement (Details) Details 74 false false R75.htm 2414405 - Disclosure - Loan and Security Agreement and Convertible Notes - 2018 Private Placement (Details) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotes2018PrivatePlacementDetails Loan and Security Agreement and Convertible Notes - 2018 Private Placement (Details) Details 75 false false R76.htm 2414406 - Disclosure - Loan and Security Agreement and Convertible Notes - Schedule of Long-Term Debt and Unamortized Discount Balances (Details) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotesScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails Loan and Security Agreement and Convertible Notes - Schedule of Long-Term Debt and Unamortized Discount Balances (Details) Details 76 false false R77.htm 2414407 - Disclosure - Loan and Security Agreement and Convertible Notes - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Details) Notes http://www.sorrentotherapeutics.com/role/LoanAndSecurityAgreementAndConvertibleNotesFutureMinimumPaymentsUnderAmendedAndRestatedLoanAndSecurityAgreementDetails Loan and Security Agreement and Convertible Notes - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Details) Details 77 false false R78.htm 2415402 - Disclosure - Stock Incentive Plans - Narrative: 2009 Non-Employee Director Grants (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansNarrative2009NonEmployeeDirectorGrantsDetails Stock Incentive Plans - Narrative: 2009 Non-Employee Director Grants (Details) Details 78 false false R79.htm 2415403 - Disclosure - Stock Incentive Plans - Narrative: 2009 Stock Incentive Plan (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansNarrative2009StockIncentivePlanDetails Stock Incentive Plans - Narrative: 2009 Stock Incentive Plan (Details) Details 79 false false R80.htm 2415404 - Disclosure - Stock Incentive Plans - Summary of Stock Option Activity (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails Stock Incentive Plans - Summary of Stock Option Activity (Details) Details 80 false false R81.htm 2415405 - Disclosure - Stock Incentive Plans - Fair Value of Employee Stock Options (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansFairValueOfEmployeeStockOptionsDetails Stock Incentive Plans - Fair Value of Employee Stock Options (Details) Details 81 false false R82.htm 2415406 - Disclosure - Stock Incentive Plans - Summary of Common Stock Reserved for Future Issuance (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansSummaryOfCommonStockReservedForFutureIssuanceDetails Stock Incentive Plans - Summary of Common Stock Reserved for Future Issuance (Details) Details 82 false false R83.htm 2415407 - Disclosure - Stock Incentive Plans - Narrative: 2017 Equity Incentive Plan (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansNarrative2017EquityIncentivePlanDetails Stock Incentive Plans - Narrative: 2017 Equity Incentive Plan (Details) Details 83 false false R84.htm 2415408 - Disclosure - Stock Incentive Plans - Narrative: 2015 Stock Option Plans (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansNarrative2015StockOptionPlansDetails Stock Incentive Plans - Narrative: 2015 Stock Option Plans (Details) Details 84 false false R85.htm 2415409 - Disclosure - Stock Incentive Plans - Narrative: 2014 Stock Option Plans (Details) Sheet http://www.sorrentotherapeutics.com/role/StockIncentivePlansNarrative2014StockOptionPlansDetails Stock Incentive Plans - Narrative: 2014 Stock Option Plans (Details) Details 85 false false R86.htm 2417401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.sorrentotherapeutics.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.sorrentotherapeutics.com/role/CommitmentsAndContingencies 86 false false R87.htm 2418402 - Disclosure - Income Taxes (Details) Sheet http://www.sorrentotherapeutics.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.sorrentotherapeutics.com/role/IncomeTaxes 87 false false R88.htm 2419401 - Disclosure - Related Party Agreements - Narrative (Details) Sheet http://www.sorrentotherapeutics.com/role/RelatedPartyAgreementsNarrativeDetails Related Party Agreements - Narrative (Details) Details 88 false false R89.htm 2420402 - Disclosure - Loss Per Share (Details) Sheet http://www.sorrentotherapeutics.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.sorrentotherapeutics.com/role/LossPerShareTables 89 false false R90.htm 2421401 - Disclosure - Subsequent Events (Details) Sheet http://www.sorrentotherapeutics.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.sorrentotherapeutics.com/role/SubsequentEvents 90 false false All Reports Book All Reports srne-20180630.xml srne-20180630.xsd srne-20180630_cal.xml srne-20180630_def.xml srne-20180630_lab.xml srne-20180630_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 true true ZIP 108 0000850261-18-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000850261-18-000031-xbrl.zip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�E1]-L$%63BP$EJ9J9'X[YABJ5CW2I]*8C+,VGQ0P80U;=UWD M4@S*/^)YV8CMZ(JI=4(^&5TWGT#%MTP.FI9NN/LQ07G& MQI,"B@&H5SK7;8,RS;"(QH3QI*NJI2*],\*IV\8341W=PC@3*'863:6H@GDS7U+GMFJKHQ*P*X\FR=!,9>D53[3SH MCB^<+*:HCD(Q8F""BGIDA5)A. F"Y)Q6LK/PZ?QZQP3D7L?94%U500H5\5]B M R?4; %+![N@L6O5!$),M19 ^;=H$.U70;4R<3XJ9J _O; M<&PW;[A3(%I06^P-_>J7-_7B=BVD&ZY+-*PZMJ.X+,^>-(FIN15!BZNG\SCP M$IWG3D=2!E,M2U$U1IBI*[;*X&_9!6JNIE<[;?<;1.\C*5>CR'!,'6L*MDQ' M,2V<5_82S;&J;.K=)%5(UKE]6FQR[?41S4S6=JE)7=,T%,(,.!L8Z7F6-MCY M%>8AW-.EY:]9S/Z+WI#*P0W.8&>.B. J-DA8 /JB:3BIIB=H2&MAT=7+<2*H,7!Q/_1A0IK\ZU9O,FG2,O*33H3*N&8W_XX ]>0E$E7%-\ M4PX7.)S9AL*YP\6%&D@SF:XHCHX)HQ:VJ\G@ZAHXK*[Q1)#(Y^0-3.PJW'8L ME^@*P31O:BXN@*[>2J[AXX'@SZ,>#L6V=8>J7.&*3FP=,6YQ<3@(-BUN5U,D M5_/GNPB)]QP.[-A B(Z[MCVYT. MQ]452S.(+6[6<2UQ^4&N]8.@I-7BB*,Q"./8L@,Y@'3$3(8M8):J8=DF$8S" M!179LDE%C!Y-=KP#$N\Y'"IS7.HRXG)*54V'T\%$0H!F$F2Y($!.)SM: ,AV MIT,W*:(*P"B @7 /SV-%J9(>I[ N#:,'U;9MR@BV M0$W3%,)-ARH\;U2D:J7ZUKP$7B6K3M0VX'>>",F2[C?'6 U5,70+; B#(UNO_B*AFZS)X)BYDB6$:!TE6FO25?P6/[[#JM9!R;&1B2C8G:[N(@O.B+FXCX\S%U7,$$VEJX6)ZU?% MO2#^W1M-_>6U;AL:=^<3X'2)-]286UXB>@B+/T2EYILWJFD?5WC-XJ__#/Q8 M-"">W8CVPZ5W+L9)^W"N5'717,O C/D5)AQ 2V6:7%+W".D(:HX#LTQXSJU=QGT$S.' M!:,JM [D M\!4')5I6Y^8P@S76I7.P=UC ,M^[2>DUPP%9WHINXJ"@-SE=H8 MV>ZBY33\5TW'K!/59XF3DXD"51%U,%QQ&%=,1],HR8N13)N6D7 8Z3L;_ M*6'8IBK10:EES!7"0,_+01"O7B]B:'T[(8>%GZXS@G6*#((HQXI+;)QK-H:B MX8IFHZZVF#P. 'O'NAW#(>)J/40-T$LHF'Q6UEW*L'5.:P0J/0UI]HX!(Z)S M&Y/T/AP" #55);_J6E8.2P8,5$UJE+N,%-# MNF78CI.[:2U.G(J8[!H'.D\G"=CA')FFJ&/@Q*#"'9M7CW!B5JO9L7Y8)TF' M<'(R46#;*@93DJC4Y(Z-5=W(,T$9$J46G64XY^DDT2G%!JBS8.53:A.#V_D- MMJJX5:K:T%HZ M&J8,:8B+NU"S VLBMR)(5(J4/PXJQ/U';"Q@L/:.V?M!,/*_?WGQXK$W2&^I!3A4N^%L>/C/U8W%*?9;%OZB(H[DU0P99VL::8RO_/WKLNMW4DZ:*OLF/^RZ>R M[K4CSD34M<>S+5&6U-/'OSI@2Z@Y'VVJ1 M!#.SJO*>7UH*3!2DICR?6.\H:/<0'2?*O0YEW/ZH#X^9N:O;:;?9N .4_>67 M!J\?X%>,&1#2>2*EM1@I)TM*NLE&T[5_4QE%-.PA^YTD=H$SF#V0T6-O]/1& M7LGJ64E4QC%#NENM%5726#=OM>.!AQ2[.EJ9!L;EVSRL]]E>@OE[?^H:_WUY M=_!@,D*)^.GRO=%#:^UP^.7C:'CS>#WI.*E\(%>W-O>NSM;<+IUU[N]>L]IQ M$YRQ,)Y*0PS7AEN>HBP0 [E7M&L3(R/&P%L[DVF?,?N5+_<9;WPZ/W\-H][G MX=WB#-:J_T0D%\H; B:B?QR3HV59:EY9I#I%N*\!.(4,/^)SQ2O1^XI7Z+^& M^<4O/KT,#E966?[*/PR_GT3=+ N0KBSA8-+K1*.'#!K)#>A8EFV952SHP91I M=(1_4G2C\'9@]0S"4K\"6DE4AY^]DC:WJP8>YS$G$_COK7S1N2H\VA&=<8]CHF,H1,*$N C2&4MK %2@\_AAD_";%1 MGL_2Z!(;VMK?^X.IE5WZF?DVWK6 .'PCDN3YQ+>4%,I+^Q8+?'[),&7E4\KW M_*49(!%YNZR]N>\/^N-)=CZ^-W/8LBVZ5^A92L)#94X)N@VDYV(BNN['2-]6TS M0K4$KSBX>2>7T_-.::5U>)%O1MN/H.W699KI7(R:;Z],&7E MZD+2H)30BKB@I",1/9*2/,'0I08*T^V!KQ>2.OO/Q[LGMJ/ A[>/XUY+O)\? M?Q]/S 9!KV[7_$C9 M<_[TPVED%V)0*N KT1H];\K1$):\D>.U'92[*9*3R_WXH_Z4_W1U>_4XR0[: M>%YX^?KMU05(^UZ 3\W7O-A[.'HJ]V#EV[R MAYJ20X_C@@=] K.^XQ&]QP<_G@SQL^WUMW[S?2E[>$(/815FPDI(/"F=0@2% M9VFF'H(6+D8?*S4]3YJ]MG-=*(#NZM]K,HS.* G"ZPP7Z@35/!@"R1IFE 97 M;X4W.X3+VZ1R%J%>7(%M>!UKI9V73S,;\O9I]'DET43:C#1 !#4A=NQH>V72 MG@O[-7IX- 7"&)/.:^Y4D-1I@Q=9.\FU5+:R"*] M >A4P@?(%B/;BS0("4/ MQ)34.!4ZU-T,C!)S+*,=H!&GY'_9HI6"XI?AQV9T.QS=HY=]-<'/ M'%>.V/!K,_I;_^ZNW[L?OV]NLE_OFQR]M$U]R0Y.6_VN;J?5Q=6N;W3C42S3 M3L!MFE 2'F-@G("++._QUO.9 QV2J+>%3%<#ONI3?6D'?+U3E3PRLNV$3_+;16]]5E Y3OZ39NRMI J'[S]#:&Y[3W>33[A<]Y< MAK62,NH/YXNJ:C^PKQE7T5 MWCHB$T$_ETKAE+/S#3V2" >I\PJ!^:>_1)_^]M[_P/=G9PW$H[8$_T<5QJ0L ML"AEP88CC'-6S0TY;!/ZIN1Y^'?3_I[GY M^0:_NW_;[RU6MY3&;CNX6;JQ^+7'>_S+&@S\59\"$9!7!2H%PBFAF67&+OK\ MK*VFQ6&7MI(CI7>NLT$;,VU6^M+[<^F+;^>L8 I;;YC6+"]N#1:D*,@(RM * M>7N'E/:)97FNDVMO3YI6=;Z@K_V7X?#FC_[=W:L[Q&<+>,"&JI\''T?#:_RU MW26O[8-8UC-!;8KX#Q%Y8^R\]F%3,O7R+K%#G>E\1[=\9WSOH3_!8\K=]3?] MR6,>Z9II[!OW./DPG/S63#[V^ATS;5OV'D>TYB'PP"!"F*;1S+P74CG+ZD7@ MG*ZN^]N5L-,PLV4?,J=82D( MOIOMD.J7XF)3WX0DW";*30J,\,BBQP:K.HL8\.Q$7'YM1?XBJ[WJ$ M?GX3FME_9\MN\%/P#].NVAR=Q-O;YGKMGK+UZURC]32FO!0=!!,J,3U7:$)S M%BI?X!W56N_R>O8F_2+2V*(1*0W@E:0A6A,=85$7]2XA**@:9BC>:G5V8-<;?.C=+_6\?/EC^.7;\''<&]RD_NVD:09+J]#RMV\%F7!1T[PH$#SE$# \ M]G.S8X,7I&5#GX<^R4]D*5@^2"HO(=:MON$91$QLXJAQ&?[;2Y1Q4L7#MXQ( MKMZ8B/G5]623B!== ^A#CY_&D^8>7<[1PW"Y'?ZH M-,=\>R?VLKBI>(/B_GS=Q[^YN^MM'6@Y@ZQMY(0EBE;+&F)0V*14M8W10MD? M[&I_'D[33,-%='@1(:?H-.6"64$,-3$)6E2TB,9'\J:$/&\97>K_G X]?\PX M,=/1,^1X)1ZW[B]K@%]61C/Z-_W>Z.DS6OBN?DXD[SO^&I3V]4[(,8KSJ<,1 M@6LOM#2ZI#%M$(&LA4+0*\72-RORFYMI4J1W5TF^G<-?\UEC][3\E24 H*;_ M#_2Q/G_#_]P-!U__[ ^6L8-^F;0S+:<_6T]RYW4P&%0$5%S"@YW'=@KCO?96 MQ'^=[4EB@084WI 5K)TW M<;#HRM*##^.W1PQBUOM=9U"9/N^CT#Q9$;SW$I_6W$HI1H,Q;TSZS#Y^%;L_ MJ[\B;]O,U+Y'^+ZY&7YO_K_J$#<@(47#=,QSPT;+ "CXXBEXEH1=Z_K"3X*^ MNC-0OW*,S:<<4WB>S.CZ["7UEG^P?/89[CQ=U3?26XZJ)C+4,58N @T?%$U\ MG;3I3_+U^66O4MHM.#\7/?YCI),QL-GJY+E3IK1II_M?N;P+AB*5NPI[]NWX MDROKO<]VNQ.@XTN,9"9:;843&-O-]3FUB:V-.O1/2IU;V@M\P,7*<=^[NVMN MW%/L77];_=X7S[T=-G;FVN"8_4D^U9\'-_WO_9O'WFK7CO_6;VY1K-?33>Q7 MM[9&93G1,(UHUQ:-/YZ6/^GSYP-=Z[( J M%+S6AGFK!?%4)UJL%N6V"U7X[1W[Z\A1OM8KX*P)0EFE!'CNE()4=J.@XY($ M_:>X A?(F[[6\Z?!@2!<):)R8C&JA0IP>/XK>P1^X/,_8R[WM1Z\](PD3:W1 M3$LAC<@8$[.'[Q5=*8V\RH-O>XIO,8I)&=G#Y$*_Y/AG(-0N&F2[$<%R"O/EJ/E5IO2JW_=;L)^[E9[]D.XML"- M%-8%YQCG%D0!QP\@V_UI_^O/9?+3LJG;5Z(G/HY6:V+K+28NB7?2>,9%WLOG"A:X-XS&+F/.A))" M,/VJ.%R_CKH_]_')C3C MZU'_8;5:\F$X*!\9^J/F>C(<[=1M0J6E6@D=!0D$N%R,M6@2&? N:5/RNN[2 M@1*;K<.:0F/MNOT&A9*$B!FWA APDB@HB1Z"UJ,KOZ=;KOZ;%==_-*/KQ[MF M_&S*UO:.%)4W SM&JA^&@ZD567X *[9]0X4B!2U-]" D&F1#M/4+-%_E3)?& M8T0J_DJ5P7XR_V78&Z#IG8O\Z2("9QX2T2XOI],98]5K4_0O QU=A\"ET(;^ M"/)>RD5\Z ]FNAD]@3S'\[W919WBU4,3E3Q0;7R(CFDVK_"X"%9W*0@@2DBZ MO&'N[=^BW%9_8)*G[4+S M^^39IIWSL@*P:#&^C!&4(E2F(.>FS />X:X<"7 -1JM7JEP/D,XY4U . T[& MI?)@O-2>Z\"**XL7O#,V L$D?1W*X.W4T;=&JN[6HS&"1V6CQ?!5L4"3!#?W;-'#\O'2&NYC;W0UFG)X,YV(+CU] M6X?.6P95TQ@533F>C-(38<*<*^T!W9P-XTJ$=$>6ZR@[FI&-R5UE#16&)HY1 MAC%!>Z+F!DA;V#P:>R)&9N=H'R??AJ.,TK'G201/@+& T;T!&=&7D67P5$.@ MHFLIN1+5'IH-]!Q,]D:Y2V:HMBI(=,2(-XSHXI%IS0CI2JJ?G^R9L*<+BW;3 M)X?E9% 1),6U2:BFJ=!:2%F:,K5+L:NZ"D#E:5CO6BT^Q_O8,XQ:^NBM'(.E MDDG@D6B#L29&D"42XJ@325=X3[2F*)H-'-<[P\_([9?1%/CM:2=^ UCO#,GQ MM?-B[/"8EI ;='5XW!9(A"5LY(1:U-(S"955A@' M?-==S,J,7"2ZDSARL2 Q^U-!Q\PM!%02Q-\RP*W96K.O/A;C /4OB< MVXDA L'(%R]DV0:K-8#HTK.:&L*$5&>C]GQ7T;!D1:1YGQ(E5*4D4MDX'-#, M=%W%U\;M7E=18E!&!$/MBJPJX"ZQ>?7=>!)9M_$_XU7<:/(9#8IZI3E>0.\% MC8X6DV\2A)PJ=9%06$ACGE"E5HF://F=Z"^SN9_2" MC6BQ"3-"X'^K\S3G_0R7CU.QA-TQOJ#K_M&,1:"HP;UA)=:$DN= M+4N-+:7=U?/MZF*)GL/IWOB2-'J0'NEE2:/IY<$"FTM:.ZU<5T5TEZNUG? # M\,D 'WWTQH&2UJ'%2:88(&FDKY&]S#HOMP;PVDK7)L0Q$6T$%(GUA#F>3-*I M &[DO6VQ31?0?0A[?FL$8 P*,#(;WS8=F05FC MB]S5*/ Z"Z]MC.B/%EE[YEE]0X@4]-3"MI/)J/_[XR1CBWX99K3FO-)O>'>' MRJ0L%]__\DN6(OHQ06EA485X5=P;S67B%<3Q.R&J5WH,P>?F?=.Q"FTXZB:" MKCOUFDHJDU_D=62J<$_? 6V#A;YBYK>\1,HL(5YD-$M4> '])S9?8:(PH&ZC M(2'SAN]\H5\#[YL.7OD0!&@KI5*"4LD<$8NJL8BJ/G@#E=&\ //X_V98BA]S M86LX.(\&2!C &>TC ''H[F@,&4HBQ;LV1E,6!N=RYZMP" N7ELY&.&$F1&3H MJ@:N@4N71[_FTK&$FEHZ3%,B?QCI;%$BD(PQ5*=$/5%.B 2Q2$>':.J'E!/, M^D>2SJ:[8X(CN683A)5>!6Z5U$7%4J>JS/N5UKEL=XWTR^9=C? D]6 M_VW3K%9S/O0&D^<.IK7"L"%R, ;#Q2"I9Y99,Q>&3H;H*@Z#CEK5*<1QT!;V MP"C+F%TF.>L24 ^^##\E0J&&G=>R_="WDW0\"YO"=?"6RKS++F#XPK7G42[F MC##DK<-UK=JJ_$(L[/4BW_=0]?5[=Y\?'Q[NGK9M?$&;GD'O+% =@]2)&$OP M-:;@*,8(M0SD/E=P7QFLV5RT]3(F[4602G!-%1<,'1)?$/QBE'64#8!&7.W. M1_>FH(-9V70I%36)1\L\U\*39#5[WB QM>[RD&C%3F>E3':V$_-]V;03GKM MX%&C8\BTI][$Q!F!Q+4N$'Z6*EWI @UMAW'IM^]'UB9WQ$D9T))&B$@*I=JP M6'#6, !(E;,&NIIC.HRN+4YDTC8E%Y*5*KG(F?&E3T$YM #U2A9*3R.O+>X; M=;'"8_7L,+-%ZRM#S?0E<=KITM&QNW)VAUN&$NY4]!Q M[7)[H-4^-W?.YR6Y4/5Z, VTG45;)6%O\C9)+DGC46S<6(<*B#K*XSRCZASG M4)'')3LI>5LNG% .74J,8AVC%J6'<4NIHEC";:53&#Z6MK$^DKR-V0GMT>=- M^%JMEA9U.5_@\WG%8B4]!43M0=[C_>-=+_?1S)8R7-U^:/ZPU].%@#F6&/4' MU_V'.XPU9OL=KF[MS7#:Q[>?#7(Y43">C!YGD,.+H1G7#)K;_C6Z4L^C-ZGIY8[(%6&%-H#,>H]?4/#$ M&A$Q"I(T W\&0BSZGVA 4>G6#Q%:[M8AQ)Z&E;0!%:!T,1M".4#0/262(JI [4]#&VI#JQ86T'4J]N&"7 M-.6I)+22]50I*L(DNF0H)<@M$V5<)5?W:A<9)20N(Z'GGYH">^Z*,;ONSF&< M=-\?CX>CI^FE"X\-)90>???..-0%)'+-B*=&24KS)N.B![V5SK82 ND'J[8O#? M\A[+YK?'WN +BB?C#FQ+TGJM'4C 1^@M&)H=4G#,.2F80&NS-3NRCH'7Q"18 MZR$ 38P8P9+46B^ 7?%W+H?)UX.GKC3DJ;FD9[G*!AG55G@:W939!(P6"ZA" MK'P$AC;2G(?/>;OXA^%WNMV'*L>8H?^OOS57@XX=YJTV0>J%0SXQ%C41 V<6 M2<%I=<2+*A]3#T&@4!2&L[$)/<3.$@1=0> MG6=N&%B#<:UR0=3)LZQ=T$"^O(16W]OLN;$S"@J-*3II3'&J43E-,=[FRDE) MQFP= Y] 4*4:G%=SSJ;HT%/)TU6]KYTMGB<& M,6*7;\A@BJ@XG0A9Z:_]N_?X3?UC&5/W4]\7\=].YS7\K_-#>A/[[N]FW;">05='4, ML:2.!)4#A22I-RJA'^+S;2;"=Y2%U$8;VT'0D=2?SC-OU>G0_[9"H_]EI$E< MI](V)#BD5+4-&:I6@$4(,2RRCX!'5FY?_2+8F 8T7V<=3<]Q_O/S1[ MJIAL+8WCG$HK6-0$HT0DU!JO16A9S%F=DNM]^7@F[9037^U;2MEJ!"\LT!Y M=$$K1B58/$4 84+M*W2IHPL)9.- BD\B,<]XTCQ%P='9*4\0?1M=-PQ/1S)> MC(\+'"P55HA!6 QGHVKRO/<@F);&DYT<319&D>KP)G MHY&Z3-MXR4FM7-\!A1?DXP(GRP)3P$E:4T+&6T!;C*%6+L%VS."\W,EN M[*I#>HG):WIC[N*F>39['G4;8%U#9*!?D(]+*&/-([&0)SII$EH8:B7@?0=0 M(DA13Z:>X&1OF]&HN9GQU$S;GR[I.J4\3,=2((%9@]=9$[IPG6BH%G#\NU$M M?CO)/XC#,\6DC)(@T";ET6B,E= _MFZI6%2]5M.^XSMS.)MQ^=+[<]Z\-NNF MV']P*P@/D5 O FI8M*I$N_F92&"DO7J(T MH6.,GK;&_=>2<2"MF[K*H_&1)H_.LN$J4;!"SZ^SM$F1:MJ(5AF6@V@]M)]? M:Q>M9& T9\([8GW9K",-$75CH"30[E5:3\KA)&^2<)(>F#8$?&16!X?$%TP* MFWO\JBJB:35U[TLR7O'2U+]^9=+:,49FJ&?H>G/"\L2GX&5>PCE&*OT-0K!N M :]2<0B=FX2*X8'/T!,2J!(Y^N-"%9T6,>:IZ&14M]W([70^C/"W]^H>V#61 MZ:E]\SUQOUK_/[0OWN7>:8-3DC=VE*LJK MGK45!B1=_ 3B,,8F(\_Q#^OO_4&7YM<=KT:^-[X6]YIB/_) M4QO?>W=Y8&-OY6-S:)LT1>T3 M-**K[P':F-53<9J-5WO ]QIV-JBW:*2**1 MADMC+?,9]H/.9P,E5:P>B7H'+1B@X[A:8!N@7Y)_,H]L]@>/>-Q7#\T,P'^G M@UH)60GASBM-K.)6H@8@Y=UXXK1:9FFIA+_6;=V&U MU1<54E1X?MQX)=%#@A1+>Y!(4M!.9K?SNA?5*T*8+UK\U-SE_HTE[_F@:-GG MM4 @%+XW(T&B[U=J.-(+6\^?<*Y7(XZM]!Q)_*8X1++(,W9T-"XXI"QZ4D+] MW-]7^5]2MG7@(<3/Y_F+\F]N\M1=,QA/3_+#< 8]<3/=O#G^,ISD\9OGK^>4 MTX?AY+=FDF_ U\$Z//7GOJ[CMQQL7CQ?-G9N;472R1%)E %A/#AOC!.EV=0* M4S7==XCYY)*[R/',AA33<#3_J_Q]L#6O?028_!(^F#$9"((8I:,E4I)B#3'8 M<"JW1;'?R'L2+B#J3BE<1/[+6XZ[$\UKEXC8T7_;0;[-_]'T[B;?]ETA,GP< MY=?5L2YWYU/=Y-=5K,+KV(4&.BD#(]'*76+V4!'G:Q*.I=X M<Z!M/LU+G\.G=A(H8]. M"-JSZ\8UDS_P2OO>:/2$CM:L0QNOY71[YEW^J]DGK,>[.1Z'Z>?[^\N77 M_=[R"K-??O%;SD-IZRCG*7CN)/HUR2PZB[GRNDKK5:=Q(N&\-8%/@:]RP6OT M>=+<;Y>S==%IQC"V8@G]7Y]L660D,0[K0!]J=[Q>3M!7$[Q!7[[EWN+[O&,- M/>?[AUY_=%\YDV&V=BIW%;R,5$7R>3NT0V$R"4:AZVK*?@;*?"55WIYGVE\" MIY:?^I6=4'[VPY?^[\.;;5A8U!FF? J:06Y>P7=>BI#:1-TQPB-?G^#F[2PO M<_%R:[VESD-TG 5F:$P6S1E817G$2*E[DN[,XOMCT(S&W_H/FR9^U"4U(%U) M0WGE6?(A)J# -5&$+>JR?F4F=2GHWRZRFNF328J?_U6V1U.L8IX(M,4Y#%?6 MJ_GP(8;E2G3GM?C+B>AE_)?E6T5E,AG+> KUG($_Q"*Y:>4J5/Z2Q,R/(+(] MWY_ &Z2<)NAV2&9SOTOWT;-UHERZ0.: M%Q.9B,EIRZ>XO7.'F,2596M+U$?LJ1NNE=1H!DA>K&I^BI08T M#V5%I/+$\.Y94/E/)\[MC[F=R-!*)N*D1 ,RK=/$"0,<-_O"*+.A-37I_)X&5,A%9!H.=A\39Y%2)*2LRKN1G@ MQG<7H?C+F(CGC#T!\_#,>]N_T'H0Q0$8WF M(FF1!T-@$>-$KW2]=6,.L+*-K_4DGI:]+=T6 4+&%B9HCO&@,(*3M.A0!;+N M!7O'"%5G9N_SX_U];[K;>&DRY'8XNI^EPF=E63L>-^WNDE(WO6QRBFL2N='1 M>>J :0G!EZ0>=RY6N16S6TYZ#RF\'9'NF;9R@;+(##X[?(8A:&;MPF:9T(9? MS/L:VYVIKU^V+UY2D=9')8%2!08U=N0\EDC;.6^KJCYK=TK_\\AX2V3>:D#W MP5D1 U72,4^5$J4Y3Z%)K-J7VVMD7HM4MXP(7%K;BH !.8U).4E4S&.XNH!4 M*0VLQF(YH;9=,Z?P!H2[@]Y=VH-K%)7B= M(GX1];LR02"CS=E-G2=24UR)PP@+9KL58YHV-().P3DHG;0RE&*N,$E5$ M5%!ICQ3IKNT AXKQ9&F9'<6H*##4K9HKHH#E9(PIAHQD2+GM.\9>3HH?FLFL M.WD=)@=%,RW;?RY(PW*FJ\A\)K9ABUHG0,>@PCJB&I-RC; M%T\AT! EA$""QX$-7$+>7Q84HXSIB)HV ME#(72:*"!!"[-6^]E'!?/I_0:J 0P5A4O!A7<0@\:%]:['D2KDY_G4RP)PP. M+B_=?;5PX%SDZA STJ?DJ JESJ %0(W$]*:E_!+Z>%7<&$(PGA<(A@P=FZ*W MH""#U1'\M_>5G_8O<>^;W>5 I)+4Y64ZP$ *VU"3%I2:0U*3ZJ4]Q)S)P3- MI;,&05$?0Q0$@YADC?$8/)2\K7&I7L2Y8[A[*/_KYV&C2\$9EC@+GMK$:=)E M] %5EJP3BNN,8J>D]*7=L,Q,D^@0P9CTD")\U;/$7-T M4%Q5:7N^FZ?XTO+8/:,6@7(:F <7+4M F"]8/(35%3?V1MC?LVA.$O%6$<-I M!@]C!HR#DDP@SM6H('HWV_32H..E>)V)_(MI9= M$26+E!%!A' 9U-JF&&"1\HMU;$_G]N#L1"Y+DH/0WB@N'348'B/)=-$%3X'6 M19XS2O*4SW[1M[V^>P.DBC%%[4G*MIHD.U=Z1BHTY#M78T[!>9G#/BVB[\J3 MD3JXR%1&,$L9-&_AG,B\$[#&+FMMB@3_F31_W!UXQ#-BZA MX5/Y%7C[[AYO,OYNP2W;CLA=*'%/BX^;;M99Z@R>(C5];:8;8\?]FSE:TU)@ MNN4"6/344O)4Z]S?9QF!TG;&\^["NI0$+ ^/+-^!BPGLC*LK^XW60^/&C(:.X3>Z2!;025)\WN=CT)ZZZA&^:S7Z7$069Q3^ MYV8RN6LZ/-<7>A,D;QCG-J.W*X%/PVH]=UMY=*S>:BQF:*+G.Y$E 9WB&,9K M?LWTLS9CY%]"_!H @Z;HB#*,HT46-.HB?BY]+7Y.6PF%LPCFI25_$E7#DJ5< M"H'_B1A,,&/4O&O(4 &DBDHU_R$%N^Q[,*[;;XGAGMTV]H;ZORW :1\*?C-Z3*FN6P+\C41F?. M:-WJ-,[(HHKC %KK-7[$ M"W );U7F5=")"7QO/)"HK&>+ )JC%UL)7A(A?GS)G\1;M=+(:)+E,D3#B+?> M%]]%I*BK2RU.$Q?O+M@^_OKFE_[WG*68H!W)R[.FG5I_'3>WCW>_]&_7YQ!R M?OI31D:?7\;)W]_W_NS?/]ZW%<;:7S)V3^][_QB.GJ]T^9F/O4FSE/Q[!K:@ M/N_QAJ@#TU8(;HPM9@(E"WF]MUG:[[T+@^<4"'[<>06B MXI$6)02B*M,,51 MY,2)%[T)QYRT?QQ/AO?-:(HDGA_SM_Y#?>[18+ +/J\,-9JFC&U51IH]M38# M.I_GV-$9N7Z\?YRBG*]?'[.M9&F(=%(XGR(/EB07K)R7FP0Z_Z["P^5,MMR] MO0D\ WOGN.#K !8""*.T0V^8);SV*(QY^50H2EUEI55K0?+;E==.[V+MDL>4 M!!@I3!0:'PS%%U->B0+540\S\(.)[>?!Q]'P&H.(3\VXR6Y_7C"3_?KA0W8G MMJ8R8Q8:HSQ$IQQ-INRE,L0'4S5Q_5"B:]G<=7U^><5\HBPYH8GW*!P%"TV, M6JW*6(A7I\HVM40(AV<>00DEB12HGM'4SA4/H!36UEHXI M(Z@GP-#IUY&R@K5/@/Y+$HS3A7I6E3R+JCY8<2W6Z:V@2;LTO1:9FWYND\ MMC^_8T*+&KV:27$I3;WT(_.UQO9VTHQ^PWN0\ ?V4]E,.$%T(,BI85P+H7RY M"H)87JML0CG9F=$MI![.\:?FOM?/L/U7MZD_ON[=Y8_8F1$6LSANX4O$_DE*B:KX0Y*C# M/OZ2M' E: MJ*BUH#+&15XC=^37;==,\]W]K0U4'LGH'\,]MVES[76PT:.R%#L#[Z//$3M16VN,F"!UIE>I5@:F>&IO0< M3?LELQ4Z, ]J@&(X*='^L+"N,H!Y<&$JE6+#"\&Q 4 M7>0K!4T=91:Q>QSU"D1RG/.*5T6A!T9#Y)P(XXWP);O%4!G6]T5)^98NS&[^ M:= Q"A)-T%0X9;R-:EX#%Z!IJ"?F9FUC%Y/"Q@6:!'UK1U0B(6>&.$8CLL1O M)OD:NN'"^N^R.0#%8QX8,CI:I@Q$3@MHHR ._;07UG\O$>!SFI<677LK,,:DJ/KVP_GO9X-TESP45E&J+2D"EP H6&KJQJ5[H=6G]=YGX7$:= MA"-$<(S&+B263#$U9=; M 0&V*^5(S9%T7U+S,?2#G:=$18>:#HRD\]R#43*FJH^+*K)SQ>6%!'&,UG-, M)I:<]-0GC%_1[R.+9'!B]<7@AK\1:1RG\*+)PX8^KT+%R(^"9F704@B68I6T MV$OAO;!D=DQ&QI@A&IGBP"T&B,&EHO(9EZ'>14C0(EY( AN3B\'2I$.423J' M?KN1OBRT$PPC^FI3NID"(UZ*[@NJ.@!JK!(9#DX3SU->V%#,E8]U8SJ5%]/Y M+^'@!9D4(\IF' W'!1KRLII)H%'D-?X[W[E#X86E<61AQB=O@U0L"/7U_:_I?O^4RS_=FU/O:U(UITED:!#X%1:UCT7M'%IE-].]W[\C; M2/$*T\,1$C5'B[Y^^C+J#<9("GYSF45US2U^SY?>GYV+:W[=L-G%HHDFCG)B MN-%,Y@3GW*%S1A&Q:77\'F2=DIN->VJX\E(0@^\0_5.C\![._3$;.=30-B_, MC=Y\-C$(F4?(67!.LXP]J I2C8O2U;//0K>*YB_#TZ83(B3YX)0R5* QT21D MM3F[;X"!5>5?O!,MX.4#>O-N.K0?PS]]0_]L??IKNC;D/S^ZKVG%TU M'IKKZ?.GL![3-'+N1$!3*"UE'@RD>5";@49T%1"]X^W=,ULI6V&C&:!:ND,+ M96_N47>,)WD>X'LSKX/L_?P)RT7CR#0ZGYIE<$L_M^K6YVGB:BL1,:LU\RT$ M'4O[IJL$PC(F4!=+8[67Q!N8=_\Y[P.M(6>(4>9BQ&]YVU8!>*'RP@'&,\"% M+W"M^&=1P[4"$'91XC=N.Y,ZXNT(P:"/[*)5>21Z)GG\HZ\M/K1Q2/8A?CB\ M^:-_=[=?RD899Z+REBMT1&E.N<<2F2=E.O#=-36K3DGYO8?1LJPC$A4,4K0 M4D;J!$>OJ+@,--9M"TQ7.F(O6C;6V;FEE!ICJ?9," NV+*I3:#WJCL\CY#(3 M"]B'44[D@5J/@_/EP_]9AK!; .$ DB&+S3<\7'@J^! M9:"]>&F3&$JL&1[SD,[,H]O[D>5U6X2!A$ 9U0%]F30ON3C*3+TPKH.V+CJZ MZ/WY_J'7'V6+LVY30UN7K>+(9C7,G<1++EU0R;&\T"I#D_%(*'IA.Y"Z2L*! M1/ZVB4@1\18F8GUN#\ED7RC) D/ 1(!DU!C<>8\*35" MX[2NYV3/0F1MNE:)C#QWZ&B&)DP2$7R8#O3.A[@[]NV=B\B-QVV35!&%)IS! MD#Q)ZU51NG@-ZFK#7D0^?^7J=BVNX2XO1^1=(VC_P;E "+=H0 N5C+NZKV2) MRC4T'$3FMA,78*V0A#)\Y")']6A%YV1B]$\V/? ]R?QE./@Z#99G(?)_-'2:/A_6QH]Q%U M[M7#?&!W'I7,O@]CDV:,KOZH-QS=] >]T=//D^9^G(&;\2='P[L[_-&?D=U1 MTX9>V\&G9TE 0+V$YWOZW5X; MD)U7&@RT!4_SYFDC.56,*1*?=_C8Z@E3M>G][H#M>[!P-KXI'1))&0<)@S,3 MM#;,ES>5P'?L$@<@] 49>6D\<\HMFCSOF.,N4$/HHMO7B)_649>^N")-@D"FSYZXPE:XT2(4T$[ M)8BJ2Y+9T7D9>9UV&]^.ZM#IR+7PU%(N,,)E:'#*J %3ND[UO%.;+,PYA;-1 M'08;4XA$>)YXGBBP?)%AEQB&5&G>=Q3()F_VW(R\]*N@3*"T+,:5H#!25XJ5 M8\_99E4E9]]5F]HO**]-ZC Q ^B#1Y<22YX(Q77)[P?AZG6'[QAI <]>EI&7 M/OB(Q\U8WMV@111!2($7P:'K8WD,(M0'S]LK60Z4%SJ7\[R]:P;-;7__D-6F MI" %(C">X.C^Y'TZI:! C*JK@L!:6>DUE!Q*;/M>KOH;C ?N-'7@8T3#S$2) MKPGQHB-2['Y@9R-V%5[38(!!G;4N!"JEEG;N$UN7;+TW'!]1JT?QE,1N4?5X M T!(JWSNJ^ V AA6RO?>T3J:!*:Z7OS)B-UT#9PDPN0% ].>6,(YB:4(%I5E M]9VE[:K.F8E=<2U#+F^@MY2"3H1FO3I/X#F\$?4\'A)+NXSH;L0VXX^]_DW5 MDK2+"\RR!TR#\(;C/R*@!S/WY5UPM0YC:R2ZH&!?^K;(42%M^!LCQ>=/4 T0 M04NO4])4=HQY'4;?I^:ZZ4\!X/8K>Z*IA)2 >>%0>HZ'4.0W+997\@.UGL)G M&@X@!O;X>/J+Q^MA[ MJNG=X5Y2C+V5<#+$A,&&L 2]DA)C2EH7XS#&E!71FVDZDH%M)7MG%17:1D$! M]3ZJJM*X+S4C']G.2>(2$9HS1T@*^ _=O]=22]$5$A,T;ZR,I8-;ZA>IP.0\EMA[*>NM-QMG6T[2H7;GH&BBCAF#'B'3I;2".D16/5-FFSD[GL]G MCW__@],\H MI)"?@>&)2V%0:ZDG4=AH_:2,T19&\YA>B55Q;P6[4A&IU= M0\LI"*=8=0KOMKVFM53/ZK]=;<%S,M_WGD MVC)S=WK7RK^/H^%]?SP>CIX^ M#"?-.#PVZ,K25D]G[JO!WW>?/^3+TT.S.J$V''QO1I,\*Y._OJV94\BH$I'< M&@;HCE"\K*"I]5&C2DW5@^15$WZ+]5VELDMN$\]*>T$T]<9ZB@%,#&5]:Y1, M5"8+VGMVCZ1M8R-"!,\"AV2T<-%%R4MGLI.4U^T;5)/V"S^ ME<>[C;?;>%EPY60TL9[#ICF1>SQ56ZZ/]82)I#-P@"5!9Q>\3%D3)WD-APJT M'2>OHZK4:69)LH.;" /%*):[Y/*:9!7P3./B]25EJP"(LK:;W4W(P<1N/.08 MOIF5*6Y_ULRB@E%_489Y7B-:A/^T'O0^OXYX&]O9WN.&G&GQ]_ M'_=O^KU13GB@$KN>_BWZB?\Y[ \F_X7?_CAJ>U(Y[2Q_A?5C)K\]?NMA%#YZ M&,XZY.:Z\(7+MH[+@,_?6-!!L4AY+ OP\.]#QVHL4BO.(V2X?!AK@[ZM90<2 MK4,KJ!QJM4#P2B_R?A2=L-J/R,6EU?SXFI!N(TD;@38I,"!QU+'/9$M$-'W"B9) 1=LGJ.ZWK+AC:M75@U!?O2MTF?S7JUM.P""S%4T$37-<%CH$M$R .6H(96ZZSZ@ MCB-X&X=U7N%Z3?+N+V+0<%@6-(8/'15>'5#W989WX)E ?+G9 \@\P95"[Q&9P!W*9AT#4*N8T(Q$)C(YK<#$: 6NWS%( IPPI6UH !;U&X/XQWKHR-E.9<<)*<&B9C67/) MO=,=FV(E69_Y>[-G=F[O/"8:"5%$Y]YQ8$#GA2T+.D%=+7IY&;^M2QRU#8Z1 M/-IA@Q6"B50 ;2PP5^$NO0(!G_G&43")B1!3(%Q:P='%F]\X8SK [(X3R*"Y MNO6CYJ8_P5\^O37O>W_V[Q_OW7 T&OZ!Y/K> WZE5429E27YA^%WRK8V;7QI M1O>_#'N#FO%5;"-0,@GO(Q$F ZH$R-9M\)S^M\+X[1]LDL8 R M/H,L,L3K];?FRQ_#;9//R<4X'<;T-F-HF" *PEMND^M8U=RNI.['VHI0AH.O M7^:--)MCUR-;;E9W$7,2M#' G8KH?KL I7U+.TL[% )M5UV7R-Z=G>7'/J-X MC-KQZG9:O7-/?QWT\:6'9GP]ZC^L8C7F\\QEOOS FT\*[Z:.(*T*,FA)72F;YKF9CCVF MAYS;0252GW*3=HI"X[WBS!!=^GY$AGK;6-JJ?_)>253F M>N/^ZL:!.)Z@D":HA!<_T6&7M^+"4*#$4R8\E8XP8)H7XX@VHKK#G,@-VF+Q M^T\GU8TB\+W1Z FMS*?F83B:[9M^'$SVEP)D7#%BE3D]3/^[J]B-Z<=?]A][=EGW79WKW*J'9SZLY03E- M*:?!+K8;A*ZE)5H9L58&^[!XH)A^'EQ<1DX2+D((6CO0PANM=.E'%&B+ZIE- M;=;;HIW9.TX^G>NESR2?0*BP*>FD,]2M4!18L1U:)*@5M&Y!Y!_$WE'R6;.7 M^EP7B'/B O'NO+^6A@NID=)W0,DSF(SN _>T:@Q[&X<>V!M2 RDB;5%(,:(V797I;+M;;& M;3F(SO%XD3B\?@J]^][79FS_Z(UNFIO:05P:YA'3'O1?\+9^G>49>^.ESO)I MV_HB4O9WO?Y]>XIG\9.?)WCM5_W)S\UD;8CUW-0,*6I'4-CDL2^U];_3?S23/(LZ3 H@@6#88:- MJ^@?+.]ZZ2:>C_5(2V3)08X@7@C+@,9I@\H9-6X)]$*%. MV+T#T)>02'\PS.FX[D&AK1,,D@C/./(?C,T *,X47!['5#U5K0A?]6_:OWX_ MTC8.@7!I !PGAD8/%J9NZGRVAH.NIMA$&_QN']*N_A@TH[Q*\V,SND81H]9S M3ZL(V[-O69,2UU,KX'.TWXP>>J/)4VO":#*\_O;HOS7W??17TBBKV&94S3,M M"X,NWSUT1+0U&04,@^*\8,3.AQ^X)=XLF\#!X_2#_IW\1-EZ6>S,[]Y"^]BK MU.E<3%?7DS1A\M=>3_O>9T>C CM];UQOI.?'HWH8@ M\$)9FO/REG6%Q!A)SYV/.0H$P8& 6TJ2T!L*:<( MC9QW( T#_L@NO.](\3EYWP;&0F7T7 J9K$.>8AY]+"X%.N@U1BV71(OS\?Z, MV;S_HB!"'?'HB08;/WZ$_WT)J6B%@/\HVPZRBHV*B#BE$ M&Z*+JAA-FT!!#;?)%&UA+!U*V38T^@C"Y[U*8!.^ (BD)/.\="C/#E!]75_] M0RG;J(NET.CCH4;V$0*G3I5"HB,LV YH-"(YJVSP#J39R634__UQ&H9\&9YJ M:Y5U"E]0Q-<4/"B"]D.4HAT&2?46#PRDUM.^"XFGYV\CE!8G>=);IB@P(E$, MW2194,-%[-K*1*467YJ_ MS1#:J).DRX!VC%+4ZJQL/506+VL'1KT!2.IYV-URK &UMK&,H3&W M/C&\Q:7\J;3BH:Y> 2/ZTNS._V8>$/3NKD:S@/6Y;6ZE3_5OO=&HE]% QN/' MMDS"4@O>^OY"&HP3G'&M511XYV&Q.P:C6;%2B1E_P]AS/(6X@N5TP5E96I7= MI%G+JOX54O/[Z+$W>J)ZD1,OT-73'\T]:1E[8A%N/5DNG//7]] MGY7%GZ_[=\V?'U%R][WK:2(!SZ!>>[RF#=D]+6B9?EH*UCX\H#?9NTO#D1_> MWS>C+-+^_ZS+]R_WB1C/=+!H=(4Q*F @FUP!,TCHN-3+O"O\F>4#6#F8:3[C MZG;AV'YNONZ<-VVMG*6,\1A80%^*HM.B34F<6C"*+2NE\>R7X$M=HG =)"QHYE1<"X6%4G'60<0N5&]+H@%!&HXZ-D M7"*-MCC^*JE8#Y:_RV5\?G(JMSD4),B(;KT#T-IZ@\*L4E73ZZ3A "(WUFAUD@9# .98DLE%%DAI/))AL!CQY[*#CY/SL8+"6KCV\( -3'- MI%U=MEH%*7::)NT9 %4Z7T3"IV%NG_RASV +;;*Y;5 J*4 MJ[)Z-H2N_3 MX*X?2E(;,24##R8Y:EG42G#CN)I+2DO/H4Z;ZQ];4!=_TXEZ MHZ3+61GCI9!!E7;-W"MNZAZ$5W4 !QM=4$9+JX3G05EF!'6Z8+\GQVD=YNQA M=$_*Q,;- PD]]8A&$!TDU,M*!]!!,"^I%<'7K1;[Z./3,;%%5T8M(! C!(? M1%)X%&4]A+)!=FSYVT-7GI2+C?E(S/J[^;?^Z-R@9E:4G-FVMN[I=217\!3]WL'\.T"J,74FV]R1%(8U+KO3- M..MK'* V7P?2>3Y^M\&Y:Z(DTQ9(1E>E(BPP!R6/H@:0!J9XAWIX,;9G6:A# MLKV$>N=RPH=%'CTZV00*I!97G&Y"6SR2U+-RO>6\ 0]:1L8%NA]2JZ0-F].0F=J";\XYX^#2\9PCWGP?_IS^X.;BV%&+ "%(1%PP >"]U*..QX(2KXB31 MVDU8D[ O@=OZ'DW&@68V3P[/T+[OWR'%Z,[AK_C6;[[O,O/LJ4Z64:VL M\\H+1464H"7:G, 9U*WUU7K9S4*YE/A.F^H^1) A,F/R&+-C&0E,,YX!2;(@ M\YYAZ!@"; ]"O@Y)_E=_-)D\NO[P;O@U=Q[V[_L8!5Q.CB08/@6<@!"LB=3F M(N%4CI$DUS&U#L??R*O;*3K$>/S8&UPW?CAN%0]FRA'>]T8@]@64N!IL&Z&5 MBB;KK"5$6NE),MDTSG*[UKF.R3:QAN$.-KJYG2(HK&=WI^8L9T!R'H%Y%R$Y M0PM(I@*#UFZ#1=]$Q^'T;FN?C)10ZP2^3:8P*-"NQ*/""%//G^;:NUPCY=W( M_C*;>\4XTQRT MYDFQR.E!G[S\>[)[I>8A_LAR_]WX;WO60;-D>&(6O::(ZBSI4E@"#$NK%V((K'G7 M9Y%@=\GZS=23B8BY_BE1WZ _2@":T H;5T44E*_3FB>7[E0=L5_YSB;W MYZ]AU/L\O%N(9HY\*738M3L MOS K^;R(A.0E%'A^Z#4)5;!IE#)U=F8/Y5(1=SJFMM@8:35S-#BF)6%.>JND M+X [-+#J=,[!SQI=M7_/OBGZJDC(IDS32?@HT>3/@^6M2)5.%E.K1N =_IO!(29K M9OIZJ'J;N[LM*C0E&RD^/L2/EH0Z7JY:<'?G<430KFZ0&-\\K MIKKD9!^_PCO\%XJI/SV$OS^?139 >07V\I#;CI%V-E%7MS9W@7UM5OWZJ=?W M\7%T_2W/3:^'%%L>RP(KI'>>&J,L!B\&/2=6 $%]Q\HXR-AYNPEXK;0V2ALY M?VA0'!_O\([@C^7+_'!?-5'LH""XRR$NY7B+6#22,45+ Z<%7C=T2:7;Z:!= M:3L51]O4MPEY/-8E]'HIZ@>N4IFA8[2#HVK2YD".1O,UQ;,+UAM=C:9%NMD0 M^\=F]#FW/F[MQ%GM9-,@(2CAO.4ZQ6"9*H-RFD<16J:H_)(\%(@<+;6T[4;< M*=AI]>RLLN.(EIKDKM!<)\@=TF6*'2TN!G278F?ZY;%]1-T_RL/0>YZ*2%8Q M DGF8^$ ;,>INKND)2;;6E,<$\ M'M3HG*V?R:27D+J(V3ZB!\"\$S,@XE=J.4 M@T''/D:B*<^U$DW1>)2H$6]+UQ4Y";%7CY/QI#?( _U[BM=8'YWE@+:.IL3P MS,O$@G;$LK0_Q4NT'$7V1D$385.0&#B&'(,PRUQ!K=_V:^MQIMYU+;Y4' +4(&D3,#*G=(XYUUTJ@R1$R$J>$:36M\ M>@>*CF9@8^,J2][0%(P'QA)&_Z:,=AGE\,G5*!.$'L? \+II;L9I-+QOP37M M/^TC@Z6H?WT>N#3"2*T+*D1B7F^,O]:3<3"UVYHN\KPE $W14B-\E#&*LG@Q MUW$[<("Y:8EZ?Z(?QY/A?1NW8S9'PSXW#Y-IH %3G(GWO7\,1XL?V!T]8OK# M\^ '/9]F]+U_O921^S1\ZMUAJ#2X^07_'N_(E@!22T^=3V:ZI-X$5 *E!F L M(S7VIVD#H';RO[^ U$Q 5&[A[W/OKIG"0D__?AJAA@PC.WS8H2[EDJ5:YL6I MV< I?(W4+9X?*NB.YW<$LZ$_G<[/T?/5[7,NJ",2GD)[O<-_+24,9CT^BU8_ MU[O+E8K/WYHF1R'VYF::@.S=/:.\CMT3_I^'X;AW]Y?1\/$AA\8S>)_\/;/Y M\.;F>3Q\U^3E2JDY)NN4XSK?&TD%5V6Z1G/7,0C>D1#?+J%U BWEFMPK<7^? M(A HU-*F:8EJ)3H L2./GK+*N#*U JF&0-E*\B93M(W6 M;;-*/BC##=J$Z"2GZ)R *J.]^/P[L,:UW$'(.U$\RCJ^P"]U6-)F@!>>Y14,@TAY*8";Y]ZEV:=I /A0>;&,:>H,$**4E>1+) : MF/6E1,IR366@M@GV69+6_:7D^O'^-OU_Y''>;_B?N^'@ZY_]/&F01LT_AD_; M+ITR>04'%YZAD2>.F06>@\O=%6T):5G5J0^6T-R+3TTS+CVA+UQR\A;#UP#H M/3CB &-8&@DB"OE,LD8K??GK2%VA8@#*=WFXT26*Z9!)2*LQNO,RY(T19.O M,<0WVY+=",[*^FJZZ6@<_\R],N,#&B_P^ ,)P3GO@K(NFBSQF<8.S/-=' M,2UX);Z#:-IS\K ;HFA+6U0&EC!>.TH$,Y18(XO(18;*Z)CU:J->78B[3\VD MUQ\T-[$WRKO>NEH(5QYK=$JA*T5-8L:@*I>L1!=&AUCS50/4[<_8EKDZ#' 4 M/L7H'#&H14QRT158 1*&/[\OK^" MQY.9Z3Z'5E!5J 7=3W(.UL1)V]VQG63RZ3D0"4E(*%(A2+DUO_ZYMQ80($!J M,2B3LF?2W;9$ E5WWV\2B2AE7@+4[E8Q,:JZNR]>$T^QK1V-3SW4<]"W'X9) MS*GP0/2%"NQL$3B1$@.%=]FW,Q3LF6[W2/H.. G])&*Q)#*D2:AX[#9Q$)Y$ M#QHFN/-F_947/>6:]^;?>,H3FDJPU@GC&8A1(CTO3D"P@QFK.@*=*DD[4:,] MI_G,6_+(()"M@40Q>JQGY8;>_*YA-E3 MH? 4F4ZB,(I(Y$?8D<'B(.)"6EH &[H;>9%Z)]I1@^$I,EV!+1-)2D*,:,LL M2UA@J4$* 4JOVR7(NPG"(X/#XV2ZCY.XJ, H84)4!@Z&;R&@",NZ\4)?=AR- MS[W_N^*QI5VA5#3U0)AG0H0D2:C;#R%IQF4WJAPP_X&&&9SEZ6?>IX7 CY<\ M$QD.0>89\\%+IFXVA*>ZT_G >GBH]GSHF?]:%1?KV4_E1;'3^\-ZFO>8W[.1 M?BP]^K6\7E\[*FK,K0;S+P&B ;<-!^G+. Q<+9 D6?CJ][_P?SS@\)M#'? . MY;SW#C')TI11!C*/A+C-%TC;AEM2&1 "=V!/O\-FAB^V=#VIAI'*,&)!S(,P M2OV88C^IVP$#L.]V[-#M38^]9WC"(?=1=J"H$AFN(N59E/A>AC4_MEPUC%0G MP@S.@__80VZ2$DK/V1I%*1!AF&+C)D"![?<*NG&8;I1 M_UU'?^+U<,"V&.IV@<=$ELE$Q0'#TJRP'M\:QS3KKJ_O)N<>>[O/RQ8EODK! M9@](EJ68&P /W&6+0N;Q3H/ZCH/N3+X\XJ3WQ"<]X @_ $T:QZ%TOQ"JJG>+NI9W'=.8%+CQ]PE+?Y)8IH$B'@AAT-2!QT5CZ4]$ M>Y9OD"VOYC-.>\A+[QT^)T1 ?,& E@."\^T#9Y K2GS:'?\MO*V$^3%>^KYA M_KA9@*>!3#/&J)^FU/7YAW"]I+M51@:4G\*E]W9BI[Y,*8V"C":"AEX6$$?> M0F6J8Y4RROFVQ7W 2]VLM4H*KM;TH0WZC-(VY14S+" MZXD0$AP=M:_3\,"GWCM6-8V2,/6"5(7@8B:*4U>1H(A0P;[AHH\Z=3NUW1B1 MG107Y:1\I"\?4)^",Y_*+%(R"&06ALY[@5MX/6L1!=?S!EK'O^],GWN#O8D4 MH.Q8J3"*X5P)#[/ 35@6@BK5T3"OJ?2$+S[K!K?%?%W8KCIM"_V]7%VY;JJZ M9PE[&N%_TZ=,\$Y4 KHRB%@4^3A+*@Q]XI9"@N;L5(G[0FQKD$CBHY_E1ZL2QDJ);/T_XB4+F(8V0+47%!.4L"XD? MHMQ'6>1:X#U/TD[DA/IDFPU.!#+M%DKS AS<\+[(+Q^09HHI\T60)G'F14$4 M@J@&\ROBX.\SF2;=(:EJ:V;,B<(I6:XO\_F#@03PB?3$;(_%X+80!F0$0"** M!."0=?NGMM?EGBB4'M"0VPJ&"T\RT/68O W3- S \M5@RJ)0D+V5S"<*H+>@ M%I=E/ONPOKF9]36>M(=A"YD$'KCQ41K&+)91X&M62[,XX:PCK=7IR6H7./D# M[FR\5WGAH \?3!61>2)-5+V8(\P23W4D3[#M(9TD. X16_JPRF^N]#L^7BV+ M(OR4+^\;)1OZ&8DD5Z'/P2+G#&=5V@!/00\]=>@%//!:ZJ6HQ2WOFKO!.SO)$ M(/-8JU$D.&81?"@/6P%%$B9N70$H,-4-2_N*':4U=#]D/MMJ#..$TR$W:DUU&-' M:38^%DJ/-1LS$<>QCT6[F8J!TU*)+9TA92'H*-:QKD\?0(\R&XDD?D0C)C+0 MV2J-@U@0346@KY*@.VC"]TY/)CW&;HPCGV$3:A(G- "3,1"9K=,*$Y%U^WY) M<)1V]&/A<22&8X*VHI]&&""(@R!2X+LDG <>_"0 T^HTH.\?0*2U-@UX)),2 MAXE&0*@I>+^>RH0?QAZ0:]S=KF7RVT<&IGM2$R0A2B5*!#$C#'>>9ZXU/$H8 M"3MBFP7D^ 23.D18EHA$)J#?HQ2[XT(GSS$MU-PR.YDA,J(AYTH^Z M>^K4$4K9)\#I<>8U%A@&# PB\.PI9W%&?&TW$AZ&*NF)RE)V?$[($Z#T2//: MRXB7JHB*+!*<1<3W@8X03$D8DR&' U%39DM L"WQ.(B(3Y>'N M<]]#799B0KBGE?1X5?;A?)%$1_3! /= 6$N2#M.>$Q9G4%950*$/F^!^*^GG<1 MQG''!3D^R.\?JL-\7Z8>\\$"X""K4V5+8R,*S-;3T@[&U#$*HN$#US1 OPJ M($)0_2"'"+5V=1@D0;<8*MB>N7$RD'FL70VWYZ' AD@OY%0F@KH94A*4?'< M .T4"9\(8#[3K@YP?BSUTS#*$I]*/Z$IT_I+)10\LV[;!^/J)0#J<89U(HE* M"54^X8P1F@C<(8$68T@("41WIQT[3HOQP''KU%=I'"H51$K&?L@3DGDZ;DU M9@?=[42,'6&VZ#!@:@W9I@'-@BB5%"Q$$2=*$C>F743M_2D63,=I6!\TR)_Y M1 #9@.,1,B\(HS"B6C !OX4ISSH"7(FC=&4'"_)':>(%&9C4,@I4(,(T]!/7 M())XFZY[/R,N^N4G>3=8YH!4>0@)Y,N4?#1(4XFR2(W:J2C 7=CN2@VUCZ M # \ ]S: X0'@))HS?U7*HDS[H&OK%26)(FK/^("_MJS4[ZG ?=YX32UDHF =&1)3R**2N$Q(40=1M[_M28,!A)T?$9HIZ@F5@Q8,1(4 IQ,IS M+29IIOR.):]VA.M>*-P:VN0!I\:^LLD*!')Y#1_Y^>(#_+2ZR/7P*M ARU4" MMLS66,DA'WLV7>!S_N^\G.U$>.ACITHF G1%9)RFE#JY2C/&._&V[5G?QX+O M@XI5"FP19BP)DX0PD7A>FKAUEAG.QCXBL>K@=!BQ"LX&80E-TA <6#"I)7&+ MOP./R=Y>VQ,&PVER.][^M2=?XU**G=4F?HJ['V,P%#C//!&[4&\LP _H!D-% M?V#K&QH/BL8 <+@/C5)ZA$0>>! )"Z1(/2]RN1(>B*ZR%GYOU.T;%I]/];8+ MQ@D@!+P77%FMX@B,+E?/PL';Z51M,-X;YSHD^MX\U])!+V9AP#*/)3'A7A83 MW$UN-6P8!]V%9<^C7_?A&[Y0+J;D&[GOT#V-L0V<)"3EB4=EPN$//(C!X$QB M2151-'GU^U_$VT=B\@&(^8;L9]10&]."Y1%B9!1G% :R9!8EF8\\M/XU>C7JOP!OO.[5ZOENG@U M^FT307J+>)17Q12W*X#_U6,W/* 5+?0BD7*:4N'C-+\L"87;R19EBG6[901M M-Z/WG^,I)[VG^$!DC#*/@5HC:>3Y.+4U<0,DTH1T\Z-Z:7S=_EU@P$^?EI\O%JLJQP' M4U^LBF+>6$&$'[]O+"]+F9#2YS$.+2-,BLQM ('_[V[*H%LCRP\!AV'@C/_Z M&V[RU2S9$3 7R\PIM;#P/NNG!?O@).O;V:+NZ)(RB5P]&*I\Q+;HN9CN<(M M>F_FT_*VG*[S62-PTGU$'078Y-$\):(@2A-)P+.(*(^HFXC!4_C)EE0?$DC/ M!7SBMS9,[UP?&B[_%6*R7R!0.Y+W,\1"TU;@";1,O MYM5ZMLH;\9O-IKF0Q21@T@/AB ,32>*F[X2 .?]%8(X_#',_A5L!PCT#GX>0 M<(U%#&$@0TX3+ X.I2#$+8/D,9$$1T;[WW#0&5@]* Y4$ @%'G2FPA1\Z\Q7 MH8U<1GZ8^#[@@'XE.-BY /DY>2(-O4 1'*-. 2-)PD3=YN1[N#O[Z^&)Q^#C M8/S!8^S.IPJ,> ];]/VZ/C;(" XS?Q'\X?\\68''"O_>AY 85]"P5B_W( K.BI?%O)Y#ZH$D(R^!2^1?V)_6L[L:;OH[G=5>/>&2Q\ ;0V7ZJX!'.%QY M6_3"VU.$"02FL%!ON31?5C MX[2-4'M/R+8?F2R(L2%*LC0.>4@B0>IYBUR)5JG62T7FWQ8S>,P,-/1S"B_/ M$\Q7H Y22@.&$V<2XN;P $?U U[X!P9\&Q9?'/2'$6"*92QD09;&"4V3" Q3 M5]<&]D_:6CB] ;TB+QGTUNX_;5F6R"1B84 "GU"P;#V?I6[$'!5IG/;B55!+!D\Q+1!#%"?=(8E45V'TD]?LE)G]>]!I 'PR][\OJ M7]FR*-[@"C*P\ ^ML?RFNYC$7AQG)&4IBZ/4$X(XL1FIF.\P%2@1!\) 'RR^ M,."'TU=-P$>^GP4X@E#Y,D@"&J;"F@JQ%\1B%^ Y?:F /UEMU<0J2R65N(B+ MR@Q8*0 6RMS$F"1M+:YN8M57SXC50VNKWG>>JJYJ(M<+J)"4=3@[:KH3ZE M7IRQ) I2SH2,!$M]-[4(VR>:P:5*7_K5[]4PE8*[8'D(1-WFY0P7A&<6J/TU MR<>.*Q'&(6,4=XREW$L3/W8*,@*[L+4IW>'J (C:AN4@^/K969O%#=K=CIB+P3C.P MLSQ!,P_,:HV$F&59FG87!W%ZTE@ )7-1E*OUT4)UYLO@/C#*1;%*>Q MI[@4*2&*12YU$28BYCU:GS ^*-9[L'!\2'Y01=NP'3>\94B'099&+(LQI<1B MEKB.FX@$0:F4^YRG+ E2&H&-Y^QJ)827[O ^OSX<[:ZD.B!R8A%P MEOJ9BD.2AG$6>$ZB":9\TJMXOD;L[.P\.!QNB**XW3U-DC1C,DR"*!$N;)-D M:="'F^U9#R>.FX/9VVV_4WF)2+(X0&U.8TJC)*O302D7?7J="NR1.AE F]"5 M>_(?EHNJ>ME=G3LW(*?$2R.94?"HI,S\0#J+(?%]TA=>&]J ZT'%\3*P%)P51R+A]W%?\-4BY0LH(B\"@PV3L%&29"P->2:< M!>>'U/=Z$,1>)-?X[Q:WY#7\BWE'A2#J*3TH(^$TE0%+?'!/+8)$2$+:@Z"A MW:#CP,]P;7$'#"( "TD_$XGB28JY5>4&#X=24J\WUC.T0W1"V'H&U[5^PH=5 MOC(#SF=Y5?U\H3_=*G@!>%POYOK7X7U,B9.=0N!)GT1I%@4DHW4YLN>G?6KM MJ\;S =W?PR X"7GH1S3@"8EHF##?X[8P(DX\^'.OU_#R$"S_0O^T!ESLX^!9 M\>L3V#?$IS<06N%'[IV[*S,AHRP-!8O2((B8G]F!K:%'6*^%/[C7_(6Q\DQ> M,_7#0'@IXUQQGGI!*N/$E?VGONR-AG,AZ,E"^N]%>7FU*J;A+9AWEX7^)0Y_ MJZN4GJOA@L=)[#./BUB$89R1")=)V094P8*MV=)P>'U),/K.Z,%@?R]PC@HO MA^G& $=6\IAD7LJ%(HI$0>;J( 5X3L$NO,@S%KP(O/R\7E4K$"CE_')?%MTM MM3A<"CTA/(UCW_,I-E"JA$D7.XV"-$NC[12Z,!&%X9"P$Q)?"-R/JGU[-+@Y M(20F ?F5/:G?H?^.*TX6T*YIZ!K-LZ-P.P"M\C81BEDM D MCB,W"XID0=KG/ KF@VEZ&% ;*#PSB)&47V9T.O%%*$/)"?,83SP_H[Z;4H]Y MB;Z,CQJH4O<4"!]D>B!?;NC1L/SNMH^RVB01$GB2R)]1F6: M<<^#O_(H(+2W5GWHL/.Q8^,YJV[:PHI+H8($K%KABTQ$-%4R2&/F1;@'123) M5RRLGJO2IHT0,-E8%$B?LB0-O,3'S5<)%Y[P6)P)U2>[OA:$?(F<)A5>$ J5 M44^E@0K]I-[D[F5M5]UA8^B<\S&@Y-C;H3R/!L S6>:Q(%:<"NF6+(:!'Z=] MK6MLT #C22'I"3'<+/&B*(R3T)=!0&D6@T#^30XS->1QLC@(=QRFL MFC@-,TY23W)&>!*#DJ>*UR-;?+4[^$O.R!"MTB\=IX]E,1I$C$4>]:,DE3'H M>4Y=(VT,* KWY$B&F/)Q0'14C^W?>CA6#I4X;"*&1$D(_L&A=*@^.DI]3TN#(%E1;G R9Z!2 B1-!$NO1ARG[/=VHD] MAG4&AM.@.-J;0_O"Z!&^PJU=$07,4.E'S$]=;BOV8BYW9QDI&Q ]#P=1!S-= MP*$Z$+J01#:VL\UPQ=0O^7)U]Q%>5IF=:XV@5?2'7];+R14<<%E%1?E/D+(? MKN _L\7\\M=R'H)ON"S^N;B[SPJ.693&82@8(7[&0DE9:NLG1:;@)[MU!=]N M 7CDA=_F=_2^"P,BFK_9W/\?ZZM\OCL"_F%]7I73,E_>X:J]OF(G.-8M/!=( M;J)1?A^?#:?S^S7M^38Y-D<$OTI3N MFIGF;4_7.DK\IK_>E$9Z];?FU8O^!AGP_YR+ ''#9LQ!J> LDR3$"M': >'* MU^M=O>T9Z4. \%GP+:8*5IK+>7'#&H]XWD_%@L MK\GP986-A*J7!#R-08.D21CA$@4W !U^ZF>XO??\4M"T!OO! M5X@,.ZVO@4.52!5Z)/8(]Z.41Y&;J4G3Q%-?.0Z'W3ER(!Q2\.9H+"3W940C M'U2]YW8N,AKZ7M]*F9>(O\^7:!D#A]@G8>;)( K#D$E>3T1/ 5 8:LE &H$5]/7W:+]V8,3.PGTHLX(RR@8%O))+;N.P_2A ^G_I^.B6,C MA"_4 =Y(OV<)XR*2:P(^\,WZ/,S!NY-%"I&:.!' M*JMS73QF_C?T]:'ON+J3-[GH3*E,R#A,DBQ)@EC*P"I,^+%(Z3=<'G/O*?$/D438GMY87Q[%,0DZ5SQ+I)X0WUE+X\=&) MU?)R7EX 1<]7\16^\LW\KW,PV1;PX_\%"SC_-2KFQ46YJMY4[XN\6LSS\]G= M+XNJ*L]G17B]6,]7/U^8KRRGQ=1^NK=08&]=91RF(V3Z7>\7E\7R M[R#?ROP:K/(IRK:XP+'\AVR[!_^8I3PC018GR@_!R?.Y,QV58+S3VM?I[GXB M2@9':R.4MWLR;!2D,9%2A!ZA5&7$#RQU*YH&<;!]6RKTC('COFV7,-)_KX&, M\0&+.>:>6\013J:9&VP6L% DG=L&Y)BY0CT?G4CB MI8(Q/Q81EQD7D@K74Z0"OEVWAY!CP4N#W#MT.D#L+T"6ZP9:O5GEOC'E::)8 MFJ8THCPF7NQYZ#%PXDFI B_RM@'WFAX(;F^J:EU,=Z9)FA?PFHC/&/%X&@<^ MZ!"5I1Z)?9(0F?H)3P3I('[[Z/:U#S].EX6;QTEPAA_AW_U':@)9P[<*)T 5E6::KL6AM,51SJC\#',C6E?EO*B:;]I\^V_E MUE1?9"F5*DXE\7F(?:DV?Z XL*/LJ^,/I*>^($BV M!-5>0HF2GWY9+J;KR:J'Q 8'9I *W%.7Q:F*/"Z#2 GKAH6,Q+2OR9YY0=#: M#GC$P'Q@$R4Q,$>:?"%SW2;/#0174 MKA\I$DB:Q7$:)9S1"#P&/PVD""*BOHPT!"?R%CQ&^,[/%^;/*W29/Q03^.BJ M+'JU#8:WY>$@)4( B
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�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¼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